Methods for modulating rna splicing

ABSTRACT

In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, and the methods utilizing a compound described herein. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene comprises an intronic REMS, and the methods utilizing a compound described herein. In another aspect, provided herein are artificial gene constructs comprising an intronic REMS, and uses of those artificial gene constructs to modulate protein production. In another aspect, provided herein are methods for altering endogenous genes to comprise an intronic REMS, and the use of a compound described herein to modulate protein produced from such altered endogenous genes.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of provisional application No. 62/426,619, filed on Nov. 28, 2016, which is incorporated by reference herein in its entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

This application incorporates by reference a Sequence Listing submitted with this application as a text file entitled “10589-275-228_Sequence_Listing.txt” created on Nov. 18, 2017 and having a size of 1,112 kilobytes.

INTRODUCTION

In one aspect, described herein is a recognition element for splicing modifier (REMS) present in an intron (i.e., an “intronic REMS” or iREMS) that can be recognized as a 5′ splice site by the U1 snRNP and/or other components of the pre-mRNA splicing machinery in the presence of a small molecule splicing modifier, wherein gene expression is modulated by inducing alternative splicing of intronic exons (iExons) in the transcribed RNA. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, a branch point and a 3′ splice site, and the methods utilize a small molecule compound described herein to induce alternative splicing of iExons. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene via alternative splicing of iExons, wherein a precursor RNA transcript transcribed from the gene comprises an endogenous or non-endogenous intronic REMS, and the methods utilize a compound described herein to induce iExon alternative splicing. In another aspect, provided herein are artificial gene constructs comprising an intronic REMS (including an endogenous or non-endogenous intronic REMS), and uses of those artificial gene constructs to modulate protein production via iExon alternative splicing in the presence of a small molecule splicing modifier compound. In another aspect, provided herein are methods for altering genes to comprise an endogenous or non-endogenous intronic REMS, and the use of a small molecule compound described herein to induce alternative splicing of iExons, subsequently modulating the amount and type of protein produced from such altered endogenous or non-endogenous gene transcripts.

BACKGROUND

Diseases associated with expression of an aberrant gene product (e.g., where the production of an aberrant RNA transcript or protein causes a disease) are often treated with a focus on affecting aberrant protein expression. However, targeting components of the splicing process responsible for production of aberrant RNA before the aberrant protein is expressed by using a small molecule may affect the underlying cause of a disease or disorder, and thus more efficiently prevent or ameliorate the disease or disorder caused by expression of the aberrant gene product. Accordingly, there is a need for methods of modulating the expression of aberrant RNA transcripts encoded by certain genes using small molecules to prevent or treat diseases associated with expression of aberrant RNA transcripts or associated proteins.

SUMMARY

In one aspect, provided herein is a recognition element for splicing modifier (otherwise referred to as “REMS”) present in an intron (i.e., an “intronic REMS”) capable of being recognized by the U1 snRNP and/or other components of the pre-mRNA splicing machinery in the presence of a small molecule splicing modifier, whereby elements of the splicing reaction are affected as further described herein. In a specific embodiment, the intronic REMS comprises the nucleotide sequence GAgurngn (SEQ ID NO: 2) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n is any nucleotide. In another specific embodiment, the intronic REMS comprises the nucleotide sequence GAguragu (SEQ ID NO: 3866) at the RNA level, wherein r is adenine or guanine. In a specific embodiment, the intronic REMS comprises the nucleotide sequence NNGAgurngn (SEQ ID NO: 1) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In another specific embodiment, the intronic REMS comprises the nucleotide sequence NNGAguragu (SEQ ID NO: 3862) at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In one or more of such specific embodiments provided herein, N is adenine or guanine.

In another aspect, in addition to the intronic REMS sequence, the RNA transcript comprises an upstream branch point and a functional upstream iExon 3′ splice site. In certain embodiments including, but not limited to, iExons, an exon 5′ splice site, a branch point and the functional iExon 3′ splice site upstream from the intronic REMS are further linked to a downstream branch point and 3′ splice site of a downstream exon (see, for example, FIG. 1A). In other embodiments including, but not limited to, extended exons, the branch point and the functional 3′ splice site for an exon are downstream from the intronic REMS sequences (see, for example, FIGS. 1B and 1C). In a particular embodiment, an RNA sequence comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, and wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site (also referred to as an iExon 3′ splice site), an iREMS, a second branch point, and a second 3′ splice site. In the presence of a compound described herein, the iREMS sequence functions as a 5′ splice site, causing the NNGA (SEQ ID NO: 3863) nucleotides of the iREMS and the intronic nucleotides downstream of the first 3′ splice site to be retained and spliced as an intronic exon to provide a non-wild-type mRNA. In other words, the nucleotides between the iREMS and the first 3′ splice site are retained and form the intronic exon, which results in the expression of a non-wild-type mRNA sequence. In the presence of a compound described herein, the iREMS sequence functions as a 5′ splice site, causing the NNGA (SEQ ID NO: 3863) nucleotides of the iREMS and the intronic nucleotides between the 3′ iExon splice site to be retained and spliced as an intronic exon to provide a non-wild-type mRNA. In other aspects, in the presence of a compound described herein and a downstream branch point, the intronic REMS will undergo splicing with the 3′ splice site of a downstream exon. In this aspect, the intronic REMS is located downstream of an exon such that there is no intervening upstream branch point and iExon 3′ splice site between the exon and the REMS sequence. In the presence of a compound described herein, the exon 5′ splice site does not undergo splicing with the downstream 3′ splice site. Instead, functioning as a 5′ splice site in the presence of a compound described herein, the iREMS sequence undergoes splicing with the downstream 3′ splice site. In other embodiments, in the presence of a compound described herein, an upstream exon 5′ splice site, an upstream branch point, and a functional iExon 3′ splice site upstream from the intronic REMS, will undergo splicing. In certain embodiments, one or more sequence elements necessary to form an iExon splice junction may be present endogenously or non-endogenously. For example, one or more of the following sequence elements may be present naturally in an intron or an intron may be engineered to comprise one or more of the following sequences in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point, and a second 3′ splice site. In certain embodiments, one or more snRNPs and trans factor elements necessary for splicing may be present beyond endogenous levels as a result of the presence of a compound described herein at various splice inducing sequence combinations. Without being bound by any theory or mechanism, the small molecule compounds described herein, in conjunction with the iREMS sequence, initiate the assembly of a splicing-competent spliceosome around a weak or incompletely defined exon (i.e., a nascent iExon). Splicing modifier compounds most likely enable a functional U1 snRNP-REMS interaction and, at least, have been shown to increase the affinity of one or more snRNPs and trans factor elements necessary for splicing, including U1, U2, U4, U5 and U6, whereby the interaction between the U1 snRNP, as well as other components of the pre-mRNA splicing machinery, and the nucleotides NNGA (SEQ ID NO: 3863) of the REMS are enhanced. In fact, we have discovered that the interaction of the U1 snRNP, the iREMS and the small molecule splicing modifier compounds described herein serve to define nascent exons by increasing the binding affinity of the pre-mRNA splicing machinery to the iREMS sequence, stabilizing U1 binding with the iREMS sequence, activating a 3′ splice site and a branch point upstream from the iREMS and recruiting U2 snRNP and other trans-acting splicing factors such as U2AF (U2AF65 and U2AF35) and SF3A (SF3A1, SF3A2 and SF3A3) to the upstream branch point and 3′ splice site. The branch point and 3′splice site may or may not be fully occupied in the absence of the compound but have been shown to become occupied after the compound has enabled the formation of a functional U1 snRNP-REMS complex. We have elaborated on the interaction of these key splicing machinery elements, showing that, in the presence of small molecule splicing modifier compounds such as, but certainly not limited to, those described herein, the mechanism of intronic spliceosome assembly can be mediated by iREMS interaction with such compounds, such that the intronic REMS sequence functions as a U1 snRNP binding site, resulting in intronic nucleotides spliced in the mature RNA transcript as an intronic exon.

In FIG. 1A, the intronic REMS is located in Intron 1 downstream from an Exon 1 5′ splice site (i.e., a 5′ splice site at the 3′ end of Exon 1), a first branch point (BP) sequence and a first 3′ splice site sequence and upstream from a second branch point sequence and a second 3′ splice site sequence of Exon 2 in an RNA transcript (i.e., the precursor mRNA). In the presence of a small molecule splicing modifier compound described herein the intronic REMS functions as a 5′ splice site, whereby the nucleotides between the Exon 1 5′ splice site and the first 3′ splice site are removed to form a splice junction between Exon 1 and a nascent intronic exon and the nucleotides between the intronic REMS and the second 3′ splice site sequence are removed to form a splice junction between iExon 1a and Exon 2, and allowing Exon 2 and the portion of the intron comprising nucleotides from the first 3′ splice site up to and including NNGA (SEQ ID NO: 3863) of the intronic REMS to be joined, thus introducing an intron-derived iExon 1a, generating a non-wildtype mRNA. In certain embodiments of FIG. 1A, one or more elements necessary to form a splice junction may be present endogenously or introduced, wherein the one or more elements are selected from the group consisting of the first branch point, the first 3′ splice site, the intronic REMS, the second branch point and the second 3′ splice site. While illustrated for Intron 1 here, this concept is generally applicable to any other intron in a pre-mRNA transcript.

In FIG. 1B, the intronic REMS is located in an intron of an RNA transcript downstream from an Exon 1 5′ splice site (i.e., a 5′ splice site at the 3′ end of Exon 1) and upstream from an Intron 1 branch point sequence and a 3′ splice site sequence of Exon 2 (i.e., a 3′ splice site at the 5′ end of Exon 2). In the presence of a small molecule splicing modifier compound described herein, the nucleotides between the Exon 1 5′ splice site and the intronic REMS are retained and those between the intronic REMS and the Intron 1 3′ splice site sequence (except the NNGA (SEQ ID NO: 3863) nucleotides of the intronic REMS) are removed, allowing Exon 1 and the portion of the intron comprising nucleotides from those adjacent to the Exon 1 5′ splice site up to and including NNGA (SEQ ID NO: 3863) of the intronic REMS and the Exon 2 nucleotides to be joined. The scope of the invention described herein is merely illustrated in this configuration for Exon 1 but is generally applicable to any other nascent iExon in an intronic sequence. The elements necessary to induce splicing of an iExon may be present in any configuration capable of recognition by the splicing machinery as an “exon.” Accordingly, in the presence of a splicing modifier compound, the spliceosome recognizes the elements as exonic boundaries for removal of intervening intronic nucleotides between those boundaries. The configuration in this instance results in an iExon spliced between at least one upstream exon and one downstream exon of the same pre-mRNA transcript.

In FIG. 1C, the intronic REMS is located in Intron 2 downstream from an Exon 2 5′ splice site (i.e., a 5′ splice site at the 3′ end of Exon 2) and upstream from an Intron 2 branch point sequence and a 3′ splice site sequence of Exon 3 (i.e., a 3′ splice site at the 5′ end of Exon 3) in an RNA transcript. In the presence of a small molecule splicing modifier compound described herein, the nucleotides between the intronic REMS and the Exon 3 3′ splice site sequence are removed, allowing Exon 3 and the portion of the intron comprising nucleotides from those adjacent to the Exon 2 5′ splice site up to and including NNGA (SEQ ID NO: 3863) of the intronic REMS to be joined. In this example, the endogenous splicing reaction between Exon 1 and Exon 2 is unaffected by the presence of a compound described herein, resulting in the complete removal of Intron 1. While illustrated for Exon 2 here, this concept is generally applicable to any other internal nascent intronic exon, i.e., an exon that is located between at least one upstream exon and one downstream exon of the same pre-mRNA transcript.

As used herein, an “exon 5′ splice site”, a “5′ splice site of an exon” or the like refers to a 5′ splice site at the 3′ end of the exon, while an “exon 3′ splice site”, a “3′ splice site of an exon” or the like refers to a 3′ splice site at the 5′ end of the exon.

In the presence of a small molecule splicing modifier compound described herein, the iREMS nucleotides retained in the formation of an iExon are selected from the group consisting of ANGA (SEQ ID NO: 5), CNGA (SEQ ID NO: 11), GNGA (SEQ ID NO: 17), UNGA (SEQ ID NO: 23), NAGA (SEQ ID NO: 6), NCGA (SEQ ID NO: 12), NGGA (SEQ ID NO: 18), NUGA (SEQ ID NO: 24), AAGA (SEQ ID NO: 7), ACGA (SEQ ID NO: 13), AGGA (SEQ ID NO: 19), AUGA (SEQ ID NO: 25), CAGA (SEQ ID NO: 8), CCGA (SEQ ID NO: 14), CGGA (SEQ ID NO: 20), CUGA (SEQ ID NO: 26), GAGA (SEQ ID NO: 9), GCGA (SEQ ID NO: 15), GGGA (SEQ ID NO: 21), GUGA (SEQ ID NO: 27), UAGA (SEQ ID NO: 10), UCGA (SEQ ID NO: 16), UGGA (SEQ ID NO: 22) and UUGA (SEQ ID NO: 28). The formation of an iExon may result in an RNA transcript having a non-functional open reading frame due to the inclusion of a frameshift, premature stop codon or internal deletions within the open reading frame. In other embodiments, the inclusion of an iExon may result in the mature mRNA having a functional open reading frame, producing a novel protein which may or may not be functional. RNA transcripts having a non-functional open reading frame due to the inclusion of a frameshift, premature stop codon or internal deletions within the open reading frame can be substrates for nonsense-mediated decay and thus have low abundance. Any intronic REMS-mediated alternative splicing modified RNA transcripts may also have altered stability, altered intracellular transport, altered 3′ end formation efficiency and altered translation efficiency.

Accordingly, in one aspect, provided herein are methods for modulating the amount of RNA transcripts produced from precursor RNA containing an endogenous or non-endogenous intronic REMS. In another aspect, provided herein are artificial gene constructs comprising an endogenous or non-endogenous intronic REMS, which may be used in the context of, e.g., gene therapy or reporter assays. In another aspect, provided herein are methods for altering endogenous genes so that they contain an intronic REMS or an additional intronic REMS.

In another aspect, provided herein are methods for modulating the amount of one or more RNA transcripts (e.g., mRNA transcripts) or proteins thereof expressed as the product of one or more genes, wherein precursor RNA transcripts transcribed by the one or more genes comprise an intronic REMS, the methods comprising contacting a cell with a compound of Formula

or a form thereof, wherein w₁, w₂, w₃, w₄, w₅, w₆ and w₇ are as defined herein. In one embodiment, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RNA containing an intronic recognition element for splicing modifier (REMS), the method comprising contacting a cell containing the precursor RNA with a compound of Formula (I) or a form thereof, wherein the intronic REMS comprises the sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, wherein the precursor RNA is a gene in Table 1. In certain embodiments, the precursor RNA is a gene in Table 7. In another embodiment, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RNA containing an intronic recognition element for splicing modifier (REMS), the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the intronic REMS comprises the sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, wherein the precursor RNA is a gene in Table 1. In some embodiments, the intronic REMS comprises the sequence NNGAguragu (SEQ ID NO: 3862) at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In certain embodiments, the intronic REMS comprises a sequence selected from the group consisting of ANGAgurngn (SEQ ID NO: 29), CNGAgurngn (SEQ ID NO: 35), GNGAgurngn (SEQ ID NO: 41), UNGAgurngn (SEQ ID NO: 47), NAGAgurngn (SEQ ID NO: 30), NCGAgurngn (SEQ ID NO: 36), NGGAgurngn (SEQ ID NO: 42), NUGAgurngn (SEQ ID NO: 48), AAGAgurngn (SEQ ID NO: 31), ACGAgurngn (SEQ ID NO: 37), AGGAgurngn (SEQ ID NO: 43), AUGAgurngn (SEQ ID NO: 49), CAGAgurngn (SEQ ID NO: 32), CCGAgurngn (SEQ ID NO: 38), CGGAgumgn (SEQ ID NO: 44), CUGAgurngn (SEQ ID NO: 50), GAGAgurngn (SEQ ID NO: 33), GCGAgurngn (SEQ ID NO: 39), GGGAgurngn (SEQ ID NO: 45), GUGAgurngn (SEQ ID NO: 51), UAGAgurngn (SEQ ID NO: 34), UCGAgurngn (SEQ ID NO: 40), UGGAgurngn (SEQ ID NO: 46) and UUGAgurngn (SEQ ID NO: 52), wherein r is adenine or guanine and n or N is any nucleotide. In some embodiments, the intronic REMS comprises a sequence selected from the group consisting of ANGAguragu (SEQ ID NO: 437), CNGAguragu (SEQ ID NO: 443), GNGAguragu (SEQ ID NO: 449), UNGAguragu (SEQ ID NO: 455), NAGAguragu (SEQ ID NO: 438), NCGAguragu (SEQ ID NO: 444), NGGAguragu (SEQ ID NO: 450), NUGAguragu (SEQ ID NO: 456), AAGAguragu (SEQ ID NO: 439), ACGAguragu (SEQ ID NO: 445), AGGAguragu (SEQ ID NO: 451), AUGAguragu (SEQ ID NO: 457), CAGAguragu (SEQ ID NO: 440), CCGAguragu (SEQ ID NO: 446), CGGAguragu (SEQ ID NO: 452), CUGAguragu (SEQ ID NO: 458), GAGAguragu (SEQ ID NO: 441), GCGAguragu (SEQ ID NO: 447), GGGAguragu (SEQ ID NO: 453), GUGAguragu (SEQ ID NO: 459), UAGAguragu (SEQ ID NO: 442), UCGAguragu (SEQ ID NO: 448), UGGAguragu (SEQ ID NO: 454) and UUGAguragu (SEQ ID NO: 460) at the RNA level, wherein r is adenine or guanine, and N is any nucleotide. In one or more embodiments provided herein, N is adenine or guanine.

In a specific embodiment, the intronic REMS referred to in a method or artificial gene construct described herein comprises, at the RNA level, a sequence presented in the following table (wherein r is adenine or guanine, and n or N is any nucleotide):

TABLE 13 Intronic REMS RNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide) SEQ ID SEQ ID SEQ ID SEQ ID NO. Sequence NO. Sequence NO. Sequence NO. Sequence 29 ANGAgurngn 35 CNGAgurngn 41 GNGAgurngn 47 UNGAgurngn 30 NAGAgurngn 36 NCGAgurngn 42 NGGAgurngn 48 NUGAgurngn 31 AAGAgurngn 37 ACGAgurngn 43 AGGAgurngn 49 AUGAgurngn 32 CAGAgurngn 38 CCGAgurngn 44 CGGAgurngn 50 CUGAgurngn 33 GAGAgurngn 39 GCGAgurngn 45 GGGAgurngn 51 GUGAgurngn 34 UAGAgurngn 40 UCGAgurngn 46 UGGAgurngn 52 UUGAgurngn 53 ANGAguragn 77 ANGAgurcgn 101 ANGAgurggn 125 ANGAgurugn 54 NAGAguragn 78 NAGAgurcgn 102 NAGAgurggn 126 NAGAgurugn 55 AAGAguragn 79 AAGAgurcgn 103 AAGAgurggn 127 AAGAgurugn 56 CAGAguragn 80 CAGAgurcgn 104 CAGAgurggn 128 CAGAgurugn 57 GAGAguragn 81 GAGAgurcgn 105 GAGAgurggn 129 GAGAgurugn 58 UAGAguragn 82 UAGAgurcgn 106 UAGAgurggn 130 UAGAgurugn 59 CNGAguragn 83 CNGAgurcgn 107 CNGAgurggn 131 CNGAgurugn 60 NCGAguragn 84 NCGAgurcgn 108 NCGAgurggn 132 NCGAgurugn 61 ACGAguragn 85 ACGAgurcgn 109 ACGAgurggn 133 ACGAgurugn 62 CCGAguragn 86 CCGAgurcgn 110 CCGAgurggn 134 CCGAgurugn 63 GCGAguragn 87 GCGAgurcgn 111 GCGAgurggn 135 GCGAgurugn 64 UCGAguragn 88 UCGAgurcgn 112 UCGAgurggn 136 UCGAgurugn 65 GNGAguragn 89 GNGAgurcgn 113 GNGAgurggn 137 GNGAgurugn 66 NGGAguragn 90 NGGAgurcgn 114 NGGAgurggn 138 NGGAgurugn 67 AGGAguragn 91 AGGAgurcgn 115 AGGAgurggn 139 AGGAgurugn 68 CGGAguragn 92 CGGAgurcgn 116 CGGAgurggn 140 CGGAgurugn 69 GGGAguragn 93 GGGAgurcgn 117 GGGAgurggn 141 GGGAgurugn 70 UGGAguragn 94 UGGAgurcgn 118 UGGAgurggn 142 UGGAgurugn 71 UNGAguragn 95 UNGAgurcgn 119 UNGAgurggn 143 UNGAgurugn 72 NUGAguragn 96 NUGAgurcgn 120 NUGAgurggn 144 NUGAgurugn 73 AUGAguragn 97 AUGAgurcgn 121 AUGAgurggn 145 AUGAgurugn 74 CUGAguragn 98 CUGAgurcgn 122 CUGAgurggn 146 CUGAgurugn 75 GUGAguragn 99 GUGAgurcgn |23 GUGAgurggn 147 GUGAgurugn 76 UUGAguragn 100 UUGAgurcgn 124 UUGAgurggn 148 UUGAgurugn 149 ANGAguraga 173 ANGAgurcga 197 ANGAgurgga 221 ANGAguruga 150 NAGAguraga 174 NAGAgurcga 198 NAGAgurgga 222 NAGAguruga 151 AAGAguraga 175 AAGAgurcga 199 AAGAgurgga 223 AAGAguruga 152 CAGAguraga 176 CAGAgurcga 200 CAGAgurgga 224 CAGAguruga 153 GAGAguraga 177 GAGAgurcga 201 GAGAgurgga 225 GAGAguruga 154 UAGAguraga 178 UAGAgurcga 202 UAGAgurgga 226 UAGAguruga 155 CNGAguraga 179 CNGAgurcga 203 CNGAgurgga 227 CNGAguruga 156 NCGAguraga 180 NCGAgurcga 204 NCGAgurgga 228 NCGAguruga 157 ACGAguraga 181 ACGAgurcga 205 ACGAgurgga 229 ACGAguruga 158 CCGAguraga 182 CCGAgurcga 206 CCGAgurgga 230 CCGAguruga 159 GCGAguraga 183 GCGAgurcga 207 GCGAgurgga 231 GCGAguruga 160 UCGAguraga 184 UCGAgurcga 208 UCGAgurgga 232 UCGAguruga 161 GNGAguraga 185 GNGAgurcga 209 GNGAgurgga 233 GNGAguruga 162 NGGAguraga 186 NGGAgurcga 210 NGGAgurgga 234 NGGAguruga 163 AGGAguraga 187 AGGAgurcga 211 AGGAgurgga 235 AGGAguruga 164 CGGAguraga 188 CGGAgurcga 212 CGGAgurgga 236 CGGAguruga 165 GGGAguraga 189 GGGAgurcga 213 GGGAgurgga 237 GGGAguruga 166 UGGAguraga 190 UGGAgurcga 214 UGGAgurgga 238 UGGAguruga 167 UNGAguraga 191 UNGAgurcga 215 UNGAgurgga 239 UNGAguruga 168 NUGAguraga 192 NUGAgurcga 216 NUGAgurgga 240 NUGAguruga 169 AUGAguraga 193 AUGAgurcga 217 AUGAgurgga 241 AUGAguruga 170 CUGAguraga 194 CUGAgurcga 218 CUGAgurgga 242 CUGAguruga 171 GUGAguraga 195 GUGAgurcga 219 GUGAgurgga 243 GUGAguruga 172 UUGAguraga 196 UUGAgurcga 220 UUGAgurgga 244 UUGAguruga 245 ANGAguragc 269 ANGAgurcgc 293 ANGAgurggc 317 ANGAgurugc 246 NAGAguragc 270 NAGAgurcgc 294 NAGAgurggc 318 NAGAgurugc 247 AAGAguragc 271 AAGAgurcgc 295 AAGAgurggo 319 AAGAgurugc 248 CAGAguragc 272 CAGAgurcgc 296 CAGAgurggc 320 CAGAgurugc 249 GAGAguragc 273 GAGAgurcgc 297 GAGAgurggc 321 GAGAgurugc 250 UAGAguragc 274 UAGAgurcgc 298 UAGAgurggc 322 UAGAgurugc 251 CNGAguragc 275 CNGAgurcgc 299 CNGAgurggc 323 CNGAgurugc 252 NCGAgurago 276 NCGAgurcgc 300 NCGAgurggc 324 NCGAgurugc 253 ACGAguragc 277 ACGAgurcgc 301 ACGAgurggc 325 ACGAgurugc 254 CCGAguragc 278 CCGAgurcgc 302 CCGAgurggc 326 CCGAgurugc 255 GCGAguragc 279 GCGAgurcgc 303 GCGAgurggc 327 GCGAgurugc 256 UCGAguragc 280 UCGAgurcgc 304 UCGAgurggc 328 UCGAgurugc 257 GNGAguragc 281 GNGAgurcgc 305 GNGAgurggc 329 GNGAgurugc 258 NGGAguragc 282 NGGAgurcgc 306 NGGAgurggc 330 NGGAgurugc 259 AGGAguragc 283 AGGAgurcgc 307 AGGAgurggc 331 AGGAgurugc 260 CGGAguragc 284 CGGAgurcgc 308 CGGAgurggc 332 CGGAgurugc 261 GGGAguragc 285 GGGAgurcgc 309 GGGAgurggc 333 GGGAgurugc 262 UGGAguragc 286 UGGAgurcgc 310 UGGAgurggc 334 UGGAgurugc 263 UNGAguragc 287 UNGAgurcgc 311 UNGAgurggc 335 UNGAgurugc 264 NUGAguragc 288 NUGAgurcgc 312 NUGAgurggc 336 NUGAgurugc 265 AUGAguragc 289 AUGAgurcgc 313 AUGAgurggc 337 AUGAgurugc 266 CUGAgurago 290 CUGAgurcgc 314 CUGAgurggc 338 CUGAgurugc 267 GUGAguragc 291 GUGAgurcgc 315 GUGAgurggc 339 GUGAgurugc 268 UUGAguragc 292 UUGAgurcgc 316 UUGAgurggc 340 UUGAgurugc 341 ANGAguragg 365 ANGAgurcgg 389 ANGAgurggg 413 ANGAgurugg 342 NAGAguragg 366 NAGAgurcgg 390 NAGAgurggg 414 NAGAgurugg 343 AAGAguragg 367 AAGAgurcgg 391 AAGAgurggg 415 AAGAgurugg 344 CAGAguragg 368 CAGAgurcgg 392 CAGAgurggg 416 CAGAgurugg 345 GAGAguragg 369 GAGAgurcgg 393 GAGAgurggg 417 GAGAgurugg 346 UAGAguragg 370 UAGAgurcgg 394 UAGAgurggg 418 UAGAgurugg 347 CNGAguragg 371 CNGAgurcgg 395 CNGAgurggg 419 CNGAgurugg 348 NCGAguragg 372 NCGAgurcgg 396 NCGAgurggg 420 NCGAgurugg 349 ACGAguragg 373 ACGAgurcgg 397 ACGAgurggg 421 ACGAgurugg 350 CCGAguragg 374 CCGAgurcgg 398 CCGAgurggg 422 CCGAgurugg 351 GCGAguragg 375 GCGAgurcgg 399 GCGAgurggg 423 GCGAgurugg 352 UCGAguragg 376 UCGAgurcgg 400 UCGAgurggg 424 UCGAgurugg 353 GNGAguragg 377 GNGAgurcgg 401 GNGAgurggg 425 GNGAgurugg 354 NGGAguragg 378 NGGAgurcgg 402 NGGAgurggg 426 NGGAgurugg 355 AGGAguragg 379 AGGAgurcgg 403 AGGAgurggg 427 AGGAgurugg 356 CGGAguragg 380 CGGAgurcgg 404 CGGAgurggg 428 CGGAgurugg 357 GGGAguragg 381 GGGAgurcgg 405 GGGAgurggg 429 GGGAgurugg 358 UGGAguragg 382 UGGAgurcgg 406 UGGAgurggg 430 UGGAgurugg 359 UNGAguragg 383 UNGAgurcgg 407 UNGAgurggg 431 UNGAgurugg 360 NUGAguragg 384 NUGAgurcgg 408 NUGAgurggg 432 NUGAgurugg 361 AUGAguragg 385 AUGAgurcgg 409 AUGAgurggg 433 AUGAgurugg 362 CUGAguragg 386 CUGAgurcgg 410 CUGAgurggg 434 CUGAgurugg 363 GUGAguragg 387 GUGAgurcgg 411 GUGAgurggg 435 GUGAgurugg 364 UUGAguragg 388 UUGAgurcgg 412 UUGAgurggg 436 UUGAgurugg 437 ANGAguragu 461 ANGAgurcgu 485 ANGAgurggu 509 ANGAgurugu 438 NAGAguragu 462 NAGAgurcgu 486 NAGAgurggu 510 NAGAgurugu 439 AAGAguragu 463 AAGAgurcgu 487 AAGAgurggu 511 AAGAgurugu 440 CAGAguragu 464 CAGAgurcgu 488 CAGAgurggu 512 CAGAgurugu 441 GAGAguragu 465 GAGAgurcgu 489 GAGAgurggu 513 GAGAgurugu 442 UAGAguragu 466 UAGAgurcgu 490 UAGAgurggu 514 UAGAgurugu 443 CNGAguragu 467 CNGAgurcgu 491 CNGAgurggu 515 CNGAgurugu 444 NCGAguragu 468 NCGAgurcgu 492 NCGAgurggu 516 NCGAgurugu 445 ACGAguragu 469 ACGAgurcgu 493 ACGAgurggu 517 ACGAgurugu 446 CCGAguragu 470 CCGAgurcgu 494 CCGAgurggu 518 CCGAgurugu 447 GCGAguragu 471 GCGAgurcgu 495 GCGAgurggu 519 GCGAgurugu 448 UCGAguragu 472 UCGAgurcgu 496 UCGAgurggu 520 UCGAgurugu 449 GNGAguragu 473 GNGAgurcgu 497 GNGAgurggu 521 GNGAgurugu 450 NGGAguragu 474 NGGAgurcgu 498 NGGAgurggu 522 NGGAgurugu 451 AGGAguragu 475 AGGAgurcgu 499 AGGAgurggu 523 AGGAgurugu 452 CGGAguragu 476 CGGAgurcgu 500 CGGAgurggu 524 CGGAgurugu 453 GGGAguragu 477 GGGAgurcgu 501 GGGAgurggu 525 GGGAgurugu 454 UGGAguragu 478 UGGAgurcgu 502 UGGAgurggu 526 UGGAgurugu 455 UNGAguragu 479 UNGAgurcgu 503 UNGAgurggu 527 UNGAgurugu 456 NUGAguragu 480 NUGAgurcgu 504 NUGAgurggu 528 NUGAgurugu 457 AUGAguragu 481 AUGAgurcgu 505 AUGAgurggu 529 AUGAgurugu 458 CUGAguragu 482 CUGAgurcgu 506 CUGAgurggu 530 CUGAgurugu 459 GUGAguragu 483 GUGAgurcgu 507 GUGAgurggu 531 GUGAgurugu 460 UUGAguragu 484 UUGAgurcgu 508 UUGAgurggu 532 UUGAgurugu 533 ANGAgurnga 557 ANGAgurngc 581 ANGAgurngg 605 ANGAgurngu 534 NAGAgurnga 558 NAGAgurngc 582 NAGAgurngg 606 NAGAgurngu 535 AAGAgurnga 559 AAGAgurngc 583 AAGAgurngg 607 AAGAgurngu 536 CAGAgurnga 560 CAGAgurngc 584 CAGAgurngg 608 CAGAgurngu 537 GAGAgurnga 561 GAGAgurngc 585 GAGAgurngg 609 GAGAgurngu 538 UAGAgurnga 562 UAGAgurngc 586 UAGAgurngg 610 UAGAgurngu 539 CNGAgurnga 563 CNGAgurngc 587 CNGAgurngg 611 CNGAgurngu 540 NCGAgurnga 564 NCGAgurngc 588 NCGAgurngg 612 NCGAgurngu 541 ACGAgurnga 565 ACGAgurngc 589 ACGAgurngg 613 ACGAgurngu 542 CCGAgurnga 566 CCGAgurngc 590 CCGAgurngg 614 CCGAgurngu 543 GCGAgurnga 567 GCGAgurngc 591 GCGAgurngg 615 GCGAgurngu 544 UCGAgurnga 568 UCGAgurngc 592 UCGAgurngg 616 UCGAgurngu 545 GNGAgurnga 569 GNGAgurngc 593 GNGAgurngg 617 GNGAgurngu 546 NGGAgurnga 570 NGGAgurngc 594 NGGAgurngg 618 NGGAgurngu 547 AGGAgurnga 571 AGGAgurngo 595 AGGAgurngg 619 AGGAgurngu 548 CGGAgurnga 572 CGGAgurngc 596 CGGAgurngg 620 CGGAgurngu 549 GGGAgurnga 573 GGGAgurngc 597 GGGAgurngg 621 GGGAgurngu 550 UGGAgurnga 574 UGGAgurngc 598 UGGAgurngg 622 UGGAgurngu 551 UNGAgurnga 575 UNGAgurngc 599 UNGAgurngg 623 UNGAgurngu 552 NUGAgurnga 576 NUGAgurngc 600 NUGAgurngg 624 NUGAgurngu 553 AUGAgurnga 577 AUGAgurngc 601 AUGAgurngg 625 AUGAgurngu 554 CUGAgurnga 578 CUGAgurngc 602 CUGAgurngg 626 CUGAgurngu 555 GUGAgurnga 579 GUGAgurngc 603 GUGAgurngg 627 GUGAgurngu 556 UUGAgurnga 580 UUGAgurngc 604 UUGAgurngg 628 UUGAgurngu 629 ANGAguangn 653 ANGAguaagr 677 ANGAguacgn 701 ANGAguaggn 630 NAGAguangn 654 NAGAguaagn 678 NAGAguacgn 702 NAGAguaggn 631 AAGAguangn 655 AAGAguaagn 679 AAGAguacgn 703 AAGAguaggn 632 CAGAguangn 656 CAGAguaagn 680 CAGAguacgn 704 CAGAguaggn 633 GAGAguangn 657 GAGAguaagn 681 GAGAguacgn 705 GAGAguaggn 634 UAGAguangn 658 UAGAguaagn 682 UAGAguacgn 706 UAGAguaggn 635 CNGAguangn 659 CNGAguaagn 683 CNGAguacgn 707 CNGAguaggn 636 NCGAguangn 660 NCGAguaagn 684 NCGAguacgn 708 NCGAguaggn 637 ACGAguangn 661 ACGAguaagn 685 ACGAguacgn 709 ACGAguaggn 638 CCGAguangn 662 CCGAguaagn 686 CCGAguacgn 710 CCGAguaggn 639 GCGAguangn 663 GCGAguaagn 687 GCGAguacgn 711 GCGAguaggn 640 UCGAguangn 664 UCGAguaagn 688 UCGAguacgn 712 UCGAguaggn 641 GNGAguangn 665 GNGAguaagn 689 GNGAguacgn 713 GNGAguaggn 642 NGGAguangn 666 NGGAguaagn 690 NGGAguacgn 714 NGGAguaggn 643 AGGAguangn 667 AGGAguaagn 691 AGGAguacgn 715 AGGAguaggn 644 CGGAguangn 668 CGGAguaagn 692 CGGAguacgn 716 CGGAguaggn 645 GGGAguangn 669 GGGAguaagn 693 GGGAguacgn 717 GGGAguaggn 646 UGGAguangn 670 UGGAguaagn 694 UGGAguacgn 718 UGGAguaggn 647 UNGAguangn 671 UNGAguaagn 695 UNGAguacgn 719 UNGAguaggn 648 NUGAguangn 672 NUGAguaagn 696 NUGAguacgn 720 NUGAguaggn 649 AUGAguangn 673 AUGAguaagn 697 AUGAguacgn 721 AUGAguaggn 650 CUGAguangn 674 CUGAguaagn 698 CUGAguacgn 722 CUGAguaggn 651 GUGAguangn 675 GUGAguaagn 699 GUGAguacgn 723 GUGAguaggn 652 UUGAguangn 676 UUGAguaagn 700 UUGAguacgn 724 UUGAguaggn 725 ANGAguaugn 749 ANGAguaaga 773 ANGAguacga 797 ANGAguagga 726 NAGAguaugn 750 NAGAguaaga 774 NAGAguacga 798 NAGAguagga 727 AAGAguaugn 751 AAGAguaaga 775 AAGAguacga 799 AAGAguagga 728 CAGAguaugn 752 CAGAguaaga 776 CAGAguacga 800 CAGAguagga 729 GAGAguaugn 753 GAGAguaaga 777 GAGAguacga 801 GAGAguagga 730 UAGAguaugn 754 UAGAguaaga 778 UAGAguacga 802 UAGAguagga 731 CNGAguaugn 755 CNGAguaaga 779 CNGAguacga 803 CNGAguagga 732 NCGAguaugn 756 NCGAguaaga 780 NCGAguacga 804 NCGAguagga 733 ACGAguaugn 757 ACGAguaaga 781 ACGAguacga 805 ACGAguagga 734 CCGAguaugn 758 CCGAguaaga 782 CCGAguacga 806 CCGAguagga 735 GCGAguaugn 759 GCGAguaaga 783 GCGAguacga 807 GCGAguagga 736 UCGAguaugr 760 UCGAguaaga 784 UCGAguacga 808 UCGAguagga 737 GNGAguaugn 761 GNGAguaaga 785 GNGAguacga 809 GNGAguagga 738 NGGAguaugn 762 NGGAguaaga 786 NGGAguacga 810 NGGAguagga 739 AGGAguaugn 763 AGGAguaaga 787 AGGAguacga 811 AGGAguagga 740 CGGAguaugn 764 CGGAguaaga 788 CGGAguacga 812 CGGAguagga 741 GGGAguaugn 765 GGGAguaaga 789 GGGAguacga 813 GGGAguagga 742 UGGAguaugn 766 UGGAguaaga 790 UGGAguacga 814 UGGAguagga 743 UNGAguaugn 767 UNGAguaaga 791 UNGAguacga 815 UNGAguagga 744 NUGAguaugn 768 NUGAguaaga 792 NUGAguacga 816 NUGAguagga 745 AUGAguaugn 769 AUGAguaaga 793 AUGAguacga 817 AUGAguagga 746 CUGAguaugn 770 CUGAguaaga 794 CUGAguacga 818 CUGAguagga 747 GUGAguaugn 771 GUGAguaaga 795 GUGAguacga 819 GUGAguagga 748 UUGAguaugn 772 UUGAguaaga 796 UUGAguacga 820 UUGAguagga 821 ANGAguauga 845 ANGAguaagc 869 ANGAguacgc 893 ANGAguaggc 822 NAGAguauga 846 NAGAguaagc 870 NAGAguacgc 894 NAGAguaggc 823 AAGAguauga 847 AAGAguaagc 871 AAGAguacgc 895 AAGAguaggc 824 CAGAguauga 848 CAGAguaagc 872 CAGAguacgc 896 CAGAguaggc 825 GAGAguauga 849 GAGAguaagc 873 GAGAguacgc 897 GAGAguaggc 826 UAGAguauga 850 UAGAguaagc 874 UAGAguacgc 898 UAGAguaggc 827 CNGAguauga 851 CNGAguaagc 875 CNGAguacgc 899 CNGAguaggc 828 NCGAguauga 852 NCGAguaagc 876 NCGAguacgc 900 NCGAguaggc 829 ACGAguauga 853 ACGAguaagc 877 ACGAguacgc 901 ACGAguaggc 830 CCGAguauga 854 CCGAguaagc 878 CCGAguacgc 902 CCGAguaggc 831 GCGAguauga 855 GCGAguaagc 879 GCGAguacgc 903 GCGAguaggc 832 UCGAguauga 856 UCGAguaagc 880 UCGAguacgc 904 UCGAguaggc 833 GNGAguauga 857 GNGAguaagc 881 GNGAguacgc 905 GNGAguaggc 834 NGGAguauga 858 NGGAguaagc 882 NGGAguacgc 906 NGGAguaggc 835 AGGAguauga 859 AGGAguaagc 883 AGGAguacgc 907 AGGAguaggc 836 CGGAguauga 860 CGGAguaagc 884 CGGAguacgc 908 CGGAguaggc 837 GGGAguauga 861 GGGAguaagc 885 GGGAguacgc 909 GGGAguaggc 838 UGGAguauga 862 UGGAguaagc 886 UGGAguacgc 910 UGGAguaggc 839 UNGAguauga 863 UNGAguaagc 887 UNGAguacgc 911 UNGAguaggc 840 NUGAguauga 864 NUGAguaagc 888 NUGAguacgc 912 NUGAguaggc 841 AUGAguauga 865 AUGAguaagc 889 AUGAguacgc 913 AUGAguaggc 842 CUGAguauga 866 CUGAguaagc 890 CUGAguacgc 914 CUGAguaggc 843 GUGAguauga 867 GUGAguaagc 891 GUGAguacgc 915 GUGAguaggc 844 UUGAguauga 868 UUGAguaagc 892 UUGAguacgc 916 UUGAguaggc 917 ANGAguaugc 941 ANGAguaagg 965 ANGAguacgg 989 ANGAguaggg 918 NAGAguaugc 942 NAGAguaagg 966 NAGAguacgg 990 NAGAguaggg 919 AAGAguaugc 943 AAGAguaagg 967 AAGAguacgg 991 AAGAguaggg 920 CAGAguaugc 944 CAGAguaagg 968 CAGAguacgg 992 CAGAguaggg 921 GAGAguaugc 945 GAGAguaagg 969 GAGAguacgg 993 GAGAguaggg 922 UAGAguaugc 946 UAGAguaagg 970 UAGAguacgg 994 UAGAguaggg 923 CNGAguaugc 947 CNGAguaagg 971 CNGAguacgg 995 CNGAguaggg 924 NCGAguaugc 948 NCGAguaagg 972 NCGAguacgg 996 NCGAguaggg 925 ACGAguaugc 949 ACGAguaagg 973 ACGAguacgg 997 ACGAguaggg 926 CCGAguaugc 950 CCGAguaagg 974 CCGAguacgg 998 CCGAguaggg 927 GCGAguaugc 951 GCGAguaagg 975 GCGAguacgg 999 GCGAguaggg 928 UCGAguaugc 952 UCGAguaagg 976 UCGAguacgg 1000 UCGAguaggg 929 GNGAguaugc 953 GNGAguaagg 977 GNGAguacgg 1001 GNGAguaggg 930 NGGAguaugc 954 NGGAguaagg 978 NGGAguacgg 1002 NGGAguaggg 931 AGGAguaugc 955 AGGAguaagg 979 AGGAguacgg 1003 AGGAguaggg 932 CGGAguaugc 956 CGGAguaagg 980 CGGAguacgg 1004 CGGAguaggg 933 GGGAguaugc 957 GGGAguaagg 981 GGGAguacgg 1005 GGGAguaggg 934 UGGAguaugc 958 UGGAguaagg 982 UGGAguacgg 1006 UGGAguaggg 935 UNGAguaugc 959 UNGAguaagg 983 UNGAguacgg 1007 UNGAguaggg 936 NUGAguaugc 960 NUGAguaagg 984 NUGAguacgg 1008 NUGAguaggg 937 AUGAguaugc 961 AUGAguaagg 985 AUGAguacgg 1009 AUGAguaggg 938 CUGAguaugc 962 CUGAguaagg 986 CUGAguacgg 1010 CUGAguaggg 939 GUGAguaugc 963 GUGAguaagg 987 GUGAguacgg 1011 GUGAguaggg 940 UUGAguaugc 964 UUGAguaagg 988 UUGAguacgg 1012 UUGAguaggg 1013 ANGAguaugg 1037 ANGAguaagu 1061 ANGAguacgu 1085 ANGAguaggu 1014 NAGAguaugg 1038 NAGAguaagu 1062 NAGAguacgu 1086 NAGAguaggu 1015 AAGAguaugg 1039 AAGAguaagu 1063 AAGAguacgu 1087 AAGAguaggu 1016 CAGAguaugg 1040 CAGAguaagu 1064 CAGAguacgu 1088 CAGAguaggu 1017 GAGAguaugg 1041 GAGAguaagu 1065 GAGAguacgu 1089 GAGAguaggu 1018 UAGAguaugg 1042 UAGAguaagu 1066 UAGAguacgu 1090 UAGAguaggu 1019 CNGAguaugg 1043 CNGAguaagu 1067 CNGAguacgu 1091 CNGAguaggu 1020 NCGAguaugg 1044 NCGAguaagu 1068 NCGAguacgu 1092 NCGAguaggu 1021 ACGAguaugg 1045 ACGAguaagu 1069 ACGAguacgu 1093 ACGAguaggu 1022 CCGAguaugg 1046 CCGAguaagu 1070 CCGAguacgu 1094 CCGAguaggu 1023 GCGAguaugg 1047 GCGAguaagu 1071 GCGAguacgu 1095 GCGAguaggu 1024 UCGAguaugg 1048 UCGAguaagu 1072 UCGAguacgu 1096 UCGAguaggu 1025 GNGAguaugg 1049 GNGAguaagu 1073 GNGAguacgu 1097 GNGAguaggu 1026 NGGAguaugg 1050 NGGAguaagu 1074 NGGAguacgu 1098 NGGAguaggu 1027 AGGAguaugg 1051 AGGAguaagu 1075 AGGAguacgu 1099 AGGAguaggu 1028 CGGAguaugg 1052 CGGAguaagu 1076 CGGAguacgu 1100 CGGAguaggu 1029 GGGAguaugg 1053 GGGAguaagu 1077 GGGAguacgu 1101 GGGAguaggu 1030 UGGAguaugg 1054 UGGAguaagu 1078 UGGAguacgu 1102 UGGAguaggu 1031 UNGAguaugg 1055 UNGAguaagu 1079 UNGAguacgu 1103 UNGAguaggu 1032 NUGAguaugg 1056 NUGAguaagu 1080 NUGAguacgu 1104 NUGAguaggu 1033 AUGAguaugg 1057 AUGAguaagu 1081 AUGAguacgu 1105 AUGAguaggu 1034 CUGAguaugg 1058 CUGAguaagu 1082 CUGAguacgu 1106 CUGAguaggu 1035 GUGAguaugg 1059 GUGAguaagu 1083 GUGAguacgu 1107 GUGAguaggu 1036 UUGAguaugg 1060 UUGAguaagu 1084 UUGAguacgu 1108 UUGAguaggu 1109 ANGAguaugu 1133 ANGAguanga 1157 ANGAguangc 1181 ANGAguangg 1110 NAGAguaugu 1134 NAGAguanga 1158 NAGAguangc 1182 NAGAguangg 1111 AAGAguaugu 1135 AAGAguanga 1159 AAGAguangc 1183 AAGAguangg 1112 CAGAguaugu 1136 CAGAguanga 1160 CAGAguangc 1184 CAGAguangg 1113 GAGAguaugu 1137 GAGAguanga 1161 GAGAguangc 1185 GAGAguangg 1114 UAGAguaugu 1138 UAGAguanga 1162 UAGAguangc 1186 UAGAguangg 1115 CNGAguaugu 1139 CNGAguanga 1163 CNGAguangc 1187 CNGAguangg 1116 NCGAguaugu 1140 NCGAguanga 1164 NCGAguangc 1188 NCGAguangg 1117 ACGAguaugu 1141 ACGAguanga 1165 ACGAguang 1189 ACGAguangg 1118 CCGAguaugu 1142 CCGAguanga 1166 CCGAguangc 1190 CCGAguangg 1119 GCGAguaugu 1143 GCGAguanga 1167 GCGAguangc 1191 GCGAguangg 1120 UCGAguaugu 1144 UCGAguanga 1168 UCGAguangc 1192 UCGAguangg 1121 GNGAguaugu 1145 GNGAguanga 1169 GNGAguangc 1193 GNGAguangg 1122 NGGAguaugu 1146 NGGAguanga 1170 NGGAguangc 1194 NGGAguangg 1123 AGGAguaugu 1147 AGGAguanga 1171 AGGAguangc 1195 AGGAguangg 1124 CGGAguaugu 1148 CGGAguanga 1172 CGGAguangc 1196 CGGAguangg 1125 GGGAguaugu 1149 GGGAguanga 1173 GGGAguangc 1197 GGGAguangg 1126 UGGAguaugu 1150 UGGAguanga 1174 UGGAguangc 1198 UGGAguangg 1127 UNGAguaugu 1151 UNGAguanga 1175 UNGAguangc 1199 UNGAguangg 1128 NUGAguaugu 1152 NUGAguanga 1176 NUGAguangc 1200 NUGAguangg 1129 AUGAguaugu 1153 AUGAguanga 1177 AUGAguangc 1201 AUGAguangg 1130 CUGAguaugu 1154 CUGAguanga 1178 CUGAguangc 1202 CUGAguangg 1131 GUGAguaugu 1155 GUGAguanga 1179 GUGAguangc 1203 GUGAguangg 1132 UUGAguaugu 1156 UUGAguanga 1180 UUGAguangc 1204 UUGAguangg 1205 ANGAguangu 1229 ANGAgugngn 1253 ANGAgugagn 1277 ANGAgugcgn 1206 NAGAguangu 1230 NAGAgugngn 1254 NAGAgugagn 1278 NAGAgugcgn 1207 AAGAguangu 1231 AAGAgugngn 1255 AAGAgugagn 1279 AAGAgugcgn 1208 CAGAguangu 1232 CAGAgugngn 1256 CAGAgugagn 1280 CAGAgugcgn 1209 GAGAguangu 1233 GAGAgugngn 1257 GAGAgugagn 1281 GAGAgugcgn 1210 UAGAguangu 1234 UAGAgugngn 1258 UAGAgugagn 1282 UAGAgugcgn 1211 CNGAguangu 1235 CNGAgugngn 1259 CNGAgugagn 1283 CNGAgugcgn 1212 NCGAguangu 1236 NCGAgugngn 1260 NCGAgugagn 1284 NCGAgugcgn 1213 ACGAguangu 1237 ACGAgugngn 1261 ACGAgugagn 1285 ACGAgugcgn 1214 CCGAguangu 1238 CCGAgugngn 1262 CCGAgugagn 1286 CCGAgugcgn 1215 GCGAguangu 1239 GCGAgugngn 1263 GCGAgugagn 1287 GCGAgugcgn 1216 UCGAguangu 1240 UCGAgugngn 1264 UCGAgugagn 1288 UCGAgugcgn 1217 GNGAguangu 1241 GNGAgugngn 1265 GNGAgugagn 1289 GNGAgugcgn 1218 NGGAguangu 1242 NGGAgugngn 1266 NGGAgugagn 1290 NGGAgugcgn 1219 AGGAguangu 1243 AGGAgugngn 1267 AGGAgugagn 1291 AGGAgugcgn 1220 CGGAguangu 1244 CGGAgugngn 1268 CGGAgugagn 1292 CGGAgugcgn 1221 GGGAguangu 1245 GGGAgugngn 1269 GGGAgugagn 1293 GGGAgugegn 1222 UGGAguangu 1246 UGGAgugngn 1270 UGGAgugagn 1294 UGGAgugcgn 1223 UNGAguangu 1247 UNGAgugngn 1271 UNGAgugagn 1295 UNGAgugcgn 1224 NUGAguangu 1248 NUGAgugngn 1272 NUGAgugagn 1296 NUGAgugcgn 1225 AUGAguangu 1249 AUGAgugngn 1273 AUGAgugagn 1297 AUGAgugcgn 1226 CUGAguangu 1250 CUGAgugngn 1274 CUGAgugagn 1298 CUGAgugcgn 1227 GUGAguangu 1251 GUGAgugngn 1275 GUGAgugagn 1299 GUGAgugcgn 1228 UUGAguangu 1252 UUGAgugngn 1276 UUGAgugagn 1300 UUGAgugcgn 1301 ANGAgugggn 1325 ANGAgugugn 1349 ANGAgugaga 1373 ANGAgugcga 1302 NAGAgugggn 1326 NAGAgugugn 1350 NAGAgugaga 1374 NAGAgugcga 1303 AAGAgugggn 1327 AAGAgugugn 1351 AAGAgugaga 1375 AAGAgugcga 1304 CAGAgugggn 1328 CAGAgugugn 1352 CAGAgugaga 1376 CAGAgugcga 1305 GAGAgugggn 1329 GAGAgugugn 1353 GAGAgugaga 1377 GAGAgugcga 1306 UAGAgugggn 1330 UAGAgugugn 1354 UAGAgugaga 1378 UAGAgugcga 1307 CNGAgugggn 1331 CNGAgugugn 1355 CNGAgugaga 1379 CNGAgugcga 1308 NCGAgugggn 1332 NCGAgugugn 1356 NCGAgugaga 1380 NCGAgugcga 1309 ACGAgugggn 1333 ACGAgugugn 1357 ACGAgugaga 1381 ACGAgugcga 1310 CCGAgugggn 1334 CCGAgugugn 1358 CCGAgugaga 1382 CCGAgugcga 1311 GCGAgugggn 1335 GCGAgugugn 1359 GCGAgugaga 1383 GCGAgugcga 1312 UCGAgugggn 1336 UCGAgugugn 1360 UCGAgugaga 1384 UCGAgugcga 1313 GNGAgugggn 1337 GNGAgugugn 1361 GNGAgugaga 1385 GNGAgugcga 1314 NGGAgugggn 1338 NGGAgugugn 1362 NGGAgugaga 1386 NGGAgugcga 1315 AGGAgugggn 1339 AGGAgugugn 1363 AGGAgugaga 1387 AGGAgugcga 1316 CGGAgugggn 1340 CGGAgugugn 1364 CGGAgugaga 1388 CGGAgugcga 1317 GGGAgugggn 1341 GGGAgugugn 1365 GGGAgugaga 1389 GGGAgugcga 1318 UGGAgugggn 1342 UGGAgugugn 1366 UGGAgugaga 1390 UGGAgugcga 1319 UNGAgugggn 1343 UNGAgugugn 1367 UNGAgugaga 1391 UNGAgugcga 1320 NUGAgugggn 1344 NUGAgugugn 1368 NUGAgugaga 1392 NUGAgugcga 1321 AUGAgugggn 1345 AUGAgugugn 1369 AUGAgugaga 1393 AUGAgugcga 1322 CUGAgugggn 1346 CUGAgugugn 1370 CUGAgugaga 1394 CUGAgugcga 1323 GUGAgugggn 1347 GUGAgugugn 1371 GUGAgugaga 1395 GUGAgugcga 1324 UUGAgugggn 1348 UUGAgugugn 1372 UUGAgugaga 1396 UUGAgugcga 1397 ANGAguggga 1421 ANGAguguga 1445 ANGAgugagc 1469 ANGAgugcgc 1398 NAGAguggga 1422 NAGAguguga 1446 NAGAgugagc 1470 NAGAgugcgc 1399 AAGAguggga 1423 AAGAguguga 1447 AAGAgugagc 1471 AAGAgugcgc 1400 CAGAguggga 1424 CAGAguguga 1448 CAGAgugagc 1472 CAGAgugcgc 1401 GAGAguggga 1425 GAGAguguga 1449 GAGAgugagc 1473 GAGAgugcgc 1402 UAGAguggga 1426 UAGAguguga 1450 UAGAgugagc 1474 UAGAgugcgc 1403 CNGAguggga 1427 CNGAguguga 1451 CNGAgugagc 1475 CNGAgugcgc 1404 NCGAguggga 1428 NCGAguguga 1452 NCGAgugagc 1476 NCGAgugcgc 1405 ACGAguggga 1429 ACGAguguga 1453 ACGAgugagc 1477 ACGAgugcgc 1406 CCGAguggga 1430 CCGAguguga 1454 CCGAgugagc 1478 CCGAgugcgc 1407 GCGAguggga 1431 GCGAguguga 1455 GCGAgugagc 1479 GCGAgugcgc 1408 UCGAguggga 1432 UCGAguguga 1456 UCGAgugagc 1480 UCGAgugcgc 1409 GNGAguggga 1433 GNGAguguga 1457 GNGAgugagc 1481 GNGAgugcgc 1410 NGGAguggga 1434 NGGAguguga 1458 NGGAgugagc 1482 NGGAgugcgc 1411 AGGAguggga 1435 AGGAguguga 1459 AGGAgugagc 1483 AGGAgugcgc 1412 CGGAguggga 1436 CGGAguguga 1460 CGGAgugagc 1484 CGGAgugcgc 1413 GGGAguggga 1437 GGGAguguga 1461 GGGAgugagc 1485 GGGAgugcgc 1414 UGGAguggga 1438 UGGAguguga 1462 UGGAgugagc 1486 UGGAgugcgc 1415 UNGAguggga 1439 UNGAguguga 1463 UNGAgugagc 1487 UNGAgugcgc 1416 NUGAguggga 1440 NUGAguguga 1464 NUGAgugagc 1488 NUGAgugcgc 1417 AUGAguggga 1441 AUGAguguga 1465 AUGAgugagc 1489 AUGAgugcgc 1418 CUGAguggga 1442 CUGAguguga 1466 CUGAgugagc 1490 CUGAgugcgc 1419 GUGAguggga 1443 GUGAguguga 1467 GUGAgugagc 1491 GUGAgugcgc 1420 UUGAguggga 1444 UUGAguguga 1468 UUGAgugagc 1492 UUGAgugcgc 1493 ANGAgugggc 1517 ANGAgugugc 1541 ANGAgugagg 1565 ANGAgugcgg 1494 NAGAgugggc 1518 NAGAgugugc 1542 NAGAgugagg 1566 NAGAgugcgg 1495 AAGAgugggc 1519 AAGAgugugc 1543 AAGAgugagg 1567 AAGAgugcgg 1496 CAGAgugggc 1520 CAGAgugugc 1544 CAGAgugagg 1568 CAGAgugcgg 1497 GAGAgugggc 1521 GAGAgugugc 1545 GAGAgugagg 1569 GAGAgugcgg 1498 UAGAgugggc 1522 UAGAgugugc 1546 UAGAgugagg 1570 UAGAgugcgg 1499 CNGAgugggc 1523 CNGAgugugc 1547 CNGAgugagg 1571 CNGAgugcgg 1500 NCGAguggg 1524 NCGAgugugc 1548 NCGAgugagg 1572 NCGAgugcgg 1501 ACGAgugggc 1525 ACGAgugugc 1549 ACGAgugagg 1573 ACGAgugcgg 1502 CCGAgugggc 1526 CCGAgugugc 1550 CCGAgugagg 1574 CCGAgugcgg 1503 GCGAgugggc 1527 GCGAgugugc 1551 GCGAgugagg 1575 GCGAgugcgg 1504 UCGAgugggc 1528 UCGAgugugc 1552 UCGAgugagg 1576 UCGAgugcgg 1505 GNGAgugggc 1529 GNGAgugugc 1553 GNGAgugagg 1577 GNGAgugcgg 1506 NGGAgugggc 1530 NGGAgugugc 1554 NGGAgugagg 1578 NGGAgugcgg 1507 AGGAgugggc 1531 AGGAgugugc 1555 AGGAgugagg 1579 AGGAgugcgg 1508 CGGAgugggc 1532 CGGAgugugc 1556 CGGAgugagg 1580 CGGAgugcgg 1509 GGGAgugggc 1533 GGGAgugugc 1557 GGGAgugagg 1581 GGGAgugcgg 1510 UGGAgugggc 1534 UGGAgugugc 1558 UGGAgugagg 1582 UGGAgugcgg 1511 UNGAgugggc 1535 UNGAgugugc 1559 UNGAgugagg 1583 UNGAgugcgg 1512 NUGAgugggc 1536 NUGAgugugc 1560 NUGAgugagg 1584 NUGAgugcgg 1513 AUGAgugggc 1537 AUGAgugugc 1561 AUGAgugagg 1585 AUGAgugcgg 1514 CUGAgugggo 1538 CUGAgugugc 1562 CUGAgugagg 1586 CUGAgugcgg 1515 GUGAgugggc 1539 GUGAgugugc 1563 GUGAgugagg 1587 GUGAgugcgg 1516 UUGAgugggc 1540 UUGAgugugc 1564 UUGAgugagg 1588 UUGAgugcgg 1589 ANGAgugggg 1613 ANGAgugugg 1637 ANGAgugagu 1661 ANGAgugcgu 1590 NAGAgugggg 1614 NAGAgugugg 1638 NAGAgugagu 1662 NAGAgugcgu 1591 AAGAgugggg 1615 AAGAgugugg 1639 AAGAgugagu 1663 AAGAgugcgu 1592 CAGAgugggg 1616 CAGAgugugg 1640 CAGAgugagu 1664 CAGAgugcgu 1593 GAGAgugggg 1617 GAGAgugugg 1641 GAGAgugagu 1665 GAGAgugcgu 1594 UAGAgugggg 1618 UAGAgugugg 1642 UAGAgugagu 1666 UAGAgugcgu 1595 CNGAgugggg 1619 CNGAgugugg 1643 CNGAgugagu 1667 CNGAgugcgu 1596 NCGAgugggg 1620 NCGAgugugg 1644 NCGAgugagu 1668 NCGAgugcgu 1597 ACGAgugggg 1621 ACGAgugugg 1645 ACGAgugagu 1669 ACGAgugcgu 1598 CCGAgugggg 1622 CCGAgugugg 1646 CCGAgugagu 1670 CCGAgugcgu 1599 GCGAgugggg 1623 GCGAgugugg 1647 GCGAgugagu 1671 GCGAgugcgu 1600 UCGAgugggg 1624 UCGAgugugg 1648 UCGAgugagu 1672 UCGAgugcgu 1601 GNGAgugggg 1625 GNGAgugugg 1649 GNGAgugagu 1673 GNGAgugcgu 1602 NGGAgugggg 1626 NGGAgugugg 1650 NGGAgugagu 1674 NGGAgugcgu 1603 AGGAgugggg 1627 AGGAgugugg 1651 AGGAgugagul 1675 AGGAgugcgu 1604 CGGAgugggg 1628 CGGAgugugg 1652 CGGAgugagu 1676 CGGAgugcgu 1605 GGGAgugggg 1629 GGGAgugugg 1653 GGGAgugagu 1677 GGGAgugcgu 1606 UGGAgugggg 1630 UGGAgugugg 1654 UGGAgugagu 1678 UGGAgugcgu 1607 UNGAgugggg 1631 UNGAgugugg 1655 UNGAgugagu 1679 UNGAgugcgu 1608 NUGAgugggg 1632 NUGAgugugg 1656 NUGAgugagu 1680 NUGAgugcgu 1609 AUGAgugggg 1633 AUGAgugugg 1657 AUGAgugagu 1681 AUGAgugcgu 1610 CUGAgugggg 1634 CUGAgugugg 1658 CUGAgugagu 1682 CUGAgugcgu 1611 GUGAgugggg 1635 GUGAgugugg 1659 GUGAgugagu 1683 GUGAgugcgu 1612 UUGAgugggg 1636 UUGAgugugg 1660 UUGAgugagu 1684 UUGAgugcgu 1685 ANGAgugggu 1709 ANGAgugugu 1733 ANGAgugnga 1757 ANGAgugngc 1686 NAGAgugggu 1710 NAGAgugugu 1734 NAGAgugnga 1758 NAGAgugngc 1687 AAGAgugggu 1711 AAGAgugugu 1735 AAGAgugnga 1759 AAGAgugngc 1688 CAGAgugggu 1712 CAGAgugugu 1736 CAGAgugnga 1760 CAGAgugngc 1689 GAGAgugggu 1713 GAGAgugugu 1737 GAGAgugnga 1761 GAGAgugngc 1690 UAGAgugggu 1714 UAGAgugugu 1738 UAGAgugnga 1762 UAGAgugngc 1691 CNGAgugggu 1715 CNGAgugugu 1739 CNGAgugnga 1763 CNGAgugngc 1692 NCGAgugggu 1716 NCGAgugugu 1740 NCGAgugnga 1764 NCGAgugngc 1693 ACGAgugggu 1717 ACGAgugugu 1741 ACGAgugnga 1765 ACGAgugngc 1694 CCGAgugggu 1718 CCGAgugugu 1742 CCGAgugnga 1766 CCGAgugngc 1695 GCGAgugggu 1719 GCGAgugugu 1743 GCGAgugnga 1767 GCGAgugngc 1696 UCGAgugggu 1720 UCGAgugugu 1744 UCGAgugnga 1768 UCGAgugngc 1697 GNGAgugggu 1721 GNGAgugugu 1745 GNGAgugnga 1769 GNGAgugngc 1698 NGGAgugggu 1722 NGGAgugugu 1746 NGGAgugnga 1770 NGGAgugngc 1699 AGGAguggg? 1723 AGGAgugugu 1747 AGGAgugnga 1771 AGGAgugngc 1700 CGGAgugggu 1724 CGGAgugugu 1748 CGGAgugnga 1772 CGGAgugngc 1701 GGGAgugggu 1725 GGGAgugugu 1749 GGGAgugnga 1773 GGGAgugngc 1702 UGGAgugggu 1726 UGGAgugugu 1750 UGGAgugnga 1774 UGGAgugngc 1703 UNGAgugggu 1727 UNGAgugugu 1751 UNGAgugnga 1775 UNGAgugngc 1704 NUGAgugggu 1728 NUGAgugugu 1752 NUGAgugnga 1776 NUGAgugngc 1705 AUGAgugggu 1729 AUGAgugugu 1753 AUGAgugnga 1777 AUGAgugngc 1706 CUGAgugggu 1730 CUGAgugugu 1754 CUGAgugnga 1778 CUGAgugngc 1707 GUGAgugggu 1731 GUGAgugugu 1755 GUGAgugnga 1779 GUGAgugngc 1708 UUGAgugggu 1732 UUGAgugugu 1756 UUGAgugnga 1780 UUGAgugngc 1781 ANGAgugngg 1793 GNGAgugngg 1805 ANGAgugngu 1817 GNGAgugngu 1782 NAGAgugngg 1794 NGGAgugngg 1806 NAGAgugngu 1818 NGGAgugngu 1783 AAGAgugngg 1795 AGGAgugngg 1807 AAGAgugngu 1819 AGGAgugngu 1784 CAGAgugngg 1796 CGGAgugngg 1808 CAGAgugngu 1820 CGGAgugngu 1785 GAGAgugngg 1797 GGGAgugngg 1809 GAGAgugngu 1821 GGGAgugngu 1786 UAGAgugngg 1798 UGGAgugngg 1810 UAGAgugngu 1822 UGGAgugngu 1787 CNGAgugngg 1799 UNGAgugngg 1811 CNGAgugngu 1823 UNGAgugngu 1788 NCGAgugngg 1800 NUGAgugngg 1812 NCGAgugngu 1824 NUGAgugngu 1789 ACGAgugngg 1801 AUGAgugngg 1813 ACGAgugngu 1825 AUGAgugngu 1790 CCGAgugngg 1802 CUGAgugngg 1814 CCGAgugngu 1826 CUGAgugngu 1791 GCGAgugngg 1803 GUGAgugngg 1815 GCGAgugngu 1827 GUGAgugngu 1792 UCGAgugngg 1804 UUGAgugngg 1816 UCGAgugngu 1828 UUGAgugngu

In one embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, by way of nonlimiting example, disclosed in Table 1, infra, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 16 or Tables 2-7, infra, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 1, infra, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene disclosed in Table 7, infra, comprising contacting a cell with a compound of Formula (I) or a form thereof. See the example section for additional information regarding the genes in Table 7. In certain embodiments, the cell is contacted with the compound of Formula (I) or a form thereof in a cell culture. In other embodiments, the cell is contacted with the compound of Formula (I) or a form thereof in a subject (e.g., a non-human animal subject or a human subject). In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described infra. In some embodiments, a compound of Formula (I) is a compound selected from a compound described herein.

In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, by way of nonlimiting example, disclosed in Table 1, infra, the methods comprising administering to a human or non-human subject thereof a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Tables 2-7, infra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject thereof a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 1, infra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene disclosed in Table 7, infra, comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described infra. In some embodiments, a compound of Formula (I) is a compound selected from a compound described herein.

In another embodiment, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer).

In another embodiment, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first branch point, a first 3′ splice site, and an iREMS, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer).

In another embodiment, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, and wherein the RNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer).

In another embodiment, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, and wherein the RNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer).

In another embodiment, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises three exons and two introns, and wherein the RNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising contacting the RNA transcript with a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer).

In a specific embodiment, the RNA transcript is the RNA transcript of a gene described in a table in this disclosure.

In another embodiment, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or a protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, a nucleotide sequence encoding an IREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, and a nucleotide sequence encoding an iREMS, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for modulating the amount of the product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In a specific embodiment, the gene is a gene described in a table in this disclosure.

In another aspect, provided herein are methods for preventing and/or treating a disease associated with the aberrant expression of a product of a gene (e.g., an mRNA transcript or protein), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in Table 1, infra, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), disclosed in Tables 2-7, infra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), disclosed in Table 1, infra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene disclosed in Table 7, infra, (e.g., an mRNA, RNA transcript or protein), comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described infra. In some embodiments, a compound of Formula (I) is a compound selected from a compound described herein.

In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, by way of nonlimiting example, disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in Tables 2-7, infra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, one, two, three or more RNA isoforms encoded by a gene disclosed in Table 7, infra, are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described infra. In some embodiments, a compound of Formula (I) is a compound selected from a compound described herein.

In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In one embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, by way of nonlimiting example, disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Tables 2-7, infra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Table 1, infra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 7, infra, are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described infra. In some embodiments, a compound of Formula (I) is a compound selected from a compound described herein.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, a nucleotide sequence encoding an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, and a nucleotide sequence encoding an iREMS, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof or another splicing inducer) to the subject.

In a specific embodiment, the gene is a gene described in a table in this disclosure.

In another aspect, provided herein are artificial gene constructs. In one embodiment, provided herein is an artificial gene construct comprising endogenous DNA is modified to introduce a non-endogenous nucleotide sequence encoding an intron comprising a 3′ splice site(s) and a branch point(s) and an intronic REMS. In another embodiment, provided herein is an artificial gene construct comprising DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, functioning as a 5′ splice site in the presence of a compound described herein, which may be upstream of an endogenous nucleotide sequence encoding a branch point and an endogenous nucleotide sequence encoding a 3′ splice site, is modified to introduce a nucleotide sequence encoding a non-endogenous branch point and a non-endogenous 3′ splice site further upstream from the endogenous intronic REMS. In another embodiment, provided herein is an artificial gene construct comprising DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS 5′ splice site, which may be downstream of an endogenous nucleotide sequence encoding a branch point and an endogenous nucleotide sequence encoding a 3′ splice site, is modified to introduce a nucleotide sequence encoding a non-endogenous branch point and a non-endogenous 3′ splice site further downstream from the endogenous intronic REMS. In another embodiment, provided herein is an artificial gene construct comprising DNA encoding an intronic REMS, comprising nucleotides encoding an intronic REMS having one or more 5′ splice site(s), 3′ splice site(s) and branch point(s). In certain embodiments, the artificial gene construct encodes a frameshift or premature stop codon or internal insertions or deletions within the open reading frame. In other embodiments, the artificial gene construct encodes a mature mRNA having a functional open reading frame, producing a novel protein which may or may not be functional. In some embodiments, the artificial gene construct encodes a detectable reporter protein. RNA transcripts having a non-functional open reading frame due to the inclusion of a frameshift, premature stop codon or internal insertions or deletions within the open reading frame can be substrates for nonsense-mediated decay and thus have low abundance. Any intronic REMS-mediated alternative splicing modified RNA transcripts may also have altered stability, altered intracellular transport, altered 3′ end formation efficiency and altered translation efficiency.

In a specific embodiment, the nucleotide sequence of the intronic REMS introduced into the nucleotide sequence of the artificial gene construct comprises the sequence NNGAgtrngn (SEQ ID NO: 3), wherein r is adenine or guanine and n or N is any nucleotide. In a specific embodiment, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1829), CNGAgtrngn (SEQ ID NO: 1835), GNGAgtrngn (SEQ ID NO: 1841), TNGAgtrngn (SEQ ID NO: 1847), NAGAgtrngn (SEQ ID NO: 1830), NCGAgtrngn (SEQ ID NO: 1836), NGGAgtrngn (SEQ ID NO: 1842), NTGAgtrngn (SEQ ID NO: 1848), AAGAgtrngn (SEQ ID NO: 1831), ACGAgtrngn (SEQ ID NO: 1837), AGGAgtrngn (SEQ ID NO: 1843), ATGAgtrngn (SEQ ID NO: 1849), CAGAgtrngn (SEQ ID NO: 1832), CCGAgtrngn (SEQ ID NO: 1838), CGGAgtrngn (SEQ ID NO: 1844), CTGAgtrngn (SEQ ID NO: 1850), GAGAgtrngn (SEQ ID NO: 1833), GCGAgtrngn (SEQ ID NO: 1839), GGGAgtrngn (SEQ ID NO: 1845), GTGAgtrngn (SEQ ID NO: 1851), TAGAgtrngn (SEQ ID NO: 1834), TCGAgtrngn (SEQ ID NO: 1840), TGGAgtrngn (SEQ ID NO: 1846) and TTGAgtrngn (SEQ ID NO: 1852), wherein r is adenine or guanine and n or N is any nucleotide.

In a further specific embodiment, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 2237), CNGAgtragt (SEQ ID NO: 2243), GNGAgtragt (SEQ ID NO: 2249), TNGAgtragt (SEQ ID NO: 2255), NAGAgtragt (SEQ ID NO: 2238), NCGAgtragt (SEQ ID NO: 2244), NGGAgtragt (SEQ ID NO: 2250), NTGAgtragt (SEQ ID NO: 2256), AAGAgtragt (SEQ ID NO: 2239), ACGAgtragt (SEQ ID NO: 2245), AGGAgtragt (SEQ ID NO: 2251), ATGAgtragt (SEQ ID NO: 2257), CAGAgtragt (SEQ ID NO: 2240), CCGAgtragt (SEQ ID NO: 2246), CGGAgtragt (SEQ ID NO: 2252), CTGAgtragt (SEQ ID NO: 2258), GAGAgtragt (SEQ ID NO: 2241), GCGAgtragt (SEQ ID NO: 2247), GGGAgtragt (SEQ ID NO: 2253), GTGAgtragt (SEQ ID NO: 2259), TAGAgtragt (SEQ ID NO: 2242), TCGAgtragt (SEQ ID NO: 2248), TGGAgtragt (SEQ ID NO: 2254) and TTGAgtragt (SEQ ID NO: 2260), wherein r is adenine or guanine and N is any nucleotide. In one or more embodiments provided herein, N is adenine or guanine. In various specific embodiments, the nucleotide sequence encoding the intronic REMS is a nucleotide sequence encoding a non-endogenous intronic REMS, i.e., a precursor RNA transcript comprising the non-endogenous intronic REMS not naturally found in the DNA sequence of the artificial construct.

In a specific embodiment, the intronic REMS referred to in a method or artificial gene construct described herein comprises, at the DNA level, a sequence presented in the following table (wherein r is adenine or guanine, and n or N is any nucleotide):

TABLE 14 Intronic REMS DNA sequence (wherein r is adenine or guanine, and n or N is any nucleotide) SEQ ID SEQ ID SEQ ID SEQ ID NO. Sequence NO. Sequence NO. Sequence NO. Sequence 1829 ANGAgtrngn 1835 CNGAgtrngn 1841 GNGAgtrngn 1847 TNGAgtrngn 1830 NAGAgtrngn 1836 NCGAgtrngn 1842 NGGAgtrngn 1848 NTGAgtrngn 1831 AAGAgtrngn 1837 ACGAgtrngn 1843 AGGAgtrngn 1849 ATGAgtrngn 1832 CAGAgtrngn 1838 CCGAgtrngn 1844 CGGAgtrngn 1850 CTGAgtrngn 1833 GAGAgtrngn 1839 GCGAgtrngn 1845 GGGAgtrngn 1851 GTGAgtrngn 1834 TAGAgtrngn 1840 TCGAgtrngn 1846 TGGAgtrngn 1852 TTGAgtrngn 1853 ANGAgtragn 1877 ANGAgtrcgn 1901 ANGAgtrggn 1925 ANGAgtrtgn 1854 NAGAgtragn 1878 NAGAgtrcgn 1902 NAGAgtrggn 1926 NAGAgtrtgn 1855 AAGAgtragn 1879 AAGAgtrcgn 1903 AAGAgtrggn 1927 AAGAgtrtgn 1856 CAGAgtragn 1880 CAGAgtrcgn 1904 CAGAgtrggn 1928 CAGAgtrtgn 1857 GAGAgtragn 1881 GAGAgtrcgn 1905 GAGAgtrggn 1929 GAGAgtrtgn 1858 TAGAgtragn 1882 TAGAgtregn 1906 TAGAgtrggn 1930 TAGAgtrtgn 1859 CNGAgtragn 1883 CNGAgtrcgn 1907 CNGAgtrggn 1931 CNGAgtrtgn 1860 NCGAgtragn 1884 NCGAgtrcgn 1908 NCGAgtrggn 1932 NCGAgtrtgn 1861 ACGAgtragn 1885 ACGAgtrcgn 1909 ACGAgtrggn 1933 ACGAgtrtgn 1862 CCGAgtragn 1886 CCGAgtrcgn 1910 CCGAgtrggn 1934 CCGAgtrtgn 1863 GCGAgtragn 1887 GCGAgtrcgn 1911 GCGAgtrggn 1935 GCGAgtrtgn 1864 TCGAgtragn 1888 TCGAgtrcgn 1912 TCGAgtrggn 1936 TCGAgtrtgn 1865 GNGAgtragn 1889 GNGAgtrcgn 1913 GNGAgtrggn 1937 GNGAgtrtgn 1866 NGGAgtragn 1890 NGGAgtrcgn 1914 NGGAgtrggn 1938 NGGAgtrtgn 1867 AGGAgtragn 1891 AGGAgtrcgn 1915 AGGAgtrggn 1939 AGGAgtrtgn 1868 CGGAgtragn 1892 CGGAgtrcgn 1916 CGGAgtrggn 1940 CGGAgtrtgn 1869 GGGAgtragn 1893 GGGAgtrcgn 1917 GGGAgtrggn 1941 GGGAgtrtgn 1870 TGGAgtragn 1894 TGGAgtrcgn 1918 TGGAgtrggn 1942 TGGAgtrtgn 1871 TNGAgtragn 1895 TNGAgtrcgn 1919 TNGAgtrggn 1943 TNGAgtrtgn 1872 NTGAgtragn 1896 NTGAgtrcgn 1920 NTGAgtrggn 1944 NTGAgtrtgn 1873 ATGAgtragn 1897 ATGAgtrcgn 1921 ATGAgtrggn 1945 ATGAgtrtgn 1874 CTGAgtragn 1898 CTGAgtregn 1922 CTGAgtrggn 1946 CTGAgtrtgn 1875 GTGAgtragn 1899 GTGAgtrcgn 1923 GTGAgtrggn 1947 GTGAgtrtgn 1876 TTGAgtragn 1900 TTGAgtrcgn 1924 TTGAgtrggn 1948 TTGAgtrtgn 1949 ANGAgtraga 1973 ANGAgtrcga 1997 ANGAgtrgga 2021 ANGAgtrtga 1950 NAGAgtraga 1974 NAGAgtrcga 1998 NAGAgtrgga 2022 NAGAgtrtga 1951 AAGAgtraga 1975 AAGAgtrcga 1999 AAGAgtrgga 2023 AAGAgtrtga 1952 CAGAgtraga 1976 CAGAgtrcga 2000 CAGAgtrgga 2024 CAGAgtrtga 1953 GAGAgtraga 1977 GAGAgtrcga 2001 GAGAgtrgga 2025 GAGAgtrtga 1954 TAGAgtraga 1978 TAGAgtrcga 2002 TAGAgtrgga 2026 TAGAgtrtga 1955 CNGAgtraga 1979 CNGAgtrcga 2003 CNGAgtrgga 2027 CNGAgtrtga 1956 NCGAgtraga 1980 NCGAgtrcga 2004 NCGAgtrgga 2028 NCGAgtrtga 1957 ACGAgtraga 1981 ACGAgtrcga 2005 ACGAgtrgga 2029 ACGAgtrtga 1958 CCGAgtraga 1982 CCGAgtrcga 2006 CCGAgtrgga 2030 CCGAgtrtga 1959 GCGAgtraga 1983 GCGAgtrcga 2007 GCGAgtrgga 2031 GCGAgtrtga 1960 TCGAgtraga 1984 TCGAgtrcga 2008 TCGAgtrgga 2032 TCGAgtrtga 1961 GNGAgtraga 1985 GNGAgtrcga 2009 GNGAgtrgga 2033 GNGAgtrtga 1962 NGGAgtraga 1986 NGGAgtrcga 2010 NGGAgtrgga 2034 NGGAgtrtga 1963 AGGAgtraga 1987 AGGAgtrcga 2011 AGGAgtrgga 2035 AGGAgtrtga 1964 CGGAgtraga 1988 CGGAgtrcga 2012 CGGAgtrgga 2036 CGGAgtrtga 1965 GGGAgtraga 1989 GGGAgtrcga 2013 GGGAgtrgga 2037 GGGAgtrtga 1966 TGGAgtraga 1990 TGGAgtrcga 2014 TGGAgtrgga 2038 TGGAgtrtga 1967 TNGAgtraga 1991 TNGAgtrcga 2015 TNGAgtrgga 2039 TNGAgtrtga 1968 NTGAgtraga 1992 NTGAgtrcga 2016 NTGAgtrgga 2040 NTGAgtrtga 1969 ATGAgtraga 1993 ATGAgtrcga 2017 ATGAgtrgga 2041 ATGAgtrtga 1970 CTGAgtraga 1994 CTGAgtrcga 2018 CTGAgtrgga 2042 CTGAgtrtga 1971 GTGAgtraga 1995 GTGAgtrcga 2019 GTGAgtrgga 2043 GTGAgtrtga 1972 TTGAgtraga 1996 TTGAgtrcga 2020 TTGAgtrgga 2044 TTGAgtrtga 2045 ANGAgtragc 2069 ANGAgtrcgc 2093 ANGAgtrggc 2117 ANGAgtrtgc 2046 NAGAgtragc 2070 NAGAgtrcgc 2094 NAGAgtrggc 2118 NAGAgtrtgc 2047 AAGAgtragc 2071 AAGAgtrcgc 2095 AAGAgtrggc 2119 AAGAgtrtgc 2048 CAGAgtragc 2072 CAGAgtrcgc 2096 CAGAgtrggc 2120 CAGAgtrtgc 2049 GAGAgtragc 2073 GAGAgtrcgc 2097 GAGAgtrggc 2121 GAGAgtrtgc 2050 TAGAgtragc 2074 TAGAgtrcgc 2098 TAGAgtrggc 2122 TAGAgtrtgc 2051 CNGAgtragc 2075 CNGAgtrcgc 2099 CNGAgtrggc 2123 CNGAgtrtgc 2052 NCGAgtragc 2076 NCGAgtrcgc 2100 NCGAgtrggc 2124 NCGAgtrtgc 2053 ACGAgtragc 2077 ACGAgtrcgc 2101 ACGAgtrggc 2125 ACGAgtrtgc 2054 CCGAgtragc 2078 CCGAgtrcgc 2102 CCGAgtrggc 2126 CCGAgtrtgc 2055 GCGAgtragc 2079 GCGAgtrcgc 2103 GCGAgtrggc 2127 GCGAgtrtgc 2056 TCGAgtragc 2080 TCGAgtrcgc 2104 TCGAgtrggc 2128 TCGAgtrtgc 2057 GNGAgtragc 2081 GNGAgtrcgc 2105 GNGAgtrggc 2129 GNGAgtrtgc 2058 NGGAgtragc 2082 NGGAgtrcgc 2106 NGGAgtrggc 2130 NGGAgtrtgc 2059 AGGAgtragc 2083 AGGAgtrcgc 2107 AGGAgtrggc 2131 AGGAgtrtgc 2060 CGGAgtragc 2084 CGGAgtrcgc 2108 CGGAgtrggc 2132 CGGAgtrtgc 2061 GGGAgtragc 2085 GGGAgtrcgc 2109 GGGAgtrggc 2133 GGGAgtrtgc 2062 TGGAgtragc 2086 TGGAgtrcgc 2110 TGGAgtrggc 2134 TGGAgtrtgc 2063 TNGAgtragc 2087 TNGAgtrcgc 2111 TNGAgtrggc 2135 TNGAgtrtgc 2064 NTGAgtragc 2088 NTGAgtrcgc 2112 NTGAgtrggc 2136 NTGAgtrtgc 2065 ATGAgtragc 2089 ATGAgtrcgc 2113 ATGAgtrggc 2137 ATGAgtrtgc 2066 CTGAgtragc 2090 CTGAgtrcgc 2114 CTGAgtrggc 2138 CTGAgtrtgc 2067 GTGAgtragc 2091 GTGAgtrcgc 2115 GTGAgtrggc 2139 GTGAgtrtgc 2068 TTGAgtragc 2092 TTGAgtrcgc 2116 TTGAgtrggc 2140 TTGAgtrtgc 2141 ANGAgtragg 2165 ANGAgtrcgg 2189 ANGAgtrggg 2213 ANGAgtrtgg 2142 NAGAgtragg 2166 NAGAgtrcgg 2190 NAGAgtrggg 2214 NAGAgtrtgg 2143 AAGAgtragg 2167 AAGAgtrcgg 2191 AAGAgtrggg 2215 AAGAgtrtgg 2144 CAGAgtragg 2168 CAGAgtrcgg 2192 CAGAgtrggg 2216 CAGAgtrtgg 2145 GAGAgtragg 2169 GAGAgtrcgg 2193 GAGAgtrggg 2217 GAGAgtrtgg 2146 TAGAgtragg 2170 TAGAgtrcgg 2194 TAGAgtrggg 2218 TAGAgtrtgg 2147 CNGAgtragg 2171 CNGAgtrcgg 2195 CNGAgtrggg 2219 CNGAgtrtgg 2148 NCGAgtragg 2172 NCGAgtrcgg 2196 NCGAgtrggg 2220 NCGAgtrtgg 2149 ACGAgtragg 2173 ACGAgtrcgg 2197 ACGAgtrggg 2221 ACGAgtrtgg 2150 CCGAgtragg 2174 CCGAgtrcgg 2198 CCGAgtrggg 2222 CCGAgtrtgg 2151 GCGAgtragg 2175 GCGAgtrcgg 2199 GCGAgtrggg 2223 GCGAgtrtgg 2152 TCGAgtragg 2176 TCGAgtrcgg 2200 TCGAgtrggg 2224 TCGAgtrtgg 2153 GNGAgtragg 2177 GNGAgtrcgg 2201 GNGAgtrggg 2225 GNGAgtrtgg 2154 NGGAgtragg 2178 NGGAgtrcgg 2202 NGGAgtrggg 2226 NGGAgtrtgg 2155 AGGAgtragg 2179 AGGAgtrcgg 2203 AGGAgtrggg 2227 AGGAgtrtgg 2156 CGGAgtragg 2180 CGGAgtrcgg 2204 CGGAgtrggg 2228 CGGAgtrtgg 2157 GGGAgtragg 2181 GGGAgtrcgg 2205 GGGAgtrggg 2229 GGGAgtrtgg 2158 TGGAgtragg 2182 TGGAgtrcgg 2206 TGGAgtrggg 2230 TGGAgtrtgg 2159 TNGAgtragg 2183 TNGAgtrcgg 2207 TNGAgtrggg 2231 TNGAgtrtgg 2160 NTGAgtragg 2184 NTGAgtrcgg 2208 NTGAgtrggg 2232 NTGAgtrtgg 2161 ATGAgtragg 2185 ATGAgtrcgg 2209 ATGAgtrggg 2233 ATGAgtrtgg 2162 CTGAgtragg 2186 CTGAgtrcgg 2210 CTGAgtrggg 2234 CTGAgtrtgg 2163 GTGAgtragg 2187 GTGAgtrcgg 2211 GTGAgtrggg 2235 GTGAgtrtgg 2164 TTGAgtragg 2188 TTGAgtrcgg 2212 TTGAgtrggg 2236 TTGAgtrtgg 2237 ANGAgtragt 2261 ANGAgtrcgt 2285 ANGAgtrggt 2309 ANGAgtrtgt 2238 NAGAgtragt 2262 NAGAgtrcgt 2286 NAGAgtrggt 2310 NAGAgtrtgt 2239 AAGAgtragt 2263 AAGAgtrcgt 2287 AAGAgtrggt 2311 AAGAgtrtgt 2240 CAGAgtragt 2264 CAGAgtrcgt 2288 CAGAgtrggt 2312 CAGAgtrtgt 2241 GAGAgtragt 2265 GAGAgtrcgt 2289 GAGAgtrggt 2313 GAGAgtrtgt 2242 TAGAgtragt 2266 TAGAgtrcgt 2290 TAGAgtrggt 2314 TAGAgtrtgt 2243 CNGAgtragt 2267 CNGAgtrcgt 2291 CNGAgtrggt 2315 CNGAgtrtgt 2244 NCGAgtragt 2268 NCGAgtrcgt 2292 NCGAgtrggt 2316 NCGAgtrtgt 2245 ACGAgtragt 2269 ACGAgtrcgt 2293 ACGAgtrggt 2317 ACGAgtrtgt 2246 CCGAgtragt 2270 CCGAgtrcgt 2294 CCGAgtrggt 2318 CCGAgtrtgt 2247 GCGAgtragt 2271 GCGAgtrcgt 2295 GCGAgtrggt 2319 GCGAgtrtgt 2248 TCGAgtragt 2272 TCGAgtrcgt 2296 TCGAgtrggt 2320 TCGAgtrtgt 2249 GNGAgtragt 2273 GNGAgtrcgt 2297 GNGAgtrggt 2321 GNGAgtrtgt 2250 NGGAgtragt 2274 NGGAgtregt 2298 NGGAgtrggt 2322 NGGAgtrtgt 2251 AGGAgtragt 2275 AGGAgtrcgt 2299 AGGAgtrggt 2323 AGGAgtrtgt 2252 CGGAgtragt 2276 CGGAgtrcgt 2300 CGGAgtrggt 2324 CGGAgtrtgt 2253 GGGAgtragt 2277 GGGAgtrcgt 2301 GGGAgtrggt 2325 GGGAgtrtgt 2254 TGGAgtragt 2278 TGGAgtrcgt 2302 TGGAgtrggt 2326 TGGAgtrtgt 2255 TNGAgtragt 2279 TNGAgtrcgt 2303 TNGAgtrggt 2327 TNGAgtrtgt 2256 NTGAgtragt 2280 NTGAgtrcgt 2304 NTGAgtrggt 2328 NTGAgtrtgt 2257 ATGAgtragt 2281 ATGAgtrcgt 2305 ATGAgtrggt 2329 ATGAgtrtgt 2258 CTGAgtragt 2282 CTGAgtrcgt 2306 CTGAgtrggt 2330 CTGAgtrtgt 2259 GTGAgtragt 2283 GTGAgtrcgt 2307 GTGAgtrggt 2331 GTGAgtrtgt 2260 TTGAgtragt 2284 TTGAgtrcgt 2308 TTGAgtrggt 2332 TTGAgtrtgt 2333 ANGAgtrnga 2357 ANGAgtrngc 2381 ANGAgtrngg 2405 ANGAgtrngt 2334 NAGAgtrnga 2358 NAGAgtrngc 2382 NAGAgtrngg 2406 NAGAgtrngt 2335 AAGAgtrnga 2359 AAGAgtrngc 2383 AAGAgtrngg 2407 AAGAgtrngt 2336 CAGAgtrnga 2360 CAGAgtrngc 2384 CAGAgtrngg 2408 CAGAgtrngt 2337 GAGAgtrnga 2361 GAGAgtrngc 2385 GAGAgtrngg 2409 GAGAgtrngt 2338 TAGAgtrnga 2362 TAGAgtrngc 2386 TAGAgtrngg 2410 TAGAgtrngt 2339 CNGAgtrnga 2363 CNGAgtrngc 2387 CNGAgtrngg 2411 CNGAgtrngt 2340 NCGAgtrnga 2364 NCGAgtrngc 2388 NCGAgtrngg 2412 NCGAgtrngt 2341 ACGAgtrnga 2365 ACGAgtrngc 2389 ACGAgtrngg 2413 ACGAgtrngt 2342 CCGAgtrnga 2366 CCGAgtrngc 2390 CCGAgtrngg 2414 CCGAgtrngt 2343 GCGAgtrnga 2367 GCGAgtrngc 2391 GCGAgtrngg 2415 GCGAgtrngt 2344 TCGAgtrnga 2368 TCGAgtrngc 2392 TCGAgtrngg 2416 TCGAgtrngt 2345 GNGAgtrnga 2369 GNGAgtrngc 2393 GNGAgtrngg 2417 GNGAgtrngt 2346 NGGAgtrnga 2370 NGGAgtrngc 2394 NGGAgtrngg 2418 NGGAgtrngt 2347 AGGAgtrnga 2371 AGGAgtrngc 2395 AGGAgtrngg 2419 AGGAgtrngt 2348 CGGAgtrnga 2372 CGGAgtrngc 2396 CGGAgtrngg 2420 CGGAgtrngt 2349 GGGAgtrnga 2373 GGGAgtrngc 2397 GGGAgtrngg 2421 GGGAgtrngt 2350 TGGAgtrnga 2374 TGGAgtrngc 2398 TGGAgtrngg 2422 TGGAgtrngt 2351 TNGAgtrnga 2375 TNGAgtrngc 2399 TNGAgtrngg 2423 TNGAgtrngt 2352 NTGAgtrnga 2376 NTGAgtrngc 2400 NTGAgtrngg 2424 NTGAgtrngt 2353 ATGAgtrnga 2377 ATGAgtrngc 2401 ATGAgtrngg 2425 ATGAgtrngt 2354 CTGAgtrnga 2378 CTGAgtrngc 2402 CTGAgtrngg 2426 CTGAgtrngt 2355 GTGAgtrnga 2379 GTGAgtrngc 2403 GTGAgtrngg 2427 GTGAgtrngt 2356 TTGAgtrnga 2380 TTGAgtrngc 2404 TTGAgtrngg 2428 TTGAgtrngt 2429 ANGAgtangn 2453 ANGAgtaagn 2477 ANGAgtacgn 2501 ANGAgtaggn 2430 NAGAglangn 2454 NAGAgtaagn 2478 NAGAgtacgn 2502 NAGAgtaggn 2431 AAGAgtangn 2455 AAGAgtaagn 2479 AAGAgtacgn 2503 AAGAgtaggn 2432 CAGAgtangn 2456 CAGAgtaagn 2480 CAGAgtacgn 2504 CAGAgtaggn 2433 GAGAgtangn 2457 GAGAgtaagn 2481 GAGAgtacgn 2505 GAGAgtaggn 2434 TAGAgtangn 2458 TAGAgtaagn 2482 TAGAgtacgn 2506 TAGAgtaggn 2435 CNGAgtangn 2459 CNGAgtaagn 2483 CNGAgtacgn 2507 CNGAgtaggn 2436 NCGAgtangn 2460 NCGAgtaagn 2484 NCGAgtacgn 2508 NCGAgtaggn 2437 ACGAgtangn 2461 ACGAgtaagn 2485 ACGAgtacgn 2509 ACGAgtaggn 2438 CCGAgtangn 2462 CCGAgtaagn 2486 CCGAgtacgn 2510 CCGAgtaggn 2439 GCGAgtangn 2463 GCGAgtaagn 2487 GCGAgtacgn 2511 GCGAgtaggn 2440 TCGAgtangn 2464 TCGAgtaagn 2488 TCGAgtacgn 2512 TCGAgtaggn 2441 GNGAgtangn 2465 GNGAgtaagn 2489 GNGAgtacgn 2513 GNGAgtaggn 2442 NGGAgtangn 2466 NGGAgtaagn 2490 NGGAgtacgn 2514 NGGAgtaggn 2443 AGGAgtangn 2467 AGGAgtaagn 2491 AGGAgtacgn 2515 AGGAgtaggn 2444 CGGAgtangn 2468 CGGAgtaagn 2492 CGGAgtacgn 2516 CGGAgtaggn 2445 GGGAgtangn 2469 GGGAgtaagn 2493 GGGAgtacgn 2517 GGGAgtaggn 2446 TGGAgtangn 2470 TGGAgtaagn 2494 TGGAgtacgn 2518 TGGAgtaggn 2447 TNGAgtangn 2471 TNGAgtaagn 2495 TNGAgtacgn 2519 TNGAgtaggn 2448 NTGAgtangn 2472 NTGAgtaagn 2496 NTGAgtacgn 2520 NTGAgtaggn 2449 ATGAgtangn 2473 ATGAgtaagn 2497 ATGAgtacgn 2521 ATGAgtaggn 2450 CTGAgtangn 2474 CTGAgtaagn 2498 CTGAgtacgn 2522 CTGAgtaggn 2451 GTGAgtangn 2475 GTGAgtaagn 2499 GTGAgtacgn 2523 GTGAgtaggn 2452 TTGAgtangn 2476 TTGAgtaagn 2500 TTGAgtacgn 2524 TTGAgtaggn 2525 ANGAgtatgn 2549 ANGAgtaaga 2573 ANGAgtacga 2597 ANGAgtagga 2526 NAGAgtatgn 2550 NAGAgtaaga 2574 NAGAgtacga 2598 NAGAgtagga 2527 AAGAgtatgn 2551 AAGAgtaaga 2575 AAGAgtacga 2599 AAGAgtagga 2528 CAGAgtatgn 2552 CAGAgtaaga 2576 CAGAgtacga 2600 CAGAgtagga 2529 GAGAgtatgn 2553 GAGAgtaaga 2577 GAGAgtacga 2601 GAGAgtagga 2530 TAGAgtatgn 2554 TAGAgtaaga 2578 TAGAgtacga 2602 TAGAgtagga 2531 CNGAgtatgn 2555 CNGAgtaaga 2579 CNGAgtacga 2603 CNGAgtagga 2532 NCGAgtatgn 2556 NCGAgtaaga 2580 NCGAgtacga 2604 NCGAgtagga 2533 ACGAgtatgn 2557 ACGAgtaaga 2581 ACGAgtacga 2605 ACGAgtagga 2534 CCGAgtatgn 2558 CCGAgtaaga 2582 CCGAgtacga 2606 CCGAgtagga 2535 GCGAgtatgn 2559 GCGAgtaaga 2583 GCGAgtacga 2607 GCGAgtagga 2536 TCGAgtatgn 2560 TCGAgtaaga 2584 TCGAgtacga 2608 TCGAgtagga 2537 GNGAgtatgn 2561 GNGAgtaaga 2585 GNGAgtacga 2609 GNGAgtagga 2538 NGGAgtatgn 2562 NGGAgtaaga 2586 NGGAgtacga 2610 NGGAgtagga 2539 AGGAgtatgn 2563 AGGAgtaaga 2587 AGGAgtacga 2611 AGGAgtagga 2540 CGGAgtatgn 2564 CGGAgtaaga 2588 CGGAgtacga 2612 CGGAgtagga 2541 GGGAgtatgn 2565 GGGAgtaaga 2589 GGGAgtacga 2613 GGGAgtagga 2542 TGGAgtatgn 2566 TGGAgtaaga 2590 TGGAgtacga 2614 TGGAgtagga 2543 TNGAgtatgn 2567 TNGAgtaaga 2591 TNGAgtacga 2615 TNGAgtagga 2544 NTGAgtatgn 2568 NTGAgtaaga 2592 NTGAgtacga 2616 NTGAgtagga 2545 ATGAgtatgn 2569 ATGAgtaaga 2593 ATGAgtacga 2617 ATGAgtagga 2546 CTGAgtatgn 2570 CTGAgtaaga 2594 CTGAgtacga 2618 CTGAgtagga 2547 GTGAgtatgn 2571 GTGAgtaaga 2595 GTGAgtacga 2619 GTGAgtagga 2548 TTGAgtatgn 2572 TTGAgtaaga 2596 TTGAgtacga 2620 TTGAgtagga 2621 ANGAgtatga 2645 ANGAgtaagc 2669 ANGAgtacgc 2693 ANGAgtaggc 2622 NAGAgtatga 2646 NAGAgtaagc 2670 NAGAgtacgc 2694 NAGAgtaggc 2623 AAGAgtatga 2647 AAGAgtaagc 2671 AAGAgtacgc 2695 AAGAgtaggc 2624 CAGAgtatga 2648 CAGAgtaagc 2672 CAGAgtacgc 2696 CAGAgtaggc 2625 GAGAgtatga 2649 GAGAgtaagc 2673 GAGAgtacgc 2697 GAGAgtaggc 2626 TAGAgtatga 2650 TAGAgtaagc 2674 TAGAgtacgc 2698 TAGAgtaggc 2627 CNGAgtatga 2651 CNGAgtaagc 2675 CNGAgtacgc 2699 CNGAgtaggc 2628 NCGAgtatga 2652 NCGAgtaagc 2676 NCGAgtacgc 2700 NCGAgtaggc 2629 ACGAgtatga 2653 ACGAgtaagc 2677 ACGAgtacgc 2701 ACGAgtaggc 2630 CCGAgtatga 2654 CCGAgtaagc 2678 CCGAgtacgc 2702 CCGAgtaggc 2631 GCGAgtatga 2655 GCGAgtaagc 2679 GCGAgtacgc 2703 GCGAgtaggc 2632 TCGAgtatga 2656 TCGAgtaagc 2680 TCGAgtacgc 2704 TCGAgtaggc 2633 GNGAgtatga 2657 GNGAgtaagc 2681 GNGAgtacgc 2705 GNGAgtaggc 2634 NGGAgtatga 2658 NGGAgtaagc 2682 NGGAgtacgc 2706 NGGAgtaggc 2635 AGGAgtatga 2659 AGGAgtaagc 2683 AGGAgtacgc 2707 AGGAgtaggc 2636 CGGAgtatga 2660 CGGAgtaagc 2684 CGGAgtacgc 2708 CGGAgtaggc 2637 GGGAgtatga 2661 GGGAgtaagc 2685 GGGAgtacgc 2709 GGGAgtaggc 2638 TGGAgtatga 2662 TGGAgtaagc 2686 TGGAgtacgc 2710 TGGAgtaggc 2639 TNGAgtatga 2663 TNGAgtaagc 2687 TNGAgtacgc 2711 TNGAgtaggc 2640 NTGAgtatga 2664 NTGAgtaagc 2688 NTGAgtacgc 2712 NTGAgtaggc 2641 ATGAgtatga 2665 ATGAgtaagc 2689 ATGAgtacgc 2713 ATGAgtaggc 2642 CTGAgtatga 2666 CTGAgtaagc 2690 CTGAgtacgc 2714 CTGAgtaggc 2643 GTGAgtatga 2667 GTGAgtaagc 2691 GTGAgtacgc 2715 GTGAgtaggc 2644 TTGAgtatga 2668 TTGAgtaagc 2692 TTGAgtacgc 2716 TTGAgtaggc 2717 ANGAgtatgc 2741 ANGAgtaagg 2765 ANGAgtacgg 2789 ANGAgtaggg 2718 NAGAgtatgc 2742 NAGAgtaagg 2766 NAGAgtacgg 2790 NAGAgtaggg 2719 AAGAgtatgc 2743 AAGAgtaagg 2767 AAGAgtacgg 2791 AAGAgtaggg 2720 CAGAgtatgc 2744 CAGAgtaagg 2768 CAGAgtacgg 2792 CAGAgtaggg 2721 GAGAgtatgc 2745 GAGAgtaagg 2769 GAGAgtacgg 2793 GAGAgtaggg 2722 TAGAgtatgc 2746 TAGAgtaagg 2770 TAGAgtacgg 2794 TAGAgtaggg 2723 CNGAgtatgc 2747 CNGAgtaagg 2771 CNGAgtacgg 2795 CNGAgtaggg 2724 NCGAgtatgc 2748 NCGAgtaagg 2772 NCGAgtacgg 2796 NCGAgtaggg 2725 ACGAgtatgc 2749 ACGAgtaagg 2773 ACGAgtacgg 2797 ACGAgtaggg 2726 CCGAgtatgc 2750 CCGAgtaagg 2774 CCGAgtacgg 2798 CCGAgtaggg 2727 GCGAgtatgc 2751 GCGAgtaagg 2775 GCGAgtacgg 2799 GCGAgtaggg 2728 TCGAgtatgc 2752 TCGAgtaagg 2776 TCGAgtacgg 2800 TCGAgtaggg 2729 GNGAgtatgc 2753 GNGAgtaagg 2777 GNGAgtacgg 2801 GNGAgtaggg 2730 NGGAgtatgc 2754 NGGAgtaagg 2778 NGGAgtacgg 2802 NGGAgtaggg 2731 AGGAgtatgc 2755 AGGAgtaagg 2779 AGGAgtacgg 2803 AGGAgtaggg 2732 CGGAgtatgc 2756 CGGAgtaagg 2780 CGGAgtacgg 2804 CGGAgtaggg 2733 GGGAgtatgc 2757 GGGAgtaagg 2781 GGGAgtacgg 2805 GGGAgtaggg 2734 TGGAgtatgc 2758 TGGAgtaagg 2782 TGGAgtacgg 2806 TGGAgtaggg 2735 TNGAgtatgc 2759 TNGAgtaagg 2783 TNGAgtacgg 2807 TNGAgtaggg 2736 NTGAgtatgc 2760 NTGAgtaagg 2784 NTGAgtacgg 2808 NTGAgtaggg 2737 ATGAgtatgc 2761 ATGAgtaagg 2785 ATGAgtacgg 2809 ATGAgtaggg 2738 CTGAgtatgc 2762 CTGAgtaagg 2786 CTGAgtacgg 2810 CTGAgtaggg 2739 GTGAgtatgc 2763 GTGAgtaagg 2787 GTGAgtacgg 2811 GTGAgtaggg 2740 TTGAgtatgc 2764 TTGAgtaagg 2788 TTGAgtacgg 2812 TTGAgtaggg 2813 ANGAgtatgg 2837 ANGAgtaagt 2861 ANGAgtacgt 2885 ANGAgtaggt 2814 NAGAgtatgg 2838 NAGAgtaagt 2862 NAGAgtacgt 2886 NAGAgtaggt 2815 AAGAgtatgg 2839 AAGAgtaagt 2863 AAGAgtacgt 2887 AAGAgtaggt 2816 CAGAgtatgg 2840 CAGAgtaagt 2864 CAGAgtacgt 2888 CAGAgtaggt 2817 GAGAgtatgg 2841 GAGAgtaagt 2865 GAGAgtacgt 2889 GAGAgtaggt 2818 TAGAgtatgg 2842 TAGAgtaagt 2866 TAGAgtacgt 2890 TAGAgtaggt 2819 CNGAgtatgg 2843 CNGAgtaagt 2867 CNGAgtacgt 2891 CNGAgtaggt 2820 NCGAgtatgg 2844 NCGAgtaagt 2868 NCGAgtacgt 2892 NCGAgtaggt 2821 ACGAgtatgg 2845 ACGAgtaagt 2869 ACGAgtacgt 2893 ACGAgtaggt 2822 CCGAgtatgg 2846 CCGAgtaagt 2870 CCGAgtacgt 2894 CCGAgtaggt 2823 GCGAgtatgg 2847 GCGAgtaagt 2871 GCGAgtacgt 2895 GCGAgtaggt 2824 TCGAgtatgg 2848 TCGAgtaagt 2872 TCGAgtacgt 2896 TCGAgtaggt 2825 GNGAgtatgg 2849 GNGAgtaagt 2873 GNGAgtacgt 2897 GNGAgtaggt 2826 NGGAgtatgg 2850 NGGAgtaagt 2874 NGGAgtacgt 2898 NGGAgtaggt 2827 AGGAgtatgg 2851 AGGAgtaagt 2875 AGGAgtacgt 2899 AGGAgtaggt 2828 CGGAgtatgg 2852 CGGAgtaagt 2876 CGGAgtacgt 2900 CGGAgtaggt 2829 GGGAgtatgg 2853 GGGAgtaagt 2877 GGGAgtacgt 2901 GGGAgtaggt 2830 TGGAgtatgg 2854 TGGAgtaagt 2878 TGGAgtacgt 2902 TGGAgtaggt 2831 TNGAgtatgg 2855 TNGAgtaagt 2879 TNGAgtacgt 2903 TNGAgtaggt 2832 NTGAgtatgg 2856 NTGAgtaagt 2880 NTGAgtacgt 2904 NTGAgtaggt 2833 ATGAgtatgg 2857 ATGAgtaagt 2881 ATGAgtacgt 2905 ATGAgtaggt 2834 CTGAgtatgg 2858 CTGAgtaagt 2882 CTGAgtacgt 2906 CTGAgtaggt 2835 GTGAgtatgg 2859 GTGAgtaagt 2883 GTGAgtacgt 2907 GTGAgtaggt 2836 TTGAgtatgg 2860 TTGAgtaagt 2884 TTGAgtacgt 2908 TTGAgtaggt 2909 ANGAgtatgt 2933 ANGAgtanga 2957 ANGAgtangc 2981 ANGAgtangg 2910 NAGAgtatgt 2934 NAGAgtanga 2958 NAGAgtangc 2982 NAGAgtangg 2911 AAGAgtatgt 2935 AAGAgtanga 2959 AAGAgtangc 2983 AAGAgtangg 2912 CAGAgtatgt 2936 CAGAgtanga 2960 CAGAgtangc 2984 CAGAgtangg 2913 GAGAgtatgt 2937 GAGAgtanga 2961 GAGAgtangc 2985 GAGAgtangg 2914 TAGAgtatgt 2938 TAGAgtanga 2962 TAGAgtangc 2986 TAGAgtangg 2915 CNGAgtatgt 2939 CNGAgtanga 2963 CNGAgtangc 2987 CNGAgtangg 2916 NCGAgtatgt 2940 NCGAgtanga 2964 NCGAgtangc 2988 NCGAgtangg 2917 ACGAgtatgt 2941 ACGAgtanga 2965 ACGAgtangc 2989 ACGAgtangg 2918 CCGAgtatgt 2942 CCGAgtanga 2966 CCGAgtangc 2990 CCGAgtangg 2919 GCGAgtatgt 2943 GCGAgtanga 2967 GCGAgtangc 2991 GCGAgtangg 2920 TCGAgtatgt 2944 TCGAgtanga 2968 TCGAgtangc 2992 TCGAgtangg 2921 GNGAgtatgt 2945 GNGAgtanga 2969 GNGAgtangc 2993 GNGAgtangg 2922 NGGAgtatgt 2946 NGGAgtanga 2970 NGGAgtangc 2994 NGGAgtangg 2923 AGGAgtatgt 2947 AGGAgtanga 2971 AGGAgtangc 2995 AGGAgtangg 2924 CGGAgtatgt 2948 CGGAgtanga 2972 CGGAgtangc 2996 CGGAgtangg 2925 GGGAgtatgt 2949 GGGAgtanga 2973 GGGAgtangc 2997 GGGAgtangg 2926 TGGAgtatgt 2950 TGGAgtanga 2974 TGGAgtangc 2998 TGGAgtangg 2927 TNGAgtatgt 2951 TNGAgtanga 2975 TNGAgtangc 2999 TNGAgtangg 2928 NTGAgtatgt 2952 NTGAgtanga 2976 NTGAgtangc 3000 NTGAgtangg 2929 ATGAgtatgt 2953 ATGAgtanga 2977 ATGAgtangc 3001 ATGAgtangg 2930 CTGAgtatgt 2954 CTGAgtanga 2978 CTGAgtangc 3002 CTGAgtangg 2931 GTGAgtatgt 2955 GTGAgtanga 2979 GTGAgtangc 3003 GTGAgtangg 2932 TTGAgtatgt 2956 TTGAgtanga 2980 TTGAgtangc 3004 TTGAgtangg 3005 ANGAgtangt 3029 ANGAgtgngn 3053 ANGAgtgagn 3077 ANGAgtgcgn 3006 NAGAgtangt 3030 NAGAgtgngn 3054 NAGAgtgagn 3078 NAGAgtgcgn 3007 AAGAglangt 3031 AAGAgtgngn 3055 AAGAgtgagn 3079 AAGAgtgcgn 3008 CAGAgtangt 3032 CAGAgtgngn 3056 CAGAgtgagn 3080 CAGAgtgcgn 3009 GAGAgtangt 3033 GAGAgtgngn 3057 GAGAgtgagn 3081 GAGAgtgcgn 3010 TAGAgtangt 3034 TAGAgtgngn 3058 TAGAgtgagn 3082 TAGAgtgcgn 3011 CNGAgtangt 3035 CNGAgtgngn 3059 CNGAgtgagn 3083 CNGAgtgcgn 3012 NCGAgtangt 3036 NCGAgtgngn 3060 NCGAgtgagn 3084 NCGAgtgcgn 3013 ACGAgtangt 3037 ACGAgtgngn 3061 ACGAgtgagn 3085 ACGAgtgcgn 3014 CCGAgtangt 3038 CCGAgtgngn 3062 CCGAgtgagn 3086 CCGAgtgcgn 3015 GCGAgtangt 3039 GCGAgtgngn 3063 GCGAgtgagn 3087 GCGAgtgcgn 3016 TCGAgtangt 3040 TCGAgtgngn 3064 TCGAgtgagn 3088 TCGAgtgcgn 3017 GNGAgtangt 3041 GNGAgtgngn 3065 GNGAgtgagn 3089 GNGAgtgcgn 3018 NGGAgtangt 3042 NGGAgtgngn 3066 NGGAgtgagn 3090 NGGAgtgcgn 3019 AGGAgtangt 3043 AGGAgtgngn 3067 AGGAgtgagn 3091 AGGAgtgcgn 3020 CGGAgtangt 3044 CGGAgtgngn 3068 CGGAgtgagn 3092 CGGAgtgcgn 3021 GGGAgtangt 3045 GGGAgtgngn 3069 GGGAgtgagn 3093 GGGAgtgcgn 3022 TGGAgtangt 3046 TGGAgtgngn 3070 TGGAgtgagn 3094 TGGAgtgcgn 3023 INGAgtangt 3047 TNGAgtgngn 3071 TNGAgtgagn 3095 TNGAgtgcgn 3024 NTGAgtangt 3048 NTGAgtgngn 3072 NTGAgtgagn 3096 NTGAgtgcgn 3025 ATGAgtangt 3049 ATGAgtgngn 3073 ATGAgtgagn 3097 ATGAgtgcgn 3026 CTGAgtangt 3050 CTGAgtgngn 3074 CTGAgtgagn 3098 CTGAgtgcgn 3027 GTGAgtangt 3051 GTGAgtgngn 3075 GTGAgtgagn 3099 GTGAgtgcgn 3028 TTGAgtangt 3052 TTGAgtgngn 3076 TTGAgtgagn 3100 TTGAgtgcgn 3101 ANGAgtgggn 3125 ANGAgtgtgn 3149 ANGAgtgaga 3173 ANGAgtgcga 3102 NAGAgtgggn 3126 NAGAgtgtgn 3150 NAGAgtgaga 3174 NAGAgtgcga 3103 AAGAgtgggn 3127 AAGAgtgtgn 3151 AAGAgtgaga 3175 AAGAgtgcga 3104 CAGAgtgggn 3128 CAGAgtgtgn 3152 CAGAgtgaga 3176 CAGAgtgcga 3105 GAGAgtgggn 3129 GAGAgtgtgn 3153 GAGAgtgaga 3177 GAGAgtgcga 3106 TAGAgtgggn 3130 TAGAgtgtgn 3154 TAGAgtgaga 3178 TAGAgtgcga 3107 CNGAgtgggn 3131 CNGAgtgtgn 3155 CNGAgtgaga 3179 CNGAgtgcga 3108 NCGAgtgggn 3132 NCGAgtgtgn 3156 NCGAgtgaga 3180 NCGAgtgcga 3109 ACGAgtgggn 3133 ACGAgtgtgn 3157 ACGAgtgaga 3181 ACGAgtgcga 3110 CCGAgtgggn 3134 CCGAgtgtgn 3158 CCGAgtgaga 3182 CCGAgtgcga 3111 GCGAgtgggn 3135 GCGAgtgtgn 3159 GCGAgtgaga 3183 GCGAgtgcga 3112 TCGAgtgggn 3136 TCGAgtgtgn 3160 TCGAgtgaga 3184 TCGAgtgcga 3113 GNGAgtgggn 3137 GNGAgtgtgn 3161 GNGAgtgaga 3185 GNGAgtgcga 3114 NGGAgtgggn 3138 NGGAgtgtgn 3162 NGGAgtgaga 3186 NGGAgtgcga 3115 AGGAgtgggn 3139 AGGAgtgtgn 3163 AGGAgtgaga 3187 AGGAgtgcga 3116 CGGAgtgggn 3140 CGGAgtgtgn 3164 CGGAgtgaga 3188 CGGAgtgcga 3117 GGGAgtgggn 3141 GGGAgtgtgn 3165 GGGAgtgaga 3189 GGGAgtgcga 3118 TGGAgtgggn 3142 TGGAgtgtgn 3166 TGGAgtgaga 3190 TGGAgtgcga 3119 TNGAgtgggn 3143 TNGAgtgtgn 3167 TNGAgtgaga 3191 TNGAgtgcga 3120 NTGAgtgggn 3144 NTGAgtgtgn 3168 NTGAgtgaga 3192 NTGAgtgcga 3121 ATGAgtgggn 3145 ATGAgtgtgn 3169 ATGAgtgaga 3193 ATGAgtgcga 3122 CTGAgtgggn 3146 CTGAgtgtgn 3170 CTGAgtgaga 3194 CTGAgtgcga 3123 GTGAgtgggn 3147 GTGAgtgtgn 3171 GTGAgtgaga 3195 GTGAgtgcga 3124 TTGAgtgggn 3148 TTGAgtgtgn 3172 TTGAgtgaga 3196 TTGAgtgcga 3197 ANGAgtggga 3221 ANGAgtgtga 3245 ANGAgtgagc 3269 ANGAgtgcgc 3198 NAGAgtggga 3222 NAGAgtgtga 3246 NAGAgtgagc 3270 NAGAgtgcgc 3199 AAGAgtggga 3223 AAGAgtgtga 3247 AAGAgtgagc 3271 AAGAgtgcgc 3200 CAGAgtggga 3224 CAGAgtgtga 3248 CAGAgtgagc 3272 CAGAgtgcgc 3201 GAGAgtggga 3225 GAGAgtgtga 3249 GAGAgtgagc 3273 GAGAgtgcgc 3202 TAGAgtggga 3226 TAGAgtgtga 3250 TAGAgtgagc 3274 TAGAgtgcgc 3203 CNGAgtggga 3227 CNGAgtgtga 3251 CNGAgtgagc 3275 CNGAgtgcgc 3204 NCGAgtggga 3228 NCGAgtgtga 3252 NCGAgtgagc 3276 NCGAgtgcgc 3205 ACGAgtggga 3229 ACGAgtgtga 3253 ACGAgtgagc 3277 ACGAgtgcgc 3206 CCGAgtggga 3230 CCGAgtgtga 3254 CCGAgtgagc 3278 CCGAgtgcgc 3207 GCGAgtggga 3231 GCGAgtgtga 3255 GCGAgtgagc 3279 GCGAgtgcgc 3208 TCGAgtggga 3232 TCGAgtgtga 3256 TCGAgtgagc 3280 TCGAgtgcgc 3209 GNGAgtggga 3233 GNGAgtgtga 3257 GNGAgtgagc 3281 GNGAgtgcgc 3210 NGGAgtggga 3234 NGGAgtgtga 3258 NGGAgtgagc 3282 NGGAgtgcgc 3211 AGGAgtggga 3235 AGGAgtgtga 3259 AGGAgtgagc 3283 AGGAgtgcgc 3212 CGGAgtggga 3236 CGGAgtgtga 3260 CGGAgtgagc 3284 CGGAgtgcgc 3213 GGGAgtggga 3237 GGGAgtgtga 3261 GGGAgtgagc 3285 GGGAgtgcgc 3214 TGGAgtggga 3238 TGGAgtgtga 3262 TGGAgtgagc 3286 TGGAgtgcgc 3215 TNGAgtggga 3239 TNGAgtgtga 3263 TNGAgtgagc 3287 TNGAgtgcgc 3216 NTGAgtggga 3240 NTGAgtgtga 3264 NTGAgtgagc 3288 NTGAgtgcgc 3217 ATGAgtggga 3241 ATGAgtgtga 3265 ATGAgtgagc 3289 ATGAgtgcgc 3218 CTGAgtggga 3242 CTGAgtgtga 3266 CTGAgtgagc 3290 CTGAgtgcgc 3219 GTGAgtggga 3243 GTGAgtgtga 3267 GTGAgtgagc 3291 GTGAgtgcgc 3220 TTGAgtggga 3244 TTGAgtgtga 3268 TTGAgtgagc 3292 TTGAgtgcgc 3293 ANGAgtgggc 3317 ANGAgtgtgc 3341 ANGAgtgagg 3365 ANGAgtgcgg 3294 NAGAgtgggc 3318 NAGAgtgtgc 3342 NAGAgtgagg 3366 NAGAgtgcgg 3295 AAGAgtgggc 3319 AAGAgtgtgc 3343 AAGAgtgagg 3367 AAGAgtgcgg 3296 CAGAgtgggc 3320 CAGAgtgtgc 3344 CAGAgtgagg 3368 CAGAgtgcgg 3297 GAGAgtgggc 3321 GAGAgtgtgc 3345 GAGAgtgagg 3369 GAGAgtgcgg 3298 TAGAgtgggc 3322 TAGAgtgtgc 3346 TAGAgtgagg 3370 TAGAgtgcgg 3299 CNGAgtgggc 3323 CNGAgtgtgc 3347 CNGAgtgagg 3371 CNGAgtgcgg 3300 NCGAgtgggc 3324 NCGAgtgtgc 3348 NCGAgtgagg 3372 NCGAgtgcgg 3301 ACGAgtgggc 3325 ACGAgtgtgc 3349 ACGAgtgagg 3373 ACGAgtgcgg 3302 CCGAgtgggc 3326 CCGAgtgtgc 3350 CCGAgtgagg 3374 CCGAgtgcgg 3303 GCGAgtgggc 3327 GCGAgtgtgc 3351 GCGAgtgagg 3375 GCGAgtgcgg 3304 TCGAgtgggc 3328 TCGAgtgtgc 3352 TCGAgtgagg 3376 TCGAgtgcgg 3305 GNGAgtgggc 3329 GNGAgtgtgc 3353 GNGAgtgagg 3377 GNGAgtgcgg 3306 NGGAgtgggc 3330 NGGAgtgtgc 3354 NGGAgtgagg 3378 NGGAgtgcgg 3307 AGGAgtgggc 3331 AGGAgtgtgc 3355 AGGAgtgagg 3379 AGGAgtgcgg 3308 CGGAgtgggc 3332 CGGAgtgtgc 3356 CGGAgtgagg 3380 CGGAgtgcgg 3309 GGGAgtgggc 3333 GGGAgtgtgc 3357 GGGAgtgagg 3381 GGGAgtgcgg 3310 TGGAgtgggc 3334 TGGAgtgtgc 3358 TGGAgtgagg 3382 TGGAgtgcgg 3311 TNGAgtgggc 3335 TNGAgtgtgc 3359 TNGAgtgagg 3383 TNGAgtgcgg 3312 NTGAgtgggc 3336 NTGAgtgtgc 3360 NTGAgtgagg 3384 NTGAgtgcgg 3313 ATGAgtgggc 3337 ATGAgtgtgc 3361 ATGAgtgagg 3385 ATGAgtgcgg 3314 CTGAgtgggc 3338 CTGAgtgtgc 3362 CTGAgtgagg 3386 CTGAgtgcgg 3315 GTGAgtgggc 3339 GTGAgtgtgc 3363 GTGAgtgagg 3387 GTGAgtgcgg 3316 TTGAgtgggc 3340 TTGAgtgtgc 3364 TTGAgtgagg 3388 TTGAgtgcgg 3389 ANGAgtgggg 3413 ANGAgtgtgg 3437 ANGAgtgagt 3461 ANGAgtgcgt 3390 NAGAgtgggg 3414 NAGAgtgtgg 3438 NAGAgtgagt 3462 NAGAgtgcgt 3391 AAGAgtgggg 3415 AAGAgtgtgg 3439 AAGAgtgagt 3463 AAGAgtgcgt 3392 CAGAgtgggg 3416 CAGAgtgtgg 3440 CAGAgtgagt 3464 CAGAgtgcgt 3393 GAGAgtgggg 3417 GAGAgtgtgg 3441 GAGAgtgagt 3465 GAGAgtgcgt 3394 TAGAgtgggg 3418 TAGAgtgtgg 3442 TAGAgtgagt 3466 TAGAgtgcgt 3395 CNGAgtgggg 3419 CNGAgtgtgg 3443 CNGAgtgagt 3467 CNGAgtgcgt 3396 NCGAgtgggg 3420 NCGAgtgtgg 3444 NCGAgtgagt 3468 NCGAgtgcgt 3397 ACGAgtgggg 3421 ACGAgtgtgg 3445 ACGAgtgagt 3469 ACGAgtgcgt 3398 CCGAgtgggg 3422 CCGAgtgtgg 3446 CCGAgtgagt 3470 CCGAgtgcgt 3399 GCGAgtgggg 3423 GCGAgtgtgg 3447 GCGAgtgagt 3471 GCGAgtgcgt 3400 TCGAgtgggg 3424 TCGAgtgtgg 3448 TCGAgtgagt 3472 TCGAgtgcgt 3401 GNGAgtgggg 3425 GNGAgtgtgg 3449 GNGAgtgagt 3473 GNGAgtgcgt 3402 NGGAgtgggg 3426 NGGAgtgtgg 3450 NGGAgtgagt 3474 NGGAgtgcgt 3403 AGGAgtgggg 3427 AGGAgtgtgg 3451 AGGAgtgagt 3475 AGGAgtgcgt 3404 CGGAgtgggg 3428 CGGAgtgtgg 3452 CGGAgtgagt 3476 CGGAgtgcgt 3405 GGGAgtgggg 3429 GGGAgtgtgg 3453 GGGAgtgagt 3477 GGGAgtgcgt 3406 TGGAgtgggg 3430 TGGAgtgtgg 3454 TGGAgtgagt 3478 TGGAgtgcgt 3407 TNGAgtgggg 3431 TNGAgtgtgg 3455 TNGAgtgagt 3479 TNGAgtgcgt 3408 NTGAgtgggg 3432 NTGAgtgtgg 3456 NTGAgtgagt 3480 NTGAgtgcgt 3409 ATGAgtgggg 3433 ATGAgtgtgg 3457 ATGAgtgagt 3481 ATGAgtgcgt 3410 CTGAgtgggg 3434 CTGAgtgtgg 3458 CTGAgtgagt 3482 CTGAgtgcgt 3411 GTGAgtgggg 3435 GTGAgtgtgg 3459 GTGAgtgagt 3483 GTGAgtgcgt 3412 TTGAgtgggg 3436 TTGAgtgtgg 3460 TTGAgtgagt 3484 TTGAgtgcgt 3485 ANGAgtgggt 3509 ANGAgtgtgt 3533 ANGAgtgnga 3557 ANGAgtgngc 3486 NAGAgtgggt 3510 NAGAgtgtgt 3534 NAGAgtgnga 3558 NAGAgtgngc 3487 AAGAgtgggt 3511 AAGAgtgtgt 3535 AAGAgtgnga 3559 AAGAgtgngc 3488 CAGAgtgggt 3512 CAGAgtgtgt 3536 CAGAgtgnga 3560 CAGAgtgngc 3489 GAGAgtgggt 3513 GAGAgtgtgt 3537 GAGAgtgnga 3561 GAGAgtgngc 3490 TAGAgtgggt 3514 TAGAgtgtgt 3538 TAGAgtgnga 3562 TAGAgtgngc 3491 CNGAgtgggt 3515 CNGAgtgtgt 3539 CNGAgtgnga 3563 CNGAgtgngc 3492 NCGAgtgggt 3516 NCGAgtgtgt 3540 NCGAgtgnga 3564 NCGAgtgngc 3493 ACGAgtgggt 3517 ACGAgtgtgt 3541 ACGAgtgnga 3565 ACGAgtgngc 3494 CCGAgtgggt 3518 CCGAgtgtgt 3542 CCGAgtgnga 3566 CCGAgtgngc 3495 GCGAgtgggt 3519 GCGAgtgtgt 3543 GCGAgtgnga 3567 GCGAgtgngc 3496 TCGAgtgggt 3520 TCGAgtgtgt 3544 TCGAgtgnga 3568 TCGAgtgngc 3497 GNGAgtgggt 3521 GNGAgtgtgt 3545 GNGAgtgnga 3569 GNGAgtgngc 3498 NGGAgtgggt 3522 NGGAgtgtgt 3546 NGGAgtgnga 3570 NGGAgtgngc 3499 AGGAgtgggt 3523 AGGAgtgtgt 3547 AGGAgtgnga 3571 AGGAgtgngc 3500 CGGAgtgggt 3524 CGGAgtgtgt 3548 CGGAgtgnga 3572 CGGAgtgngc 3501 GGGAgtgggt 3525 GGGAgtgtgt 3549 GGGAgtgnga 3573 GGGAgtgngc 3502 TGGAgtgggt 3526 TGGAgtgtgt 3550 TGGAgtgnga 3574 TGGAgtgngc 3503 TNGAgtgggt 3527 TNGAgtgtgt 3551 TNGAgtgnga 3575 TNGAgtgngc 3504 NTGAgtgggt 3528 NTGAgtgtgt 3552 NTGAgtgnga 3576 NTGAgtgngc 3505 ATGAgtgggt 3529 ATGAgtgtgt 3553 ATGAgtgnga 3577 ATGAgtgngc 3506 CTGAgtgggt 3530 CTGAgtgtgt 3554 CTGAgtgnga 3578 CTGAgtgngc 3507 GTGAgtgggt 3531 GTGAgtgtgt 3555 GTGAgtgnga 3579 GTGAgtgngc 3508 TTGAgtgggt 3532 TTGAgtgtgt 3556 TTGAgtgnga 3580 TTGAgtgngc 3581 ANGAgtgngg 3593 GNGAgtgngg 3605 ANGAgtgngt 3617 GNGAgtgngt 3582 NAGAgtgngg 3594 NGGAgtgngg 3606 NAGAgtgngt 3618 NGGAgtgngt 3583 AAGAgtgngg 3595 AGGAgtgngg 3607 AAGAgtgngt 3619 AGGAgtgngt 3584 CAGAgtgngg 3596 CGGAgtgngg 3608 CAGAgtgngt 3620 CGGAgtgngt 3585 GAGAgtgngg 3597 GGGAgtgngg 3609 GAGAgtgngt 3621 GGGAgtgngt 3586 TAGAgtgngg 3598 TGGAgtgngg 3610 TAGAgtgngt 3622 TGGAgtgngt 3587 CNGAgtgngg 3599 TNGAgtgngg 3611 CNGAgtgngt 3623 TNGAgtgngt 3588 NCGAgtgngg 3600 NTGAgtgngg 3612 NCGAgtgngt 3624 NTGAgtgngt 3589 ACGAgtgngg 3601 ATGAgtgngg 3613 ACGAgtgngt 3625 ATGAgtgngt 3590 CCGAgtgngg 3602 CTGAgtgngg 3614 CCGAgtgngt 3626 CTGAgtgngt 3591 GCGAgtgngg 3603 GTGAgtgngg 3615 GCGAgtgngt 3627 GTGAgtgngt 3592 TCGAgtgngg 3604 TTGAgtgngg 3616 TCGAgtgngt 3628 TTGAgtgngt

In certain embodiments, provided herein is a vector comprising the artificial gene construct described herein. In some embodiments, provided herein is a cell comprising an artificial gene construct described herein or a vector comprising an artificial gene construct described herein.

In another aspect, provided herein is a method of modulating the amount and type of a protein produced by a cell containing an artificial gene construct described herein. In one embodiment, provided herein is a method of modulating the amount and type of a protein produced by a cell containing an artificial gene construct described herein, the method comprising contacting the cell with a compound of Formula (I) or a form thereof. In certain embodiments, the artificial gene construct encodes a therapeutic protein. In certain embodiments, the artificial gene construct encodes a non-functional protein. In some embodiments producing a therapeutic protein, the artificial gene construct may also encode a detectable reporter protein. In some embodiments producing a non-functional protein, the artificial gene construct may also encode a detectable reporter protein.

In another aspect, provided herein is a method of modulating the amount of a protein produced by a subject, wherein the subject is or was administered an artificial gene construct described herein. In one embodiment, provided herein is method of regulating the amount of a protein produced by a subject, the method comprising: (a) administering an artificial gene construct or a vector comprising the artificial gene construct described herein to the subject; and (b) administering a compound of Formula (I) or a form thereof to the subject. In another embodiment, provided herein is a method of regulating the amount of a protein produced by a subject, the method comprising administering a compound of Formula (I) or a form thereof to a subject carrying a gene containing a nucleotide sequence encoding an intronic REMS. In another embodiment, provided herein is a method of regulating the amount of a protein produced by a subject, the method comprising administering a compound of Formula (I) to the subject, wherein the subject was previously administered an artificial gene construct described herein. In certain embodiments, the artificial gene construct may encode a therapeutic or a non-functional protein. In some embodiments, the artificial gene construct encodes a detectable reporter protein. In certain embodiments, the subject is a non-human. In specific embodiments, the subject is a human.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RNA containing an endogenous or non-endogenous intronic recognition element for splicing modifier (REMS), the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the endogenous or non-endogenous intronic REMS comprises the sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein Formula (I) is

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript produced from precursor RNA containing an endogenous or non-endogenous intronic recognition element for splicing modifier (REMS), the method comprising contacting the precursor RNA with a compound of Formula (I) or a form thereof, wherein the endogenous or non-endogenous intronic REMS comprises the sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide, and wherein Formula (I) is

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R substituents and         optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method of regulating the amount and type of a protein produced by a gene comprising a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises the sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein Formula (I) is

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R substituents and         optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₁ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method of regulating the amount and type of a protein produced by a gene comprising a nucleotide sequence encoding an endogenous or non-endogenous intronic REMS in a subject, wherein the nucleotide sequence encoding the endogenous or non-endogenous intronic REMS comprises the sequence NNGAgtrngn (SEQ ID NO: 3), wherein r is adenine or guanine and n or N is any nucleotide, the method comprising administering a compound of Formula (I) to the subject, wherein Formula (I) is

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In specific embodiments of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA1, ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM12, ADAM15, ADAM17, ADAM33, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP3, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFY1, ANKHD1-EIF4EBP3, ANKRA2, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, AP4B1-AS1, APAF1, APIP, APLP2, APP, APPL2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGEF16, ARID1A, ARID2, ARID5B, ARL9, ARL15, ARMCX3, ARMCX6, ASAP1, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRN1, BECN1, BEND6, BHMT2, BICD1, BIN1, BIN3-IT1, BIRC3, BIRC6, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1orf86, C10orf54, C11orf30, C11orf70, C11orf73, C11orf94, C12orf4, C12orf56, C14orf132, C17orf76-AS1, C19orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB39, CACNA2D2, CACNB1, CADM1, CALU, CAMKK1, CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CEP68, CFH, CFLAR, CHD8, CHEK1, CIITA, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CNTD1, COG1, COL1A1, COL11A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRYBG3, CRYL1, CSDE1, CSNK1A1, CSNK1E, CSNK1G1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYPIB1, CYP51A1, DAB2, DACT1, DAGLB, DARS, DAXX, DCAF10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1, DENND1A, DENND1B, DENND5A, DEPTOR, DFNB59, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP8, DSEL, DST, DSTN, DYNC1I1, DYRK1A, DZIP1L, EBF1, EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELN, ELP4, EMX2OS, ENAH, ENG, ENPP1, ENPP2, ENSA, EP300, EPN1, EPT1, ERC1, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXO1, EXTL2, EYA3, F2R, FADS1, FADS2, FAF1, FAIM, FAM111A, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM198B, FAM20A, FAM219A, FAM219B, FAM3C, FAM46B, FAM65A, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FBXL6, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FCHO1, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFR2, FGFRL1, FGL2, FHOD3, FLII, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GCFC2, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1, GRK6, GRTP1, GSE1, GTF2H2B, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEY1, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1, HMGCR, HMGN3-AS1, HMGCS1, HOOK3, HMOX1, HNMT, HNRNPR, HNRNPUL1, HP1BP3, HPS1, HRH1, HSD17B12, HSD17B4, HSPA1L, HTATIP2, HTT, TARS, IDH1, IDI1, IFT57, TGDCC4, TGF2BP2, TGF2R, TGFBP3, IL16, IL6ST, INA, INHBA, INPP5K, INSIG1, INTU, IQCE, IQCG, ITGA11, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIAA1755, KIF14, KIF2A, KIF3A, KIT, KLC1, KLC2, KLF17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAP1-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB1, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINC00341, LINC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMAN2L, LMO7, LMOD1, LOC400927, LONP1, LOX, LRBA, LRCH4, LRIG1, LRP4, LRP8, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRM1, LZTS2, MADD, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MAP4K4, MAPK13, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM10, MDM2, MED1, MED13L, MEDAG, MEF2D, MEGF6, MEIS2, MEMO1, MEPCE, MFGE8, MFN2, MIAT, MICAL2, MINPP1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSC, MSH2, MSH4, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MYADM, MYCBP2, MYLK, MYO1D, MYO9B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NELFA, NEO1, NEURLIB, NF2, NFE2L1, NFX1, NGF, NGFR, NHLH1, NID1, NID2, NIPA1, NKX3-1, NLN, NOL10, NOMO3, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRD1, NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, OLR1, OS9, OSBPL6, OSBPL10, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC1, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PBLD, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE1C, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PEAR1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, P14K2A, PIEZO1, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1, PTTPNM3, PLAU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMS1, PNISR, PODN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC1A, PPARA, PPARG, PPHLN1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKG1, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF1, RALB, RAPlA, RAP1GDS1, RAPGEF1, RARG, RARS, RARS2, RASSF8, RBBP8, RBCK1, RBFOX2, RBKS, RBM10, RCC1, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, ROR1, ROR2, RPA1, RPL10, RPS10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SGK3, SGOL2, SH3RF1, SH3YL1, SHROOM3, SIGLEC10, SKA2, SKIL, SLC12A2, SLC24A3, SLC25A17, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SOCS2, SON, SORBS2, SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRGAP1, SRRM1, SRSF3, STAC2, STARD4, STAT1, STAT3, STAT4, STAU1, STC2, STEAP2, STK32B, STRIP1, STRN3, STRN4, STS, STX16, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNPO2, SYNPO2L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANGO6, TARBP1, TARS, TASP1, TBC1D15, TBL2, TCF12, TCF4, TCF7L2, TENC1, TENM2, TEP1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFB1, TGFBR1, TGFBRAP1, TGM2, THADA, THAP4, THBS2, THRB, TIAM1, TIMP2, TJP2, TLE3, TLK1, TMC3, TMEM102, TMEM119, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, TNFRSF14, TNIP1, TNKS1BP1, TNPO3, TNRC18P1, TNRC6A, TNS1, TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIP1, TP531NP1, TPRG1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMT1L, TRPC4, TRPS1, TSC2, TSHZ1, TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE1, TXNIP, TXNL1, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, URGCP, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VIM-AS1, VIPAS39, VPS13A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR91, WIPF1, WISP1, WNK1, WNT5B, WNT10B, WSB1, WWTR1, XIAP, XRN2, YAP1, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ1-AS1, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF431, ZNF583, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF79, ZNF827, ZNF837, ZNF839 or ZNF91.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is not described in International Publication No. WO 2015/105657. In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is not described in International Publication No. WO 2016/196386. In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is not described in International Publication No. WO 2015/105657 and not described in International Publication No. WO 2016/196386.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA1, ABCB7, ABCC1, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ADAM12, ADAM15, ADAM17, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK2, ANKFY1, ANKHD1-EIF4EBP3, ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, APAF1, APLP2, APP, APPL2, APTX, ARHGAP22, ARID1A, ARTD2, ARMCX3, ASAP1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG9A, ATMIN, ATP2C1, ATXN3, AURKA, AXIN1, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BEND6, BICD1, BIN1, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BZW1, C11orf30, C11orf73, C17orf76-AS1, C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKK1, CAPNS1, CASC3, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CEP68, CFLAR, CHD8, CIZ1, CLIC1, CLK4, CNOT1, COG1, COL12A1, COL1A1, COL6A1, COPS7B, CPEB2, CREB5, CRLS1, CRTAP, CSDE1, CSNK1A1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYBRD1, CYP51A1, DAB2, DACT1, DARS, DAXX, DCAF10, DCAF11, DCBLD2, DCUN1D4, DDAH1, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENND1A, DENND1B, DENND5A, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLC1, DNM2, DOCK1, DPP8, DSEL, DST, DSTN, EBF1, EEA1, EEF1A1, EFCAB14, EGR1, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ENG, ENPP2, ENSA, EPN1, EPT1, ERC1, ERGTC3, ETV5, EXO1, EXTL2, EYA3, FADS1, FADS2, FAF1, FAM111A, FAM198B, FAM219A, FAM219B, FAM3C, FAM65A, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFRL1, FHOD3, FLII, FLNB, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FUS, FYN, GABPB1, GALC, GALNT1, GAS7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJC1, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR89A, GPSM2, GREM1, GRK6, GSE1, GTF2H2B, HAS2, HAT1, HAUS3, HAUS6, HDAC7, HEG1, HLA-A, HLA-E, HLTF, HMGA1, HMGB1, HMGCR, HMGCS1, HMOX1, HNRNPR, HNRNPUL1, HP1BP3, HRH1, HSD17B12, HSD17B4, HTT, IARS, IDH1, IDI1, IGF2BP2, IL6ST, INHBA, INSIG1, IQCE, ITGAV, ITGB5, ITM2C, ITSN1, KANSL3, KCNK2, KIAA1033, KIAA1143, KIAA1199, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIF14, KIF2A, KIF3A, KLC1, KLC2, KLF6, KLHL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMB1, LARP4, LARP7, LATS2, LDLR, LEMD3, LGALS8, LIMS1, LINC00341, LINC00657, LMAN2L, LMO7, LONP1, LOX, LRCH4, LRIG1, LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4, MAGED4B, MAN1A2, MAP4K4, MBD1, MBOAT7, MDM2, MED1, MEDAG, MEF2D, MEIS2, MEMO1, MEPCE, MFGE8, MICAL2, MINPP1, MKL1, MKLN1, MKNK2, MLLT4, ML ST8, MMAB, MMS19, MMS22L, MPPE1, MPZL1, MRPL3, MSANTD3, MSC, MSH2, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MYADM, MYLK, MYO1D, MYO9B, MYOF, NAA35, NADK, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NELFA, NEO1, NEURLIB, NF2, NFE2L1, NFX1, NID1, NID2, NIPA1, NKX3-1, NOL10, NOMO3, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, ODF2, OS9, OSBPL6, OSMR, P4HA1, P4HB, PABPC1, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE4A, PDE7A, PDLIM7, PDXDC1, PEPD, PEX5, PFKP, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZO1, PIGU, PIK3C2B, PITPNA, PITPNB, PITPNM1, PLAU, PLEC, PLEKHB2, PLSCR3, PLXNB2, PLXNC1, PMS1, POLE3, POLR3D, POSTN, POU2F1, PPAPDC1A, PPARA, PPHLN1, PPIP5K1, PPPIR12A, PPP6R1, PPP6R2, PRKACB, PRKDC, PRMT1, PRNP, PRSS23, PSMA4, PSMC1, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RAD1, RAD23B, RALB, RAPlA, RAP1GDS1, RARG, RASSF8, RBCK1, RBFOX2, RBM10, RCC1, RFTN1, RFWD2, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, RPL10, RPS6KC1, RRBP1, RWDD4, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24B, SEC61 A1, SEPT9, SERPINE2, SF1, SGOL2, SH3RF1, SKIL, SLC25A17, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNHG16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRSF3, STARD4, STAT1, STAT3, STAU1, STC2, STEAP2, STRIP1, STRN3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC1, TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENC1, TENM2, TEP1, TET3, TFCP2, TGFB1, TGFBR1, TGFBRAP1, THADA, THAP4, THRB, TIMP2, TJP2, TLE3, TLK1, TMEM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, TNIP1, TNKS1BP1, TNPO3, TNS1, TNS3, TOE1, TOMM40, TOMM5, TOPORS, TP53INP1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT1L, TRPS1, TSC2, TSHZ1, TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS13A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WIPF1, WNT5B, WSB1, WWTR1, XIAP, XRN2, YAP1, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZHX3, ZMIZ1, ZMYM2, ZNF12, ZNF148, ZNF219, ZNF227, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF37A, ZNF37BP, ZNF395, ZNF583, ZNF621, ZNF652, ZNF655, ZNF674, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF827, ZNF839 or ZNF91.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ANKRD36, APLP2, ARHGAP12, ARMCX6, ASAP1, ATG5, AXIN1, BIRC6, C1orf86, CDC42BPA, CLTA, DYRK1A, ERGIC3, FBXL6, FOXM1, GGCT, KAT6B, KDM6A, KIF3A, KMT2D, LARP7, LYRM1, MADD, MAN2C1, MRPL55, MYCBP2, MYO9B, PNISR, RAPlA, RAPGEF1, SENP6, SH3YL1, SLC25A17, SMN2, SREK1, STRN3, TAF2, TMEM134, VPS29, ZFAND1 or ZNF431.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ANKRD36, ARHGAP12, ARMCX6, ATG5, BIRC6, C1orf86, CLTA, DYRK1A, FBXL6, KAT6B, KDM6A, KMT2D, LYRM1, MAN2C1, MRPL55, MYCBP2, PNISR, RAPGEF1, SENP6, SH3YL1, TMEM134 or ZNF431.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA10, ABCC1, ACTA2, ADAL, ADAM12, ADAMTS1, ADAMTS5, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPS, AKAP3, ANK1, ANK2, ANK3, ANKRD33B, ANXA11, ANXA6, AP4B1-AS1, ARHGEF16, ARID5B, ARL9, ARMCX3, ASAP1, ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BIN3-IT1, BIRC3, BTG2, C10orf54, C11orf70, C11orf73, C11orf94, C12orf56, C19orf47, C3, C4orf27, C7orf31, C8orf34, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CCDC79, CCER2, CCNF, CDCA7, CDKAL1, CELSR1, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTD1, COL11A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLF1, CRYL1, CUX1, CYB5B, CYB5R2, CYGB, CYPIB1, DCLK1, DCN, DDIT4L, DDX42, DDX50, DEGS1, DENND1A, DENND5A, DEPTOR, DFNB59, DGKA, DHFR, DIAPH3, DIRAS3, DIS3L, DLG5, DNAH8, DNAJC27, DOCK1, DOCK11, DYNC1I1, DZIP1L, EBF1, EFEMP1, EGR3, EIF2B3, ELN, ELP4, EMX2OS, ENPP1, ERCC8, ESM1, EVC2, F2R, FAM160A1, FAM198B, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FCHO1, FER, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALC, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GNAQ, GOLGB1, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, HEY1, HLTF, HMGN3-AS1, HMOX1, HOOK3, HSD17B12, HSPA1L, HTATIP2, HTT, IGDCC4, IGF2R, IGFBP3, IL16, INA, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1524, KIAA1715, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN1A2, MAN2A1, MAPK13, MASP1, MB, MC4R, MEDAG, MEGF6, MEMO1, MIAT, MIR612, MLLT10, MMP10, MMP24, MMS19, MN1, MOXD1, MRVI1, MSH4, MTERF3, MXRA5, MYO1D, NA, NAALADL2, NAE1, NAGS, NDNF, NEURLIB, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, NTNG1, OCLN, OLR1, OSBPL10, OXCT2, PAIP2B, PAPD4, PBLD, PCM1, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PDXDC1, PEAR1, PEPD, PHACTR3, P14K2B, PIK3R1, PIM2, PITPNB, PITPNM3, PLAU, PLEK2, PLEKHA6, PLEKHH2, PLXNC1, PMS1, PODN, POLN, POLR1A, POSTN, PPM1E, PPP3CA, PRKCA, PRKDC, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RCC1, RDX, RFWD2, RFX3-AS1, RGCC, RNFT1, ROR1, ROR2, RWDD4, SCARNA9, SCO1, SEC22A, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SMYD3, SNED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, SQRDL, STAC2, STAT1, STAT4, STEAP2, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TARBP1, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THADA, THBS2, THRB, TMEM102, TMEM119, TMEM256-PLSCR3, TMEM50B, TNC, TNFAIP8L3, TNFRSF14, TNRC18P1, TNS3, TNXB, TP53AIP1, TPRG1, TRAF3, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TXNIP, UNC5B, USP27X, UVRAG, VIM-AS1, VPS41, VSTM2L, VWA8, VWF, WDR91, WISP1, WNT10B, XRN2, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, ZNF212, ZNF350, ZNF660, ZNF79 or ZNF837.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCA10, ACTA2, ADAL, ADAMTS1, ADAMTS5, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AKAP3, ANK1, ANK3, ANKRD33B, AP4B1-AS1, ARHGEF16, ARID5B, ARL9, ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BIN3-IT1, BIRC3, BTG2, C10orf54, C11orf70, C11orf94, C12orf56, C19orf47, C3, C7orf31, C8orf34, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CCDC79, CCER2, CCNF, CELSR1, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLF1, CRYL1, CYB5R2, CYGB, CYP1B1, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DNAH8, DNAJC27, DOCK11, DYNC1I1, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENPP1, ERCC8, ESM1, EVC2, F2R, FAM160A1, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GXYLT1, HAPLN1, HAPLN2, HA S3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, HEY1, HMGN3-AS1, HOOK3, HSPA1L, HTATIP2, IGDCC4, IGF2R, IGFBP3, 1L16, INA, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, MAFB, MAMDC2, MAN2A1, MAPK13, MASP1, MB, MC4R, MEGF6, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRVI1, MSH4, MTERF3, MXRA5, NA, NAALADL2, NAE1, NAGS, NDNF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PI4K2B, PIK3R1, PIM2, PITPNM3, PLEK2, PLEKHA6, PLEKHH2, PODN, POLN, POLR1A, PPM1E, PPP3CA, PRKCA, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RDX, RFX3-AS1, RGCC, ROR1, ROR2, SCARNA9, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THBS2, TMEM102, TMEM119, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TXNIP, USP27X, UVRAG, VIM-AS1, VPS41, VSTM2L, VWF, WDR91, WISP1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, ZNF212, ZNF350, ZNF660, ZNF79 or ZNF837.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APLP2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAPlA, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, K1AA1524, K1AA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: APLP2, AXIN1, CECR7, DAGLB, DLGAP4, ERCC1, ERGIC3, FAM198B, GGCT, HAT1, HPS1, INPP5K, MADD, PPHLN1, PRUNE2, RAPlA, RNFT1, RPS6KB2, SH3YL1, SKA2, SPATA18, STRN3, TMEM189-UBE2V1, TRIM65, TUBE1, UBE2V1, VPS29 or ZNF680.

In another specific embodiment of the aspects and embodiments described herein, the gene is, or the RNA transcript is transcribed from a gene that is selected from: ABCB8, ABCC3, ADCY3, AGPAT4, ANKRA2, APIP, ARHGAP1, ARL15, ATXN1, BECN1, BHMT2, BTN3A1, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASP7, CCDC122, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DLGAP4, DNAJC13, DNMBP, DYRK1A, ENAH, EP300, ERCC1, ERLIN2, ERRFI1, EVC, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, GGACT, GLCE, GULP1, GXYLT1, HDX, HMGA2, HNMT, HPS1, IFT57, INPP5K, IVD, KDM6A, LETM2, LOC400927, LRRC42, LYRM1, MB21D2, MCM10, MED13L, MFN2, MRPL45, MRPS28, MTERF3, MYCBP2, NGF, OXCT1, PDS5B, PIGN, PIK3CD, PIK3R1, PIKFYVE, PLEKHA1, PLSCR1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRUNE2, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RPA1, RPS10, RPS6KB2, SAMD4A, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC44A2, SNX7, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STXBP6, TASP1, TCF12, TCF4, TIAM1, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TTC7B, TUBE1, TYW5, URGCP, VAV2, WDR27, WDR91, WNK1, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF680.

In another aspect, provide herein is a method of modulating the amount and type of a protein produced by a cell containing the artificial gene construct as described above, the method comprising contacting the cell with a compound of Formula (I) or a form thereof, wherein Formula (I) is

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,     -   C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In a specific embodiment, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1829), CNGAgtrngn (SEQ ID NO: 1835), GNGAgtrngn (SEQ ID NO: 1841), TNGAgtrngn (SEQ ID NO: 1847), NAGAgtrngn (SEQ ID NO: 1830), NCGAgtrngn (SEQ ID NO: 1836), NGGAgtrngn (SEQ ID NO: 1842), NTGAgtrngn (SEQ ID NO: 1848), AAGAgtrngn (SEQ ID NO: 1831), ACGAgtrngn (SEQ ID NO: 1837), AGGAgtrngn (SEQ ID NO: 1843), ATGAgtrngn (SEQ ID NO: 1849), CAGAgtrngn (SEQ ID NO: 1832), CCGAgtrngn (SEQ ID NO: 1838), CGGAgtrngn (SEQ ID NO: 1844), CTGAgtrngn (SEQ ID NO: 1850), GAGAgtrngn (SEQ ID NO: 1833), GCGAgtrngn (SEQ ID NO: 1839), GGGAgtrngn (SEQ ID NO: 1845), GTGAgtrngn (SEQ ID NO: 1851), TAGAgtrngn (SEQ ID NO: 1834), TCGAgtrngn (SEQ ID NO: 1840), TGGAgtrngn (SEQ ID NO: 1846) and TTGAgtrngn (SEQ ID NO: 1852), wherein r is adenine or guanine and n or N is any nucleotide.

In a further specific embodiment, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 2237), CNGAgtragt (SEQ ID NO: 2243), GNGAgtragt (SEQ ID NO: 2249), TNGAgtragt (SEQ ID NO: 2255), NAGAgtragt (SEQ ID NO: 2238), NCGAgtragt (SEQ ID NO: 2244), NGGAgtragt (SEQ ID NO: 2250), NTGAgtragt (SEQ ID NO: 2256), AAGAgtragt (SEQ ID NO: 2239), ACGAgtragt (SEQ ID NO: 2245), AGGAgtragt (SEQ ID NO: 2251), ATGAgtragt (SEQ ID NO: 2257), CAGAgtragt (SEQ ID NO: 2240), CCGAgtragt (SEQ ID NO: 2246), CGGAgtragt (SEQ ID NO: 2252), CTGAgtragt (SEQ ID NO: 2258), GAGAgtragt (SEQ ID NO: 2241), GCGAgtragt (SEQ ID NO: 2247), GGGAgtragt (SEQ ID NO: 2253), GTGAgtragt (SEQ ID NO: 2259), TAGAgtragt (SEQ ID NO: 2242), TCGAgtragt (SEQ ID NO: 2248), TGGAgtragt (SEQ ID NO: 2254) and TTGAgtragt (SEQ ID NO: 2260), wherein r is adenine or guanine and N is any nucleotide. In one or more embodiments provided herein, N is adenine or guanine.

In various specific embodiments, the nucleotide sequence encoding the intronic REMS is a nucleotide sequence encoding a non-endogenous intronic REMS, i.e., a precursor RNA transcript comprising the non-endogenous intronic REMS not naturally found in the DNA sequence of the artificial construct.

In one aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence comprising in 5′ to 3′ order: a branch point, a 3′ splice site and an endogenous intronic recognition element for splicing modifier (iREMS), wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the RNA transcript is an RNA transcript of a gene that is selected from: ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837; the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence comprising in 5′ to 3′ order: a branch point, a 3′ splice site and an endogenous intronic recognition element for splicing modifier (iREMS); wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the RNA transcript is an RNA transcript of a gene not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both; the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C3.14cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence comprising in 5′ to 3′ order: a branch point, a 3′ splice site and a non-endogenous intronic recognition element for splicing modifier (iREMS); wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In certain embodiments, the iREMS comprises an RNA sequence GAguragu (SEQ ID NO: 3866), wherein r is adenine or guanine and n is any nucleotide. In some embodiments, the iREMS comprises an RNA sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide. In a specific embodiment, the RNA sequence NNGAgurngn (SEQ ID NO: 1) is selected from the group consisting of ANGAgurngn (SEQ ID NO: 29), CNGAgurngn (SEQ ID NO: 35), GNGAgurngn (SEQ ID NO: 41), UNGAgurngn (SEQ ID NO: 47), NAGAgurngn (SEQ ID NO: 30), NCGAgurngn (SEQ ID NO: 36), NGGAgurngn (SEQ ID NO: 42), NUGAgurngn (SEQ ID NO: 48), AAGAgurngn (SEQ ID NO: 31), ACGAgurngn (SEQ ID NO: 37), AGGAgurngn (SEQ ID NO: 43), AUGAgurngn (SEQ ID NO: 49), CAGAgurngn (SEQ ID NO: 32), CCGAgurngn (SEQ ID NO: 38), CGGAgurngn (SEQ ID NO: 44), CUGAgurngn (SEQ ID NO: 50), GAGAgurngn (SEQ ID NO: 33), GCGAgurngn (SEQ ID NO: 39), GGGAgurngn (SEQ ID NO: 45), GUGAgurngn (SEQ ID NO: 51), UAGAgurngn (SEQ ID NO: 34), UCGAgurngn (SEQ ID NO: 40), UGGAgurngn (SEQ ID NO: 46) and UUGAgurngn (SEQ ID NO: 52), wherein r is adenine or guanine and n or N is any nucleotide. In certain embodiments, n is adenine or guanine.

In certain embodiments, the iREMS comprises an RNA sequence NNGAguragu (SEQ ID NO: 3862), wherein r is adenine or guanine and N is any nucleotide. In a specific embodiment, the RNA sequence NNGAguragu (SEQ ID NO: 3862) is selected from the group consisting of ANGAguragu (SEQ ID NO: 437), CNGAguragu (SEQ ID NO: 443), GNGAguragu (SEQ ID NO: 449), UNGAguragu (SEQ ID NO: 455), NAGAguragu (SEQ ID NO: 438), NCGAguragu (SEQ ID NO: 444), NGGAguragu (SEQ ID NO: 450), NUGAguragu (SEQ ID NO: 456), AAGAguragu (SEQ ID NO: 439), ACGAguragu (SEQ ID NO: 445), AGGAguragu (SEQ ID NO: 451), AUGAguragu (SEQ ID NO: 457), CAGAguragu (SEQ ID NO: 440), CCGAguragu (SEQ ID NO: 446), CGGAguragu (SEQ ID NO: 452), CUGAguragu (SEQ ID NO: 458), GAGAguragu (SEQ ID NO: 441), GCGAguragu (SEQ ID NO: 447), GGGAguragu (SEQ ID NO: 453), GUGAguragu (SEQ ID NO: 459), UAGAguragu (SEQ ID NO: 442), UCGAguragu (SEQ ID NO: 448), UGGAguragu (SEQ ID NO: 454) and UUGAguragu (SEQ ID NO: 460), wherein r is adenine or guanine, and N is any nucleotide. the iREMS comprises an RNA sequence presented in Table 13. In certain embodiments, n is adenine or guanine.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript produced from a DNA sequence comprising a DNA nucleotide sequence encoding exons and one or more introns, comprising in 5′ to 3′ order: a branch point, a 3′ splice site and an endogenous iREMS; wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₄alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In a specific embodiment, the DNA sequence is in a gene selected from: ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-TT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, P1K3CD, P1K3R₁, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837. In another specific embodiment, the DNA sequence is a gene not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript produced from a DNA sequence comprising a DNA nucleotide sequence encoding exons and one or more introns, comprising in 5′ to 3′ order: a branch point, a 3′ splice site and a non-endogenous iREMS; wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In certain embodiments, the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide. In certain embodiments, n is adenine or guanine. In certain embodiments, the iREMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 3), wherein r is adenine or guanine and n or N is any nucleotide. In a specific embodiment, the DNA sequence NNGAgtrngn (SEQ ID NO: 3) is selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1829), CNGAgtrngn (SEQ ID NO: 1835), GNGAgtrngn (SEQ ID NO: 1841), TNGAgtrngn (SEQ ID NO: 1847), NAGAgtrngn (SEQ ID NO: 1830), NCGAgtrngn (SEQ ID NO: 1836), NGGAgtrngn (SEQ ID NO: 1842), NTGAgtrngn (SEQ ID NO: 1848), AAGAgtrngn (SEQ ID NO: 1831), ACGAgtrngn (SEQ ID NO: 1837), AGGAgtrngn (SEQ ID NO: 1843), ATGAgtrngn (SEQ ID NO: 1849), CAGAgtrngn (SEQ ID NO: 1832), CCGAgtrngn (SEQ ID NO: 1838), CGGAgtrngn (SEQ ID NO: 1844), CTGAgtrngn (SEQ ID NO: 1850), GAGAgtrngn (SEQ ID NO: 1833), GCGAgtrngn (SEQ ID NO: 1839), GGGAgtrngn (SEQ ID NO: 1845), GTGAgtrngn (SEQ ID NO: 1851), TAGAgtrngn (SEQ ID NO: 1834), TCGAgtrngn (SEQ ID NO: 1840), TGGAgtrngn (SEQ ID NO: 1846) and TTGAgtrngn (SEQ ID NO: 1852). In certain embodiments, n is adenine or guanine.

In certain embodiments, the iREMS comprises a DNA sequence NNGAgtragt (SEQ ID NO: 3864), wherein r is adenine or guanine and N is any nucleotide. In a specific embodiment, the DNA sequence NNGAgtragt (SEQ ID NO: 3864) is selected from the group consisting of ANGAgtragt (SEQ ID NO: 2237), CNGAgtragt (SEQ ID NO: 2243), GNGAgtragt (SEQ ID NO: 2249), TNGAgtragt (SEQ ID NO: 2255), NAGAgtragt (SEQ ID NO: 2238), NCGAgtragt (SEQ ID NO: 2244), NGGAgtragt (SEQ ID NO: 2250), NTGAgtragt (SEQ ID NO: 2256), AAGAgtragt (SEQ ID NO: 2239), ACGAgtragt (SEQ ID NO: 2245), AGGAgtragt (SEQ ID NO: 2251), ATGAgtragt (SEQ ID NO: 2257), CAGAgtragt (SEQ ID NO: 2240), CCGAgtragt (SEQ ID NO: 2246), CGGAgtragt (SEQ ID NO: 2252), CTGAgtragt (SEQ ID NO: 2258), GAGAgtragt (SEQ ID NO: 2241), GCGAgtragt (SEQ ID NO: 2247), GGGAgtragt (SEQ ID NO: 2253), GTGAgtragt (SEQ ID NO: 2259), TAGAgtragt (SEQ ID NO: 2242), TCGAgtragt (SEQ ID NO: 2248), TGGAgtragt (SEQ ID NO: 2254) and TTGAgtragt (SEQ ID NO: 2260), wherein r is adenine or guanine, and N is any nucleotide. In a specific embodiment, the iREMS comprises a DNA sequence presented in Table 14. In certain embodiments, n is adenine or guanine. In certain embodiments of the aspects and embodiments described herein, n is adenine or guanine.

In certain embodiments of a method for modulating the amount of an RNA transcript described herein, modulation of the amount of the RNA transcript is modulation of the amount of the RNA transcript in a cell or a lysate of the cell, the method comprising contacting the compound of Formula (I) or a form thereof with the cell or the cell lysate. In a specific embodiment of a method for modulating the amount of an RNA transcript described herein, modulation of the amount of the RNA transcript is modulation of the amount of the RNA transcript in a cell, the method comprising contacting the compound of Formula (I) or a form thereof with the cell. In certain embodiments of a method of modulating the amount of an RNA transcript described herein, the modulation modulates the amount and/or type of a protein translated from the RNA transcript and produced in the cell or lysate of the cell.

In certain embodiments of a method for modulating the amount of an RNA transcript described herein, modulation of the amount of the RNA transcript is modulation of the amount of the RNA transcript in a subject, the method comprising administering the compound of Formula (I) or a form thereof to the subject. In certain embodiments of a method for modulating the amount of an RNA transcript described herein, the modulation modulates the amount and/or type of a protein translated from the RNA transcript and produced in the subject. In a specific embodiment, the subject is a non-human subject. In another specific embodiment, the subject is a human subject.

In certain embodiments, the RNA transcript encodes a detectable reporter protein.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises an iREMS that is downstream of a branch point and a 3′ splice site and wherein the iREMS comprises the sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In certain embodiments, n is adenine or guanine. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are non-endogenous. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are endogenous.

In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence encoding at least one intron comprises an iREMS that is downstream of the nucleotide sequence encoding a branch point and the nucleotide sequence encoding a 3′ splice site, and wherein the iREMS comprises the sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide. In certain embodiments, n is adenine or guanine. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are non-endogenous. In certain embodiments, one, two, or all of the IREMS, the branch point, and the 3′ splice site are endogenous.

In another aspect, provided herein is a cell comprising an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises an iREMS that is downstream of a branch point and a 3′ splice site and wherein the iREMS comprises the sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In certain embodiments, n is adenine or guanine. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are non-endogenous. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are endogenous.

In another aspect, provided herein is a cell comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence encoding at least one intron comprises an iREMS that is downstream of the nucleotide sequence encoding a branch point and the nucleotide sequence encoding a 3′ splice site, and wherein the iREMS comprises the sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are non-endogenous. In certain embodiments, one, two, or all of the iREMS, the branch point, and the 3′ splice site are endogenous.

In another aspect, provided herein is a cell comprising an artificial gene construct described herein.

In another aspect, provided herein is a cell comprising a vector comprising an artificial gene construct described herein.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence comprising in 5′ to 3′ order: a branch point, a 3′ splice site, and an endogenous intronic recognition element for splicing modifier (iREMS), wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the RNA transcript is an RNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837; the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence comprising in 5′ to 3′ order: a branch point, a 3′ splice site and an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS); wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In certain embodiments, the RNA transcript is an RNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DTAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, TVD, KDM6A, KTAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAPlA, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃,         w₄, w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₄alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In another aspect, provided herein is a method for modulating the amount of an RNA transcript comprising a RNA nucleotide sequence, wherein the RNA nucleotide sequence comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a first branch point and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting the RNA transcript with a compound of Formula (I) or a form thereof, wherein Formula (I) is:

-   -   wherein:     -   w₁ and w₅ are independently C—R_(a) or N;     -   w₂ is C—R_(b) or N;     -   w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;     -   w₆ is C—R₁, C—R₂, C—R_(c) or N;     -   wherein one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄,         w₆ and w₇ is C—R₂, provided that,     -   when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently         C—R_(a) or N; or,     -   when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆         is C—R_(c) or N; or,     -   when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is         C—R_(c) or N; and,     -   wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇         may optionally be N;     -   R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino,         (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (C₁₋₈alkoxy-C₁₋₈alkyl)C₁₋₈alkyl)amino-C₁₋₈alkoxy,         amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl,         (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl,         C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl,         halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino,         (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy,         hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino,         [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy,         heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino,         heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino,         (heterocyclyl-C₁₋₈alkyl)₂-amino,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl,         heterocyclyl-oxy, heterocyclyl-carbonyl,         heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl,         aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl,         heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino,         heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino,         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl,         (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or         (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two or three         R₃ substituents and optionally, with one additional R₄         substituent; or,     -   wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl         and heteroaryl is optionally substituted with one, two, three or         four R₃ substituents;     -   R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl,         heteroaryl or heteroaryl-amino;     -   wherein, each instance of aryl, heterocyclyl and heteroaryl is         optionally substituted with one, two or three R₆ substituents         and optionally, with one additional R₇ substituent;     -   R_(a) is, in each instance, independently selected from         hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;     -   R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;     -   R₃ is, in each instance, independently selected from cyano,         halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl,         C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino,         C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl,         C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl,         amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino,         (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino,         C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino,         (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino,         C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino,         hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or         (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;     -   R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl,         C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl,         aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or         heterocyclyl-C₁₋₈alkyl; wherein, each instance of         C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted         with one, two or three R₅ substituents;     -   R₅ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy,         halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or         C₁₋₈alkyl-thio;     -   R₆ is, in each instance, independently selected from halogen,         hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl,         hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,         C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino         or C₁₋₈alkyl-thio; and,     -   R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl         or heteroaryl.

In certain embodiments, the iREMS is an endogenous iREMS, and the RNA transcript is an RNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, K1AA1462, K1AA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LTNC00702, LINC00886, LTNC00961, LINC01011, LTNC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837.

In certain embodiments, the iREMS is an endogenous iREMS, and the RNA transcript is an RNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf38, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAPlA, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBCID15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680.

In certain embodiments, the iREMS is a non-endogenous IREMS. In a specific embodiment, the iREMS is a non-endogenous iREMS and the RNA transcript is an RNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, IVD, KDM6A, K1AA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAPlA, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680.

In one aspect, provided herein is a method for producing a mature mRNA transcript comprising iExon from a pre-mRNA transcript, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In one embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In another embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In some embodiments, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

In a particular embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP. In another particular embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP.

In another aspect, provided herein is a method modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In one embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In another embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In some embodiments, the intron further comprises a first 5′ splice site, a second branch point, and a second 3′ splice site upstream of the iREMS. In some embodiments, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

In a particular embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837. In a particular embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orfB6, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, TQCG, TTGA11, ITGA8, TTGB8, ITIH1, TTPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-A S1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837. In some embodiments, the intron further comprises a first 5′ splice site, a second branch point, and a second 3′ splice site upstream of the iREMS.

In one aspect, provided herein is a method for preventing, treating or preventing and treating a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.

In one aspect, provided herein is a method for preventing, treating or preventing and treating a disease or disorder in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, the method comprising administering a compound described herein to a subject in need thereof, wherein the one, two, three or more RNA isoforms are produced from a pre-mRNA transcript comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises an iREMS that is downstream of a branch point and a 3′ splice site, and wherein the iREMS comprises the sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provide herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a first branch point and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises an RNA sequence GAguragu, wherein r is adenine or guanine.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises an RNA sequence NNGAgurngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide. In a specific embodiment, the RNA sequence NNGAgurngn (SEQ ID NO: 1) is selected from the group consisting of ANGAgurngn (SEQ ID NO: 29), CNGAgurngn (SEQ ID NO: 35), GNGAgurngn (SEQ ID NO: 41), UNGAgurngn (SEQ ID NO: 47), NAGAgurngn (SEQ ID NO: 30), NCGAgurngn (SEQ ID NO: 36), NGGAgurngn (SEQ ID NO: 42), NUGAgurngn (SEQ ID NO: 48), AAGAgurngn (SEQ ID NO: 31), ACGAgurngn (SEQ ID NO: 37), AGGAgurngn (SEQ ID NO: 43), AUGAgurngn (SEQ ID NO: 49), CAGAgurngn (SEQ ID NO: 32), CCGAgurngn (SEQ ID NO: 38), CGGAgurngn (SEQ ID NO: 44), CUGAgurngn (SEQ ID NO: 50), GAGAgurngn (SEQ ID NO: 33), GCGAgurngn (SEQ ID NO: 39), GGGAgurngn (SEQ ID NO: 45), GUGAgurngn (SEQ ID NO: 51), UAGAgurngn (SEQ ID NO: 34), UCGAgurngn (SEQ ID NO: 40), UGGAgurngn (SEQ ID NO: 46) and UUGAgurngn (SEQ ID NO: 52), wherein r is adenine or guanine and n or N is any nucleotide.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises an RNA sequence NNGAguragu (SEQ ID NO: 3862), wherein r is adenine or guanine and N is any nucleotide. In a specific embodiment, the RNA sequence NNGAguragu (SEQ ID NO: 3862) is selected from the group consisting of ANGAguragu (SEQ ID NO: 437), CNGAguragu (SEQ ID NO: 443), GNGAguragu (SEQ ID NO: 449), UNGAguragu (SEQ ID NO: 455), NAGAguragu (SEQ ID NO: 438), NCGAguragu (SEQ ID NO: 444), NGGAguragu (SEQ ID NO: 450), NUGAguragu (SEQ ID NO: 456), AAGAguragu (SEQ ID NO: 439), ACGAguragu (SEQ ID NO: 445), AGGAguragu (SEQ ID NO: 451), AUGAguragu (SEQ ID NO: 457), CAGAguragu (SEQ ID NO: 440), CCGAguragu (SEQ ID NO: 446), CGGAguragu (SEQ ID NO: 452), CUGAguragu (SEQ ID NO: 458), GAGAguragu (SEQ ID NO: 441), GCGAguragu (SEQ ID NO: 447), GGGAguragu (SEQ ID NO: 453), GUGAguragu (SEQ ID NO: 459), UAGAguragu (SEQ ID NO: 442), UCGAguragu (SEQ ID NO: 448), UGGAguragu (SEQ ID NO: 454) and UUGAguragu (SEQ ID NO: 460), wherein r is adenine or guanine, and N is any nucleotide.

In various embodiments of the method for modulating the amount of an RNA transcript described herein, modulation of the amount of the RNA transcript is modulation of the amount of the RNA transcript in a cell or a lysate of the cell, and the method comprises contacting the compound of Formula (I) or a form thereof with the cell or cell lysate. In a specific embodiment, modulation of the amount of the RNA transcript is modulation of the amount of the RNA transcript in a cell, and the method comprises contacting the compound of Formula (I) or a form thereof with the cell. In a specific embodiment, the modulation modulates the amount and/or type of a protein translated from the RNA transcript and produced in the cell or lysate of the cell.

In various embodiments of the method for modulating the amount of an RNA transcript described herein, the RNA transcript encodes a detectable reporter protein.

In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence encoding at least one intron comprises an iREMS that is downstream of the nucleotide sequence encoding a branch point and the nucleotide sequence encoding a 3′ splice site, and wherein the iREMS comprises the sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: the nucleotide sequence encoding a first 5′ splice site, the nucleotide sequence encoding a first branch point, the nucleotide sequence encoding a first 3′ splice site, an iREMS, the nucleotide sequence encoding a second branch point and the nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: an iREMS, the nucleotide sequence encoding a first branch point and the nucleotide sequence encoding a first 3′ splice site, wherein the iREMS comprises an DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises a DNA sequence GAgtragt, wherein r is adenine or guanine.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises a DNA sequence NNGAgtrngn (SEQ ID NO: 1), wherein r is adenine or guanine and n or N is any nucleotide. In a specific embodiment, the DNA sequence NNGAgtrngn (SEQ ID NO: 1) is selected from the group consisting of ANGAgtrngn (SEQ ID NO: 29), CNGAgtrngn (SEQ ID NO: 35), GNGAgtrngn (SEQ ID NO: 41), TNGAgtrngn (SEQ ID NO: 47), NAGAgtrngn (SEQ ID NO: 30), NCGAgtrngn (SEQ ID NO: 36), NGGAgtrngn (SEQ ID NO: 42), NTGAgtrngn (SEQ ID NO: 48), AAGAgtrngn (SEQ ID NO: 31), ACGAgtrngn (SEQ ID NO: 37), AGGAgtrngn (SEQ ID NO: 43), ATGAgtrngn (SEQ ID NO: 49), CAGAgtrngn (SEQ ID NO: 32), CCGAgtrngn (SEQ ID NO: 38), CGGAgtrngn (SEQ ID NO: 44), CTGAgtrngn (SEQ ID NO: 50), GAGAgtrngn (SEQ ID NO: 33), GCGAgtrngn (SEQ ID NO: 39), GGGAgtrngn (SEQ ID NO: 45), GTGAgtrngn (SEQ ID NO: 51), TAGAgtrngn (SEQ ID NO: 34), TCGAgtrngn (SEQ ID NO: 40), TGGAgtrngn (SEQ ID NO: 46) and TTGAgtrngn (SEQ ID NO: 52), wherein r is adenine or guanine and n or N is any nucleotide.

In various embodiments of the aspects and embodiments described herein, the iREMS comprises a DNA sequence NNGAgtragt (SEQ ID NO: 3862), wherein r is adenine or guanine and N is any nucleotide. In a specific embodiment, the DNA sequence NNGAgtragt (SEQ ID NO: 3862) is selected from the group consisting of ANGAgtragt (SEQ ID NO: 437), CNGAgtragt (SEQ ID NO: 443), GNGAgtragt (SEQ ID NO: 449), TNGAgtragt (SEQ ID NO: 455), NAGAgtragt (SEQ ID NO: 438), NCGAgtragt (SEQ ID NO: 444), NGGAgtragt (SEQ ID NO: 450), NTGAgtragt (SEQ ID NO: 456), AAGAgtragt (SEQ ID NO: 439), ACGAgtragt (SEQ ID NO: 445), AGGAgtragt (SEQ ID NO: 451), ATGAgtragt (SEQ ID NO: 457), CAGAgtragt (SEQ ID NO: 440), CCGAgtragt (SEQ ID NO: 446), CGGAgtragt (SEQ ID NO: 452), CTGAgtragt (SEQ ID NO: 458), GAGAgtragt (SEQ ID NO: 441), GCGAgtragt (SEQ ID NO: 447), GGGAgtragt (SEQ ID NO: 453), GTGAgtragt (SEQ ID NO: 459), TAGAgtragt (SEQ ID NO: 442), TCGAgtragt (SEQ ID NO: 448), TGGAgtragt (SEQ ID NO: 454) and TTGAgtragt (SEQ ID NO: 460), wherein r is adenine or guanine, and N is any nucleotide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1C. Representative schematics of intronic exon splicing mediated by an intronic REMS, where 5′ss represents a 5′ splice site, 3′ss represents a 3′ splice site and BP represents a splicing branch point. Exon 1e and Exon 2e represent extended exons. iExon 1a represents an intronic exon. Splicing events mediated by an intronic REMS in the absence of a compound described herein are illustrated by solid lines, splicing events mediated by an intronic REMS in the presence of a compound described herein are illustrated by dashed lines.

FIGS. 2A-2D, 3, 4, 5, 6A. The dose dependent production of iExons for certain genes (as specified in the figures) in the presence of certain compounds or control (DMSO) are shown, each of which represent aspects of the operation of an intronic REMS and compounds as described herein. Compounds used in the experiments depicted in FIGS. 3, 4, 5, and 6A are described herein. Compound 774 was used for the experiments depicted in FIGS. 2A-2D.

FIGS. 6B and 6C. FIG. 6B illustrates the production of exon isoforms with control (DMSO). FIG. 6C illustrates the production of certain intronic Exon isoforms for ELMO2 in the presence of a compound described herein, each of which represent aspects of the interactions of an intronic REMS, one or more branch points, one or more 3′ splice sites and compounds as described herein.

DETAILED DESCRIPTION Intronic Recognition Element for Splicing Modifier (Rems)

In one aspect, provided herein is an intronic recognition element for splicing modifier (otherwise referred to as “iREMS”) recognized by a small molecule splicing modifier, whereby elements of the associated iREMS complex affect interactions with the spliceosome as further described herein. In a specific embodiment, the intronic REMS has the nucleotide sequence GAgurngn (SEQ ID NO: 2) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n is any nucleotide. In another specific embodiment, the intronic REMS has the nucleotide sequence GAguragu (SEQ ID NO: 3866) at the RNA level, wherein r is adenine or guanine. In one or more of such specific embodiments provided herein, n is adenine or guanine. In a more specific embodiment, the intronic REMS has the nucleotide sequence NNGAgurngn (SEQ ID NO: 1) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In another more specific embodiment, the intronic REMS has the nucleotide sequence NNGAguragu (SEQ ID NO: 3862) at the RNA level, wherein r is adenine or guanine and N is any nucleotide. In one or more of such more specific embodiments provided herein, N is adenine or guanine.

In another specific embodiment, the intronic REMS is downstream of an intronic branch point and a functional intronic 3′ splice site, wherein the intronic REMS comprises a nucleotide sequence selected from the group consisting of ANGAgurngn (SEQ ID NO: 29), CNGAgurngn (SEQ ID NO: 35), GNGAgurngn (SEQ ID NO: 41), UNGAgurngn (SEQ ID NO: 47), NAGAgurngn (SEQ ID NO: 30), NCGAgurngn (SEQ ID NO: 36), NGGAgurngn (SEQ ID NO: 42), NUGAgurngn (SEQ ID NO: 48), AAGAgurngn (SEQ ID NO: 31), ACGAgurngn (SEQ ID NO: 37), AGGAgurngn (SEQ ID NO: 43), AUGAgurngn (SEQ ID NO: 49), CAGAgurngn (SEQ ID NO: 32), CCGAgurngn (SEQ ID NO: 38), CGGAgurngn (SEQ ID NO: 44), CUGAgurngn (SEQ ID NO: 50), GAGAgurngn (SEQ ID NO: 33), GCGAgurngn (SEQ ID NO: 39), GGGAgurngn (SEQ ID NO: 45), GUGAgurngn (SEQ ID NO: 51), UAGAgurngn (SEQ ID NO: 34), UCGAgurngn (SEQ ID NO: 40), UGGAgurngn (SEQ ID NO: 46) and UUGAgurngn (SEQ ID NO: 52) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide, by which the intronic REMS, in the presence of a compound described herein, functions as an intronic 5′ splice site, causing the NNGA (SEQ ID NO: 3863) nucleotides of the REMS and the intronic nucleotide sequence between the intronic 3′ splice site down to and including the NNGA (SEQ ID NO: 3863) nucleotides to be spliced into the mature RNA as an intronic exon to provide a non-wild-type, nonfunctional mRNA.

In a preferred embodiment, the REMS has a nucleotide sequence selected from the group consisting of ANGAguragu (SEQ ID NO: 437), CNGAguragu (SEQ ID NO: 443), GNGAguragu (SEQ ID NO: 449), UNGAguragu (SEQ ID NO: 455), NAGAguragu (SEQ ID NO: 438), NCGAguragu (SEQ ID NO: 444), NGGAguragu (SEQ ID NO: 450), NUGAguragu (SEQ ID NO: 456), AAGAguragu (SEQ ID NO: 439), ACGAguragu (SEQ ID NO: 445), AGGAguragu (SEQ ID NO: 451), AUGAguragu (SEQ ID NO: 457), CAGAguragu (SEQ ID NO: 440), CCGAguragu (SEQ ID NO: 446), CGGAguragu (SEQ ID NO: 452), CUGAguragu (SEQ ID NO: 458), GAGAguragu (SEQ ID NO: 441), GCGAguragu (SEQ ID NO: 447), GGGAguragu (SEQ ID NO: 453), GUGAguragu (SEQ ID NO: 459), UAGAguragu (SEQ ID NO: 442), UCGAguragu (SEQ ID NO: 448), UGGAguragu (SEQ ID NO: 454) and UUGAguragu (SEQ ID NO: 460) at the RNA level, wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and N is any nucleotide. In one or more embodiments provided herein, N is A or G.

In the context of DNA, in a specific embodiment, the nucleotide sequence encoding an intronic REMS has the sequence GAgtrngn (SEQ ID NO: 4), wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n is any nucleotide. In another specific embodiment, in the context of DNA, the nucleotide sequence encoding an intronic REMS has the sequence GAgtragt (SEQ ID NO: 3865), wherein r is A or G. In a specific embodiment, in the context of DNA, the nucleotide sequence encoding an intronic REMS has the sequence NNGAgtrngn (SEQ ID NO: 3), wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide. In another specific embodiment, in the context of DNA, the nucleotide sequence encoding an intronic REMS has the sequence NNGAgtragt (SEQ ID NO: 3864), wherein r is A or G and N is any nucleotide.

In a specific embodiment, in the context of DNA, the nucleotide sequence encoding an intronic REMS comprises a sequence selected from the group consisting of ANGAgtrngn (SEQ ID NO: 1829), CNGAgtrngn (SEQ ID NO: 1835), GNGAgtrngn (SEQ ID NO: 1841), TNGAgtrngn (SEQ ID NO: 1847), NAGAgtrngn (SEQ ID NO: 1830), NCGAgtrngn (SEQ ID NO: 1836), NGGAgtrngn (SEQ ID NO: 1842), NTGAgtrngn (SEQ ID NO: 1848), AAGAgtrngn (SEQ ID NO: 1831), ACGAgtrngn (SEQ ID NO: 1837), AGGAgtrngn (SEQ ID NO: 1843), ATGAgtrngn (SEQ ID NO: 1849), CAGAgtrngn (SEQ ID NO: 1832), CCGAgtrngn (SEQ ID NO: 1838), CGGAgtrngn (SEQ ID NO: 1844), CTGAgtrngn (SEQ ID NO: 1850), GAGAgtrngn (SEQ ID NO: 1833), GCGAgtrngn (SEQ ID NO: 1839), GGGAgtrngn (SEQ ID NO: 1845), GTGAgtrngn (SEQ ID NO: 1851), TAGAgtrngn (SEQ ID NO: 1834), TCGAgtrngn (SEQ ID NO: 1840), TGGAgtrngn (SEQ ID NO: 1846) and TTGAgtrngn (SEQ ID NO: 1852), wherein r is A or G (i.e., a purine nucleotide adenine or guanine) and n or N is any nucleotide.

In a preferred embodiment, in the context of DNA, the nucleotide sequence encoding the intronic REMS comprises a sequence selected from the group consisting of ANGAgtragt (SEQ ID NO: 2237), CNGAgtragt (SEQ ID NO: 2243), GNGAgtragt (SEQ ID NO: 2249), TNGAgtragt (SEQ ID NO: 2255), NAGAgtragt (SEQ ID NO: 2238), NCGAgtragt (SEQ ID NO: 2244), NGGAgtragt (SEQ ID NO: 2250), NTGAgtragt (SEQ ID NO: 2256), AAGAgtragt (SEQ ID NO: 2239), ACGAgtragt (SEQ ID NO: 2245), AGGAgtragt (SEQ ID NO: 2251), ATGAgtragt (SEQ ID NO: 2257), CAGAgtragt (SEQ ID NO: 2240), CCGAgtragt (SEQ ID NO: 2246), CGGAgtragt (SEQ ID NO: 2252), CTGAgtragt (SEQ ID NO: 2258), GAGAgtragt (SEQ ID NO: 2241), GCGAgtragt (SEQ ID NO: 2247), GGGAgtragt (SEQ ID NO: 2253), GTGAgtragt (SEQ ID NO: 2259), TAGAgtragt (SEQ ID NO: 2242), TCGAgtragt (SEQ ID NO: 2248), TGGAgtragt (SEQ ID NO: 2254) and TTGAgtragt (SEQ ID NO: 2260), wherein r is A or G and N is any nucleotide. In one or more embodiments provided herein, N is A or G.

An intronic REMS can be part of an endogenous RNA or can be introduced into an RNA sequence that does not naturally contain the intronic REMS sequence (in which case, the introduced intronic REMS is a non-endogenous intronic REMS, i.e., an intronic REMS not naturally present in the corresponding RNA. A nucleotide sequence encoding an intronic REMS can also be part of an endogenous DNA sequence, or a nucleotide sequence encoding the intronic REMS can be introduced into a DNA sequence that does not naturally contain the nucleotide sequence encoding an intronic REMS.

In a specific embodiment, the intronic REMS is located in an intron which further comprises is downstream of a branch point and a functional 3′ splice site which, in the presence of a small molecule splicing modifier, enables the REMS to function as a 5′ splice site. In a specific embodiment, the intronic REMS is located in an intron and is downstream of a branch point and a functional 3′ splice site which, in the presence of a small molecule splicing modifier, enables the REMS to function as a 5′ splice site. Without being bound by any theory or mechanism, the small molecule compounds described herein have been shown to increase the affinity of the interaction between the U1 snRNP, as well as other components of the pre-mRNA splicing machinery, and the nucleotides NNGA (SEQ ID NO: 3863) of the REMS whereby, in the presence of the compound, the intronic REMS functions as a U1 snRNP binding site, causing the intronic nucleotides to be spliced as an intronic exon.

Compounds

Provided herein are compounds of Formula (I) for use in the methods described herein:

or a form thereof, wherein:

w₁ and w₅ are independently C—R_(a) or N;

w₂ is C—R_(b) or N;

w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N;

w₆ is C—R₁, C—R₂, C—R_(c) or N;

wherein one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; and,

wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇ may optionally be N;

R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;

wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R₃ substituents and optionally, with one additional R₄ substituent; or,

wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R₃ substituents;

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino;

wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent;

R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl or deuterium;

R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium;

R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium;

R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;

R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or heterocyclyl-C₁₋₈alkyl;

wherein, each instance of C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R₅ substituents;

R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio;

R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; and,

R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl.

In one embodiment of the use of a compound of Formula (I), w₁ is C—R_(a).

In another embodiment of the use of a compound of Formula (I), w₁ is N.

In one embodiment of the use of a compound of Formula (I), w₂ is C—R_(b).

In another embodiment of the use of a compound of Formula (I), w₂ is N.

In one embodiment of the use of a compound of Formula (I), w₃ is C—R_(a).

In another embodiment of the use of a compound of Formula (I), w₃ is N.

In one embodiment of the use of a compound of Formula (I), w₄ is C—R_(a).

In another embodiment of the use of a compound of Formula (I), w₄ is N.

In one embodiment of the use of a compound of Formula (I), w₅ is C—R_(a).

In another embodiment of the use of a compound of Formula (I), w₅ is N.

In one embodiment of the use of a compound of Formula (I), w₆ is C—R_(c).

In another embodiment of the use of a compound of Formula (I), w₆ is N.

In one embodiment of the use of a compound of Formula (I), w₇ is C—R_(a).

In another embodiment of the use of a compound of Formula (I), w₇ is N.

In one embodiment of the use of a compound of Formula (I), w₃ is C—R₁and w₆ is C—R₂.

In another embodiment of the use of a compound of Formula (I), w₃ is C—R₂ and w₆ is C—R₁.

In one embodiment of the use of a compound of Formula (I), w₄ is C—R₁and w₇ is C—R₂.

In another embodiment of the use of a compound of Formula (I), w₄ is C—R₂ and w₇ is C—R₁.

In one embodiment of the use of a compound of Formula (I), w₃ is C—R₁, w₆ is C—R₂ and w₁, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of a compound of Formula (I), w₃ is C—R₂, w₆ is C—R₁and w₁, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In one embodiment of the use of a compound of Formula (I), w₄ is C—R₁, w₇ is C—R₂, w₁, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of a compound of Formula (I), w₄ is C—R₂, w₇ is C—R₁, w₁, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₂ are N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₃ are N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₄ are N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₅ are N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₆ are N.

In one embodiment of the use of a compound of Formula (I), w₁ and w₇ are N.

In one embodiment of the use of a compound of Formula (I),

R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino or [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl or heterocyclyl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is C₃₋₁₄cycloalkyl optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of aryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is aryl-C₁₋₈alkyl-amino optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heteroaryl optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-h]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl selected from azetidin-1-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, 1,4-diazepan-1-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazin-2-yl, 3-azabicyclo[3.1.0]hex-3-yl, 8-azabicyclo[3.2.1]oct-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl, 8-azabicyclo[3.2.1]oct-2-en-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl, 9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl, 2,5-diazabicyclo[2.2.1]hept-2-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl, 2,5-diazabicyclo[2.2.2]oct-2-yl, 3,8-diazabicyclo[3.2.1]oct-3-yl, (1R,5S)-3,8-diazabicyclo[3.2.1]oct-3-yl, 1,4-diazabicyclo[3.2.2]non-4-yl, azaspiro[3.3]hept-2-yl, 2,6-diazaspiro[3.3]hept-2-yl, 2,7-diazaspiro[3.5]non-7-yl, 5,8-diazaspiro[3.5]non-8-yl, 2,7-diazaspiro[4.4]non-2-yl or 6,9-diazaspiro[4.5]dec-9-yl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is substituted heterocyclyl selected from 4-methyl-1,4-diazepan-1-yl, (3aS,6aS)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aS,6aS)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-ethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl, (4aR,7aR)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-ethyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (7R,8aS)-7-hydroxyhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-8a-methyloctahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-8a-methyloctahydropyrrolo[1,2-a]pyrazin-2(1H)-yl, (1R,5S,6s)-6-(dimethylamino)-3-azabicyclo[3.1.0]hex-3-yl, (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl, 9-methyl-9-azabicyclo[3.3.1]non-3-yl, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl or (1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkyl, wherein heterocyclyl is selected from morpholinyl, piperidinyl, piperazinyl, imidazolyl or pyrrolidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkyl selected from morpholin-4-yl-methyl, morpholin-4-yl-ethyl, morpholin-4-yl-propyl, piperidin-1-yl-methyl, piperazin-1-yl-methyl, piperazin-1-yl-ethyl, piperazin-1-yl-propyl, piperazin-1-yl-butyl, imidazol-1-yl-methyl, imidazol-1-yl-ethyl, imidazol-1-yl-propyl, imidazol-1-yl-butyl, pyrrolidin-1-yl-methyl, pyrrolidin-1-yl-ethyl, pyrrolidin-1-yl-propyl or pyrrolidin-1-yl-butyl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkoxy, wherein heterocyclyl is selected from pyrrolidinyl, piperidinyl or morpholinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkoxy selected from pyrrolidin-2-yl-methoxy, pyrrolidin-2-yl-ethoxy, pyrrolidin-1-yl-methoxy, pyrrolidin-1-yl-ethoxy, piperidin-1-yl-methoxy, piperidin-1-yl-ethoxy, morpholin-4-yl-methoxy or morpholin-4-yl-ethoxy; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-amino, wherein heterocyclyl is selected from azetidinyl, pyrrolidinyl, piperidinyl, 9-azabicyclo[3.3.1]nonyl or (1R,5S)-9-azabicyclo[3.3.1]nonyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-amino selected from azetidin-3-yl-amino, pyrrolidin-3-yl-amino, piperidin-4-yl-amino, 9-azabicyclo[3.3.1]non-3-yl-amino, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl-amino, 9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino or (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is (heterocyclyl)(C₁₋₈alkyl)amino, wherein heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is (heterocyclyl)(C₁₋₈alkyl)amino selected from (pyrrolidin-3-yl)(methyl)amino or (piperidin-4-yl)methyl)amino; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-amino-C₁₋₈alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-amino-C₁₋₈alkyl, selected from 3-(tetrahydrofuran-3-yl-amino)propyl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, wherein heterocyclyl is selected from tetrahydrofuranyl, thienyl or pyridinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, selected from 3-[(tetrahydrofuran-2-ylmethyl)amino]propyl, 3-[(thienyl-3-ylmethyl)amino]propyl, 3-[(pyridin-2-ylmethyl)amino]propyl or 3-[(pyridin-4-ylmethyl)amino]propyl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-oxy, wherein heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-oxy selected from pyrrolidin-3-yl-oxy or piperidin-4-yl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-carbonyl, wherein heterocyclyl is selected from piperazinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-carbonyl selected from piperazin-1-yl-carbonyl; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-carbonyl-oxy, wherein heterocyclyl is selected from piperazinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heterocyclyl-carbonyl-oxy selected from piperazin-1-yl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is C₃₋₁₄cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or cycloheptyl; wherein, each instance of C₃₋₁₄cycloalkyl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is C₃₋₈cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl or cycloheptyl; wherein, each instance of C₃₋₈cycloalkyl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl selected from 3-(benzylamino)propyl; wherein, each instance of aryl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heteroaryl, wherein heteroaryl is selected from pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heteroaryl selected from pyridin-4-yl; wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heteroaryl-C₁₋₈alkyl, wherein heteroaryl is selected from 1H-imidazolyl; and, wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heteroaryl-C₁₋₈alkyl selected from 1H-imidazol-1-yl-methyl; wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, wherein heteroaryl is selected from pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino selected from (pyridin-3-ylmethylxmethyl)amino; wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₁ is heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, wherein heteroaryl is selected from thienyl or pyridinyl; and, wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In another embodiment of the use of a compound of Formula (I), R₁ is heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl selected from thien-3-yl-methyl-amino-propyl, pyridin-2-yl-methyl-amino-propyl, pyridin-3-yl-methyl-amino-propyl or pyridin-4-yl-methyl-amino-propyl; wherein, each instance of heteroaryl is optionally substituted with R₃ and R₄ substituents.

In one embodiment of the use of a compound of Formula (I), R₃ is selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino.

In another embodiment of the use of a compound of Formula (I), R₃ is selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino.

In one embodiment of the use of a compound of Formula (I), R₃ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

In another embodiment of the use of a compound of Formula (I), R₃ is C₁₋₈alkyl selected from ethyl, propyl, isopropyl or tert-butyl.

In one embodiment of the use of a compound of Formula (I), R₃ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In another embodiment of the use of a compound of Formula (I), R₃ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, trihalo-propyl or dihalo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₃ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

In another embodiment of the use of a compound of Formula (I), R₃ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

In one embodiment of the use of compound of Formula (I), R₃ is C₁₋₈alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.

In one embodiment of the use of a compound of Formula (I), R₃ is halo-C₁₋₈alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₃ is C₁₋₈alkoxy-carbonyl-amino selected from methoxy-carbonyl-amino, ethoxy-carbonyl-amino, propoxy-carbonyl-amino, isopropoxy-carbonyl-amino, tert-butoxy-carbonyl-amino.

In one embodiment of the use of a compound of Formula (I), R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl.

In one embodiment of the use of a compound of Formula (I), R_(a) is, in each instance, optionally and independently deuterium.

In one embodiment of the use of a compound of Formula (I), R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy.

In one embodiment of the use of a compound of Formula (I), R_(c) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl.

In one embodiment of the use of a compound of Formula (I), R_(c) is, in each instance, optionally and independently deuterium.

In one embodiment of the use of a compound of Formula (I), R_(b) is deuterium.

In one embodiment of the use of a compound of Formula (I), R₄ is C₃₋₁₄cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; wherein, each instance of C₃₋₁₄cycloalkyl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is C-s-cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; wherein, each instance of C₃₋₈cycloalkyl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₄ is C₃₋₁₄cycloalkyl-C₁₋₈alkyl, wherein C₃₋₁₄cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C₃₋₁₄cycloalkyl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is C₃₋₈cycloalkyl-C₁₋₈alkyl, wherein C₃₋₈cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C₃₋₈cycloalkyl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₄ is C₃₋₁₄cycloalkyl-amino, wherein C₃₋₁₄cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C₃₋₁₄cycloalkyl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is C₃₋₈cycloalkyl-amino, wherein C₃₋₈cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; and, wherein, each instance of C₃₋₈cycloalkyl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₄ is aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl or aryl-sulfonyloxy-C₁₋₈alkyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is aryl-C₁₋₈alkyl or aryl-C₁₋₈alkoxy-carbonyl, wherein each instance of aryl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₄ is heterocyclyl selected from oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,3-dioxanyl or morpholinyl, wherein each instance of heterocyclyl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is heterocyclyl selected from oxetan-3-yl, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 1,3-dioxan-5-yl or morpholin-4-yl, wherein each instance of heterocyclyl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₄ is heterocyclyl-C₁₋₈alkyl, wherein each instance of heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₅ substituents.

In another embodiment of the use of a compound of Formula (I), R₄ is heterocyclyl-C₁₋₈alkyl selected from pyrrolidin-1-yl-C₁₋₈alkyl or piperidin-1-yl-C₁₋₈alkyl, wherein each instance of heterocyclyl is optionally substituted with R₅ substituents.

In one embodiment of the use of a compound of Formula (I), R₅ is selected from halogen, hydroxy, cyano, nitro, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; wherein, halogen and halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₅ is hydroxy.

In one embodiment of the use of a compound of Formula (I), R₅ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl, n-butyl or tert-butyl.

In another embodiment of the use of a compound of Formula (I), R₅ is C₁₋₈alkyl selected from ethyl, propyl, isopropyl or tert-butyl.

In one embodiment of the use of a compound of Formula (I), R₁ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₅ is C₁₋₈alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.

In one embodiment of the use of a compound of Formula (I), R₅ is halo-C₁₋₈alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₂ is aryl selected from phenyl optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I), R₂ is aryl-amino, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I), R₂ is aryl-amino selected from phenyl-amino; wherein, each instance of aryl is optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I), R₂ is aryl-amino-carbonyl, wherein aryl is selected from phenyl; and, wherein, each instance of aryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I), R₂ is aryl-amino-carbonyl selected from phenyl-amino-carbonyl; wherein, each instance of aryl is optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I),

R₂ is heterocyclyl selected from 1,2,3,6-tetrahydropyridinyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl; wherein, each instance of heterocyclyl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₂ is heterocyclyl selected from 1,2,3,6-tetrahydropyridin-4-yl, 1,3-benzodioxol-5-yl or 2,3-dihydro-1,4-benzodioxin-6-yl; wherein, each instance of heterocyclyl is optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I),

R₂ is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl or quinoxalinyl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₂ is heteroaryl selected from thien-2-yl, thien-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, indolizin-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, benzothien-3-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-6-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 9H-purin-8-yl, furo[3,2-b]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, furo[2,3-c]pyridin-2-yl, thieno[3,2-c]pyridin-2-yl, thieno[2,3-d]pyrimidin-6-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, pyrrolo[1,2-a]pyrimidin-7-yl, pyrrolo[1,2-a]pyrazin-7-yl, pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyrazin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-a]pyrimidin-6-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl or quinoxalin-2-yl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₂ is substituted heteroaryl selected from 4-methylthien-2-yl, 1-methyl-1H-pyrazol-3-yl, 4-methyl-1H-pyrazol-3-yl, 1-phenyl-1H-pyrazol-3-yl, 1-phenyl-1H-imidazol-4-yl, 2-methyl-1-(pyridin-2-yl)-1H-imidazol-4-yl, 4-methyl-1,3-thiazol-2-yl, 4-(trifluoromethyl)-1,3-thiazol-2-yl, 4-phenyl-1,3-thiazol-2-yl, 5-phenyl-1,2,4-oxadiazol-3-yl, 3-fluoropyridin-4-yl, 6-fluoropyridin-2-yl, 2-chloropyridin-4-yl, 4-chloropyridin-3-yl, 5-chloropyridin-2-yl, 6-methylpyridin-3-yl, 2-(trifluoromethyl)pyridin-3-yl, 4-(trifluoromethyl)pyridin-2-yl, 6-(trifluoromethyl)pyridin-2-yl, 2-methoxypyridin-4-yl, 4-methoxypyridin-3-yl, 6-methoxypyridin-2-yl, 2-ethoxypyridin-3-yl, 6-ethoxypyridin-2-yl, 6-(propan-2-yloxy)pyridin-2-yl, 6-(dimethylamino)pyridin-3-yl, 6-(methylsulfanyl)pyridin-2-yl, 6-(cyclobutyloxy)pyridin-2-yl, 6-(pyrrolidin-1-yl)pyridin-2-yl, 2-methylpyrimidin-4-yl, 2-(propan-2-yl)pyrimidin-4-yl, 2-cyclopropylpyrimidin-4-yl, 1-methyl-1H-indol-3-yl, 2-methyl-2H-indazol-5-yl, 2-methyl-1-benzofuran-5-yl, 1-methyl-1H-benzimidazol-2-yl, 4-methyl-1H-benzimidazol-2-yl 5-fluoro-1FH-benzimidazol-2-yl, 4-fluoro-1,3-benzoxazol-2-yl, 5-fluoro-1,3-benzoxazol-2-yl, 4-chloro-1,3-benzoxazol-2-yl, 4-iodo-1,3-benzoxazol-2-yl, 2-methyl-1,3-benzoxazol-6-yl, 4-methyl-1,3-benzoxazol-2-yl, 4-(trifluoromethyl)-1,3-benzoxazol-2-yl, 7-(trifluoromethyl)-1,3-benzoxazol-2-yl, 2-methyl-1,3-benzothiazol-2-yl, 2-methyl-1,3-benzothiazol-5-yl, 2-methyl-1,3-benzothiazol-6-yl, 4-chloro-1,3-benzothiazol-2-yl, 7-chloro-1,3-benzothiazol-2-yl, 4-(trifluoromethyl)-1,3-benzothiazol-2-yl, 5-methylfuro[3,2-b]pyridin-2-yl, 4,6-dimethylfuro[3,2-c]pyridin-2-yl, 5,7-dimethylfuro[2,3-c]pyridin-2-yl, 4,6-dimethylthieno[3,2-c]pyridin-2-yl, 2,4-dimethylthieno[2,3-d]pyrimidin-6-yl, 1-methylpyrrolo[1,2-a]pyrazin-7-yl, 3-methylpyrrolo[1,2-a]pyrazin-7-yl, 1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl, 2-methylpyrrolo[1,2-b]pyridazin-2-yl, 4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl, 5-methylpyrazolo[1,5-a]pyridin-2-yl, 4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl, 2-chloroimidazo[2,1-b][1,3]thiazol-6-yl, 2-methylimidazo[2,1-b][1,3]thiazol-6-yl, 3-methylimidazo[2,1-b][1,3]thiazol-6-yl, 2-ethylimidazo[2,1-b][1,3]thiazol-6-yl, 2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl, 6-cyanoimidazo[1,2-a]pyridin-2-yl (also referred to as 2-imidazo[1,2-a]pyridine-6-carbonitrile), 6-fluoroimidazo[1,2-a]pyridin-2-yl, 8-fluoroimidazo[1,2-a]pyridin-2-yl, 6,8-difluoroimidazo[1,2-a]pyridin-2-yl, 7-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl, 8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl, 6-chloroimidazo[1,2-a]pyridin-2-yl, 7-chloroimidazo[1,2-a]pyridin-2-yl, 8-chloroimidazo[1,2-a]pyridin-2-yl, 8-bromoimidazo[1,2-a]pyridin-2-yl, 2-methylimidazo[1,2-a]pyridin-2-yl, 5-methylimidazo[1,2-a]pyridin-2-yl, 6-methylimidazo[1,2-a]pyridin-2-yl, 7-methylimidazo[1,2-a]pyridin-2-yl, 8-methylimidazo[1,2-a]pyridin-2-yl, 7-ethylimidazo[1,2-a]pyridin-2-yl, 8-ethylimidazo[1,2-a]pyridin-2-yl, 6,8-dimethylimidazo[1,2-a]pyridin-2-yl, 8-ethyl-6-methylimidazo[1,2-a]pyridin-2-yl, 7-methoxyimidazo[1,2-a]pyridin-2-yl, 8-methoxyimidazo[1,2-a]pyridin-2-yl, 6-fluoro-8-methylimidazo[1,2-a]pyridin-2-yl, 8-fluoro-6-methylimidazo[1,2-a]pyridin-2-yl, 8-chloro-6-methylimidazo[1,2-a]pyridin-2-yl, 6-methyl-8-nitroimidazo[1,2-a]pyridin-2-yl, 8-cyclopropylimidazo[1,2-a]pyridin-2-yl, 2-methylimidazo[1,2-a]pyridin-6-yl, 2-ethylimidazo[1,2-a]pyridin-6-yl, 2,3-dimethylimidazo[1,2-a]pyridin-6-yl, 2,8-dimethylimidazo[1,2-a]pyridin-6-yl, 2-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl, 8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl, 8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl, 6-fluoroimidazo[1,2-a]pyrimidin-2-yl, 6-chloroimidazo[1,2-a]pyrimidin-2-yl, 6-methylimidazo[1,2-a]pyrimidin-2-yl, 7-methylimidazo[1,2-a]pyrimidin-2-yl, 2-methylimidazo[1,2-a]pyrimidin-6-yl, 6-methylimidazo[1,2-b]pyridazin-2-yl, 2-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl, 6-methylimidazo[1,2-a]pyrazin-2-yl, 8-methylimidazo[1,2-a]pyrazin-2-yl, 6,8-dimethylimidazo[1,2-a]pyrazin-2-yl, 6-chloro-8-methylimidazo[1,2-a]pyrazin-2-yl, 6-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyrazin-2-yl, 8-(methylsulfanyl)imidazo[1,2-a]pyrazin-2-yl, 2-methylimidazo[2,1-b][1,3]thiazol-6-yl, 3-methylimidazo[2,1-b][1,3]thiazol-6-yl or 2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl.

In another embodiment of the use of a compound of Formula (I),

R₂ is heteroaryl selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₂ is heteroaryl selected from furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl or quinoxalinyl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I), R₂ is heteroaryl-amino, wherein heteroaryl is selected from pyridinyl or pyrimidinyl; and, wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I), R₂ is heteroaryl-amino selected from pyridin-2-yl-amino, pyridin-3-yl-amino or pyrimidin-2-yl-amino; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

In one embodiment of the use of a compound of Formula (I), R₆ is selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; wherein, halogen and halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₆ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

In another embodiment of the use of a compound of Formula (I), R₆ is C₁₋₈alkyl selected from ethyl, propyl, isopropyl or tert-butyl.

In one embodiment of the use of a compound of Formula (I), R₆ is C₂₋₈alkenyl selected from ethenyl, allyl or buta-1,3-dienyl.

In another embodiment of the use of a compound of Formula (I), R₆ is C₂₋₈alkenyl selected from ethenyl or allyl.

In one embodiment of the use of a compound of Formula (I), R₆ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₆ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

In another embodiment of the use of a compound of Formula (I), R₆ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

In one embodiment of the use of a compound of Formula (I), R₆ is C₁₋₈alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.

In one embodiment of the use of a compound of Formula (I), R₆ is halo-C₁₋₈alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.

In one embodiment of the use of a compound of Formula (I), R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl; wherein C₃₋₁₄cycloalkyl is selected from cyclopropyl or cyclobutoxy; wherein aryl is selected from phenyl; wherein heterocyclyl is selected from oxetanyl, pyrrolidinyl or 1,2,3,6-tetrahydropyridinyl; and, wherein heteroaryl is selected from thienyl or pyridinyl.

In another embodiment of the use of a compound of Formula (I), R₇ is C₃₋₁₄cycloalkyl or C₃₋₁₄cycloalkyl-oxy, wherein each instance of C₃₋₁₄cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

In another embodiment of the use of a compound of Formula (I), R₇ is C₃₋₈cycloalkyl or C₃₋₈cycloalkyl-oxy, wherein each instance of C₃₋₈cycloalkyl is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

In one embodiment of the use of a compound of Formula (I), R₇ is aryl selected from phenyl.

In one embodiment of the use of a compound of Formula (I), R₇ is heterocyclyl selected from oxetanyl, pyrrolidinyl or 1,2,3,6-tetrahydropyridinyl.

In another embodiment of the use of a compound of Formula (I), R₇ is heterocyclyl selected from oxetan-3-yl, pyrrolidin-1-yl or 1,2,3,6-tetrahydropyridin-4-yl.

In one embodiment of the use of a compound of Formula (I), R₇ is heteroaryl selected from thienyl or pyridinyl.

In another embodiment of the use of a compound of Formula (I), R₇ is heteroaryl selected from pyridinyl.

In one embodiment of the use of a compound of Formula (I), R₇ is heteroaryl selected from thien-2-yl or pyridin-2-yl.

In another embodiment of the use of a compound of Formula (I), R₇ is heteroaryl selected from pyridin-2-yl.

In one embodiment of the use of a compound of Formula (I), R_(c) is hydrogen or C₁₋₈alkyl.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents; and,

wherein, heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl.

In another embodiment of the use of a compound of Formula (I),

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino;

wherein, aryl is phenyl;

wherein, heterocyclyl is selected from 1,2,3,6-tetrahydropyridinyl, 1,3-benzodioxolyl or 2,3-dihydro-1,4-benzodioxinyl;

wherein, heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl or quinoxalinyl; and, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl;

wherein, heterocyclyl is selected from azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl or 6,9-diazaspiro[4.5]decyl; and, wherein, each instance of heterocyclyl, C3.4cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino;

wherein, heterocyclyl is selected from 1,2,3,6-tetrahydropyridin-4-yl, 1,3-benzodioxol-5-yl or 2,3-dihydro-1,4-benzodioxin-6-yl;

wherein, heteroaryl is selected from thienyl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl or quinoxalinyl; and, wherein, each instance of heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino or [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl or heterocyclyl-carbonyl-oxy; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heterocyclyl optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is C₃₋₁₄cycloalkyl optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of aryl is optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is aryl-C₁₋₈alkyl-amino optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In another embodiment of the use of a compound of Formula (I),

R₁ is heteroaryl optionally substituted with R₃ and R₄ substituents; and

R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino, wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with R₆ and R₇ substituents.

In one embodiment, the compound of Formula (I), used in a method disclosed herein, is a compound selected from Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII) or Formula (XIV):

or a form thereof.

In an embodiment of the use of the compound of Formula (I), w₃ is C—R₁, w₆ is C—R₂, w₁, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (I), w₃ is C—R₂, w₆ is C—R₁, w₁, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (I), w₄ is C—R₁, w₇ is C—R₂, w₁, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (I), w₄ is C—R₂, w₇ is C—R₁, w₁, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (II), w₃ is C—R₁, w₆ is C—R₂, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (II), w₃ is C—R₂, w₆ is C—R₁, w₄, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (II), w₄ is C—R₁, w₇ is C—R₂, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (II), w₄ is C—R₂, w₇ is C—R₁, w₃ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (III), w₃ is C—R₁, w₆ is C—R₂ and w₁, w₄, w₅ and w₇ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (III), w₃ is C—R₂, w₆ is C—R₁and w₁, w₄, w₅ and w₇ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (III), w₄ is C—R₁, w₇ is C—R₂, w₁, w₃ and w₅ are independently C—R_(a) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (III), w₄ is C—R₂, w₇ is C—R₁, w₁, w₃ and w₅ are independently C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (IV), w₄ is C—R₁, w₇ is C—R₂, w₁ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (IV), w₄ is C—R₂, w₇ is C—R₁, w₁ and w₅ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (V), w₃ is C—R₁, w₆ is C—R₂, w₁, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (V), w₃ is C—R₂, w₆ is C—R₁, w₁, w₅ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In an embodiment of the use of the compound of Formula (VI), w₃ is C—R₁, w₆ is C—R₂, w₁, w₄ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (VI), w₃ is C—R₂, w₆ is C—R₁, w₁, w₄ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (VI), w₄ is C—R₁, w₇ is C—R₂, w₁ and w₃ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (VI), w₄ is C—R₂, w₇ is C—R₁, w₁ and w₃ are independently C—R_(a) or N, w₂ is C—R_(b) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (VII), w₄ is C—R₁, w₇ is C—R₂, w₁, w₃ and w₅ are C—R_(a) or N and w₂ is C—R₁ or N.

In another embodiment of the use of the compound of Formula (VII), w₄ is C—R₂, w₇ is C—R₁, w₁, w₃ and w₅ are C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (VIII), w₃ is C—R₁, w₆ is C—R₂, w₁, w₄ and w₅ are C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (VIII), w₃ is C—R₂, w₆ is C—R₁, w₁, w₄ and w₅ are C—R_(a) or N and w₂ is C—R_(b) or N.

In an embodiment of the use of the compound of Formula (IX), w₃ is C—R₁, w₆ is C—R₂, w₄ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (IX), w₃ is C—R₂, w₆ is C—R₁, w₄ and w₇ are independently C—R_(a) or N and w₂ is C—R_(b) or N.

In another embodiment of the use of the compound of Formula (IX), w₄ is C—R₁, w₇ is C—R₂, w₂ is C—R_(b) or N, w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (IX), w₄ is C—R₂, w₇ is C—R₁, w₂ is C—R_(b) or N, w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (X), w₃ is C—R₁, w₆ is C—R₂, w₂ is C—R_(b) or N and w₅ and w₇ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (X), w₃ is C—R₂, w₆ is C—R₁, w₂ is C—R₁ or N and w₅ and w₇ are independently C—R_(a) or N.

In an embodiment of the use of the compound of Formula (XI), w₄ is C—R₁, w₇ is C—R₂, w₂ is C—R_(b) or N, w₅ is C—R_(a) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (XI), w₄ is C—R₂, w₇ is C—R₁, w₂ is C—R_(b) or N, w₅ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (XII), w₃ is C—R₁, w₆ is C—R₂ and w₄, w₅ and w₇ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (XII), w₃ is C—R₂, w₆ is C—R₁and w₄, w₅ and w₇ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (XII), w₄ is C—R₁, w₇ is C—R₂, w₃ and w₅ are independently C—R_(c) or N and w₆ is C—R_(c) or N.

In another embodiment of the use of the compound of Formula (XII), w₄ is C—R₂, w₇ is C—R₁, w₃ and w₅ are independently C—R_(c) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (XIII), w₃ is C—R₁, w₆ is C—R₂, w₂ is C—R_(b) or N and w₄ and w₅ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (XIII), w₃ is C—R₂, w₆ is C—R₁, w₂ is C—R_(b) or N and w₄ and w₅ are independently C—R_(a) or N.

In an embodiment of the use of the compound of Formula (XIV), w₄ is C—R₁, w₇ is C—R₂, w₂ is C—R_(b) or N and w₃ and w₅ are independently C—R_(a) or N.

In another embodiment of the use of the compound of Formula (XIV), w₄ is C—R₂, w₇ is C—R₁, w₂ is C—R_(b) or N and w₃ and w₅ are independently C—R_(a) or N.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound selected from Formula (II), Formula (III), Formula (IX), Formula (XI) or Formula (XII):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (II):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (III):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (IV):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (V):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (VI):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (VII):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (VIII):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (IX):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (X):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (XI):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (XII):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (XIII):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (XIV):

or a form thereof.

In one embodiment, the compound of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII) or Formula (XIV) used in a method disclosed herein is a compound selected from Formula (Ia), Formula (IIa), Formula (IIIa), Formula (IVa), Formula (Va), Formula (VIa), Formula (VIIa), Formula (VIIIa), Formula (IXa), Formula (Xa), Formula (XIa), Formula (XIIa), Formula (XIIIa) or Formula (XIVa), respectively:

or a form thereof.

In an embodiment of the use of the compound of Formula (Ia), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (IIa), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (IIa), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (IVa), one of w₆ and w₇ is C—R₁and the other is C—R₂, provided that, when w₄ is C—R₁, then w₇ is C—R₂; or, when w₄ is C—R₂, then w₇ is C—R₁.

In an embodiment of the use of the compound of Formula (Va), one of w₃ and w₆ is C—R₁and the other is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂; or, when w₃ is C—R₂, then w₆ is C—R₁.

In an embodiment of the use of the compound of Formula (VIa), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (VIIa), one of w₄ and w₇ is C—R₁and the other is C—R₂, provided that, when w₄ is C—R₁, then w₇ is C—R₂; or, when w₄ is C—R₂, then w₇ is C—R₁.

In an embodiment of the use of the compound of Formula (VIIIa), one of w₃ and w₆ is C—R₁and the other is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂; or, when w₃ is C—R₂, then w₆ is C—R₁.

In an embodiment of the use of the compound of Formula (IXa), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (Xa), one of w₃ and w₆ is C—R₁and the other is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂; or, when w₃ is C—R₂, then w₆ is C—R₁.

In an embodiment of the use of the compound of Formula (XIa), one of w₄ and w₇ is C—R₁and the other is C—R₂, provided that, when w₄ is C—R₁, then w₇ is C—R₂; or, when w₄ is C—R₂, then w₇ is C—R₁.

In an embodiment of the use of the compound of Formula (XIIa), one of w₃, w₄, w₆ and w₇ is C—R₁and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that,

when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or,

when w₃ is C—R₂, then w₆ is C—R₁and w₄ and w₇ are independently C—R_(a) or N; or,

when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or,

when w₄ is C—R₂, then w₇ is C—R₁and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N.

In an embodiment of the use of the compound of Formula (XIIIa), one of w₃ and w₆ is C—R₁and the other is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂; or, when w₃ is C—R₂, then w₆ is C—R₁.

In an embodiment of the use of the compound of Formula (XIVa), one of w₄ and w₇ is C—R₁and the other is C—R₂, provided that, when w₆ is C—R₁, then w₇ is C—R₂; or, when w₄ is C—R₂, then w₇ is C—R₁.

In another embodiment, the compound of Formula (I), Formula (II), Formula (III), Formula (IX), Formula (XI) or Formula (XII), used in a method disclosed herein, is a compound selected from Formula (Ia), Formula (IIa), Formula (IIIa), Formula (IXa), Formula (XIa) or Formula (XIIa), respectively:

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound of Formula (Ia):

or a form thereof.

In another embodiment, the compound of Formula (II) used in a method disclosed herein is a compound of Formula (IIa):

or a form thereof.

In another embodiment, the compound of Formula (III) used in a method disclosed herein is a compound of Formula (IIa):

or a form thereof.

In another embodiment, the compound of Formula (IV) used in a method disclosed herein is a compound of Formula (IVa):

or a form thereof.

In another embodiment, the compound of Formula (V) used in a method disclosed herein is a compound of Formula (Va):

or a form thereof.

In another embodiment, the compound of Formula (VI) used in a method disclosed herein is a compound of Formula (VIa):

or a form thereof.

In another embodiment, the compound of Formula (VII) used in a method disclosed herein is a compound of Formula (VIIa):

or a form thereof.

In another embodiment, the compound of Formula (VIII) used in a method disclosed herein is a compound of Formula (VIIIa):

or a form thereof.

In another embodiment, the compound of Formula (IX) used in a method disclosed herein is a compound of Formula (IXa):

or a form thereof.

In another embodiment, the compound of Formula (X) used in a method disclosed herein is a compound of Formula (Xa):

or a form thereof.

In another embodiment, the compound of Formula (XI) used in a method disclosed herein is a compound of Formula (XIa):

or a form thereof.

In another embodiment, the compound of Formula (XII) used in a method disclosed herein is a compound of Formula (XIIa):

or a form thereof.

In another embodiment, the compound of Formula (XIII) used in a method disclosed herein is a compound of Formula (XIIIa):

or a form thereof.

In another embodiment, the compound of Formula (XIV) used in a method disclosed herein is a compound of Formula (XIVa):

or a form thereof.

In one embodiment, the compound of Formula (Ia) used in a method disclosed herein is a compound of Formula (Ia1), Formula (Ia2), Formula (Ia3) or Formula (Ia4):

or a form thereof.

In one embodiment, the compound of Formula (IIa) used in a method disclosed herein is a compound of Formula (IIa1), Formula (IIa2), Formula (IIa3) or Formula (IIa4):

or a form thereof.

In one embodiment, the compound of Formula (IIIa) used in a method disclosed herein is a compound of Formula (IIIa1), Formula (IIIa2), Formula (IIIa3) or Formula (IIIa4):

or a form thereof.

In one embodiment, the compound of Formula (IVa) used in a method disclosed herein is a compound of Formula (IVa1) or Formula (IVa2):

or a form thereof.

In one embodiment, the compound of Formula (Va) used in a method disclosed herein is a compound of Formula (Va1) or Formula (Va2):

or a form thereof.

In one embodiment, the compound of Formula (VIa) used in a method disclosed herein is a compound of Formula VIa1 Formula VIa2 Formula VIa3 or Formula (VIa4):

or a form thereof.

In one embodiment, the compound of Formula (VIIa) used in a method disclosed herein is a compound Formula (VIIa1) of Formula (VIIa2)

or a form thereof.

In one embodiment, the compound of Formula (VIIIa) used in a method disclosed herein is a compound of Formula (VIIIa1) or Formula (VIIIa2):

or a form thereof.

In one embodiment, the compound of Formula (IXa) used in a method disclosed herein is a compound of Formula (IXa1), Formula (IXa2), Formula (IXa3) or Formula (IXa4):

or a form thereof.

In one embodiment, the compound of Formula (Xa) used in a method disclosed herein is a compound of Formula (Xa1) or Formula (Xa2):

or a form thereof.

In one embodiment, the compound of Formula (XIa) used in a method disclosed herein is a compound of Formula (Xia1) or Formula (Xia2):

or a form thereof.

In one embodiment, the compound of Formula (XIIa) used in a method disclosed herein is a compound of Formula (XIIa1), Formula (XIIa2), Formula (XIIa3) or Formula (XIIa4):

or a form thereof.

In one embodiment, the compound of Formula (XIIIa) used in a method disclosed herein is a compound of Formula (XIIIa1) or Formula (XIIIa2):

or a form thereof.

In one embodiment, the compound of Formula (XIVa) used in a method disclosed herein is a compound of Formula (XIVa1) or Formula (XIVa2):

or a form thereof.

In one embodiment, the compound of Formula (Ia) used in a method disclosed herein is a compound of Formula (Ia1):

or a form thereof.

In one embodiment, the compound of Formula (Ia) used in a method disclosed herein is a compound of Formula (Ia2):

or a form thereof.

In one embodiment, the compound of Formula (Ia) used in a method disclosed herein is a compound of Formula (Ia3):

or a form thereof.

In one embodiment, the compound of Formula (Ia) used in a method disclosed herein is a compound of Formula (Ia4):

or a form thereof.

In one embodiment, the compound of Formula (IIa) used in a method disclosed herein is a compound of Formula (IIa1):

or a form thereof.

In one embodiment, the compound of Formula (IIa) used in a method disclosed herein is a compound of Formula (IIa2):

or a form thereof.

In one embodiment, the compound of Formula (IIa) used in a method disclosed herein is a compound of Formula (IIa3):

or a form thereof.

In one embodiment, the compound of Formula (IIa) used in a method disclosed herein is a compound of Formula (IIa4):

or a form thereof.

In one embodiment, the compound of Formula (IIIa) used in a method disclosed herein is a compound of Formula (IIIa1):

or a form thereof.

In one embodiment, the compound of Formula (IIIa) used in a method disclosed herein is a compound of Formula (IIIa2):

or a form thereof.

In one embodiment, the compound of Formula (IIIa) used in a method disclosed herein is a compound of Formula (IIIa3):

or a form thereof.

In one embodiment, the compound of Formula (IIIa) used in a method disclosed herein is a compound of Formula (IIIa4):

or a form thereof.

In one embodiment, the compound of Formula (IVa) used in a method disclosed herein is a compound of Formula (IVa1):

or a form thereof.

In one embodiment, the compound of Formula (IVa) used in a method disclosed herein is a compound of Formula (IVa2):

or a form thereof.

In one embodiment, the compound of Formula (Va) used in a method disclosed herein is a compound of Formula (Va1):

or a form thereof.

In one embodiment, the compound of Formula (Va) used in a method disclosed herein is a compound of Formula (Va2):

or a form thereof.

In one embodiment, the compound of Formula (VIa) used in a method disclosed herein is a compound of Formula (VIa1):

or a form thereof.

In one embodiment, the compound of Formula (VIa) used in a method disclosed herein is a compound of Formula Formula (VIa2):

or a form thereof.

In one embodiment, the compound of Formula (VIa) used in a method disclosed herein is a compound of Formula Formula (VIa3):

or a form thereof.

In one embodiment, the compound of Formula (VIa) used in a method disclosed herein is a compound of Formula (VIa4):

or a form thereof.

In one embodiment, the compound of Formula (VIIa) used in a method disclosed herein is a compound of Formula (VIIa1):

or a form thereof.

In one embodiment, the compound of Formula (VIIa) used in a method disclosed herein is a compound of Formula (VIIa2):

or a form thereof.

In one embodiment, the compound of Formula (VIIIa) used in a method disclosed herein is a compound of Formula Formula (VIIIa1):

or a form thereof.

In one embodiment, the compound of Formula (VIIa) used in a method disclosed herein is a compound of Formula (VIIIa2):

or a form thereof.

In one embodiment, the compound of Formula (IXa) used in a method disclosed herein is a compound of Formula (IXa1):

or a form thereof.

In one embodiment, the compound of Formula (IXa) used in a method disclosed herein is a compound of Formula (IXa2):

or a form thereof.

In one embodiment, the compound of Formula (IXa) used in a method disclosed herein is a compound of Formula (IXa3):

or a form thereof.

In one embodiment, the compound of Formula (IXa) used in a method disclosed herein is a compound of Formula (IXa4):

or a form thereof.

In one embodiment, the compound of Formula (Xa) used in a method disclosed herein is a compound of Formula (Xa1):

or a form thereof.

In one embodiment, the compound of Formula (Xa) used in a method disclosed herein is a compound of Formula (Xa2):

or a form thereof.

In one embodiment, the compound of Formula (XIa) used in a method disclosed herein is a compound of Formula (XIa1):

or a form thereof.

In one embodiment, the compound of Formula (XIa) used in a method disclosed herein is a compound of Formula (XIa2):

or a form thereof.

In one embodiment, the compound of Formula (XIIa) used in a method disclosed herein is a compound of Formula (XIIa1):

or a form thereof.

In one embodiment, the compound of Formula (XIIa) used in a method disclosed herein is a compound of Formula (XIIa2):

or a form thereof.

In one embodiment, the compound of Formula (XIIa) used in a method disclosed herein is a compound of Formula (XIIa3):

or a form thereof.

In one embodiment, the compound of Formula (XIIa) used in a method disclosed herein is a compound of Formula (XIIa4):

or a form thereof.

In one embodiment, the compound of Formula (XIIIa) used in a method disclosed herein is a compound of Formula (XIIIa1):

or a form thereof.

In one embodiment, the compound of Formula (XIIIa) used in a method disclosed herein is a compound of Formula (XIIIa2):

or a form thereof.

In one embodiment, the compound of Formula (XVa) used in a method disclosed herein is a compound of Formula (XIVa1):

or a form thereof.

In one embodiment, the compound of Formula (XIVa) used in a method disclosed herein is a compound of Formula (XIVa2):

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound selected from the group consisting of:

or a form thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound selected from the group consisting of:

-   2-(4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(3,3-dimethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,3-dimethylpiperazin-1-yl)-2-(4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-benzodioxol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-benzodioxol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-benzodioxol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-benzodioxol-5-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-methoxyphenyl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(3-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methylimidazo[1,2-a]pyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-phenyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(3,3-dimethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-fluoro-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-chlorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-chlorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-[3-(trifluoromethyl)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-[4-(trifluoromethyl)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-fluoro-7-(piperidin-4-ylamino)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)phenyl]-9-fluoro-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)phenyl]-9-fluoro-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   3-(3,4-dimethoxyphenyl)-8-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethylphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(dimethylamino)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(dimethylamino)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(difluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(difluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-fluoro-4,5-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-fluoro-4,5-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,8-diazabicyclo[3.2.1]oct-3-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-methoxy-3-(trifluoromethyl)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methoxy-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,5-difluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   4-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile -   2-(6-methylimidazo[1,2-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methylimidazo[1,2-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-fluoro-5-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[2-methoxy-3-(trifluoromethyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,5-difluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-[3-(trifluoromethoxy)phenyl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-methoxy-3-(trifluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-hydroxy-3-(trifluoromethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-methoxy-3-(trifluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-hydroxy-3-(trifluoromethoxy)phenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-4-oxo-7-(piperazin-1-yl)-4H-quinolizine-1-carbonitrile -   2-(3-fluoro-4-methoxyphenyl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one -   2-(5-fluoropyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-fluoropyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-chloropyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-chloropyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-chloro-6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1H-indol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1H-indol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(difluoromethoxy)-4-methoxyphenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(difluoromethoxy)-4-hydroxyphenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(difluoromethoxy)-4-methoxyphenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-(difluoromethoxy)-4-hydroxyphenyl]-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-quinolizin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one -   2-(3,5-difluorophenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-quinolizin-4-one -   2-(imidazo[1,2-a]pyridin-7-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(imidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-chloro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-chloro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-ethoxy-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-ethoxy-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(2-methylpyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-[2-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-ethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,3-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-aminopiperidin-1-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-5-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-5-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4,5-dimethoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(4-hydroxypiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxy-3-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   3-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile -   2-methoxy-5-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile -   2-(3-fluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethoxy-3-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methylphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methylphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-aminopyrrolidin-1-yl]-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-(4-methyl-1,3-thiazol-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methyl-1,3-thiazol-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3S)-3-(propan-2-ylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxy-3-nitrophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[3-fluoro-4-(methylsulfanyl)phenyl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methyl-1,4-diazepan-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-fluoro-6-methoxypyridin-3-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(5-fluoro-6-methoxypyridin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-5-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methyl-1H-imidazol-1-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methyl-1H-imidazol-1-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{[2-(methylamino)ethyl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-fluoro-6-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,5-difluoro-4-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,5-difluoro-4-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-ylamino)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-chloro-5-fluorophenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-chloro-5-fluorophenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-(1-methyl-1H-pyrazol-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-pyrazol-4-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,3-dimethylpiperazin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,5-dimethoxypyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one -   7-(4-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,4R)-3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-aminopiperidin-1-yl)-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[4-(methylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-3-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-3-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-difluoro-5-methoxyphenyl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-difluoro-5-methoxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-fluoro-4-methoxyphenyl)-2-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3S)-3-(methylamino)pyrrolidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-{4-[(methylamino)methyl]piperidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-aminopyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-{[(3R)-1-methylpyrrolidin-3-yl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{4-[(dimethylamino)methyl]piperidin-1-yl}-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methoxypyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(piperazin-1-yl)-2-(pyridin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5-methoxypyridin-3-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   3-fluoro-5-{7-[(3S)-3-methylpiperazin-1-yl]-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl}benzonitrile -   3-fluoro-5-[4-oxo-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-2-yl]benzonitrile -   2-(3-fluoro-4-methoxyphenyl)-7-[(3′S,4′S)-4′-hydroxy-1,3′-bipyrrolidin-1′-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-{methyl[(3R)-pyrrolidin-3-yl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(1-methylpiperidin-4-yl)oxy]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3S)-pyrrolidin-3-yloxy]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperidin-4-yloxy)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-{methyl[(3R)-1-methylpyrrolidin-3-yl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-quinolizin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aR)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-quinolizin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl]-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,5,6-tetrahydropyridin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-ethyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-ethyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-aminopiperidin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-aminopiperidin-1-yl)-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aS,6aS)-1-methylhexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(3aR,6aS)-5-(propan-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,3-dimethylpiperazin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yloxy)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-fluoro-4-methoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)piperidin-1-yl]-7-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3aR,6aS)-5-ethylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-[(4aR,7aR)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-fluoro-4-methoxyphenyl)-2-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-fluoro-4-methoxyphenyl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(2R)-2-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-quinolizin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-quinolizin-4-one -   7-[(3S)-4-ethyl-3-methylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinolizin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinolizin-4-one -   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-quinolizin-4-one -   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(cyclopropylamino)piperidin-1-yl]-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3,4-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(3R)-3,4-dimethylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-di     methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,3-dimethylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-cyclopropylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)piperidin-1-yl]-9-ethyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(2-methyl-1,3-benzothiazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrimido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrinmidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(methylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(ethylamino)piperidin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-8-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(propan-2-ylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(methylamino)cyclohex-1-en-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)cyclohex-1-en-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[ethyl(methyl)amino]cyclohex-1-en-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[methyl(propyl)amino]cyclohex-1-en-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,4-dimethoxyphenyl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,4-dimethoxyphenyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   7-(4-aminopiperidin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-aminopyrrolidin-1-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(2-methoxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-8-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-8-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzothiazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   7-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(3-fluoro-4-methoxyphenyl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[cis-4-(methylamino)cyclohexyl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-(piperidin-3-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(propylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-cyclopropylpiperazin-1-yl)-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(propan-2-ylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-methyl-7-[4-(morpholin-4-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one     hydrochloride (1:1) -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4′-bipiperidin-1′-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(morpholin-4-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[(2-hydroxyethyl)amino]piperidin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(diethylamino)piperidin-1-yl]-2-(3,4-dimethoxyphenyl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methylpiperazin-1-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[6-(dimethylamino)pyridin-3-yl]-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(diethylamino)piperidin-1-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[(2-hydroxyethyl)(methyl)amino]piperidin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[6-(dimethylamino)pyridin-3-yl]-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(diethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-9-ethyl-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[(2-methoxyethyl)amino]piperidin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2-methylimidazo[1,2-a]pyridin-6-yl)-2-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1-propyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[6-(dimethylamino)pyridin-3-yl]-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-methylpiperazin-1-yl]-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methyl-1,4-diazepan-1-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-ethyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(2-methyl-1,3-benzoxazol-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-methoxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-{(3S)-4-[2-(2-hydroxyethoxy)ethyl]-3-methylpiperazin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-cyclopropyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-methoxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-{(3S)-4-[2-(2-hydroxyethoxy)ethyl]-3-methylpiperazin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-4-cyclopropyl-3-methylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3,3-dimethylpiperazin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)piperidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(diethylamino)piperidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(2-methylimidazo[1,2-a]pyridin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-7-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R,5S)-3,4,5-trimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-{4-[(dimethylamino)methyl]piperidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(piperidin-1-ylmethyl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-{4-[(dimethylamino)methyl]piperidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(3,4-dimethoxyphenyl)-7-[4-(piperidin-1-yl     methyl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)-1,2,3,6-tetrahydropyridin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)methyl)amino]piperidin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(propylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-amino-4-methylpiperidin-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(ethylamino)piperidin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{4-[bis(2-hydroxyethyl)amino]piperidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-1,3-benzoxazol-6-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(8-chloro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-methyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-2H-indazol-5-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)amino]piperidin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(methylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[4-(propan-2-ylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-propylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-cyclopropylpiperazin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-cyclobutylpiperazin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(oxetan-3-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethyloctahydro-5H-pyrrolo[3,2-c]pyridin-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-methoxy-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-hydroxy-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-2-(2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-propylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(pyrrolidin-1-yl)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-4-cyclopropyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methyl-4-(oxetan-3-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-cyclobutylpiperazin-1-yl)-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-4-cyclobutyl-3-methylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-fluoroethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(3-fluoropropyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-fluoroethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(3-fluoropropyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-fluoroethyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(3-fluoropropyl)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-fluoroethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(3-fluoropropyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{(3R)-4-[2-(2-hydroxyethoxy)ethyl]-3-methylpiperazin-1-yl}-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3R)-4-(2-hydroxyethyl)-3-methylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-methyl-1,4-diazepan-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-[8-(hydroxymethyl)-2-methylimidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(propan-2-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(oxetan-3-yl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-cyclopropyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[4-(dimethylamino)-6-methylpyrazolo[1,5-a]pyrazin-2-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2-methyl-1H-benzimidazol-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(2-methyl-1H-benzimidazol-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   2-(2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one -   7-[1-(2,2-dimethyl-1,3-dioxan-5-yl)piperidin-4-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(1,3-dihydroxypropan-2-yl)piperidin-4-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-4-ethyl-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(dimethylamino)-4-methylpiperidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-(ethylamino)-4-methylpiperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[4-methyl-4-(propylamino)piperidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{4-[(2-hydroxyethyl)amino]-4-methylpiperidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-propylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-cyclopropyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-cyclopropylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(2-methyl-2H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(1-methylpiperidin-4-yl)oxy]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methylpiperazin-1-yl)-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-ethylpiperazin-1-yl)-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[4-(2-hydroxyethyl)piperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-methylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(3R)-3-methyl-4-(propan-2-yl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-amino-4-methylpiperidin-1-yl)-2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3S)-3-ethylpiperazin-1-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-methylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-methylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-amino-4-methylpiperidin-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-aminoprop-1-yn-1-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(3-aminopropyl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-[(3S)-3,4-dimethylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[3-(dimethylamino)azetidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[3-(diethylamino)azetidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(pyrrolidin-1-yl)azetidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1,4-diazepan-1-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(aminomethyl)pyrrolidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(piperidin-1-yl)azetidin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(6-methyl-4-propylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2,7-diazaspiro[4.4]non-2-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,7-dimethyl-2H-indazol-5-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[3-(dimethylamino)propyl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{(3S)-3-[(dimethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(1-methyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,7-dimethyl-1H-indazol-5-yl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1,7-dimethyl-1H-indazol-5-yl)-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{(3S)-3-[(diethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-{(3S)-3-[(ethylamino)methyl]pyrrolidin-1-yl}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{3-[(dimethylamino)methyl]azetidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{3-[(diethylamino)methyl]azetidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(1-ethyl-3-methylpyrrolo[1,2-a]pyrazin-7-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3R)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(1-methyl-1H-indazol-5-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(1-ethylpiperidin-4-yl)-9-methyl-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-[(3S)-3-methylpiperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-2-(1-methyl-1H-indazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3,4-dimethylpiperazin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-(1-cyclobutylpiperidin-4-yl)-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[1-(2-hydroxyethyl)piperidin-4-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-ethyl-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   9-methyl-2-(2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(aminomethyl)pyrrolidin-1-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(2S,6S)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{(3R)-3-[(dimethylamino)methyl]pyrrolidin-1-yl}-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(2S,6S)-2,6-dimethylpiperidin-4-yl]-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[4-(2-hydroxyethyl)piperazin-1-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(imidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(2,7-diazaspiro[3.5]non-7-yl)-2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methylpiperazin-1-yl)-2-(2-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4-methylpiperazin-1-yl)-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-methyl-6-[7-(4-methylpiperazin-1-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yl]imidazo[1,2-a]pyridine-8-carbonitrile     2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(4-methylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-(4,7-diazaspiro[2.5]oct-7-yl)-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1-methylpiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(4-hydroxypiperidin-4-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-8a-methylhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-ethylpiperazin-1-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(4-ethylpiperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(8a-methylhexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-{[2-(morpholin-4-yl)ethyl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{[2-(dimethylamino)ethyl]amino}-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-{[2-(dimethylamino)ethyl](methyl)amino}-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-{methyl[2-(methylamino)ethyl]amino}-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-2-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[2-(dimethylamino)ethoxy]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[2-(dimethylamino)ethoxy]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-(piperidin-4-ylmethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[2-(piperidin-1-yl)ethoxy]-4H-pyrido[1,2-a]pyrimidin-4-one -   2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-7-[3-(morpholin-4-yl)propoxy]-4H-pyrido[1,2-a]pyrimidin-4-one -   7-[3-(dimethylamino)propoxy]-2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-4H-pyrido[1,2-a]pyrimidin-4-one,     or -   2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-[(3aR,6aS)-5-methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-4H-pyrido[1,2-a]pyrimidin-4-one     or a salt, isotopologue, stereoisomer, racemate, enantiomer,     diastereomer or tautomer thereof.

In another embodiment, the compound of Formula (I) used in a method disclosed herein is a compound selected from the group consisting of:

-   2-(3,5-difluoro-4-hydroxyphenyl)-7-(piperazin-1-yl)-4H-pyrido[1,2-a]pyrimidin-4-one     hydrochloride -   7-[4-(dimethylamino)piperidin-1-yl]-2-(3-fluoro-4-methoxyphenyl)-4H-quinolizin-4-one     acetate -   2-(2-methyl-1,3-benzothiazol-6-yl)-7-(piperidin-4-yl)-4H-pyrimido[1,2-b]pyridazin-4-one     trifluoroacetate (1:1), or -   2-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)-4H-pyrazino[1,2-a]pyrimidin-4-one     hydrochloride (1:2)     or a free base, isotopologue, stereoisomer, racemate, enantiomer,     diastereomer or tautomer thereof.

Compounds of Formula (I) can be prepared using reagents and methods known in the art, including the methods provided in International Application No. PCT/US2013/025292, filed on Feb. 8, 2013, and published as International Publication No. WO 2013/119916 on Aug. 15, 2013, the entire contents which are incorporated herein by reference (see in particular, General Synthetic Methods, Schemes A-J, at paragraphs [001126] to [001159]; and Specific Synthetic Examples, at paragraphs [001160] to [001573] and Table 1, therein).

Terminology

The chemical terms used above and throughout the description herein, unless specifically defined otherwise, shall be understood by one of ordinary skill in the art to have the following indicated meanings.

As used herein, the term “C₁₋₈alkyl” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butanyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also referred to as pentyl or pentanyl), n-hexyl (also referred to as hexyl or hexanyl), n-heptyl (also referred to as heptyl or heptanyl), n-octyl and the like. In some embodiments, C₁₋₈alkyl includes, but is not limited to, C₁₋₆alkyl, C₁₋₈alkyl and the like. A C₁₋₈alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₂₋₈alkenyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like. In some embodiments, C₂₋₈alkenyl includes, but is not limited to, C₂₋₆alkenyl, C₂₋₄alkenyl and the like. A C₂₋₈alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₂₋₄alkynyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like. In some embodiments, C₂₋₈alkynyl includes, but is not limited to, C₂₋₈alkynyl, C₂₋₄alkynyl and the like. A C₂₋₈alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₁₋₈alkoxy” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration of the formula: —O—C₁₋₈alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy and the like. In some embodiments, C₁₋₈alkoxy includes, but is not limited to, C₁₋₈alkoxy, C₁₋₈alkoxy and the like. A C₁₋₈alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₃₋₁₄cycloalkyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl and the like. In some embodiments, C₃₋₁₄cycloalkyl includes, but is not limited to, C₃₋₈cycloalkyl, C₅₋₈cycloalkyl, C₃₋₁₀cycloalkyl and the like. A C₃₋₁₄cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “aryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “heteroaryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, but not limited to, furanyl (also referred to as furyl), thienyl (also referred to as thiophenyl), pyrrolyl, 2H-pyrrolyl, 3H-pyrrolyl, pyrazolyl, 1H-pyrazolyl, imidazolyl, 1H-imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl (such as 1H-1,2,3-triazolyl and the like), oxadiazolyl (such as 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like), thiadiazolyl, tetrazolyl (such as 1H-tetrazolyl, 2H-tetrazolyl and the like), pyridinyl (also referred to as pyridyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, 1H-indolyl, indazolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl (also referred to as benzothiophenyl), benzoimidazolyl, 1H-benzoimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl (also referred to as 1,3-benzooxazolyl), purinyl, 9H-purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-diazanaphthalenyl, acridinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 6H-thieno[2,3-b]pyrrolyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl and the like. A heteroaryl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.

As used herein, the term “heterocyclyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro-2H-pyranyl, thiopyranyl, 1,3-dioxanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl (also referred to as benzo[d][1,3]dioxolyl), 1,4-benzodioxanyl, 2,3-dihydro-1,4-benzodioxinyl (also referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl), hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 6,9-diazaspiro[4.5]decyl and the like. A heterocyclyl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-O—C₁₋₈alkyl).

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-O—C₁₋₈alkyl).

As used herein, the term “C₁₋₈alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-carbonyl-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-C(O)—O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-NH—C₁₋₈alkyl)₂.

As used herein, the term “[(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino” refers to a radical of the formula: —N[C₁₋₈alkyl-N(C₁₋₈alkyl)₂]₂.

As used herein, the term “(C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-NH—C₁₋₈alkyl).

As used herein, the term “[(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)[C₁₋₈alkyl-N(C₁₋₈alkyl)₂].

As used herein, the term “C₁₋₈alkyl-amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-carbonyl” refers to a radical of the formula: —C(O)—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkyl-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkyl-thio” refers to a radical of the formula: —S—C₁₋₈alkyl.

As used herein, the term “amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-NH₂.

As used herein, the term “amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH₂.

As used herein, the term “amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH₂.

As used herein, the term “amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-NH₂.

As used herein, the term “(amino-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-NH₂)₂.

As used herein, the term “(amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-NH₂).

As used herein, the term “amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-NH₂.

As used herein, the term “aryl-C₁₋₈alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C₁₋₈alkyl-aryl.

As used herein, the term “aryl-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-aryl.

As used herein, the term “aryl-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-aryl.

As used herein, the term “(aryl-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-aryl)₂.

As used herein, the term “(aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-aryl).

As used herein, the term “aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-aryl.

As used herein, the term “(aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-aryl)₂.

As used herein, the term “(aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-aryl).

As used herein, the term “aryl-amino” refers to a radical of the formula: —NH-aryl.

As used herein, the term “aryl-amino-carbonyl” refers to a radical of the formula: —C(O)—NH-aryl.

As used herein, the term “aryl-sulfonyloxy-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-O—SO₂-aryl.

As used herein, the term “benzoxy-carbonyl” refers to a radical of the formula: —C(O)O—CH₂-phenyl.

As used herein, the term “C₃₋₁₄cycloalkyl-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-C₃₋₁₄cycloalkyl.

As used herein, the term “C₃₋₁₄cycloalkyl-amino” refers to a radical of the formula: —NH—C₃₋₁₄cycloalkyl.

As used herein, the term “C₃₋₁₄cycloalkyl-oxy” refers to a radical of the formula: —O—C₃₋₁₄cycloalkyl.

As used herein, the term “halo” or “halogen” generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.

As used herein, the term “halo-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-halo, wherein C₁₋₈alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.

As used herein, the term “halo-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-halo, wherein C₁₋₈alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.

As used herein, the term “halo-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-halo.

As used herein, the term “(halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-halo).

As used herein, the term “(halo-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-halo)₂.

As used herein, the term “heteroaryl-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-heteroaryl.

As used herein, the term “heteroaryl-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-heteroaryl.

As used herein, the term “heteroaryl-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-heteroaryl.

As used herein, the term “(heteroaryl-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-heteroaryl)₂.

As used herein, the term “(heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-heteroaryl).

As used herein, the term “heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-heteroaryl.

As used herein, the term “(heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-heteroaryl)₂.

As used herein, the term “(heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-heteroaryl).

As used herein, the term “heteroaryl-amino” refers to a radical of the formula: —NH-heteroaryl.

As used herein, the term “heterocyclyl-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-heterocyclyl.

As used herein, the term “heterocyclyl-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-heterocyclyl.

As used herein, the term “heterocyclyl-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-heterocyclyl.

As used herein, the term “(heterocyclyl-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-heterocyclyl)₂.

As used herein, the term “(heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-heterocyclyl).

As used herein, the term “heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-heterocyclyl.

As used herein, the term “(heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-heterocyclyl)₂.

As used herein, the term “(heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-heterocyclyl).

As used herein, the term “heterocyclyl-amino” refers to a radical of the formula: —NH-heterocyclyl.

As used herein, the term “(heterocyclyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(heterocyclyl).

As used herein, the term “heterocyclyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH-heterocyclyl.

As used herein, the term “heterocyclyl-carbonyl” refers to a radical of the formula: —C(O)-heterocyclyl.

As used herein, the term “heterocyclyl-carbonyl-oxy” refers to a radical of the formula: —O—C(O)-heterocyclyl.

As used herein, the term “heterocyclyl-oxy” refers to a radical of the formula: —O-heterocyclyl.

As used herein, the term “hydroxy” refers to a radical of the formula: —OH.

As used herein, the term “hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-O—C₁₋₈alkyl-OH.

As used herein, the term “hydroxy-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-OH, wherein C₁₋₈alkyl is partially or completely substituted with one or more hydroxy radicals where allowed by available valences.

As used herein, the term “hydroxy-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-OH.

As used herein, the term “(hydroxy-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-OH)₂.

As used herein, the term “(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term “hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-OH.

As used herein, the term “(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term “(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term “hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl-OH.

As used herein, the term “(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term “(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term “hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-NH—C₁₋₈alkyl-OH.

As used herein, the term “(hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-NH—C₁₋₈alkyl-OH)₂.

As used herein, the term “(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term “(hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-NH—C₁₋₈alkyl-OH).

As used herein, the term “[(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)[C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂].

As used herein, the term “(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl,C₁₋₈alkyl-OH).

As used herein, the term “[(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino” refers to a radical of the formula: —N(C₁₋₈alkyl)[C₁₋₈alkyl —N(C₁₋₈alkyl)(C₁₋₈alkyl-OH)].

As used herein, the term “substituent” means positional variables on the atoms of a core molecule that are attached at a designated atom position, replacing one or more hydrogen atoms on the designated atom, provided that the atom of attachment does not exceed the available valence or shared valences, such that the substitution results in a stable compound. Accordingly, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. It should also be noted that any carbon as well as heteroatom with a valence level that appears to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown.

For the purposes of this description, where one or more substituent variables for a compound of Formula (I) encompass functionalities incorporated into a compound of Formula (I), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.

As used herein, the terms “independently selected,” or “each selected” refer to functional variables in a substituent list that may be attached more than once on the structure of a core molecule, where the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. Further, the use of a generic substituent on a core structure for a compound provided herein is understood to include the replacement of the generic substituent with specie substituents that are included within the particular genus, e.g., aryl may be independently replaced with phenyl or naphthalenyl (also referred to as naphthyl) and the like, such that the resulting compound is intended to be included within the scope of the compounds described herein.

As used herein, the term “each instance of” when used in a phrase such as “ . . . aryl, aryl-C₁₋₈alkyl, heterocyclyl and heterocyclyl-C₁₋₈alkyl, wherein each instance of aryl and heterocyclyl is optionally substituted with one or two substituents . . . ” is intended to include optional, independent substitution on each of the aryl and heterocyclyl rings and on the aryl and heterocyclyl portions of aryl-C₁₋₈alkyl and heterocyclyl-C₁₋₈alkyl.

As used herein, the term “optionally substituted” means that the specified substituent variables, groups, radicals or moieties represent the scope of the genus and may be independently chosen as needed to replace one or more hydrogen atoms on the designated atom of attachment of a core molecule.

As used herein, the terms “stable compound” or “stable structure” mean a compound that is sufficiently robust to be isolated to a useful degree of purity from a reaction mixture and formulations thereof into an efficacious therapeutic agent.

Compound names provided herein were obtained using ACD Labs Index Name software provided by ACD Labs and/or ChemDraw Ultra software provided by CambridgeSoft®. When the compound name disclosed herein conflicts with the structure depicted, the structure shown will supercede the use of the name to define the compound intended. Nomenclature for substituent radicals defined herein may differ slightly from the chemical name from which they are derived; one skilled in the art will recognize that the definition of the substituent radical is intended to include the radical as found in the chemical name.

As used herein the term “aberrant” refers to a deviation from the norm of, e.g., the average healthy subject or a cell(s) or tissue sample from a healthy subject. The term “aberrant expression,” as used herein, refers to abnormal expression (up-regulated or down-regulated resulting in an excessive or deficient amount thereof) of a gene product (e.g., RNA transcript or protein) by a cell, tissue sample, or subject relative to a corresponding normal, healthy cell, tissue sample or subject. In a specific embodiment, the “aberrant expression” refers to an altered level of a gene product (e.g., RNA transcript or protein) in a cell, tissue sample, or subject relative to a corresponding normal, healthy cell, tissue sample or subject. The term “aberrant amount” as used herein refers to an altered level of a gene product (e.g., RNA, protein, polypeptide, or peptide) in a cell, tissue sample, or subject relative to a corresponding normal, healthy cell, tissue sample or subject. In specific embodiments, the amount of a gene product (e.g., RNA, protein, polypeptide, or peptide) in a cell, tissue sample, or subject relative to a corresponding cell or tissue sample from a healthy subject or a healthy subject, is considered aberrant if it is 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6-fold or more above or below the amount of the gene product in the corresponding cell or tissue sample from a healthy subject or healthy subject.

The term “intronic REMS” refers to a REMS sequence present in an intron that functions as a 5′ splice site in the presence of a compound described herein. The intronic REMS, when downstream of a first branch point (BP) sequence and a first 3′ splice site (3′ ss) sequence and upstream of a second branch point (BP) sequence and a second 3′ splice site (3′ ss) sequence) (as shown in FIG. 1A) and in the presence of a compound described herein, can function as a 5′ splice site. The intronic REMS may also function as a 5′ splice site when upstream of a first branch point and a first 3′ splice site in the presence of a compound described herein (see FIG. 1B or 1C). Any one, two, three, or more or all of the following may be present endogenously or non-endogenously in the affected intron: the intronic REMS, the first BP, the second BP, the first 3′ ss, and the second 3′ss.

As used herein, a “non-endogenous” nucleotide sequence (such as a non-endogenous 5′ splice site, a non-endogenous branch point or a non-endogenous 3′ splice site) is a nucleotide sequence not naturally found to be part of a pre-RNA or a DNA sequence encoding a pre-RNA sequence. In other words, the hand of man is required to synthesize or manipulate the RNA or DNA sequence to introduce the nucleotide sequence.

As used herein, the term “non-endogenous intronic REMS” refers to a REMS sequence not naturally found to be part of an RNA sequence or naturally encoded by a DNA sequence. In other words, the hand of man is required to manipulate the RNA or DNA sequence to introduce the intronic REMS or the nucleotide sequence encoding the REMS into an intron.

As used herein, the terms “intron-derived exon,” “intronic exon,” “iExon” and “intronic exon” (collectively iExon) refers to the formation of an exon from an RNA sequence present in an intron following splicing of an RNA transcript in the presence of a compound described herein or another agent which results in an iREMS functioning as an intronic 5′ splice site. In particular, an iExon comprises the following RNA sequence as an exon when RNA splicing of an RNA transcript comprising two exons and an intron occurs in the presence of a compound described herein, wherein a first exon is upstream of the intron and a second exon is downstream of the intron, and wherein the intron comprises a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point, and a second 3′ splice site: the RNA sequence between the first 3′ splice site and the iREMS, as shown in FIG. 1A. One or more of the iREMS sequence, branch point and 3′ splice site may be naturally present in an intron or may be introduced into the intron. When all such elements are present or introduced, in the presence of a compound described herein the elements define an exonic boundary that enables the splicing machinery to generate an iExon in RNA, a result that would not naturally occur without the addition of a splicing modulator compound.

As used herein, the term “pseudoexon” refers to a potential exon in intronic regions of pre-mRNA that is not normally spliced into mature mRNA. A subset of pseudoexons are spliced in the presence of a compound described herein or another agent resulting from an iREMS functioning as a 5′ splice site within the pseudoexon, to form an iExon. An intronic REMS-containing pseudoexon is not known to be endogenously recognized by the splicing machinery for producing an iExon, but in the presence of a splicing modulator compound as described herein, the splicing machinery produces an iExon. Accordingly, production of an iExon from a pseudoexon is intended to be included within the scope of various aspects of the collective term “iExon.”

As used herein, the term “unannotated exon” refers to endogenous sequences that are naturally present as exons in mature mRNA product according to experimental evidence but are not annotated in NCBI's RefSeq database (https://www.ncbi.nlm.nih.gov/refseq/). Some unannotated exons contain an intronic REMS at the 5′ splice site. A REMS-containing unannotated exon is not known to be endogenously recognized by the splicing machinery for producing an iExon, but in the presence of a splicing modulator compound as described herein, the splicing machinery produces an iExon. Accordingly, production of an iExon from an unannotated exon is intended to be included within the scope of various aspects of the collective term “iExon.”

As used herein, the term “substantial change” in the context of the amount of one or more RNA transcripts (e.g., rRNA, tRNA, miRNA, siRNA, piRNA, lncRNA, pre-mRNA or mRNA transcripts), an alternative splice variant thereof or an isoform thereof, or one or more proteins thereof, each expressed as the product of one or more of genes, means that the amount of such products changes by a statistically significant amount such as, in a nonlimiting example, a p value less than a value selected from 0.1, 0.01, 0.001, or 0.0001.

As used herein, the terms “subject” and “patient” are used interchangeably to refer to an animal or any living organism having sensation and the power of voluntary movement, and which requires for its existence oxygen and organic food. Non-limiting examples include members of the human, equine, porcine, bovine, rattus, murine, canine and feline species. In some embodiments, the subject is a mammal or a warm-blooded vertebrate animal. In certain embodiments, the subject is a non-human animal. In specific embodiments, the subject is a human.

As used herein, the term “functional protein” refers to a form of a protein that retains a certain biological function or the functions of a full length protein or protein isoform encoded by a gene. Accordingly, inclusion of an iExon that is located in the protein coding region of an mRNA that expresses a functional protein is intended to be included within the scope of the description herein.

As used herein, the term “non-functional protein” refers to a form of a protein that does not retain any biological function compared to full length protein or a protein isoform encoded by a gene in the absence of a splicing modifier compound as described herein. Accordingly, inclusion of an iExon that is located in the protein coding region of an mRNA that expresses a non-functional protein is intended to be included within the scope of the description herein.

As used herein, in the context of a functional protein produced from an artificial construct, the term “produce substantially less” means that the amount of functional protein produced in the presence of a compound described herein is at least substantially 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 100% less than the amount of functional protein produced in the absence of the compound.

Compound Forms

As used herein, the terms “a compound of Formula (Ia),” “a compound of Formula (Ia1),” “a compound of Formula (Ia2),” “a compound of Formula (Ia3),” “a compound of Formula (Ia4),” “a compound of Formula (II),” “a compound of Formula (IIa),” “a compound of Formula (IIa1),” “a compound of Formula (IIa2),” “a compound of Formula (IIa3),” “a compound of Formula (IIa4),” “a compound of Formula (III),” “a compound of Formula (IIIa),” “a compound of Formula (IIIa1),” “a compound of Formula (IIIa2),” “a compound of Formula (IIIa3),” “a compound of Formula (IIIa4),” “a compound of Formula (IV),” “a compound of Formula (IVa),” “a compound of Formula (IVa1),” “a compound of Formula (IVa2),” “a compound of Formula (V),” “a compound of Formula (Va),” “a compound of Formula (Va1),” “a compound of Formula (Va2),” “a compound of Formula (VI),” “a compound of Formula (VIa),” “a compound of Formula (VIa1),” “a compound of Formula (VIa2),” “a compound of Formula (VIa3),” “a compound of Formula (VIa4),” “a compound of Formula (VII),” “a compound of Formula (VIIa),” “a compound of Formula (VIIa1),” “a compound of Formula (VIIa2),” “a compound of Formula (VIII),” “a compound of Formula (VIIIa),” “a compound of Formula (VIIIa1),” “a compound of Formula (VIIIa2),” “a compound of Formula (IX),” “a compound of Formula (IXa),” “a compound of Formula (IXa1),” “a compound of Formula (IXa2),” “a compound of Formula (IXa3),” “a compound of Formula (IXa4),” “a compound of Formula (X),” “a compound of Formula (Xa),” “a compound of Formula (Xa1),” “a compound of Formula (Xa2),” “a compound of Formula (XI),” “a compound of Formula (XIa),” “a compound of Formula (XIa1),” “a compound of Formula (XIa2),” “a compound of Formula (XII),” “a compound of Formula (XIIa),” “a compound of Formula (XIIa1),” “a compound of Formula (XIIa2),” “a compound of Formula (XIIa3),” “a compound of Formula (XIIa4),” “a compound of Formula (XIII),” “a compound of Formula (XIIIa),” “a compound of Formula (XIIIa1),” “a compound of Formula (XIIIa2),” “a compound of Formula (XIV),” “a compound of Formula (XIVa),” “a compound of Formula (XIVa1),” and “a compound of Formula (XIVa2),” each refer to subgenera of the compound of Formula (I) or a form thereof.

Rather than repeat embodiments for the various subgenera of the compound of Formula (I), in certain embodiments, the term “a compound of Formula (I) or a form thereof” is used to inclusively to refer to a compound of Formula (Ia) or a form thereof, a compound of Formula (Ia1) or a form thereof, a compound of Formula (Ia2) or a form thereof, a compound of Formula (Ia3) or a form thereof, a compound of Formula (Ia4) or a form thereof, a compound of Formula (II) or a form thereof, a compound of Formula (IIa) or a form thereof, a compound of Formula (IIa1) or a form thereof, a compound of Formula (IIa2) or a form thereof, a compound of Formula (IIa3) or a form thereof, a compound of Formula (IIa4) or a form thereof, a compound of Formula (III) or a form thereof, a compound of Formula (IIIa) or a form thereof, a compound of Formula (IIIa1) or a form thereof, a compound of Formula (IIIa2) or a form thereof, a compound of Formula (IIIa3) or a form thereof, a compound of Formula (IIIa4) or a form thereof, a compound of Formula (IV) or a form thereof, a compound of Formula (IVa) or a form thereof, a compound of Formula (IVa1) or a form thereof, a compound of Formula (IVa2) or a form thereof, a compound of Formula (V) or a form thereof, a compound of Formula (Va) or a form thereof, a compound of Formula (Va1) or a form thereof, a compound of Formula (Va2) or a form thereof, a compound of Formula (VI) or a form thereof, a compound of Formula (VIa) or a form thereof, a compound of Formula (VIa1) or a form thereof, a compound of Formula (VIa2) or a form thereof, a compound of Formula (VIa3) or a form thereof, a compound of Formula (VIa4) or a form thereof, a compound of Formula (VII) or a form thereof, a compound of Formula (VIIa) or a form thereof, a compound of Formula (VIIa1) or a form thereof, a compound of Formula (VIIa2) or a form thereof, a compound of Formula (VIII) or a form thereof, a compound of Formula (VIIIa) or a form thereof, a compound of Formula (VIIIa1) or a form thereof, a compound of Formula (VIIIa2) or a form thereof, a compound of Formula (IX) or a form thereof, a compound of Formula (IXa) or a form thereof, a compound of Formula (IXa1) or a form thereof, a compound of Formula (IXa2) or a form thereof, a compound of Formula (IXa3) or a form thereof, a compound of Formula (IXa4) or a form thereof, a compound of Formula (X) or a form thereof, a compound of Formula (Xa) or a form thereof, a compound of Formula (Xa1) or a form thereof, a compound of Formula (Xa2) or a form thereof, a compound of Formula (XI) or a form thereof, a compound of Formula (XIa) or a form thereof, a compound of Formula (XIa1) or a form thereof, a compound of Formula (XIa2) or a form thereof, a compound of Formula (XII) or a form thereof, a compound of Formula (XIIa) or a form thereof, a compound of Formula (XIIa1) or a form thereof, a compound of Formula (XIIa2) or a form thereof, a compound of Formula (XIIa3) or a form thereof, a compound of Formula (XIIa4) or a form thereof, a compound of Formula (XIII) or a form thereof, a compound of Formula (XIIIa) or a form thereof, a compound of Formula (XIIIa1) or a form thereof, a compound of Formula (XIIIa2) or a form thereof, a compound of Formula (XIV) or a form thereof, a compound of Formula (XIVa) or a form thereof, a compound of Formula (XIVa1) or a form thereof or a compound of Formula (XIVa2) or a form thereof, either separately or together.

Thus, embodiments and references to “a compound of Formula (I)” are intended to be inclusive of compounds of Formula (Ia), Formula (Ia1), Formula (Ia2), Formula (Ia3), Formula (Ia4), Formula (II), Formula (IIa), Formula (IIa1), Formula (IIa2), Formula (IIa3), Formula (IIa4), Formula (III), Formula (IIIa), Formula (IIIa1), Formula (IIIa2), Formula (IIIa3), Formula (IIIa4), Formula (IV), Formula (IVa), Formula (IVa1), Formula (IVa2), Formula (V), Formula (Va), Formula (Va1), Formula (Va2), Formula (VI), Formula (VIa), Formula (VIa1), Formula (VIa2), Formula (VIa3), Formula (VIa4), Formula (VII), Formula (VIIa), Formula (VIIa1), Formula (VIIa2), Formula (VIII), Formula (VIIIa), Formula (VIIIa1), Formula (VIIIa2), Formula (IX), Formula (IXa), Formula (IXa1), Formula (IXa2), Formula (IXa3), Formula (IXa4), Formula (X), Formula (Xa), Formula (Xa1), Formula (Xa2), Formula (XI), Formula (XIa), Formula (XIa1), Formula (XIa2), Formula (XII), Formula (XIIa), Formula (XIIa1), Formula (XIIa2), Formula (XIIa3), Formula (XIIa4), Formula (XIII), Formula (XIIIa), Formula (XIIIa1), Formula (XIIIa2), Formula (XIV), Formula (XIVa), Formula (XIVa1) and Formula (XIVa2).

As used herein, the term “form” means a compound of Formula (I) selected from a free acid, free base, salt, isotopologue, stereoisomer, racemate, enantiomer, diastereomer, or tautomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a selected from a salt, isotopologue, stereoisomer, racemate, enantiomer, diastereomer or tautomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a selected from a free acid, isotopologue, stereoisomer, racemate, enantiomer, diastereomer or tautomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a selected from a free base, isotopologue, stereoisomer, racemate, enantiomer, diastereomer or tautomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a free acid, free base or salt thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is an isotopologue thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a tautomer thereof.

In certain embodiments described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form.

In certain embodiments described herein, the compound of Formula (I) or a form thereof is isolated for use.

As used herein, the term “isolated” means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.

As used herein, the term “protected” means that a functional group on a compound of Formula (I) is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991), Wiley, New York.

Prodrugs of a compound of Formula (I) or a form thereof are also contemplated herein.

As used herein, the term “prodrug” means that a functional group on a compound of Formula (I) is in a form (e.g., acting as an active or inactive drug precursor) that is transformed in vivo to yield an active or more active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by V. J. Stella, et. al., “Biotechnology: Pharmaceutical Aspects, Prodrugs: Challenges and Rewards,” American Association of Pharmaceutical Scientists and Springer Press, 2007.

In one example, when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or a form thereof contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a functional group such as alkyl or substituted carbonyl and the like. In another example, when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug can be formed by the replacement of one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. In another example, when a compound of Formula (I) or a form thereof contains a hydrogen substituent, a prodrug can be formed by the replacement of one or more hydrogen atoms with an alkyl substituent.

Pharmaceutically acceptable prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters phosphonate esters, mono-, di- or triphosphate esters or alkyl substituents where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof for use as a prodrug.

The compounds of Formula (I) can form salts which are intended to be included within the scope of this description. Reference to a compound of Formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein.

The term “pharmaceutically acceptable salt(s)”, as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent or stoichiometric amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Embodiments of acid addition salts include, and are not limited to, acetate, acid phosphate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, hydrobromide, hydrochloride, dihydrochloride, hydroiodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. One or more embodiments of acid addition salts include a chloride, hydrochloride, dihydrochloride, trihydrochloride, hydrobromide, acetate, diacetate or trifluoroacetate salt. More particular embodiments include a chloride, hydrochloride, dihydrochloride, hydrobromide or trifluoroacetate salt.

Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33, 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (see, website for Food & Drug Administration, Washington, D.C.). These disclosures are incorporated herein by reference thereto.

Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts. Certain compounds described herein can also form pharmaceutically acceptable salts with organic bases (for example, organic amines) such as, but not limited to, dicyclohexylamines, tert-butyl amines and the like, and with various amino acids such as, but not limited to, arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.

All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the description herein and all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for the purposes described herein.

Compounds of Formula I and forms thereof may further exist in a tautomeric form. All such tautomeric forms are contemplated herein as part of the present description.

The compounds of Formula (I) may contain asymmetric or chiral centers, and, therefore, may exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures.

The compounds of Formula (I) described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R/S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one embodiment, the compounds of Formula (I) described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another embodiment, the compounds of Formula (I) described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds of Formula (I) described herein may also include portions described as an (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations.

As used herein, the term “substantially pure” refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.

In one aspect, a compound of Formula (I) is a substantially pure (S) enantiomer present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.

In one aspect, a compound of Formula (I) is a substantially pure (R) enantiomer present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.

As used herein, a “racemate” is any mixture of isometric forms that are not “enantiomerically pure”, including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, about 80/20, about 85/15 or about 90/10.

In addition, the present description embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description herein.

Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art.

Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered part of this description.

All stereoisomer forms (for example, geometric isomers, optical isomers, positional isomers and the like) of the present compounds (including salts, solvates, esters and prodrugs and transformed prodrugs thereof) which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, diastereomeric forms and regioisomeric forms are contemplated within the scope of the description herein. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures thereof, are embraced within the scope of the description herein. Also, for example, all keto-enol and imine-enamine tautomeric forms of the compounds are included in the description herein. Individual stereoisomers of the compounds of Formula (I) described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra.

The use of the terms “salt,” “prodrug” and “transformed prodrug” are intended to equally apply to the salts, prodrugs and transformed prodrugs of all contemplated isotopologues, stereoisomers, racemates or tautomers of the instant compounds.

The term “isotopologue” refers to isotopically-enriched compounds which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as H², H³, C³, C¹⁴, N¹⁵, O¹⁸, O¹⁷, P³¹, P³², S³⁵, F¹⁸, Cl³⁵ and Cl³⁶, respectively, each of which is also within the scope of this description.

Certain isotopically-enriched compounds described herein (e.g., those labeled with H³ and C⁴) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., H³) and carbon-14 (i.e., C¹⁴) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., “deuterium enriched”) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically-enriched compounds of Formula (I) can generally be prepared using procedures known to persons of ordinary skill in the art by substituting an appropriate isotopically-enriched reagent for a non-isotopically-enriched reagent.

When the compounds are enriched with deuterium, the deuterium-to-hydrogen ratio on the deuterated atoms of the molecule substantially exceeds the naturally occurring deuterium-to-hydrogen ratio.

An embodiment described herein may include an isotopologue form of the compound of Formula (T), wherein the isotopologue is substituted on one or more atom members of the compound of Formula (I) with one or more deuterium atoms in place of one or more hydrogen atoms.

An embodiment described herein may include a compound of Formula (I) and forms thereof, wherein a carbon atom may have from 1 to 3 hydrogen atoms optionally replaced with deuterium.

One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms.

As used herein, the term “solvate” means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

One or more compounds described herein may optionally be converted to a solvate. Preparation of solvates is generally known. A typical, non-limiting process involves dissolving a compound in a desired amount of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example infrared spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).

As used herein, the term “hydrate” means a solvate wherein the solvent molecule is water.

Polymorphic crystalline and amorphous forms of the compounds of Formula (I), and of the salts, solvates, esters and prodrugs of the compounds of Formula (I), are further intended to be included in the scope of the compounds described herein

Methods for Determining which Genes May be Modulated by the Compounds

In another aspect, provided herein are methods for determining whether the splicing of the precursor RNA of a gene is likely to be modulated by a compound of Formula (I) or a form thereof, comprising searching for the presence of an intronic REMS (i.e., a sequence functioning as a 5′ splice site) in a gene intronic sequence, wherein the presence of the intronic REMS 3′ splice site and an intronic branch point in the gene sequence indicates that the splicing of the precursor RNA of the gene is likely to be modulated by the compound of Formula (I) or a form thereof, and the absence of the intronic REMS and an intronic 3′ splice site and an intronic branch point in the gene sequence indicates that the splicing of the precursor RNA of the gene is unlikely to be modulated by the compound of Formula (I) or a form thereof. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described herein. In specific embodiments, the methods further comprise searching for the presence of the combination of an intronic REMS, an intronic 3′ splice site and an intronic branch point in the gene sequence.

In another aspect, provided herein are methods for determining whether the amount of a product (e.g., an mRNA transcript or protein) of a gene is likely to be modulated by a compound of Formula (I) or a form thereof, comprising searching for the presence of an intronic REMS in the gene sequence, wherein the presence of the combination of an intronic REMS, an intronic 3′ splice site and an intronic branch point in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is likely to be modulated by the compound of Formula (I) or a form thereof, and the absence of the combination of an intronic REMS, an intronic 3′ splice site and an intronic branch point in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is unlikely to be modulated by the compound of Formula (I) or a form thereof. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described herein. In specific embodiments, the methods further comprise searching for the presence of any of an intronic REMS, an intronic 3′ splice site, and an intronic branch point in the gene sequence.

The step of searching for the presence of an intronic REMS, an intronic 3′ splice site, and an intronic branch point in the gene sequence described herein can be performed by a computer system comprising a memory storing instructions for searching for the presence of the intronic REMS, the intronic 3′ splice site, and the intronic branch point in the gene sequence, or such a search can be performed manually.

In another aspect, provided herein are methods for determining whether the splicing of the precursor RNA of a gene is likely to be modulated via iExon inclusion by a compound of Formula (I) or a form thereof. In one particular aspect, the method comprises searching for the presence of an intronic REMS (i.e., a sequence functioning as a 5′ splice site) in combination with, in order, an upstream branch point and an upstream 3′ splice site in a gene intronic sequence. The presence of these elements with the intronic REMS and the endogenous presence of a downstream 3′ splice site and a downstream branch point in the gene sequence indicates that the splicing of the precursor RNA of the gene is likely to be modulated by the compound of Formula (I) or a form thereof. In this aspect, the presence of an upstream branch point and upstream 3′ splice site and the REMS in the intron enable the presence of the compound of Formula (I) or a form thereof to modulate iExon inclusion, i.e., splicing the iExon with the downstream endogenous exon (as shown in FIG. 1A). Otherwise, in the absence of these elements, the iREMS will be either ignored by the spliceosome or, in a limited set of circumstances, will become an extended/cryptic 5′ splice site for the upstream endogenous exon (as shown in FIGS. 1B and 1C). The absence of the intronic REMS in the gene sequence indicates that the splicing of the precursor RNA of the gene is unlikely to be modulated via iExon inclusion by the compound of Formula (I) or a form thereof. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described herein. In other specific embodiments, the methods further comprise searching for the presence of the combination of, in 5′ to 3′ order: an upstream branch point, an upstream 3′ splice site, an intronic REMS, a downstream branch point and a downstream 3′ splice site in the gene sequence.

In another aspect, provided herein are methods for determining whether the amount of a product (e.g., an mRNA transcript or protein) of a gene is likely to be modulated via iExon inclusion by a compound of Formula (T) or a form thereof, comprising searching for the presence of an intronic REMS in the gene sequence, wherein the presence of the combination of at least an upstream branch point, an upstream 3′ splice site and an intronic REMS in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is likely to be modulated via iExon inclusion by the compound of Formula (I) or a form thereof, and the absence of the combination of an upstream branch point, an upstream 3′ splice site and an intronic REMS in the gene sequence indicates that the amount of a product (e.g., an mRNA transcript or protein) of the gene is unlikely to be modulated via iExon inclusion by the compound of Formula (I) or a form thereof. In certain embodiments, a compound of Formula (I) is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV) described herein. In specific embodiments, the methods further comprise searching for the presence of any of, in 5′ to 3′ order: an upstream branch point, an upstream 3′ splice site, an intronic REMS, a downstream 3′ splice site, and a downstream branch point in the gene sequence.

The step of searching for the presence of an upstream branch point, an upstream 3′ splice site and an intronic REMS in any of the gene sequences in any of the genes described herein can be performed by a computer system comprising a memory storing instructions for searching for the presence of the intronic REMS, the upstream 3′ splice site, and the upstream branch point in the gene sequence, or such a search can be performed manually.

In certain embodiments, the splicing of a precursor RNA containing an intronic REMS is assessed by contacting a compound described herein with the precursor RNA in cell culture. In some embodiments, the splicing of a precursor RNA containing an intronic REMS is assessed by contacting a compound described herein with the precursor RNA in a cell-free extract. In a specific embodiment, the compound is one known to modulate the splicing of a precursor RNA containing an exonic REMS. See, e.g., the section below relating to methods for determining whether a compound modulates the expression of certain genes, and the example below for techniques that could be used in these assessments.

Methods for Determining which Compounds of Formula (I) Modulate the Expression of Certain Genes

Provided herein are methods for determining whether a compound of Formula (I) or a form thereof modulates the amount of one, two, three or more RNA transcripts (e.g., pre-mRNA or mRNA transcripts or isoforms thereof) of one, two, three or more genes. In some embodiments, the gene is any one of the genes disclosed in Tables 2-7 or any one of the genes disclosed in Table 1. In certain embodiments, the gene is a gene disclosed in Tables 2-6. In some embodiments, the gene is a gene disclosed in Table 7. In other embodiments, the gene is a gene disclosed in Table 1. In certain embodiments, the gene is a gene not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both.

In one embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript, comprising: (a) contacting a cell(s) with a compound of Formula (I) or a form thereof, and (b) determining the amount of the RNA transcript produced by the cell(s), wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell(s) with a compound of Formula (I) or a form thereof, (b) contacting a second cell(s) with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RNA transcript produced by the first cell(s) and the second cell(s); and (d) comparing the amount of the RNA transcript produced by the first cell(s) to the amount of the RNA transcript expressed by the second cell(s), wherein an alteration in the amount of the RNA transcript produced by the first cell(s) relative to the amount of the RNA transcript produced by the second cell(s) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain embodiments, the contacting of the cell(s) with the compound occurs in cell culture. In other embodiments, the contacting of the cell(s) with the compound occurs in a subject, such as a non-human animal subject.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof; and (b) determining the amount of the two or more RNA transcript splice variants produced by the cell(s), wherein an alteration in the amount of the two or more RNA transcript in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof; (b) isolating two or more RNA transcript splice variants from the cell(s) after a certain period of time; and (c) determining the amount of the two or more RNA transcript splice variants produced by the cell(s), wherein an alteration in the amount of the two or more RNA transcript in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising (a) culturing a first cell(s) in the presence of a compound of Formula (I) or a form thereof; (b) culturing a second cell(s) in the presence of a negative control (e.g., a vehicle control, such as PBS or DMSO); (c) isolating two or more RNA transcript splice variants produced by the first cell(s) and isolating two or more RNA transcript splice variants produced by the second cell(s); (d) determining the amount of the two or more RNA transcript splice variants produced by the first cell(s) and the second cell(s); and (e) comparing the amount of the two or more RNA transcript splice variants produced by the first cell(s) to the amount of the two or more RNA transcript splice variants produced by the second cell(s), wherein an alteration in the amount of the two or more RNA transcript splice variants produced by the first cell(s) relative to the amount of the two or more RNA transcript splice variants produced by the second cell(s) indicates that the compound of Formula (I) or a form thereof modulates the aplicing of the RNA transcript.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a cell-free system with a compound of Formula (I) or a form thereof, and (b) determining the amount of the RNA transcript produced by the cell-free system, wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell-free system with a compound of Formula (I) or a form thereof, (b) contacting a second cell-free system with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RNA transcript produced by the first cell-free system and the second cell-free system; and (d) comparing the amount of the RNA transcript produced by the first cell-free system to the amount of the RNA transcript expressed by the second cell-free system, wherein an alteration in the amount of the RNA transcript produced by the first cell-free system relative to the amount of the RNA transcript produced by the second cell-free system indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain embodiments, the cell-free system comprises purely synthetic RNA, synthetic or recombinant (purified) enzymes, and protein factors. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template, synthetic or recombinant (purified) enzymes, and protein factors. In other embodiments, the cell-free system comprises purely synthetic RNA and nuclear extract. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template and nuclear extract. In other embodiments, the cell-free system comprises purely synthetic RNA and whole cell extract. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template and whole cell extract. In certain embodiments, the cell-free system additionally comprises regulatory RNAs (e.g., microRNAs).

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a cell-free system with a compound of Formula (I) or a form thereof; and (b) determining the amount of two or more RNA transcript splice variants produced by the cell-free system, wherein an alteration in the amount of the two or more RNA transcript splice variants in the presence of the compound relative to the amount of the two or more RNA transcript splice variants in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first cell-free system with a compound of Formula (I) or a form thereof; (b) contacting a second cell-free system with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of two or more RNA transcript splice variants produced by the first cell-free system and the second cell-free system; and (d) comparing the amount of the two or more RNA transcript splice variants produced by the first cell-free system to the amount of the RNA transcript expressed by the second cell-free system, wherein an alteration in the amount of the two or more RNA transcript splice variants produced by the first cell-free system relative to the amount of the two or more RNA transcript splice variants produced by the second cell-free system indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript. In certain embodiments, the cell-free system comprises purely synthetic RNA, synthetic or recombinant (purified) enzymes, and protein factors. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template, synthetic or recombinant (purified) enzymes, and protein factors. In other embodiments, the cell-free system comprises purely synthetic RNA and nuclear extract. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template and nuclear extract. In other embodiments, the cell-free system comprises purely synthetic RNA and whole cell extract. In other embodiments, the cell-free system comprises RNA transcribed from a synthetic DNA template and whole cell extract. In certain embodiments, the cell-free system additionally comprises regulatory RNAs (e.g., microRNAs).

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof, (b) isolating the RNA transcript from the cell(s) after a certain period of time; and (c) determining the amount of the RNA transcript produced by the cell(s), wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising (a) culturing a first cell(s) in the presence of a compound of Formula (I) or a form thereof, (b) culturing a second cell(s) in the presence of a negative control (e.g., a vehicle control, such as PBS or DMSO); (c) isolating the RNA transcript produced by the first cell(s) and isolating the RNA transcript produced by the second cell(s); (d) determining the amount of the RNA transcript produced by the first cell(s) and the second cell(s); and (e) comparing the amount of the RNA transcript produced by the first cell(s) to the amount of the RNA transcript produced by the second cell(s), wherein an alteration in the amount of the RNA transcript produced by the first cell(s) relative to the amount of the RNA transcript produced by the second cell(s) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript.

In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject. In some embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject with a disease. In specific embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject with a disease associated with an aberrant amount of an RNA transcript(s) for a particular gene(s). In some specific embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a primary cell(s) from a subject with a disease associated with an aberrant amount of an isoform(s) of a particular gene(s). In some embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a fibroblast (e.g., GM03813 or PNN 1-46 fibroblasts), an immune cell (e.g., a T cell, B cell, natural killer cell, macrophage), or a muscle cell. In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell.

In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line. In some embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cell line derived from a subject with a disease. In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line known to have aberrant RNA transcript levels for a particular gene(s). In specific embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is from a cell line derived from a subject with a disease known to have aberrant RNA transcript levels for a particular gene(s). In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell line. In some specific embodiments, the cell(s) contacted or cultured with the compound of Formula (I) or a form thereof is from a cell line derived from a subject with a disease known to have an aberrant amount of an RNA isoform(s) and/or protein isoform(s) of a particular gene(s). Non-limiting examples of cell lines include 3T3, 4T1, 721, 9L, A2780, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1, BEAS-2B, bEnd.3, BHK, BR 293, BT2O, BT483, BxPC3, C2Cl2, C3H-10T1/2, C6/36, C6, Cal-27, CHO, COR-L23, COS, COV-434, CML T1, CMT, CRL7O3O, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6, FM3, H1299, H69, HB54, HB55, HCA2, HDF (human dermal fibroblasts), HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, Hs578T, HsS78Bst, HT-29, HTB2, HUVEC, Jurkat, J558L, JY, K562, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK, MG63, MOR/0.2R, MONO-MAC 6, MRC5, MTD-1A, NCI-H69, NIH-3T3, NALM-1, NS0, NW-145, OPCN, OPCT, PNT-1A, PNT-2, Raji, RBL, RenCa, RIN-5F, RMA, Saos-2, Sf21, Sf9, SH-SY5Y, SiHa, SKBR3, SKOV-3, T2, T-47D, T84, THP1, U373, U87, U937, VCaP, Vero, VERY, W138, WM39, WT-49, X63, YAC-1, and YAR cells. In one embodiment, the cells are from a patient. In another embodiment, the patient cells are GM03813 cells.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a tissue sample with a compound of Formula (I) or a form thereof; and (b) determining the amount of the RNA transcript produced by the tissue sample, wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) contacting a first tissue sample with a compound of Formula (I) or a form thereof, (b) contacting a second tissue sample with a negative control (e.g., a vehicle control, such as PBS or DMSO); and (c) determining the amount of the RNA transcript produced by the first tissue sample and the second tissue sample; and (d) comparing the amount of the RNA transcript produced by the first tissue sample to the amount of the RNA transcript produced by the second tissue sample, wherein an alteration in the amount of the RNA transcript produced by the first tissue sample relative to the amount of the RNA transcript produced by the second tissue sample indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. Any tissue sample containing cells may be used in the accordance with these methods. In certain embodiments, the tissue sample is a blood sample, a skin sample, a muscle sample, or a tumor sample. Techniques known to one skilled in the art may be used to obtain a tissue sample from a subject.

In some embodiments, a dose-response assay is performed. In one embodiment, the dose response assay comprises: (a) contacting a cell(s) with a concentration of a compound of Formula (I) or a form thereof; (b) determining the amount of the RNA transcript produced by the cell(s), wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript; (c) repeating steps (a) and (b), wherein the only experimental variable changed is the concentration of the compound or a form thereof; and (d) comparing the amount of the RNA transcript produced at the different concentrations of the compound or a form thereof. In another embodiment, the dose response assay comprises: (a) culturing a cell(s) in the presence of a compound of Formula (I) or a form thereof, (b) isolating the RNA transcript from the cell(s) after a certain period of time; (c) determining the amount of the RNA transcript produced by the cell(s), wherein an alteration in the amount of the RNA transcript in the presence of the compound relative to the amount of the RNA transcript in the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO) indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript; (d) repeating steps (a), (b), and (c), wherein the only experimental variable changed is the concentration of the compound or a form thereof; and (e) comparing the amount of the RNA transcript produced at the different concentrations of the compound or a form thereof. In another embodiment, the dose-response assay comprises: (a) contacting each well of a microtiter plate containing cells with a different concentration of a compound of Formula (I) or a form thereof; (b) determining the amount of an RNA transcript produced by cells in each well; and (c) assessing the change of the amount of the RNA transcript at the different concentrations of the compound or form thereof.

In one embodiment, the dose response assay comprises: (a) contacting a cell(s) with a concentration of a compound of Formula (I) or a form thereof, wherein the cells are within the wells of a tissue culture container (e.g., a 96-well plate) at about the same density within each well, and wherein the cells are contacted with different concentrations of compound in different wells; (b) isolating the RNA from said cells in each well; (c) determining the amount of the RNA transcript produced by the cell(s) in each well; and (d) assessing change in the amount of the RNA transcript in the presence of one or more concentrations of compound relative to the amount of the RNA transcript in the presence of a different concentration of the compound or the absence of the compound or the presence of a negative control (e.g., a vehicle control such as PBS or DMSO).

In certain embodiments, the contacting of the cell(s) with the compound occurs in cell culture. In other embodiments, the contacting of the cell(s) with the compound occurs in a subject, such as a non-human animal subject.

In certain embodiments described herein, the cell(s) is contacted or cultured with a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a compound of Formula (I) or a form thereof, or a negative control for a period of 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours or more. In other embodiments described herein, the cell(s) is contacted or cultured with a compound of Formula (T) or a form thereof, or a tissue sample is contacted with a compound of Formula (I) or a form thereof, or a negative control for a period of 15 minutes to 1 hour, 1 to 2 hours, 2 to 4 hours, 6 to 12 hours, 12 to 18 hours, 12 to 24 hours, 28 to 24 hours, 24 to 48 hours, 48 to 72 hours.

In certain embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0.0001 μM, 0.0003 μM, 0.001 μM, 0.003 μM, 0.01 μM, 0.05 μM, 1 μM, 2 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM, 50 μM, 75 μM, 100 μM, or 150 μM. In other embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0.0001 μM, 0.0003 μM, 0.0005 μM, 0.001 μM, 0.003 μM, 0.005 μM, 0.01 μM, 0.03 μM, 0.05 μM, 0.1 μM, 0.3 μM, 0.5 μM or 1 μM. In other embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 175 μM, 200 μM, 250 μM, 275 μM, 300 μM, 350 μM, 400 μM, 450 μM, 500 μM, 550 μM 600 μM, 650 μM, 700 μM, 750 μM, 800 μM, 850 μM, 900 μM, 950 μM or 1 mM. In some embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, or 950 nM. In certain embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, or a tissue sample is contacted with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is between 0.0001 μM to 0.001 μM, 0.0001 μM to 0.01 μM, 0.0003 μM to 0.001 μM, 0.0003 μM to 0.01 μM, 0.001 μM to 0.01 μM, 0.003 μM to 0.01 μM, 0.01 μM to 0.1 μM, 0.1 μM to 1 μM, 1 μM to 50 μM, 50 μM to 100 μM, 100 μM to 500 μM, 500 μM to 1 nM, 1 nM to 10 nM, 10 nM to 50 nM, 50 nM to 100 nM, 100 nM to 500 nM, 500 nM to 1000 nM.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a subject (in certain embodiments, a non-human animal); and (b) determining the amount of the RNA transcript in a sample obtained from the subject, wherein an alteration in the amount of the RNA transcript measured in the sample from the subject administered the compound or form thereof relative to the amount of the RNA transcript in a sample from the subject prior to administration of the compound or form thereof or a sample from a different subject from the same species not administered the compound or form thereof indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the amount of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a first subject (in certain embodiments, a non-human animal); (b) administering a negative control (e.g., a pharmaceutical carrier) to a second subject (in certain embodiments, a non-human animal) of the same species as the first subject; and (c) determining the amount of the RNA transcript in a first tissue sample from the first subject and the amount of the RNA transcript in the second tissue sample from the second subject; and (d) comparing the amount of the RNA transcript in the first tissue sample to the amount of the RNA transcript in the second tissue sample, wherein an alteration in the amount of the RNA transcript in the first tissue sample relative to the amount of the RNA transcript in the second tissue sample indicates that the compound of Formula (I) or a form thereof modulates the amount of the RNA transcript. In certain embodiments, a compound of Formula (I) or form thereof is administered to a subject at a dose of about 0.001 mg/kg/day to about 500 mg/kg/day. In some embodiments, a single dose of a compound of Formula (I) or a form thereof is administered to a subject in accordance with the methods described herein. In other embodiments, 2, 3, 4, 5 or more doses of a compound of Formula (I) is administered to a subject in accordance with the methods described herein. In specific embodiments, the compound of Formula (I) or a form thereof is administered in a subject in a pharmaceutically acceptable carrier, excipient or diluent.

In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a subject (in certain embodiments, a non-human animal); and (b) determining the amount of two or more RNA transcript splice variants in a sample obtained from the subject, wherein an alteration in the amount of the two or more RNA transcript splice variants measured in the sample from the subject administered the compound or form thereof relative to the amount of the two or more RNA transcript splice variants in a sample from the subject prior to administration of the compound or form thereof or a sample from a different subject from the same species not administered the compound or form thereof indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript. In another embodiment, provided herein is a method for determining whether a compound of Formula (I) or a form thereof modulates the splicing of an RNA transcript (e.g., an mRNA transcript), comprising: (a) administering a compound of Formula (I) or a form thereof to a first subject (in certain embodiments, a non-human animal); (b) administering a negative control (e.g., a pharmaceutical carrier) to a second subject (in certain embodiments, a non-human animal) of the same species as the first subject; and (c) determining the amount of two or more RNA transcript splice variants in a first tissue sample from the first subject and the amount of two or more RNA transcript splice variants in the second tissue sample from the second subject; and (d) comparing the amount of the two or more RNA transcript splice variants in the first tissue sample to the amount of the two or more RNA transcript splice variants in the second tissue sample, wherein an alteration in the amount of the two or more RNA transcript splice variants in the first tissue sample relative to the amount of the two or more RNA transcript splice variants in the second tissue sample indicates that the compound of Formula (I) or a form thereof modulates the splicing of the RNA transcript. In certain embodiments, a compound of Formula (I) or form thereof is administered to a subject at a dose of about 0.001 mg/kg/day to about 500 mg/kg/day. In some embodiments, a single dose of a compound of Formula (I) or a form thereof is administered to a subject in accordance with the methods described herein. In other embodiments, 2, 3, 4, 5 or more doses of a compound of Formula (I) is administered to a subject in accordance with the methods described herein. In specific embodiments, the compound of Formula (I) or a form thereof is administered in a subject in a pharmaceutically acceptable carrier, excipient or diluent.

In some embodiments, the compound of Formula (I) or a form thereof that is contacted or cultured with a cell(s) or a tissue sample, or administered to a subject is a compound of Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV). In some embodiments, the compound of Formula (I) or a form thereof that is contacted or cultured with a cell(s) or a tissue sample, or administered to a subject is a compound described herein.

Techniques known to one skilled in the art may be used to determine the amount of an RNA transcript(s). In some embodiments, the amount of one, two, three or more RNA transcripts is measured using deep sequencing, such as ILLUMINA® RNASeq, ILLUMINA® next generation sequencing (NGS), ION TORRENT™ RNA next generation sequencing, 454™ pyrosequencing, or Sequencing by Oligo Ligation Detection (SOLID™). In other embodiments, the amount of multiple RNA transcripts is measured using an exon array, such as the GENECHIP® human exon array. In certain embodiments, the amount of one, two, three or more RNA transcripts is determined by RT-PCR. In other embodiments, the amount of one, two, three or more RNA transcripts is measured by RT-qPCR or digital color-coded barcode technology. Techniques for conducting these assays are known to one skilled in the art.

In some embodiments, analysis is performed on data derived from the assay to measure the magnitude of splicing to determine the amount of exons spliced into an mRNA transcript that is produced in the presence of the compound relative to the amount in the absence of the compound or presence of a negative control. In a preferred embodiment, the method utilized is calculation of change in Percent Spliced In (APSI). The method utilizes read data from RNAseq (or any other method that can distinguish mRNA splice isoforms) to calculate the ratio (percentage) between reads that either demonstrate inclusion (junctions between the upstream exon and the exon of interest) or exclusion (junction between the upstream and downstream exons, excluding the exon of interest), to demonstrate whether the presence of the compound affects the amount of exon inclusion relative to the amount of inclusion in the absence of the compound or the presence of a negative control.

The APSI value is derived from the formula:

ΔPSI (%)={(a+b)/2/[(a+b)/2+c]} ^(C)−{(a+b)/2/[(a+b)/2+c]} ^(U)×100

Where “U” represents the value for probability of iExon inclusion (a+b)/2/[(a+b)/2+c]^(U) in the absence of the compound; and, where “C” represents the value for probability of iExon inclusion (a+b)/2/[(a+b)/2+c]^(C) in the presence of the compound. The values for “a” and “b” represent the number of reads supporting inclusion of an iExon in an RNA transcript. In other words, the “a” value is derived from the amount of reads for a first intronic nucleotide sequence comprising, in 5′ to 3′ order: a first exon having a 5′ splice site operably linked and upstream from a first intronic nucleotide sequence comprising a first branch point further operably linked and upstream from a first intronic 3′ splice site (upstream of the nascent iExon). The “b” value is derived from the amount of reads for a second intronic nucleotide sequence comprising, in 5′ to 3′ order: an iREMS sequence operably linked downstream from the first intronic 3′ splice site and upstream from a second intronic nucleotide sequence comprising a second branch point further operably linked and upstream from a second intronic 3′ splice site of a second exon. The value for “c” represents the number of reads supporting exclusion of an iExon. Accordingly, when a compound enables the splicing machinery to recognize a nascent iExon, the value for (a+b)/2/[(a+b)/2+c]^(C) in the presence of the splicing modifier compound will differ from the value for (a+b)/2/[(a+b)/2+c]^(U) in the absence of the compound. The statistically significant value for the likelihood of iExon inclusion may be obtained according to statistical analysis methods or other probability analysis methods known to those of ordinary skill in the art.

In some embodiments, a statistical analysis or other probability analysis is performed on data from the assay utilized to measure an RNA transcript. In certain embodiments, for example, a Fisher's Exact Test statistical analysis is performed by comparing the total number of reads for the inclusion and exclusion of an iExon (or region) based on data from one or more assays used to measure whether the amount of an RNA transcript is altered in the presence of the compound relative to the amount in the absence of the compound or presence of a negative control. In specific embodiments, the statistical analysis results in a confidence value for those RNA transcripts with the alternation of 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%. In some specific embodiments, the confidence value is a p value of those altered RNA transcripts of is 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%. In certain specific embodiments, an exact test, student t-test or p value of those RNA transcripts with the alteration is 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1% and 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.01%, 0.001% or 0.0001%, respectively.

In certain embodiments, a further analysis is performed to determine how the compound of Formula (I) or a form thereof is changing the amount of an RNA transcript(s). In specific embodiments, a further analysis is performed to determine if an alternation in the amount of an RNA transcript(s) in the presence of a compound of Formula (I) or a form thereof relative the amount of the RNA transcript(s) in the absence of the compound or a form thereof, or the presence of a negative control is due to changes in transcription, splicing, and/or stability of the RNA transcript(s). Techniques known to one skilled in the art may be used to determine whether a compound of Formula (I) or a form thereof changes, e.g., the transcription, splicing and/or stability of an RNA transcript(s).

In certain embodiments, the stability of one or more RNA transcripts is determined by serial analysis of gene expression (SAGE), differential display analysis (DD), RNA arbitrary primer (RAP)-PCR, restriction endonuclease-lytic analysis of differentially expressed sequences (READS), amplified restriction fragment-length polymorphism (ALFP), total gene expression analysis (TOGA), RT-PCR, RT-qPCR, RNA-Seq, digital color-coded barcode technology, high-density cDNA filter hybridization analysis (HDFCA), suppression subtractive hybridization (SSH), differential screening (DS), cDNA arrays, oligonucleotide chips, or tissue microarrays. In other embodiments, the stability of one or more RNA transcripts is determined by Northern blot, RNase protection, or slot blot.

In some embodiments, the transcription in a cell(s) or tissue sample is inhibited before (e.g., 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 72 hours before) or after (e.g., 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, or 72 hours after) the cell or the tissue sample is contacted or cultured with an inhibitor of transcription, such as α-amanitin, DRB, flavopiridol, triptolide, or actinomycin-D. In other embodiments, the transcription in a cell(s) or tissue sample is inhibited with an inhibitor of transcription, such as α-amanitin, DRB, flavopiridol, triptolide, or actinomycin-D, while the cell(s) or tissue sample is contacted or cultured with a compound of Formula (I) or a form thereof.

In certain embodiments, the level of transcription of one or more RNA transcripts is determined by nuclear run-on assay or an in vitro transcription initiation and elongation assay. In some embodiments, the detection of transcription is based on measuring radioactivity or fluorescence. In some embodiments, a PCR-based amplification step is used. In specific embodiments, the amount of alternatively spliced forms of the RNA transcripts of a particular gene are measured to see if there is an alteration in the amount of one, two or more alternatively spliced forms of the RNA transcripts of the gene. In some embodiments, the amount of an isoform(s) encoded by a particular gene is measured to see if there is an alteration in the amount of the isoform(s). In certain embodiments, the levels of spliced forms of RNA are quantified by RT-PCR, RT-qPCR, RNA-Seq, digital color-coded barcode technology, or Northern blot. In other embodiments, sequence-specific techniques may be used to detect the levels of an individual splice form. In certain embodiments, splicing is measured in vitro using nuclear extracts. In some embodiments, detection is based on measuring radioactivity or fluorescence. Techniques known to one skilled in the art may be used to measure alterations in the amount of alternatively spliced forms of an RNA transcript of a gene and alterations in the amount of an isoform encoded by a gene. In a specific embodiment, modulation of RNA transcripts is assessed as described in the Examples described herein.

Also provided herein are methods of screening for new compounds that can be used to modulate the amount of a product (e.g., a precursor RNA, an mRNA, or protein) of a gene comprising an intronic REMS in its DNA or RNA sequence. The methods described above in this section with respect to determining whether the amount of a product (e.g., a precursor RNA, an mRNA, or protein) of a gene is likely to be modulated by a compound of Formula (I) or a form thereof can be also used in the methods of screening for new compounds. In a specific embodiment, the method comprises contacting a candidate compound with an RNA transcript, wherein the RNA transcript comprises exons and one or more introns, wherein at least one intron comprises, in 5′ to 3′ order, a branch point, a 3′ splice site, and an intronic REMS. In another specific embodiment, the method comprises contacting a candidate compound with an RNA transcript, wherein the RNA transcript comprises exons and one or more introns, wherein at least one intron comprises an intronic REMS downstream of a branch point and a 3′ splice site. The RNA transcript may be present in a cell or cell lysate. The methods described above regarding the techniques of contacting a compound with an RNA transcript, the dosage, etc., may be used in the methods of screening. The candidate compounds to be screened can be provided by any source. For example, the candidate compounds to be screened can be from a compound library, such as a commercial compound library.

Pharmaceutical Compositions and Modes of Administration

When administered to a patient, a compound of Formula (I) or a form thereof is preferably administered as a component of a composition that optionally comprises a pharmaceutically acceptable carrier, excipient or diluent. The composition can be administered orally, or by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa) and may be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, and can be used to administer the compound.

Methods of administration include, but are not limited to, parenteral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intraocular, intratumoral, intracerebral, intravaginal, transdermal, ocularly, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of a compound into the bloodstream, tissue or cell(s). In a specific embodiment, a compound is administered orally.

The amount of a compound of Formula (I) or a form thereof that will be effective in the treatment of a disease resulting from an aberrant amount of mRNA transcripts depends, e.g., on the route of administration, the disease being treated, the general health of the subject, ethnicity, age, weight, and gender of the subject, diet, time, and the severity of disease progress, and should be decided according to the judgment of the practitioner and each patient's or subject's circumstances.

In specific embodiments, an “effective amount” in the context of the administration of a compound of Formula (I) or a form thereof, or composition or medicament thereof refers to an amount of a compound of Formula (I) or a form thereof to a patient which has a therapeutic effect and/or beneficial effect. In certain specific embodiments, an “effective amount” in the context of the administration of a compound of Formula (I) or a form thereof, or composition or medicament thereof to a patient results in one, two or more of the following effects: (i) reduces or ameliorates the severity of a disease; (ii) delays onset of a disease; (iii) inhibits the progression of a disease; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life of a subject; (viii) reduces the number of symptoms associated with a disease; (ix) reduces or ameliorates the severity of a symptom(s) associated with a disease; (x) reduces the duration of a symptom associated with a disease associated; (xi) prevents the recurrence of a symptom associated with a disease; (xii) inhibits the development or onset of a symptom of a disease; and/or (xiii) inhibits of the progression of a symptom associated with a disease. In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to restore the amount of a RNA transcript of a gene to the amount of the RNA transcript detectable in healthy patients or cells from healthy patients. In other embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to restore the amount an RNA isoform and/or protein isoform of gene to the amount of the RNA isoform and/or protein isoform detectable in healthy patients or cells from healthy patients.

In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to decrease the aberrant amount of an RNA transcript of a gene which associated with a disease. In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to decrease the amount of the aberrant expression of an isoform of a gene. In some embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to result in a substantial change in the amount of an RNA transcript (e.g., mRNA transcript), alternative splice variant or isoform.

In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an RNA transcript (e.g., an mRNA transcript) of gene which is beneficial for the prevention and/or treatment of a disease. In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an alternative splice variant of an RNA transcript of gene which is beneficial for the prevention and/or treatment of a disease. In certain embodiments, an effective amount of a compound of Formula (I) or a form thereof is an amount effective to increase or decrease the amount of an isoform of gene which is beneficial for the prevention and/or treatment of a disease. Non-limiting examples of effective amounts of a compound of Formula (I) or a form thereof are described herein.

For example, the effective amount may be the amount required to prevent and/or treat a disease associated with the aberrant amount of an mRNA transcript of gene in a human subject.

In general, the effective amount will be in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day for a patient having a weight in a range of between about 1 kg to about 200 kg. The typical adult subject is expected to have a median weight in a range of between about 70 and about 100 kg.

Within the scope of the present description, the “effective amount” of a compound of Formula (I) or a form thereof for use in the manufacture of a medicament, the preparation of a pharmaceutical kit or in a method for preventing and/or treating a disease in a human subject in need thereof, is intended to include an amount in a range of from about 0.001 mg to about 35,000 mg.

The compositions described herein are formulated for administration to the subject via any drug delivery route known in the art. Non-limiting examples include oral, ocular, rectal, buccal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, transdermal, and pulmonary routes of administration.

Embodiments described herein include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition. In a specific embodiment, described herein is the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for preventing and/or treating a disease in a human subject in need thereof comprising administering an effective amount of a compound of Formula (I) or a form thereof in admixture with a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the human subject is a patient with a disease associated with the aberrant amount of an mRNA transcript(s).

A compound of Formula (I) or a form thereof may optionally be in the form of a composition comprising the compound or a form thereof and an optional carrier, excipient or diluent. Other embodiments provided herein include pharmaceutical compositions comprising an effective amount of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient, or diluent. In a specific embodiment, the pharmaceutical compositions are suitable for veterinary and/or human administration. The pharmaceutical compositions provided herein can be in any form that allows for the composition to be administered to a subject.

In a specific embodiment and in this context, the term “pharmaceutically acceptable carrier, excipient or diluent” means a carrier, excipient or diluent approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which a therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a specific carrier for intravenously administered pharmaceutical compositions. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.

Typical compositions and dosage forms comprise one or more excipients. Suitable excipients are well-known to those skilled in the art of pharmacy, and non limiting examples of suitable excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Whether a particular excipient is suitable for incorporation into a pharmaceutical composition or dosage form depends on a variety of factors well known in the art including, but not limited to, the way in which the dosage form will be administered to a patient and the specific active ingredients in the dosage form. Further provided herein are anhydrous pharmaceutical compositions and dosage forms comprising one or more compounds of Formula (I) or a form thereof as described herein. The compositions and single unit dosage forms can take the form of solutions or syrups (optionally with a flavoring agent), suspensions (optionally with a flavoring agent), emulsions, tablets (e.g., chewable tablets), pills, capsules, granules, powder (optionally for reconstitution), taste-masked or sustained-release formulations and the like.

Pharmaceutical compositions provided herein that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets, caplets, capsules, granules, powder, and liquids. Such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art.

Examples of excipients that can be used in oral dosage forms provided herein include, but are not limited to, binders, fillers, disintegrants, and lubricants.

Methods of Modulating the Amount of RNA Transcripts Encoded by Certain Genes

In one aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, and the methods utilize a compound described herein. In certain embodiments, the gene contains a nucleotide sequence encoding an endogenous intronic REMS. In a specific embodiment, the precursor RNA transcript further contains a branch point and a 3′ splice site upstream from the intronic REMS. In certain embodiments, the gene is any one of the genes disclosed in Tables 2-7 or 1. In certain embodiments, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In one embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, by way of nonlimiting example, disclosed in Tables 2-7 or 1, infra, the method comprising contacting a cell with a compound of Formula (I) or a form thereof.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or a protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting a cell with a compound described herein (for example, a compound of Formula (I) or a form thereof).

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising contacting a cell with a compound described herein (for example, a compound of Formula (I) or a form thereof).

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising contacting a cell with a compound described herein.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising contacting a cell with a compound described herein.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein), wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising contacting a cell with a compound described herein.

In a specific embodiment, the gene is a gene described in a table in this disclosure.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Tables 2-7, infra, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In a specific embodiment, the precursor RNA transcript further contains a branch point and a 3′ splice site upstream from the intronic REMS.

In certain embodiments, the gene is a gene not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 1, infra, wherein the precursor transcript transcribed from the gene comprises an intronic REMS, the method comprising contacting a cell with a compound of Formula (I) or a form thereof. In a specific embodiment, the precursor RNA transcript further contains a branch point and a 3′ splice site upstream from the intronic REMS.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 7, infra, comprising contacting a cell with a compound of Formula (I) or a form thereof. See the example section for additional information regarding the genes in Table 7. In certain embodiments, the cell is contacted with the compound of Formula (I) or a form thereof in a cell culture. In other embodiments, the cell is contacted with the compound of Formula (I) or a form thereof in a subject (e.g., a non-human animal subject or a human subject). In a specific embodiment, the RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In one aspect, provided herein is a method for producing a mature mRNA transcript comprising iExon from a pre-mRNA transcript, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In one embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In another embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In some embodiments, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

In a particular embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DTAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SARIA, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP. In another particular embodiment, provided herein is a method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a cell or cell lysate containing a pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLTN2, ERRFT1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP.

In another aspect, provided herein is a method modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In one embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In another embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous or non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide. In some embodiments, the intron further comprises a first 5′ splice site, a second branch point, and a second 3′ splice site upstream of the iREMS. In some embodiments, the pre-mRNA transcript is encoded by a gene disclosed herein (e.g., in a table herein).

In a particular embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, K1AA1462, K1AA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LTNC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837. In a particular embodiment, provided herein is a method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting a cell or cell lysate containing the pre-mRNA transcript with a compound described herein (e.g., a compound of Formula (I) or a form thereof), wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, IGFBP3, IL16, INA, INPP5K, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, IVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837. In some embodiments, the intron further comprises a first 5′ splice site, a second branch point, and a second 3′ splice site upstream of the iREMS.

In certain embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is primary cell(s) or cell(s) from a cell line. In some embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a fibroblast(s), an immune cell(s), or a muscle cell(s). In some embodiments, the cell(s) contacted or cultured with a compound of Formula (I) or a form thereof is a cancer cell. Non-limiting examples of cell lines include 3T3, 4T1, 721, 9L, A2780, A172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1, BEAS-2B, bEnd.3, BHK, BR 293, BT20, BT483, BxPC3, C2C12, C3H-10T1/2, C6/36, C6, Cal-27, CHO, COR-L23, COS, COV-434, CML T1, CMT, CRL7030, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6, FM3, H1299, H69, HB54, HB55, HCA2, HDF, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, Hs578T, HsS78Bst, HT-29, HTB2, HUVEC, Jurkat, J558L, JY, K562, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel, MC-38, MCF-7, MCF-1OA, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK, MG63, MOR/0.2R, MONO-MAC 6, MRC5, MTD-1A, NCI-H69, NIH-3T3, NALM-1, NS0, NW-145, OPCN, OPCT, PNT-1A, PNT-2, Raji, RBL, RenCa, RIN-5F, RMA, Saos-2, Sf21, Sf9, SH-SY5Y, SiHa, SKBR3, SKOV-3, T2, T-47D, T84, THP1, U373, U87, U937, VCaP, Vero, VERY, W138, WM39, WT-49, X63, YAC-1, and YAR cells. In one embodiment, the cells are from a patient. In another embodiment, the patient cells are GM03813 cells.

In certain embodiments described herein, the cell(s) is contacted or cultured with a compound of Formula (I) or a form thereof with a compound of Formula (I) or a form thereof for a period of 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours, 48 hours, 72 hours or more. In other embodiments described herein, the cell(s) is contacted or cultured with a compound of Formula (I) or a form thereof with a compound of Formula (I) or a form thereof for a period of 15 minutes to 1 hour, 1 to 2 hours, 2 to 4 hours, 6 to 12 hours, 12 to 18 hours, 12 to 24 hours, 28 to 24 hours, 24 to 48 hours, 48 to 72 hours.

In certain embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 0.01 μM, 0.05 μM, 1 μM, 2 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM, 50 μM, 75 μM, 100 μM, or 150 μM. In other embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 175 μM, 200 μM, 250 μM, 275 μM, 300 μM, 350 μM, 400 μM, 450 μM, 500 μM, 550 μM 600 μM, 650 μM, 700 μM, 750 μM, 800 μM, 850 μM, 900 μM, 950 μM or 1 mM. In some embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is 5 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, or 950 nM. In certain embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof, wherein the certain concentration is between 0.01 μM to 0.1 μM, 0.1 μM to 1 μM, 1 μM to 50 μM, 50 μM to 100 μM, 100 μM to 500 μM, 500 μM to 1 nM, 1 nM to 10 nM, 10 nM to 50 nM, 50 nM to 100 nM, 100 nM to 500 nM, 500 nM to 1000 nM. In certain embodiments described herein, the cell(s) is contacted or cultured with a certain concentration of a compound of Formula (I) or a form thereof that results in a substantial change in the amount of an RNA transcript (e.g., an mRNA transcript), an alternatively spliced variant, or an isoform of a gene (e.g., a gene in Table 1, infra).

In another aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript further contains a branch point and a 3′ splice site upstream from the intronic REMS.

In one embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, by way of nonlimiting example, disclosed in Table 1, infra, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Tables 2-7, infra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene in a subject, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene in a subject, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In a particular aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS (for example, an endogenous intronic REMS or a non-endogenous intronic REMS), the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order a branch point, a 3′ splice site and an intronic REMS. In specific embodiments of the foregoing aspects, as listed in Table 1, the gene is ABCA1, ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM12, ADAM15, ADAM17, ADAM33, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP3, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFY1, ANKHD1-EIF4EBP3, ANKRA2, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, AP4B1-AS1, APAF1, APIP, APLP2, APP, APPL2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGEF16, ARID1A, ARID2, ARID5B, ARL9, ARL15, ARMCX3, ARMCX6, ASAP1, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF71P, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRN1, BECN1, BEND6, BHMT2, BICD1, BIN1, BIN3-IT1, BIRC3, BIRC6, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1orf86, C10orf54, C11orf30, C11orf70, C11orf73, C11orf94, C12orf4, C12orf56, C14orf132, C17orf76-AS1, C19orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB39, CACNA2D2, CACNB1, CADM1, CALU, CAMKK1, CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CEP68, CFH, CFLAR, CHD8, CHEK1, CIITA, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CNTD1, COG1, COL1A1, COL11A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRYBG3, CRYL1, CSDE1, CSNK1A1, CSNK1E, CSNK1G1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYP1B1, CYP51A1, DAB2, DACT1, DAGLB, DARS, DAXX, DCAF10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1, DENND1A, DENND1B, DENND5A, DEPTOR, DFNB59, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP8, DSEL, DST, DSTN, DYNC1I1, DYRK1A, DZIP1L, EBF1, EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELN, ELP4, EMX2OS, ENAH, ENG, ENPP1, ENPP2, ENSA, EP300, EPN1, EPT1, ERC1, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXO1, EXTL2, EYA3, F2R, FADS1, FADS2, FAF1, FAIM, FAM111A, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM198B, FAM20A, FAM219A, FAM219B, FAM3C, FAM46B, FAM65A, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FBXL6, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FCHO1, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFR2, FGFRL1, FGL2, FHOD3, FLII, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GCFC2, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1, GRK6, GRTP1, GSE1, GTF2H2B, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEY1, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1, HMGCR, HMGN3-AS1, HMGCS1, HOOK3, HMOX1, HNMT, HNRNPR, HNRNPUL1, HP1BP3, HPS1, HRH1, HSD17B12, HSD17B4, HSPA1L, HTATIP2, HTT, IARS, IDH1, IDI1, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IL16, IL6ST, INA, INHBA, INPP5K, INSIG1, INTU, IQCE, IQCG, ITGA11, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIAA1755, KIF14, KIF2A, KIF3A, KIT, KLC1, KLC2, KLF17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAP1-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB1, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINC00341, LINC00472, LINC00570, L1NC00578, LINC00607, L1NC00657, L1NC00678, LINC00702, L1NC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMAN2L, LMO7, LMOD1, LOC400927, LONP1, LOX, LRBA, LRCH4, LRIG1, LRP4, LRP8, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRM1, LZTS2, MADD, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MAP4K4, MAPK13, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM10, MDM2, MED1, MED13L, MEDAG, MEF2D, MEGF6, MEIS2, MEMO1, MEPCE, MFGE8, MFN2, MIAT, MICAL2, MINPP1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSC, MSH2, MSH4, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MYADM, MYCBP2, MYLK, MYO1D, MYO9B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NELFA, NEO1, NEURLIB, NF2, NFE2L1, NFX1, NGF, NGFR, NHLH1, NID1, NID2, NIPA1, NKX3-1, NLN, NOL10, NOMO3, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRD1, NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, OLR1, OS9, OSBPL6, OSBPL10, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC1, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PBLD, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE1C, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PEAR1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZO1, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1, PITPNM3, PLAU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMS1, PNISR, PODN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC1A, PPARA, PPARG, PPHLN1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKG1, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF1, RALB, RAPlA, RAP1GDS1, RAPGEF1, RARG, RARS, RARS2, RASSF8, RBBP8, RBCK1, RBFOX2, RBKS, RBM10, RCC1, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, ROR1, ROR2, RPA1, RPL10, RPS10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SGK3, SGOL2, SH3RF1, SH3YL1, SHROOM3, SIGLEC10, SKA2, SKIL, SLC12A2, SLC24A3, SLC25A17, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SOCS2, SON, SORBS2, SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRGAP1, SRRM1, SRSF3, STAC2, STARD4, STAT1, STAT3, STAT4, STAU1, STC2, STEAP2, STK32B, STRIP1, STRN3, STRN4, STS, STX16, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNPO2, SYNPO2L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANGO6, TARBP1, TARS, TASP1, TBC1D15, TBL2, TCF12, TCF4, TCF7L2, TENC1, TENM2, TEP1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFB1, TGFBR1, TGFBRAP1, TGM2, THADA, THAP4, THBS2, THRB, TIAM1, TIMP2, TJP2, TLE3, TLK1, TMC3, TMEM102, TMEM119, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, TNFRSF14, TNIP1, TNKS1BP1, TNPO3, TNRC18P1, TNRC6A, TNS1, TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIP1, TP53INP1, TPRG1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMT1L, TRPC4, TRPS1, TSC2, TSHZ1, TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE1, TXNIP, TXNL1, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, URGCP, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VIM-AS1, VIPAS39, VPS13A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR91, WIPF1, WISP1, WNK1, WNT5B, WNT10B, WSB1, WWTR1, XIAP, XRN2, YAP1, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ1-AS1, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF431, ZNF583, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF79, ZNF827, ZNF837, ZNF839 or ZNF91.

In a specific embodiment of the foregoing aspect, as listed in Table 2, the gene is: ABCA1, ABCB7, ABCC1, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ADAM12, ADAM15, ADAM17, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK2, ANKFY1, ANKHD1-EIF4EBP3, ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, APAF1, APLP2, APP, APPL2, APTX, ARHGAP22, ARID1A, ARID2, ARMCX3, ASAP1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG9A, ATMIN, ATP2C1, ATXN3, AURKA, AXIN1, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BEND6, BICD1, BIN1, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BZW1, C11orf30, C11orf73, C17orf76-AS1, C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKK1, CAPNS1, CASC3, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CEP68, CFLAR, CHD8, CIZ1, CLIC1, CLK4, CNOT1, COG1, COL12A1, COL1A1, COL6A1, COPS7B, CPEB2, CREB5, CRLS1, CRTAP, CSDE1, CSNK1A1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYBRD1, CYP51A1, DAB2, DACT1, DARS, DAXX, DCAF10, DCAF11, DCBLD2, DCUN1D4, DDAH1, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENND1A, DENND1B, DENND5A, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLC1, DNM2, DOCK1, DPP8, DSEL, DST, DSTN, EBF1, EEA1, EEF1A1, EFCAB14, EGR1, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ENG, ENPP2, ENSA, EPN1, EPT1, ERC1, ERGIC3, ETV5, EXO1, EXTL2, EYA3, FADS1, FADS2, FAF1, FAM111A, FAM198B, FAM219A, FAM219B, FAM3C, FAM65A, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFRL1, FHOD3, FLII, FLNB, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FUS, FYN, GABPB1, GALC, GALNT1, GAS7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJC1, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR89A, GPSM2, GREM1, GRK6, GSE1, GTF2H2B, HAS2, HAT1, HAUS3, HAUS6, HDAC7, HEG1, HLA-A, HLA-E, HLTF, HMGA1, HMGB1, HMGCR, HMGCS1, HMOX1, HNRNPR, HNRNPUL1, HP1BP3, HRH1, HSD17B12, HSD17B4, HTT, IARS, IDH1, 1DI1, IGF2BP2, IL6ST, INHBA, INSIG1, IQCE, ITGAV, ITGB5, ITM2C, ITSN1, KANSL3, KCNK2, KIAA1033, KIAA1143, KIAA1199, KIAA1522, KIAA1524, KIAA1549, KTAA1715, KIF14, KIF2A, KIF3A, KLC1, KLC2, KLF6, KLHL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMB1, LARP4, LARP7, LATS2, LDLR, LEMD3, LGALS8, LIMS1, LINC00341, LINC00657, LMAN2L, LMO7, LONP1, LOX, LRCH4, LRIG1, LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4, MAGED4B, MAN1A2, MAP4K4, MBD1, MBOAT7, MDM2, MED1, MEDAG, MEF2D, MEIS2, MEMO1, MEPCE, MFGE8, MICAL2, MINPP1, MKL1, MKLN1, MKNK2, MLLT4, MLST8, MMAB, MMS19, MMS22L, MPPE1, MPZL1, MRPL3, MSANTD3, MSC, MSH2, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MYADM, MYLK, MYO1D, MYO9B, MYOF, NAA35, NADK, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NELFA, NEO1, NEURLIB, NF2, NFE2L1, NFX1, NID1, NID2, NIPA1, NKX3-1, NOL10, NOMO3, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, ODF2, OS9, OSBPL6, OSMR, P4HA1, P4HB, PABPC1, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE4A, PDE7A, PDLIM7, PDXDC1, PEPD, PEX5, PFKP, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZO1, PIGU, PIK3C2B, PITPNA, PITPNB, PITPNM1, PLAU, PLEC, PLEKHB2, PLSCR3, PLXNB2, PLXNC1, PMS1, POLE3, POLR3D, POSTN, POU2F1, PPAPDC1A, PPARA, PPHLN1, PPIP5K1, PPP1R12A, PPP6R1, PPP6R2, PRKACB, PRKDC, PRMT1, PRNP, PRSS23, PSMA4, PSMC1, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RAD1, RAD23B, RALB, RAPlA, RAP1GDS1, RARG, RASSF8, RBCK1, RBFOX2, RBM10, RCC1, RFTN1, RFWD2, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, RPL10, RPS6KC1, RRBP1, RWDD4, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24B, SEC61A1, SEPT9, SERPINE2, SF1, SGOL2, SH3RF1, SKIL, SLC25A17, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNHG16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRSF3, STARD4, STAT1, STAT3, STAU1, STC2, STEAP2, STRIP1, STRN3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC1, TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENC1, TENM2, TEP1, TET3, TFCP2, TGFB1, TGFBR1, TGFBRAP1, THADA, THAP4, THRB, TIMP2, TJP2, TLE3, TLK1, TMEM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, TNIP1, TNKS1BP1, TNPO3, TNS1, TNS3, TOE1, TOMM40, TOMM5, TOPORS, TP531NP1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT1L, TRPS1, TSC2, TSHZ1, TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS13A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WIPF1, WNT5B, WSB1, WWTR1, XIAP, XRN2, YAP1, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZHX3, ZMIZ1, ZMYM2, ZNF12, ZNF148, ZNF219, ZNF227, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF37A, ZNF37BP, ZNF395, ZNF583, ZNF621, ZNF652, ZNF655, ZNF674, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF827, ZNF839 or ZNF91.

In a specific embodiment of the foregoing aspect, the gene is: ABCB8, ANKRD36, APLP2, ARHGAP12, ARMCX6, ASAP1, ATG5, AXIN1, BIRC6, C1orf86, CDC42BPA, CLTA, DYRK1A, ERGIC3, FBXL6, FOXM1, GGCT, KAT6B, KDM6A, KIF3A, KMT2D, LARP7, LYRM1, MADD, MAN2C1, MRPL55, MYCBP2, MYO9B, PNISR, RAP1A, RAPGEF1, SENP6, SH3YL1, SLC25A17, SMN2, SREK1, STRN3, TAF2, TMEM134, VPS29, ZFAND1 or ZNF431.

In another specific embodiment of the foregoing aspect, the gene is: ABCB8, ANKRD36, ARHGAP12, ARMCX6, ATG5, BIRC6, C1orf86, CLTA, DYRK1A, FBXL6, KAT6B, KDM6A, KMT2D, LYRM1, MAN2C1, MRPL55, MYCBP2, PNISR, RAPGEF1, SENP6, SH3YL1, TMEM134 or ZNF431.

In another specific embodiment of the foregoing aspect, the gene is: ABCA10, ABCC1, ACTA2, ADAL, ADAM12, ADAMTS1, ADAMTS5, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPS, AKAP3, ANK1, ANK2, ANK3, ANKRD33B, ANXA11, ANXA6, AP4B1-AS1, ARHGEF16, ARID5B, ARL9, ARMCX3, ASAP1, ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BIN3-IT1, BIRC3, BTG2, C10orf54, C11orf70, C11orf73, C11orf94, C12orf56, C19orf47, C3, C4orf27, C7orf31, C8orf34, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CCDC79, CCER2, CCNF, CDCA7, CDKAL1, CELSR1, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTD1, COL11A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLF1, CRYL1, CUX1, CYB5B, CYB5R2, CYGB, CYP1B1, DCLK1, DCN, DDTT4L, DDX42, DDX50, DEGS1, DENND1A, DENND5A, DEPTOR, DFNB59, DGKA, DHFR, DIAPH3, DIRAS3, DIS3L, DLG5, DNAH8, DNAJC27, DOCK1, DOCK11, DYNC1I1, DZIP1L, EBF1, EFEMP1, EGR3, EIF2B3, ELN, ELP4, EMX2OS, ENPP1, ERCC8, ESM1, EVC2, F2R, FAM160A1, FAM198B, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FCHO1, FER, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALC, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GNAQ, GOLGB1, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, HEY1, HLTF, HMGN3-AS1, HMOX1, HOOK3, HSD17B12, HSPA1L, HTATIP2, HTT, IGDCC4, IGF2R, IGFBP3, IL16, INA, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1524, KIAA1715, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN1 A2, MAN2A1, MAPK13, MASP1, MB, MC4R, MEDAG, MEGF6, MEMO1, MIAT, MIR612, MLLT10, MMP10, MMP24, MMS19, MN1, MOXD1, MRVI1, MSH4, MTERF3, MXRA5, MYO1D, NA, NAALADL2, NAE1, NAGS, NDNF, NEURLIB, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, NTNG1, OCLN, OLR1, OSBPL10, OXCT2, PAIP2B, PAPD4, PBLD, PCM1, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PDXDC1, PEAR1, PEPD, PHACTR3, PI4K2B, PIK3R1, PIM2, PITPNB, PITPNM3, PLAU, PLEK2, PLEKHA6, PLEKHH2, PLXNC1, PMS1, PODN, POLN, POLR1AA, POSTN, PPM1E, PPP3CA, PRKCA, PRKDC, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RCC1, RDX, RFWD2, RFX3-AS1, RGCC, RNFT1, ROR1, ROR2, RWDD4, SCARNA9, SCO1, SEC22A, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SMYD3, SNED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, SQRDL, STAC2, STAT1, STAT4, STEAP2, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TARBP1, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THADA, THBS2, THRB, TMEM102, TMEM119, TMEM256-PLSCR3, TMEM50B, TNC, TNFAIP8L3, TNFRSF14, TNRC18P1, TNS3, TNXB, TP53AIP1, TPRG1, TRAF3, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TXNIP, UNC5B, USP27X, UVRAG, VIM-AS1, VPS41, VSTM2L, VWA8, VWF, WDR91, WISP1, WNT10B, XRN2, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, ZNF212, ZNF350, ZNF660, ZNF79 or ZNF837.

In another specific embodiment of the foregoing aspect, the gene is: ABCA10, ACTA2, ADAL, ADAMTS1, ADAMTS5, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AKAP3, ANK1, ANK3, ANKRD33B, AP4B1-AS1, ARHGEF16, ARID5B, ARL9, ASIC1, ATP2A3, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BIN3-IT1, BIRC3, BTG2, C10orf54, C11orf70, C11orf94, C12orf56, C19orf47, C3, C7orf31, C8orf34, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CCDC79, CCER2, CCNF, CELSR1, CEMIP, CEP170, CFH, CIITA, CLDN23, CMAHP, CNGA4, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CRISPLD2, CRLF1, CRYL1, CYB5R2, CYGB, CYP1B1, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DNAH8, DNAJC27, DOCK11, DYNC1I1, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENPP1, ERCC8, ESM1, EVC2, F2R, FAM160A1, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GXYLT1, HAPLN1, HAPLN2, HA S3, HAVCR2, HDAC5, HECTD2-AS1, HEPH, HEY1, HMGN3-AS1, HOOK3, HSPA1L, HTATIP2, IGDCC4, IGF2R, IGFBP3, IL16, INA, INTU, IQCG, ITGA11, ITGA8, ITGB8, ITIH1, ITPKA, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LRBA, LRP4, LRRC32, LRRC39, LSAMP, LUM, LYPD1, MAFB, MAMDC2, MAN2A1, MAPK13, MASP1, MB, MC4R, MEGF6, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRVI1, MSH4, MTERF3, MXRA5, NA, NAALADL2, NAE1, NAGS, NDNF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PI4K2B, PIK3R1, PIM2, PITPNM3, PLEK2, PLEKHA6, PLEKHH2, PODN, POLN, POLR1A, PPM1E, PPP3CA, PRKCA, PRKG1, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, RAB30, RAB38, RAB44, RAD9B, RARS, RBBP8, RBKS, RDX, RFX3-AS1, RGCC, ROR1, ROR2, SCARNA9, SHROOM3, SIGLEC10, SLC24A3, SLC35F3, SLC39A10, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SORBS2, SORCS2, SOX7, SPDYA, SPEF2, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TEX21P, TGFA, TGFB2, TGFB3, TGM2, THBS2, TMEM102, TMEM119, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TXNIP, USP27X, UVRAG, VIM-AS1, VPS41, VSTM2L, VWF, WDR91, WISP1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZFP82, ZMIZ1-AS1, ZNF212, ZNF350, ZNF660, ZNF79 or ZNF837.

In another specific embodiment of the foregoing aspect, as listed in Table 7, the gene is ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APLP2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf8, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAPlA, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SP1DR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680.

In another specific embodiment of the foregoing aspect, the gene is ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, 1FT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP.

In another specific embodiment of the foregoing aspect, the gene is APLP2, AXIN1, CECR7, DAGLB, DLGAP4, ERCC1, ERGIC3, FAM198B, GGCT, HAT1, HPS1, INPP5K, MADD, PPHLN1, PRUNE2, RAPlA, RNFT1, RPS6KB2, SH3YL1, SKA2, SPATA18, STRN3, TMEM189-UBE2V1, TRIM65, TUBE1, UBE2V1, VPS29 or ZNF680.

In another specific embodiment of the foregoing aspect, the gene is ABCB8, ABCC3, ADCY3, AGPAT4, ANKRA2, APIP, ARHGAP1, ARL15, ATXN1, BECN1, BHMT2, BTN3A1, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASP7, CCDC122, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DLGAP4, DNAJC13, DNMBP, DYRK1A, ENAH, EP300, ERCC1, ERLIN2, ERRFI1, EVC, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, GGACT, GLCE, GULP1, GXYLT1, HDX, HMGA2, HNMT, HPS1, IFT57, INPP5K, IVD, KDM6A, LETM2, LOC400927, LRRC42, LYRM1, MB21D2, MCM10, MED13L, MFN2, MRPL45, MRPS28, MTERF3, MYCBP2, NGF, OXCT1, PDS5B, PIGN, PIK3CD, PIK3R1, PIKFYVE, PLEKHA1, PLSCR1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRUNE2, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RPA1, RPS10, RPS6KB2, SAMD4A, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC44A2, SNX7, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STXBP6, TASP1, TCF12, TCF4, TIAM1, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TTC7B, TUBE1, TYW5, URGCP, VAV2, WDR27, WDR91, WNK1, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF680.

In another particular aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS (for example, an endogenous intronic REMS or a non-endogenous intronic REMS), the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another particular aspect, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene in a subject, wherein the precursor RNA transcript transcribed from the gene comprises a non-endogenous intronic REMS, the methods comprising administering to the subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the precursor RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or a protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for modulating the amount of a product of a gene (such as an RNA transcript or protein) in a subject, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In a specific embodiment, the gene is a gene described in a table in this disclosure.

In another embodiment, provided herein are methods for modulating the amount of one, two, three or more RNA transcripts of a gene, disclosed in Table 7, infra, comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In a specific embodiment, the RNA transcript contains in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS. In a specific embodiment, the method for modulating the amount of one or more RNA transcripts of a gene using a compound of Formula (I) or a form thereof is as described in the Examples described herein.

In certain embodiments, a compound of Formula (I) or a form thereof contacted or cultured with a cell(s), or administered to a subject is a compound of Formula (II), Formula (11), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV). In some embodiments, a compound of Formula (I) or a form thereof contacted or cultured with a cell(s), or administered to a subject is a compound described herein.

Table 1 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 1 Table 1 ABCA1, ABCA10, ABCB7, ABCB8, ABCC1, ABCC3, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ACTA2, ADAL, ADAM12, ADAM15, ADAM17, ADAM33, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF2, AFF3, AGK, AGPAT3, AGPAT4, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP3, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK1, ANK2, ANK3, ANKFY1, ANKHD1-EIF4EBP3, ANKRA2, ANKRD17, ANKRD33B, ANKRD36, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, AP4B1-AS1, APAF1, APIP, APLP2, APP, APPL2, APTX, ARHGAP1, ARHGAP12, ARHGAP22, ARHGEF16, ARID1A, ARID2, ARID5B, ARL9, ARL15, ARMCX3, ARMCX6, ASAP1, ASIC1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG5, ATG9A, ATMIN, ATP2A3, ATP2C1, ATXN1, ATXN3, AURKA, AXIN1, B3GALT2, B3GNT6, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BCL2L15, BCYRN1, BECN1, BEND6, BHMT2, BICD1, BIN1, BIN3-IT1, BIRC3, BIRC6, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BTG2, BTN3A1, BZW1, C1orf86, C10orf54, C11orf30, C11orf70, C11orf73, C11orf94, C12orf4, C12orf56, C14orf132, C17orf76-AS1, C19orf47, C3, C4orf27, C5orf24, C6orf48, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, C9orf69, CA13, CA3, CAB39, CACNA2D2, CACNB1, CADM1, CALU, CAMKK1, CAND2, CAPNS1, CASC3, CASP7, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC79, CCDC88A, CCDC92, CCDC122, CCER2, CCNF, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CEP68, CFH, CFLAR, CHD8, CHEK1, CIITA, CIZ1, CLDN23, CLIC1, CLK4, CLTA, CMAHP, CNGA4, CNOT1, CNRIP1, CNTD1, COG1, COL1A1, COL11A1, COL12A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A1, COL6A6, COL8A1, COLEC12, COMP, COPS7B, CPA4, CPEB2, CPQ, CPSF4, CREB5, CRISPLD2, CRLF1, CRLS1, CRTAP, CRYBG3, CRYL1, CSDE1, CSNK1A1, CSNK1E, CSNK1G1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYB5R2, CYBRD1, CYGB, CYP1B1, CYP51A1, DAB2, DACT1, DAGLB, DARS, DAXX, DCAF10, DCAF11, DCAF17, DCBLD2, DCLK1, DCN, DCUN1D4, DDAH1, DDAH2, DDHD2, DDIT4L, DDR1, DDX39B, DDX42, DDX50, DEGS1, DENND1A, DENND1B, DENND5A, DEPTOR, DFNB59, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIRAS3, DIS3L, DKFZp434M1735, DKK3, DLC1, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNM2, DNMBP, DOCK1, DOCK11, DPP8, DSEL, DST, DSTN, DYNC1I1, DYRK1A, DZIP1L, EBF1, EEA1, EEF1A1, EFCAB14, EFEMP1, EGR1, EGR3, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ELN, ELP4, EMX2OS, ENAH, ENG, ENPP1, ENPP2, ENSA, EP300, EPN1, EPT1, ERC1, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, ETV5, EVC, EVC2, EXO1, EXTL2, EYA3, F2R, FADS1, FADS2, FAF1, FAIM, FAM111A, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM198B, FAM20A, FAM219A, FAM219B, FAM3C, FAM46B, FAM65A, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXO9, FBXL6, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FCHO1, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFR2, FGFRL1, FGL2, FHOD3, FLII, FLNB, FLT1, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FRAS1, FSCN2, FUS, FYN, GABPB1, GAL3ST4, GALC, GALNT1, GALNT15, GAS7, GATA6, GBA2, GBGT1, GCFC2, GCNT1, GDF6, GGACT, GGCT, GHDC, GIGYF2, GJC1, GLCE, GMIP, GNA13, GNAQ, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR183, GPR50, GPR89A, GPRC5A, GPRC5B, GPSM2, GREM1, GRK6, GRTP1, GSE1, GTF2H2B, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS2, HAS3, HAT1, HAUS3, HAUS6, HAVCR2, HDAC5, HDAC7, HDX, HECTD2-AS1, HEG1, HEPH, HEY1, HLA-A, HLA-E, HLTF, HMGA1, HMGA2, HMGB1, HMGCR, HMGN3-AS1, HMGCS1, HOOK3, HMOX1, HNMT, HNRNPR, HNRNPUL1, HP1BP3, HPS1, HRH1, HSD17B12, HSD17B4, HSPA1L, HTATIP2, HTT, IARS, IDH1, IDI1, IFT57, IGDCC4, IGF2BP2, IGF2R, IGFBP3, IL16, IL6ST, INA, INHBA, INPP5K, INSIG1, INTU, IQCE, IQCG, ITGA11, ITGA8, ITGAV, ITGB5, ITGB8, ITIH1, ITM2C, ITPKA, ITSN1, IVD, KANSL3, KAT6B, KCNK2, KCNS1, KCNS2, KDM6A, KDSR, KIAA1033, KIAA1143, KIAA1199, KIAA1456, KIAA1462, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIAA1755, KIF14, KIF2A, KIF3A, KIT, KLC1, KLC2, KLF17, KLF6, KLHL7, KLRG1, KMT2D, KRT7, KRT18, KRT19, KRT34, KRTAP1-1, KRTAP1-5, KRTAP2-3, L3MBTL2, LAMA2, LAMB1, LAMB2P1, LARP4, LARP7, LATS2, LDLR, LEMD3, LETM2, LGALS8, LGI2, LGR4, LHX9, LIMS1, LINC00341, LINC00472, LINC00570, LINC00578, LINC00607, LINC00657, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMAN2L, LMO7, LMOD1, LOC400927, LONP1, LOX, LRBA, LRCH4, LRIG1, LRP4, LRP8, LRRC32, LRRC39, LRRC42, LRRC8A, LSAMP, LSS, LTBR, LUC7L2, LUM, LYPD1, LYRM1, LZTS2, MADD, MAFB, MAGED4, MAGED4B, MAMDC2, MAN1A2, MAN2A1, MAN2C1, MAP4K4, MAPK13, MASP1, MB, MB21D2, MBD1, MBOAT7, MC4R, MCM10, MDM2, MED1, MED13L, MEDAG, MEF2D, MEGF6, MEIS2, MEMO1, MEPCE, MFGE8, MFN2, MIAT, MICAL2, MINPP1, MIR612, MKL1, MKLN1, MKNK2, MLLT4, MLLT10, MLST8, MMAB, MMP10, MMP24, MMS19, MMS22L, MN1, MOXD1, MPPE1, MPZL1, MRPL3, MRPL45, MRPL55, MRPS28, MRVI1, MSANTD3, MSC, MSH2, MSH4, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERF3, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MXRA5, MYADM, MYCBP2, MYLK, MYO1D, MYO9B, MYOF, NA, NAA35, NAALADL2, NADK, NAE1, NAGS, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NDNF, NELFA, NEO1, NEURL1B, NF2, NFE2L1, NFX1, NGF, NGFR, NHLH1, NID1, NID2, NIPA1, NKX3-1, NLN, NOL10, NOMO3, NOTCH3, NOTUM, NOVA2, NOX4, NPEPPS, NRD1, NREP, NRG1, NRROS, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, OCLN, ODF2, OLR1, OS9, OSBPL6, OSBPL10, OSMR, OXCT1, OXCT2, P4HA1, P4HB, PABPC1, PAIP2B, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PBLD, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE1C, PDE4A, PDE5A, PDE7A, PDGFD, PDGFRB, PDLIM7, PDS5B, PDXDC1, PEAR1, PEPD, PEX5, PFKP, PHACTR3, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZO1, PIGN, PIGU, PIK3C2B, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNA, PITPNB, PITPNM1, PITPNM3, PLAU, PLEC, PLEK2, PLEKHA1, PLEKHA6, PLEKHB2, PLEKHH2, PLSCR1, PLSCR3, PLXNB2, PLXNC1, PMS1, PNISR, PODN, POLE3, POLN, POLR1A, POLR3D, POMT2, POSTN, POU2F1, PPAPDC1A, PPARA, PPARG, PPHLN1, PPIP5K1, PPIP5K2, PPM1E, PPP1R12A, PPP1R26, PPP3CA, PPP6R1, PPP6R2, PRKACB, PRKCA, PRKDC, PRKG1, PRMT1, PRNP, PRPF31, PRPH2, PRRG4, PRSS23, PRUNE2, PSMA4, PSMC1, PSMD6, PSMD6-AS2, PTGIS, PTK2B, PTPN14, PTX3, PUF60, PUS7, PVR, PXK, PXN, QKI, RAB23, RAB2B, RAB30, RAB34, RAB38, RAB44, RAD1, RAD9B, RAD23B, RAF1, RALB, RAP1A, RAP1GDS1, RAPGEF1, RARG, RARS, RARS2, RASSF8, RBBP8, RBCK1, RBFOX2, RBKS, RBM10, RCC1, RDX, RERE, RFTN1, RFWD2, RFX3-AS1, RGCC, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, ROR1, ROR2, RPA1, RPL10, RPS10, RPS6KB2, RPS6KC1, RRBP1, RWDD4, SAMD4A, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCARNA9, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24A, SEC24B, SEC61A1, SENP6, SEPT9, SERGEF, SERPINE2, SF1, SGK3, SGOL2, SH3RF1, SH3YL1, SHROOM3, SIGLEC10, SKA2, SKIL, SLC12A2, SLC24A3, SLC25A17, SLC35F3, SLC39A3, SLC39A10, SLC4A4, SLC4A11, SLC41A1, SLC44A2, SLC46A2, SLC6A15, SLC7A6, SLC7A8, SLC7A11, SLC9A3, SLIT3, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMG1P3, SMN2, SMPD4, SMTN, SMYD3, SMYD5, SNAP23, SNED1, SNHG16, SNX7, SNX14, SOCS2, SON, SORBS2, SORCS2, SOS2, SOX7, SPATA18, SPATA20, SPATA5, SPATS2, SPDYA, SPEF2, SPG20, SPIDR, SPRED2, SPRYD7, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRGAP1, SRRM1, SRSF3, STAC2, STARD4, STAT1, STAT3, STAT4, STAU1, STC2, STEAP2, STK32B, STRIP1, STRN3, STRN4, STS, STX16, STXBP6, SULF1, SUPT20H, SVEP1, SYNE1, SYNE2, SYNGR2, SYNPO, SYNPO2, SYNPO2L, SYT15, SYTL2, TACC1, TAF2, TAGLN3, TANC2, TANGO6, TARBP1, TARS, TASP1, TBC1D15, TBL2, TCF12, TCF4, TCF7L2, TENC1, TENM2, TEP1, TET3, TEX21P, TFCP2, TGFA, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBRAP1, TGM2, THADA, THAP4, THBS2, THRB, TIAM1, TIMP2, TJP2, TLE3, TLK1, TMC3, TMEM102, TMEM119, TMEM134, TMEM154, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM47, TMEM50B, TMEM63A, TNC, TNFAIP3, TNFAIP8L3, TNFRSF12A, TNFRSF14, TNIP1, TNKS1BP1, TNPO3, TNRC18P1, TNRC6A, TNS1, TNS3, TNXB, TOE1, TOMM40, TOMM5, TOPORS, TP53AIP1, TP53INP1, TPRG1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRIM66, TRMT1L, TRPC4, TRPS1, TSC2, TSHZ1, TSHZ2, TSPAN11, TSPAN18, TSPAN2, TSPAN7, TSSK3, TTC7A, TTC7B, TUBB2C, TUBB3, TUBE1, TXNIP, TXNL1, TXNRD1, TYW5, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, URGCP, USP19, USP7, USP27X, UVRAG, VANGL1, VARS2, VAV2, VCL, VIM-AS1, VIPAS39, VPS13A, VPS29, VPS41, VPS51, VSTM2L, VWA8, VWF, WDR19, WDR27, WDR37, WDR48, WDR91, WIPF1, WISP1, WNK1, WNT5B, WNT10B, WSB1, WWTR1, XIAP, XRN2, YAP1, YDJC, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB26, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC5, ZCCHC8, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZFP82, ZHX3, ZMIZ1, ZMIZ1-AS1, ZMYM2, ZNF12, ZNF138, ZNF148, ZNF212, ZNF219, ZNF227, ZNF232, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF350, ZNF37A, ZNF37BP, ZNF395, ZNF431, ZNF583, ZNF621, ZNF652, ZNF655, ZNF660, ZNF674, ZNF680, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF79, ZNF827, ZNF837, ZNF839 or ZNF91

Table 2 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 2 ABCA1, ABCB7, ABCC1, ABHD10, ABL2, ABLIM3, ACACA, ACADVL, ACAT2, ADAM12, ADAM15, ADAM17, ADAM33, AFF2, AGK, AGPAT3, AGPS, AHCYL2, AHDC1, AHRR, AJUBA, AK021888, AK310472, AKAP1, AKAP9, AKNA, ALCAM, ALDH4A1, AMPD2, ANK2, ANKFY1, ANKHD1-EIF4EBP3, ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, AP2B1, APAF1, APLP2, APP, APPL2, APTX, ARHGAP22, ARID1A, ARID2, ARMCX3, ASAP1, ASL, ASNS, ASPH, ATAD2B, ATF7IP, ATG9A, ATMIN, ATP2C1, ATXN3, AURKA, AXIN1, B4GALT2, BACE1, BAG2, BASP1, BC033281, BCAR3, BEND6, BICD1, BIN1, BNC1, BRD2, BRPF1, BSCL2, BTBD10, BZW1, C11orf30, C11orf73, C17orf76-AS1, C4orf27, C5orf24, C6orf48, C9orf69, CAB39, CALU, CAMKK1, CAPNS1, CASC3, CASP8AP2, CAV1, CCAR1, CCDC77, CCDC88A, CCDC92, CCT6A, CD276, CD46, CDC25B, CDC40, CDC42BPA, CDCA7, CDH11, CDH13, CDK11B, CDK16, CDKAL1, CEP68, CFLAR, CHD8, CIZ1, CLIC1, CLK4, CNOT1, COG1, COL12A1, COL1A1, COL6A1, COPS7B, CPEB2, CREB5, CRLS1, CRTAP, CSDE1, CSNK1A1, CTDSP2, CTNND1, CUL2, CUL4A, CUX1, CYB5B, CYBRD1, CYP51A1, DAB2, DACT1, DARS, DAXX, DCAF10, DCAF11, DCBLD2, DCUN1D4, DDAH1, DDAH2, DDHD2, DDR1, DDX39B, DDX42, DENND1A, DENND1B, DENND5A, DGCR2, DGKA, DHCR24, DHCR7, DHFR, DHX9, DIAPH1, DIAPH3, DIS3L, DKFZp434M1735, DKK3, DLC1, DNM2, DOCK1, DPP8, DSEL, DST, DSTN, EBF1, EEA1, EEF1A1, EFCAB14, EGR1, EHMT2, EIF2B3, EIF4G1, EIF4G2, EIF4G3, ELF2, ENG, ENPP2, ENSA, EPN1, EPT1, ERC1, ERGIC3, ETV5, EXO1, EXTL2, EYA3, FADS1, FADS2, FAF1, FAM111A, FAM198B, FAM219A, FAM219B, FAM3C, FAM65A, FBXO10, FBXO18, FBXO31, FBXO34, FBXO9, FDFT1, FDPS, FER, FEZ1, FGD5-AS1, FGFRL1, FHOD3, FLII, FLNB, FN1, FNBP1, FOCAD, FOS, FOSB, FOSL1, FOXK1, FOXM1, FUS, FYN, GABPB1, GALC, GALNT1, GAS7, GBA2, GCFC2, GGCT, GHDC, GIGYF2, GJC1, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GOLGA4, GOLGB1, GORASP1, GPR1, GPR89A, GPSM2, GREM1, GRK6, GSE1, GTF2H2B, HAS2, HAT1, HAUS3, HAUS6, HDAC7, HEG1, HLA-A, HLA-E, HLTF, HMGA1, HMGB1, HMGCR, HMGCS1, HMOX1, HNRNPR, HNRNPUL1, HP1BP3, HRH1, HSD17B12, HSD17B4, HTT, IARS, IDH1, IDI1, IGF2BP2, IL6ST, INHBA, INSIG1, IQCE, ITGAV, ITGB5, ITM2C, ITSN1, KANSL3, KCNK2, KIAA1033, KIAA1143, KIAA1199, KIAA1522, KIAA1524, KIAA1549, KIAA1715, KIF14, KIF2A, KIF3A, KLC1, KLC2, KLF6, KLHL7, KRT18, KRT19, KRT34, KRTAP2-3, LAMA2, LAMB1, LARP4, LARP7, LATS2, LDLR, LEMD3, LGALS8, LIMS1, LINC00341, LINC00657, LMAN2L, LMO7, LONP1, LOX, LRCH4, LRIG1, LRP8, LRRC8A, LSS, LTBR, LUC7L2, LZTS2, MADD, MAGED4, MAGED4B, MAN1A2, MAP4K4, MBD1, MBOAT7, MDM2, MED1, MEDAG, MEF2D, MEIS2, MEMO1, MEPCE, MFGE8, MICAL2, MINPP1, MKL1, MKLN1, MKNK2, MLLT4, MLST8, MMAB, MMS19, MMS22L, MPPE1, MPZL1, MRPL3, MSANTD3, MSC, MSH2, MSH6, MSL3, MSMO1, MSRB3, MTAP, MTERFD1, MTHFD1L, MTMR9, MTRR, MUM1, MVD, MVK, MYADM, MYLK, MYO1D, MYO9B, MYOF, NAA35, NADK, NASP, NAV1, NAV2, NCOA1, NCOA3, NCOA4, NCSTN, NELFA, NEO1, NEURL1B, NF2, NFE2L1, NFX1, NID1, NID2, NIPA1, NKX3-1, NOL10, NOMO3, NPEPPS, NRD1, NREP, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUDT4, NUP153, NUP35, NUP50, NUPL1, NUSAP1, ODF2, OS9, OSBPL6, OSMR, P4HA1, P4HB, PABPC1, PAK4, PAPD4, PARD3, PARN, PARP14, PARP4, PARVB, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PCNXL2, PCSK9, PDE4A, PDE7A, PDLIM7, PDXDC1, PEPD, PEX5, PFKP, PHF19, PHF8, PHRF1, PHTF2, PI4K2A, PIEZO1, PIGU, PIK3C2B, PITPNA, PITPNB, PITPNM1, PLAU, PLEC, PLEKHB2, PLSCR3, PLXNB2, PLXNC1, PMS1, POLE3, POLR3D, POSTN, POU2F1, PPAPDC1A, PPARA, PPHLN1, PPIP5K1, PPP1R12A, PPP6R1, PPP6R2, PRKACB, PRKDC, PRMT1, PRNP, PRSS23, PSMA4, PSMC1, PSMD6, PTK2B, PTPN14, PUF60, PUS7, PVR, PXN, QKI, RAB23, RAB2B, RAB34, RAD1, RAD23B, RALB, RAP1A, RAP1GDS1, RARG, RASSF8, RBCK1, RBFOX2, RBM10, RCC1, RFTN1, RFWD2, RGS10, RGS3, RIF1, RNF14, RNF19A, RNF38, RNFT1, RPL10, RPS6KC1, RRBP1, RWDD4, SAMD9, SAMD9L, SAR1A, SART3, SCAF4, SCAF8, SCD, SCLT1, SCO1, SDCBP, SEC14L1, SEC22A, SEC24B, SEC61A1, SEPT9, SERPINE2, SF1, SGOL2, SH3RF1, SKIL, SLC25A17, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SLC7A8, SMARCA4, SMARCC2, SMC4, SMC6, SMCHD1, SMG1, SMN2, SMPD4, SMYD3, SMYD5, SNAP23, SNHG16, SNX14, SOCS2, SON, SOS2, SPATA20, SPATS2, SPG20, SPRED2, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, SREK1, SRSF3, STARD4, STAT1, STAT3, STAU1, STC2, STEAP2, STRIP1, STRN3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TACC1, TAF2, TANC2, TARBP1, TARS, TBC1D15, TBL2, TCF7L2, TENC1, TENM2, TEP1, TET3, TFCP2, TGFBI, TGFBR1, TGFBRAP1, THADA, THAP4, THRB, TIMP2, TJP2, TLE3, TLK1, TMEM154, TMEM47, TMEM63A, TNC, TNFAIP3, TNFRSF12A, TNIP1, TNKS1BP1, TNPO3, TNS1, TNS3, TOE1, TOMM40, TOMM5, TOPORS, TP53INP1, TRAF3, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM26, TRIM28, TRIM65, TRMT1L, TRPS1, TSC2, TSHZ1, TSPAN2, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, U2SURP, UBAP2L, UBE2G2, UBE2V1, UBQLN4, UCHL5, UHMK1, UHRF1BP1L, UNC5B, USP19, USP7, VANGL1, VARS2, VCL, VIPAS39, VPS13A, VPS29, VPS51, VWA8, WDR19, WDR37, WDR48, WIPF1, WNT5B, WSB1, WWTR1, XIAP, XRN2, YAP1, YES1, YPEL5, YTHDF3, Z24749, ZAK, ZBTB10, ZBTB24, ZBTB7A, ZC3H12C, ZC3H14, ZC3H18, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZHX3, ZMIZ1, ZMYM2, ZNF12, ZNF148, ZNF219, ZNF227, ZNF24, ZNF268, ZNF28, ZNF281, ZNF335, ZNF37A, ZNF37BP, ZNF395, ZNF583, ZNF621, ZNF652, ZNF655, ZNF674, ZNF74, ZNF764, ZNF778, ZNF780A, ZNF827, ZNF839 or ZNF91

Table 3 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 3 ABCA1, ABCC1, ABL2, ACACA, ACAT2, AFF2, AHRR, AK021888, AK310472, AKAP1, ANK2, ANKHD1-EIF4EBP3, AP2B1, APAF1, APLP2, ARID1A, ARMCX3, ASAP1, ASPH, ATAD2B, ATF7IP, ATG9A, AXIN1, BACE1, BIN1, BNC1, BRPF1, BZW1, C11orf30, C11orf73, C17orf76-AS1, C4orf27, C6orf48, CAB39, CAMKK1, CCDC88A, CCDC92, CDC25B, CDC42BPA, CDCA7, CDH11, CDH13, CEP68, CFLAR, COPS7B, CREB5, CUL2, CUL4A, CUX1, CYP51A1, DCUN1D4, DDR1, DDX39B, DDX42, DENND1A, DENND5A, DGKA, DHCR24, DHCR7, DIAPH1, DIAPH3, DNM2, DOCK1, EFCAB14, EIF2B3, EPN1, EPT1, ERC1, ETV5, FADS1, FADS2, FAF1, FAM198B, FAM219B, FBXO10, FBXO9, FDFT1, FDPS, FER, FEZ1, FHOD3, FLII, FLNB, FNBP1, FOS, FOSB, FOXM1, FYN, GABPB1, GALC, GAS7, GGCT, GJC1, GPSM2, GRK6, HAS2, HAT1, HLTF, HMGA1, HMGB1, HMGCR, HMGCS1, HMOX1, HP1BP3, HSD17B12, HTT, IDI1, INHBA, INSIG1, KANSL3, KIAA1199, KIAA1524, KIAA1715, KIF3A, KLF6, KRT19, KRT34, KRTAP2-3, LAMA2, LARP7, LDLR, LEMD3, LMAN2L, LRCH4, LRP8, LSS, MAGED4, MAGED4B, MAN1A2, MEDAG, MEF2D, MEMO1, MFGE8, MICAL2, MMAB, MMS19, MMS22L, MSL3, MSMO1, MTAP, MTERFD1, MVD, MVK, NASP, NAV2, NEURL1B, NFE2L1, NID1, NPEPPS, NREP, NRG1, NSUN4, NT5C2, NUP153, P4HA1, PABPC1, PAPD4, PCBP2, PCM1, PCSK9, PDXDC1, PEPD, PHF19, PHF8, PHTF2, PIK3C2B, PITPNB, PLEC, PMS1, POU2F1, PPHLN1, PRKDC, PRSS23, PSMC1, PTPN14, PUF60, PVR, RAB23, RAD23B, RAP1A, RASSF8, RBM10, RCC1, RFWD2, RNFT1, RWDD4, SAMD9L, SART3, SCAF4, SCD, SEC22A, SEC61A1, SERPINE2, SF1, SLC25A17, SLC7A6, SLC7A8, SMN2, SMYD3, SMYD5, SNAP23, SNHG16, SQLE, SQRDL, SQSTM1, SRCAP, SREBF1, STARD4, STAT1, STAU1, STEAP2, STRN3, SYNE1, TACC1, TAF2, TANC2, TARBP1, TBC1D15, TEP1, TFCP2, TGFBRAP1, THADA, TIMP2, TLK1, TMEM154, TNS3, TOMM5, TRAF3, TRAK1, TRAPPC12, TRIM2, TRIM26, TRIM65, TSPAN2, U2SURP, UBAP2L, UBE2V1, UCHL5, UHRF1BPIL, VANGL1, VARS2, VPS13A, VPS29, VWA8, WSB1, XIAP, XRN2, YPEL5, ZAK, ZC3H18, ZFAND5, ZMIZ1, ZMYM2, ZNF219, ZNF227, ZNF24, ZNF37A, ZNF37BP, ZNF395, ZNF652, ZNF674, ZNF74 or ZNF778

Table 4 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 4 ABCC1, ACADVL, ADAM15, AGPAT3, AHRR, AJUBA, AKAP1, AKAP9, ALCAM, ALDH4A1, ANKFY1, AP2B1, APLP2, APP, ARID1A, ARID2, ASPH, ATMIN, BASP1, BC033281, BCAR3, C11orf73, C17orf76-AS1, C5orf24, C6orf48, CAB39, CASP8AP2, CAV1, CCAR1, CCT6A, CD276, CD46, CDC25B, CDK16, CEP68, CHD8, CLIC1, COL12A1, CPEB2, CREB5, CRLS1, CRTAP, CTNND1, CUX1, CYBRD1, DACT1, DCAF10, DCAF11, DDHD2, DDX39B, DIAPH3, DKK3, DLC1, DSTN, EBF1, EGR1, EIF4G1, EIF4G3, ENG, ERC1, ETV5, FAM198B, FAM219A, FAM3C, FEZ1, FGD5-AS1, FLII, FN1, FNBP1, FOS, FOSB, FOXK1, FOXM1, FYN, GABPB1, GALC, GALNT1, GBA2, GGCT, GHDC, GMIP, GNA13, GNAS, GNL3L, GOLGA2, GORASP1, GREM1, GSE1, HAUS6, HDAC7, HEG1, HLA-A, HLA-E, HMGA1, HP1BP3, IL6ST, ITGAV, KIAA1549, KIF14, KLC1, KLF6, KLHL7, KRT18, LAMA2, LAMB1, LARP7, LATS2, LGALS8, LIMS1, LINC00341, LONP1, LOX, MDM2, MEPCE, MINPP1, MLLT4, MPPE1, MRPL3, MSH2, MSH6, MSL3, MTMR9, MTRR, MUM1, MYADM, MYLK, NADK, NAV2, NCSTN, NFE2L1, NID1, NIPA1, NPEPPS, NRD1, NUDT4, NUSAP1, P4HB, PABPC1, PAK4, PAPD4, PCNXL2, PDE4A, PDXDC1, PHRF1, PHTF2, PI4K2A, PIK3C2B, PLAU, PLEKHB2, PLSCR3, PLXNB2, POSTN, POU2F1, PPARA, PPP1R12A, PRKACB, PSMD6, PTPN14, PUS7, QKI, RAB34, RAD1, RAD23B, RASSF8, RBCK1, RBFOX2, RFTN1, RNF19A, RNF38, RPS6KC1, RWDD4, SEC14L1, SEC24B, SERPINE2, SF1, SLC39A3, SLC41A1, SLC4A4, SLC7A6, SMARCA4, SMN2, SNHG16, SNX14, SON, SPRED2, STAU1, STEAP2, STRIP1, STRN3, TBL2, TGFBI, TGFBR1, THAP4, TLE3, TMEM47, TNKS1BP1, TOMM40, TOPORS, TRAK1, TRAPPC12, TRIB1, TRIM2, TRIM23, TRIM65, TRMT1L, TRPS1, TXNL1, TXNRD1, U2SURP, UBE2G2, UBE2V1, UHMK1, USP7, VPS29, VWA8, WDR19, WDR37, WIPF1, YPEL5, YTHDF3, Z24749, ZBTB10, ZBTB7A, ZFAND5, ZMIZ1, ZNF12, ZNF148, ZNF335, ZNF395, ZNF583, ZNF621, ZNF655, ZNF74 or ZNF780A

Table 5 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 5 ABCB7, ABHD10, ABLIM3, ACACA, ADAM12, ADAM17, ADAM33, AGK, AGPS, AHCYL2, AHDC1, AHRR, AK021888, AK310472, AKAP1, AKAP9, AKNA, AMPD2, ANKRD17, ANKS6, ANP32A, ANXA11, ANXA6, APLP2, APP, APPL2, APTX, ARHGAP22, ARMCX3, ASAP1, ASNS, ASPH, ATG9A, ATP2C1, AURKA, AXIN1, B4GALT2, BACE1, BASP1, BEND6, BICD1, BIN1, BRD2, BRPF1, BTBD10, C11orf30, C11orf73, C17orf76-AS1, C4orf27, C6orf48, CAB39, CAPNS1, CASC3, CCDC77, CCDC88A, CD46, CDC40, CDC42BPA, CDCA7, CDH13, CDK11B, CEP68, CIZ1, CLK4, CNOT1, COG1, COL12A1, COL1A1, COL6A1, COPS7B, CSDE1, CSNK1A1, CUX1, CYB5B, CYBRD1, DAB2, DARS, DCBLD2, DCUN1D4, DDAH2, DDR1, DDX39B, DDX42, DENND1A, DENND1B, DENND5A, DGKA, DHFR, DHX9, DIAPH1, DIAPH3, DIS3L, DNM2, DOCK1, DPP8, DSEL, EEA1, EFCAB14, EIF2B3, EIF4G1, EIF4G3, ELF2, ENG, ENPP2, EPN1, EXTL2, EYA3, FAF1, FAM198B, FAM3C, FBXO10, FBXO18, FBXO31, FBXO9, FER, FEZ1, FHOD3, FLII, FN1, FNBP1, FOCAD, FOSL1, FOXM1, GABPB1, GALC, GALNT1, GCFC2, GGCT, GIGYF2, GMIP, GNAS, GNL3L, GOLGB1, GPR89A, GPSM2, GREM1, GRK6, GTF2H2B, HAT1, HAUS3, HEG1, HLA-A, HLTF, HP1BP3, HRH1, HSD17B12, HSD17B4, HTT, IARS, IDH1, IGF2BP2, ITM2C, KCNK2, KIAA1033, KIAA1143, KIAA1522, KIAA1524, KIAA1715, KIF3A, KLHL7, LAMA2, LARP4, LARP7, LATS2, LIMS1, LINC00341, LINC00657, LMAN2L, LMO7, LRCH4, LRIG1, LRRC8A, LTBR, LUC7L2, LZTS2, MADD, MAGED4B, MAN1A2, MAP4K4, MED1, MEDAG, MEF2D, MEIS2, MEMO1, MICAL2, MKLN1, MLLT4, MMS19, MPZL1, MSANTD3, MSC, MSL3, MTAP, MTERFD1, MTHFD1L, MYADM, MYLK, MYO9B, MYOF, NASP, NAV2, NCOA3, NCOA4, NELFA, NEO1, NEURL1B, NF2, NID2, NOL10, NPEPPS, NRG1, NSUN4, NT5C2, NT5E, NTNG1, NUP153, NUP35, NUP50, NUSAP1, ODF2, OS9, OSBPL6, P4HA1, P4HB, PABPC1, PAPD4, PARN, PARP4, PCBP2, PCBP4, PCDHGB3, PCGF3, PCM1, PCMTD2, PDE7A, PDXDC1, PEPD, PFKP, PHF19, PHRF1, PHTF2, PIEZO1, PIGU, PITPNA, PITPNB, PITPNM1, PLAU, PLSCR3, PLXNC1, PMS1, POU2F1, PPAPDC1A, PPHLN1, PPIP5K1, PPP1R12A, PRKDC, PRMT1, PRSS23, PSMA4, PTK2B, PUF60, PVR, RAB23, RAB2B, RAD1, RAD23B, RAP1A, RAP1GDS1, RARG, RASSF8, RBCK1, RCC1, RFWD2, RGS3, RNF14, RNFT1, RPL10, RRBP1, RWDD4, SAR1A, SCAF4, SCAF8, SCLT1, SCO1, SDCBP, SEC22A, SEPT9, SF1, SGOL2, SLC25A17, SLC4A4, SLC7A6, SMARCC2, SMC4, SMC6, SMCHD1, SMN2, SMPD4, SMYD3, SNAP23, SNHG16, SOCS2, SOS2, SPATA20, SPATS2, SPG20, SQRDL, SREBF1, SREK1, SRSF3, STAT1, STAU1, STEAP2, STRN3, STX16, SUPT20H, SYNE1, SYNE2, SYT15, SYTL2, TAF2, TARBP1, TARS, TBL2, TCF7L2, TENC1, TENM2, TEP1, TET3, TGFBR1, THADA, THRB, TJP2, TLE3, TMEM47, TMEM63A, TNFAIP3, TNIP1, TNPO3, TNS1, TNS3, TOE1, TOMM5, TP53INP1, TRAF3, TRAPPC12, TRIM2, TRIM23, TRIM65, TSC2, TSPAN2, TUBB2C, TXNRD1, UBAP2L, UBE2V1, UCHL5, USP19, VANGL1, VIPAS39, VPS29, VPS51, VWA8, WDR48, WNT5B, WSB1, WWTR1, XRN2, YAP1, YES1, YPEL5, YTHDF3, Z24749, ZBTB24, ZC3H14, ZFAND1, ZFAND5, ZHX3, ZMIZ1, ZMYM2, ZNF219, ZNF268, ZNF395, ZNF827 or ZNF91

Table 6 shows certain genes that are expected to demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of iExon generation in RNA having intronic REMS elements in the presence of a compound as described herein. The change in abundance is expected to have a statistically significant p value.

TABLE 6 ACACA, ACADVL, AFF2, AHCYL2, AHRR, AKAP1, ALDH4A1, ANKRD17, AP2B1, APLP2, ASL, ASPH, ATG9A, ATMIN, ATXN3, BAG2, BASP1, BRPF1, BSCL2, C11orf30, C11orf73, C17orf76-AS1, C6orf48, C9orf69, CAB39, CALU, CDC25B, CDC42BPA, CDKAL1, CLIC1, COL12A1, COL1A1, COL6A1, CSNK1A1, CTDSP2, CUL2, CUL4A, DAXX, DCAF10, DDAH1, DDR1, DDX39B, DENND1A, DGCR2, DKFZp434M1735, DKK3, DNM2, DST, EEF1A1, EFCAB14, EHMT2, EIF4G1, EIF4G2, EIF4G3, ENSA, EXO1, FAM111A, FAM198B, FAM65A, FBXO34, FEZ1, FGD5-AS1, FGFRL1, FLII, FN1, FOXK1, FOXM1, FUS, GALC, GALNT1, GAS7, GCFC2, GGCT, GJC1, GNA13, GNL3L, GOLGA4, GPR1, GREM1, HEG1, HLA-A, HLA-E, HLTF, HNRNPR, HNRNPUL1, IQCE, ITGB5, ITSN1, KIAA1033, KIF2A, KIF3A, KLC2, LATS2, LIMS1, LINC00341, LINC00657, LONP1, LOX, LUC7L2, MBD1, MBOAT7, MEF2D, MEIS2, MICAL2, MKL1, MKNK2, MLST8, MPPE1, MSL3, MSRB3, MTRR, MYADM, MYLK, MYO1D, NAA35, NAV1, NAV2, NCOA1, NFX1, NKX3-1, NOMO3, NRG1, NUDT4, NUPL1, NUSAP1, OSMR, P4HA1, P4HB, PAPD4, PARD3, PARN, PARP14, PARVB, PCBP2, PCBP4, PCGF3, PDLIM7, PDXDC1, PEX5, PFKP, PHRF1, PI4K2A, POLE3, POLR3D, POSTN, PPARA, PPP6R1, PPP6R2, PRNP, PXN, RAB34, RAD23B, RALB, RAP1A, RASSF8, RBCK1, RBFOX2, RGS10, RIF1, RNF14, RNF19A, SAMD9, SCAF4, SDCBP, SERPINE2, SF1, SH3RF1, SKIL, SLC25A17, SLC4A4, SMG1, SMN2, SNHG16, SREBF1, STAT3, STC2, STEAP2, STRN3, SYNE1, SYNE2, TACC1, TARS, TGFBI, TMEM47, TNC, TNFRSF12A, TNS1, TRAF3, TRIM28, TSC2, TSHZ1, TTC7A, TUBB2C, TUBB3, TXNL1, TXNRD1, UBE2G2, UBE2V1, UBQLN4, UNC5B, USP19, VARS2, VCL, VPS29, WDR37, WIPF1, WWTR1, ZC3H12C, ZCCHC11, ZEB1, ZEB2, ZFAND1, ZFAND5, ZMIZ1, ZNF28, ZNF281, ZNF655, ZNF764 or ZNF839

Table 7 shows genes that demonstrate an effect on change in isoform abundance as a result of having intronic REMS elements in the presence of Compound 774 (at doses ranging from 0.3 μM to 3 μM), having statistically significant adjusted Fisher's Exact Test p value.

TABLE 7 ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APLP2, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, AXIN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44- SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DAGLB, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DLGAP4, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERCC1, ERGIC3, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FAM198B, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GGCT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HAT1, HDX, HLTF, HMGA2, HNMT, HPS1, HSD17B12, HSD17B4, HTT, IFT57, INPP5K, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MADD, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPHLN1, PPIP5K2, PPP1R26, PRPF31, PRSS23, PRUNE2, PSMA4, PXK, RAF1, RAP1A, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RNFT1, RPA1, RPS10, RPS6KB2, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SKA2, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA18, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STRN3, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM189-UBE2V1, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TRIM65, TSPAN2, TTC7B, TUBE1, TYW5, UBAP2L, UBE2V1, URGCP, VAV2, VPS29, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232, ZNF37BP or ZNF680

Table 7a shows genes that demonstrate an effect on inclusion of an iExon with a corresponding change in isoform abundance as a result of having intronic REMS elements in the presence of Compound 774 (at doses ranging from 0.3 μM to 3 μM), having statistically significant adjusted Fisher's Exact Test p value.

TABLE 7a ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP

Table 7b shows genes that demonstrate an effect on inclusion of an exon with a corresponding change in isoform abundance as a result of having iREMS elements in the presence of Compound 774 (at doses ranging from 0.3 μM to 3 μM), having statistically significant adjusted Fisher's Exact Test value.

TABLE 7b APLP2, AXIN1, CECR7, DAGLB, DLGAP4, ERCC1, ERGIC3, FAM198B, GGCT, HAT1, HPS1, INPP5K, MADD, PPHLN1, PRUNE2, RAP1A, RNFT1, RPS6KB2, SH3YL1, SKA2, SPATA18, STRN3, TMEM189-UBE2V1, TRIM65, TUBE1, UBE2V1, VPS29 or ZNF680 Methods of Preventing and/or Treating Diseases

In another aspect, provided herein are methods for preventing and/or treating a disease associated with the aberrant expression of a product of a gene (e.g., an mRNA transcript or protein), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In certain embodiments, the gene is any one of the genes disclosed in Tables 2-7 or 1. In certain embodiments, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In certain embodiments, the gene contains a nucleotide sequence encoding an endogenous intronic REMS. In one embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in Table 1, supra, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one of the introns comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), disclosed in Tables 2-7, supra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), by way of nonlimiting example, not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene (e.g., an mRNA, RNA transcript or protein), disclosed in Table 1, supra, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease associated with aberrant expression of a product of a gene, disclosed in Table 7, supra, (e.g., an mRNA, RNA transcript or protein), comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more RNA isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In certain embodiments, the gene is any one of the genes disclosed in Tables 2-7 or 1. In certain embodiments, the gene contains a nucleotide sequence encoding ae non-endogenous intronic REMS. In certain embodiments, the gene contains a nucleotide sequence encoding an endogenous intronic REMS. In one embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, by way of nonlimiting example, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in Tables 2-7, supra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, not disclosed in either International Publication No. WO 2015/105657, International Publication No. WO 2016/196386, or both, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 7, supra, are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another aspect, provided herein are methods for preventing and/or treating a disease in which a change in the level of expression of one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In certain embodiments, the gene is any one of the genes disclosed in Tables 2-7 or 1. In certain embodiments, the gene contains a nucleotide sequence encoding a non-endogenous intronic REMS. In certain embodiments, the gene contains a nucleotide sequence encoding an endogenous intronic REMS. In one embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, by way of nonlimiting example, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Tables 2-7, supra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2014/071252 (International Publication No. WO 2015/105657), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in International Patent Application No. PCT/US2016/034864 (International Publication No. WO 2016/196386), is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, wherein the precursor RNA transcript transcribed from the gene comprises an intronic REMS, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein are methods for preventing and/or treating a disease in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene, disclosed in Table 1, supra, is beneficial to the prevention and/or treatment of the disease, the methods comprising administering to a human or non-human subject a compound of Formula (I) or a form thereof, or a pharmaceutical composition comprising a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. In a specific embodiment, one, two, three or more RNA isoforms encoded by a gene, disclosed in Table 7, supra, are decreased following administration of a compound of Formula (I) or a form thereof and a pharmaceutically acceptable carrier, excipient or diluent. See the example section for additional information regarding the genes in Table 7. In a specific embodiment, the gene comprises one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, an IREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for either preventing, treating and preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the DNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3′ splice site, wherein the IREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for either preventing, treating and preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1A, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron, and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1B, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In another embodiment, provided herein is a method for either preventing, treating or preventing and treating a disease in a subject in which the alteration (e.g., increase or decrease) in the expression one, two, three or more protein isoforms encoded by a gene is beneficial to the prevention and/or treatment of the disease, wherein the gene comprises a DNA nucleotide sequence encoding two exons and an intron and wherein the DNA nucleotide sequence comprises exonic and intronic elements illustrated in FIG. 1C, the method comprising administering a compound described herein (for example, a compound of Formula (I) or a form thereof) to the subject.

In a specific embodiment, the gene is a gene described in a table in this disclosure.

In some embodiments, the compound of Formula (I) or a form thereof that is administered to a subject is a compound of Formula (11), Formula (111), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X), Formula (XI), Formula (XII), Formula (XIII), or Formula (XIV). In some embodiments, the compound of Formula (I) or a form thereof that is administered to a subject is a compound described herein.

In a specific embodiment, the methods for preventing a disease described herein prevent the onset or development of one or symptoms of the disease. In another embodiment, the methods for preventing a disease described herein prevent the recurrence of the disease or delays the recurrence of the disease. In another embodiment, the methods for treating a disease described herein has one, two or more of the effects: (i) reduce or ameliorate the severity of the disease; (ii) inhibit the progression of the disease; (iii) reduce hospitalization of a subject; (iv) reduce hospitalization length for a subject; (v) increase the survival of a subject; (vi) improve the quality of life of a subject; (vii) reduce the number of symptoms associated with the disease; (viii) reduce or ameliorates the severity of a symptom(s) associated with the disease; (ix) reduce the duration of a symptom(s) associated with the disease; (x) prevent the recurrence of a symptom associated with the disease; (xi) inhibit the development or onset of a symptom of the disease; and/or (xii) inhibit of the progression of a symptom associated with the disease.

In certain embodiments, the disease or disorder prevented and/or treated in accordance with a method described herein is a disease or disorder associated with a gene listed in Table 1 or Table 7. In specific embodiments, the disease or disorder prevented and/or treated in accordance with a method described herein is leukemia, acute myeloid leukemia, colon cancer, gastric cancer, macular degeneration, acute monocytic leukemia, breast cancer, combined methylmalonic aciduria and homocystinuria, cblC type, hepatocellular carcinoma, cone-rod dystrophy, alveolar soft part sarcoma, myeloma, skin melanoma, prostatitis, pancreatitis, pancreatic cancer, retinitis, adenocarcinoma, adenoiditis, adenoid cystic carcinoma, cataract, retinal degeneration, gastrointestinal stromal tumor, Wegener's granulomatosis, sarcoma, myopathy, prostate adenocarcinoma, Alzheimer's disease, hyperprolinemia, acne, tuberculosis, succinic semialdehyde dehydrogenase deficiency, esophagitis, mental retardation, esophageal adenocarcinoma, glycine encephalopathy, Crohn's disease, spina bifida, tuberculosis, autosomal recessive disease, schizophrenia, neural tube defects, lung cancer, myelodysplastic syndromes, amyotropic lateral sclerosis, neuronitis, germ cell tumors, Parkinson's disease, talipes equinovarus, dystrophinopathies, Hodgkin's lymphoma, ovarian cancer, non-Hodgkin's lymphoma, multiple myeloma, chronic myeloid leukemia, ischemia, acute lymphoblastic leukemia, renal cell carcinoma, transitional cell carcinoma, colorectal cancer, chronic lymphocytic leukemia, anaplastic large cell lymphoma, kidney cancer, cerebritis, bladder related disorders, breast cancer, cervical cancer, cleft lip, cleft palate, cervicitis, spasticity, lipoma, scleroderma, Gitelman syndrome, poliomyelitis, paralysis, Aagenaes syndrome, or oculomotor nerve paralysis.

In specific embodiments, the disease or disorder prevented and/or treated in accordance with a method described herein is basal cell carcinoma, goblet cell metaplasia, or a malignant glioma. In other specific embodiments, the disease or disorder prevented and/or treated in accordance with a method described herein is a cancer of the liver, breast, lung, prostate, cervix, uterus, colon, pancreas, kidney, stomach, bladder, ovary, or brain.

In other specific embodiments, the disease or disorder prevented and/or treated in accordance with a method described herein is Duchenne muscular dystrophy, Beckers muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Charcot-Marie-Tooth disease (CMT), spinal muscular atrophy, Huntington's disease, amyotrophic lateral sclerosis, cystic fibrosis, congenital myopathies, muscle dystrophies, Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorders, cognitive impairment, hereditary sensory and autonomic neuropathies, diseases of chronic inflammation, immune check point-dependent diseases, retinitis pigmentosa, aniridia, Dravet disease, or an epilepsy.

In certain embodiments, the disease prevented and/or treated in accordance with a method described herein is a disease caused by expression of one or more aberrant RNA transcripts, including a cancer amenable to treatment by downregulation of a gene or isoform thereof as described herein. In specific embodiments, cancers that can be prevented and/or treated in accordance with a method described herein include, but are not limited to, cancer of the head, neck, eye, mouth, throat, esophagus, esophagus, chest, bone, lung, kidney, colon, rectum or other gastrointestinal tract organs, stomach, spleen, skeletal muscle, subcutaneous tissue, prostate, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain or central nervous system.

Specific examples of cancers that can be prevented and/or treated in accordance with the methods provided herein include, but are not limited to, the following: renal cancer, kidney cancer, glioblastoma multiforme, metastatic breast cancer; breast carcinoma; breast sarcoma; neurofibroma; neurofibromatosis; pediatric tumors; neuroblastoma; malignant melanoma; carcinomas of the epidermis; leukemias such as but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myclodysplastic syndrome, chronic leukemias such as but not limited to, chronic myclocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas such as but not limited to smoldering multiple mycloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone cancer and connective tissue sarcomas such as but not limited to bone sarcoma, myeloma bone disease, multiple myeloma, cholesteatoma-induced bone osteosarcoma, Paget's disease of bone, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; brain tumors such as but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; breast cancer including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease (including juvenile Paget's disease) and inflammatory breast cancer; adrenal cancer such as but not limited to pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer such as but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers such as but limited to Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipius; eye cancers such as but not limited to ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancers such as squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer such as squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers such as but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers such as but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancers such as but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; cervical carcinoma; esophageal cancers such as but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers such as but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; KRAS-mutated colorectal cancer; PD-1-dependent cancers; PD-1L-dependent cancers; colon carcinoma; rectal cancers; liver cancers such as but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancers such as adenocarcinoma; cholangiocarcinomas such as but not limited to papillary, nodular, and diffuse; lung cancers such as KRAS-mutated non-small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; lung carcinoma; testicular cancers such as but not limited to germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers such as but not limited to, androgen-independent prostate cancer, androgen-dependent prostate cancer, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancers such as but not limited to squamous cell carcinoma; basal cancers; salivary gland cancers such as but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers such as but not limited to squamous cell cancer, and verrucous; skin cancers such as but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers such as but not limited to renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/or uterer); renal carcinoma; Wilms' tumor; bladder cancers such as but not limited to transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesotheliorna, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.

In certain embodiments cancers that can be prevented and/or treated in accordance with the methods provided herein include, the following: pediatric solid tumor, Ewing's sarcoma, Wilms tumor, neuroblastoma, neurofibroma, carcinoma of the epidermis, malignant melanoma, cervical carcinoma, colon carcinoma, lung carcinoma, renal carcinoma, breast carcinoma, breast sarcoma, metastatic breast cancer, HIV-related Kaposi's sarcoma, prostate cancer, androgen-independent prostate cancer, androgen-dependent prostate cancer, neurofibromatosis, lung cancer, non-small cell lung cancer, KRAS-mutated non-small cell lung cancer, malignant melanoma, melanoma, colon cancer, KRAS-mutated colorectal cancer, glioblastoma multiforme, renal cancer, kidney cancer, bladder cancer, ovarian cancer, hepatocellular carcinoma, thyroid carcinoma, rhabdomyosarcoma, acute myeloid leukemia, and multiple myeloma.

In certain embodiments, cancers and conditions associated therewith that are prevented and/or treated in accordance with the methods provided herein are breast carcinomas, lung carcinomas, gastric carcinomas, esophageal carcinomas, colorectal carcinomas, liver carcinomas, ovarian carcinomas, thecomas, arrhenoblastomas, cervical carcinomas, endometrial carcinoma, endometrial hyperplasia, endometriosis, fibrosarcomas, choriocarcinoma, head and neck cancer, nasopharyngeal carcinoma, laryngeal carcinomas, hepatoblastoma, Kaposi's sarcoma, melanoma, skin carcinomas, hemangioma, cavernous hemangioma, hemangioblastoma, pancreas carcinomas, retinoblastoma, astrocytoma, glioblastoma, Schwannoma, oligodendroglioma, medulloblastoma, neuroblastomas, rhabdomyosarcoma, osteogenic sarcoma, leiomyosarcomas, urinary tract carcinomas, thyroid carcinomas, Wilm's tumor, renal cell carcinoma, prostate carcinoma, abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), or Meigs' syndrome. In specific embodiment, the cancer astrocytoma, an oligodendroglioma, a mixture of oligodendroglioma and an astrocytoma elements, an ependymoma, a meningioma, a pituitary adenoma, a primitive neuroectodermal tumor, a medullblastoma, a primary central nervous system (CNS) lymphoma, or a CNS germ cell tumor. In specific embodiments, the cancer treated in accordance with the methods provided herein is an acoustic neuroma, an anaplastic astrocytoma, a glioblastoma multiforme, or a meningioma. In other specific embodiments, the cancer treated in accordance with the methods provided herein is a brain stem glioma, a craniopharyngioma, an ependyoma, a juvenile pilocytic astrocytoma, a medulloblastoma, an optic nerve glioma, primitive neuroectodermal tumor, or a rhabdoid tumor.

Specific examples of conditions caused by expression of one or more aberrant RNA transcripts that can be prevented and/or treated in accordance with the methods described herein include cystic fibrosis, muscular dystrophy, polycystic autosomal-dominant kidney disease, cancer-induced cachexia, benign prostatic hyperplasia, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, retinopathies (including diabetic retinopathy and retinopathy of prematurity), retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, exudative macular degeneration, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, and pterygium keratitis sicca, viral infections, inflammation associated with viral infections, chronic inflammation, lung inflammation, nephrotic syndrome, preeclampsia, ascites, pericardial effusion (such as that associated with pericarditis), pleural effusion, Sjogren's syndrome, acne rosacea, phylectenulosis, syphilis, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infection, Herpes zoster infections, protozoan infections, Mooren's ulcer, Terrien's marginal degeneration, marginal keratolysis, systemic lupus, polyarteritis, trauma, Wegener's sarcoidosis, Paget's disease, scleritis, Stevens-Johnson's disease, pemphigoid, radial keratotomy, Eales' disease, Behcet's disease, sickle cell anemia, pseudoxanthoma elasticum, Stargardt's disease, pars planitis, chronic retinal detachment, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis, ocular histoplasmosis, Mycobacteria infections, Lyme's disease, Best's disease, myopia, optic pits, hyperviscosity syndromes, toxoplasmosis, sarcoidosis, trauma, post-laser complications, diseases associated with rubeosis (neovascularization of the iris and of the angle), and diseases caused by the abnormal proliferation of fibrovascular or fibrous tissue, including all forms of prolific vitreoretinopathy. Certain examples of non-neoplastic conditions that can be prevented and/or treated in accordance with the methods described herein include viral infections, including but not limited to, those associated with viruses belonging to Flaviviridae, flavivirus, pestivirus, hepacivirus, West Nile virus, hepatitis C virus (HCV) or human papilloma virus (HPV).

Particular examples of conditions caused by expression of one or more of aberrant RNA transcripts that can be prevented and/or treated in accordance with the methods described herein include Duchenne muscular dystrophy, Beckers muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Charcot-Marie-Tooth disease (CMT), spinal muscular atrophy, Huntington's disease, amyotrophic lateral sclerosis, cystic fibrosis, congenital myopathies, muscle dystrophies, Alzheimer's disease, Parkinson's disease, schizophrenia, bipolar disorders, cognitive impairment, hereditary sensory and autonomic neuropathies, diseases of chronic inflammation, immune check point-dependent diseases, retinitis pigmentosa, aniridia, Dravet disease, or an epilepsy.

Artificial Gene Constructs

Also provided herein are artificial gene constructs comprising a DNA sequence encoding exons and one or more introns, wherein the nucleotide sequence of at least one intron encodes an intronic REMS downstream of the nucleotide sequence encoding a branch point and the nucleotide sequence encoding a 3′ splice site in 5′ to 3′ order, and artificial gene constructs comprising an RNA sequence that comprises exons and one or more introns, wherein at least one intron comprises a branch point, a 3′ splice site and an intronic REMS in 5′ to 3′ order. The DNA sequence described herein can be or derived from, for example, a genomic DNA sequence or a DNA analog thereof. The RNA sequence described herein can be or derived from, for example, a precursor RNA transcript or an RNA analog thereof. As used herein, the term “artificial gene construct” refers to a DNA or RNA gene construct that comprises a nucleotide sequence not found in nature.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provide herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a first branch point and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1A.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1B.

In another aspect, provided herein is an artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1C.

In another aspect, provided herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), and wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: an iREMS, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3′ splice site, wherein the iREMS comprises an DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1A.

In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1B.

In another aspect, provide herein is an artificial gene construct comprising a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1C.

In one aspect, provided herein are artificial gene constructs comprising an intronic REMS. In one embodiment, an artificial gene construct comprises genomic DNA or DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site, is modified to introduce a nucleotide sequence encoding the intronic REMS. In another embodiment, an artificial gene construct comprises DNA encoding exons, an intronic REMS, a 3′ splice site(s) and a branch point(s) sequence, wherein a nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of at least one nucleotide sequence encoding a branch point and at least one nucleotide sequence encoding a 3′ splice site, is modified to introduce a nucleotide sequence encoding an intronic REMS. In another embodiment, an artificial gene construct comprises genomic DNA or DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site, is introduced into an intron by genetic engineering. In another embodiment, an artificial gene construct comprises genomic DNA or DNA encoding exons and one, two or more introns, wherein a nucleotide sequence encoding an intronic REMS, which may be upstream or downstream of a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site, is endogenously present in an intron. In some embodiments, an artificial gene construct comprises a DNA sequence that is genetically engineered to introduce a nucleotide sequence encoding an intronic REMS, wherein the location of the intronic REMS is as illustrated in any of FIGS. 1A-1C. In some embodiments, an artificial gene construct comprises a DNA sequence that is genetically engineered to comprise one, two, or all of the following: intronic REMS, branch point, and 3′ splice site. In some embodiments, an artificial gene construct comprises a DNA sequence that is genetically engineered to comprise a branch point, a 3′ splice site and an intronic REMS, in 5′ to 3′ order. In certain embodiments, the DNA sequence chosen to be used in the production of an artificial gene construct may contain a nucleotide sequence encoding an intronic REMS and an additional nucleotide sequence encoding an intronic REMS or a branch point or a 3′ splice site sequence is introduced. In specific embodiments, the nucleotide sequence encoding an intronic REMS or a branch point or a 3′ splice site is a non-endogenous sequence, i.e., a sequence not naturally found in the DNA sequence of the artificial gene construct. In certain embodiments, the artificial gene construct comprises other elements, such as a promoter (e.g., a constitutive, inducible or tissue specific promoter), a Poly(A) site, a transcription termination site, and a transcription binding site(s). In certain embodiments, the artificial gene construct comprises at least the sequences to encode a therapeutic protein. In some embodiments, the artificial gene construct comprises at least an intronic REMS for a gene listed in Table 1-7. In a specific embodiment, the artificial gene construct further comprises exons of a gene listed in Table 1-7. In certain embodiments, the artificial gene construct comprises at least the exons of a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta galactosidase, renilla luciferase, firefly luciferase, etc.

In certain embodiments, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS is introduced into a nucleotide sequence encoding an existing intronic branch point and intronic 3′ splice site of genomic DNA or DNA, wherein the DNA encodes two or more exons and one or more introns, and wherein the nucleotide sequence encoding the intronic REMS is downstream (in a preferred embodiment) or upstream of a nucleotide sequence encoding a branch point and a 3′ splice site. In some embodiments, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS is introduced downstream (in a preferred embodiment) or upstream of a nucleotide sequence encoding a branch point and a 3′ splice site of genomic DNA or DNA, wherein the DNA encodes two or more exons and an intron(s). In a specific embodiment, the nucleotide sequence encoding the intronic REMS is introduced internally within a nucleotide sequence encoding an intron. In certain embodiments, an artificial gene construct is produced as follows: a nucleotide sequence encoding an intronic REMS, a nucleotide sequence encoding a branch point, and a nucleotide sequence encoding a 3′ splice site are introduced into a cDNA, wherein the nucleotide sequence encoding the intronic REMS may be upstream of the branch point and 3′ splice site, respectively; or may be downstream (in a preferred embodiment) of the 3′ splice site and branch point, respectively. The nucleotide sequence encoding the intronic REMS functions as a 5′ splice site. In certain embodiments, the nucleotide sequence encoding the intronic REMS is internally within an intron. In a specific embodiment, the genomic DNA or DNA chosen for use in the production of an artificial gene construct does not contain one or more of a nucleotide sequence encoding an intronic REMS or a nucleotide sequence encoding a branch point or a nucleotide sequence encoding a 3′ splice site. In certain embodiments, the genomic DNA or DNA chosen for use in the production of an artificial gene construct contains an intronic REMS and an additional intronic REMS is introduced. In some embodiments, in introducing a nucleotide sequence encoding an intronic REMS into a DNA sequence, care should be taken so as not to disrupt an open reading frame or introduce a stop codon. The introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence may or may not result in an amino acid change at the protein level. In certain embodiments, the introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence results in an amino acid change at the protein level. In some embodiments, this amino acid change is a conservative amino acid substitution. In other embodiments, the introduction of a nucleotide sequence encoding an intronic REMS into a DNA sequence does not result in an amino acid change at the protein level. Techniques known to one of skill in the art may be used to introduce an intronic REMS and other elements, such as a branch point sequence or 3′ splice site sequence into a DNA sequence, e.g., gene editing techniques such as the CRISPR-Cas approach, Transcription Activator-Like Effector Nucleases (TALENs), or Zinc finger nucleases (ZFNs) may be used.

In certain embodiments, an artificial gene construct comprises an RNA sequence comprising exons and one, two or more introns, wherein an intronic REMS 5′ splice site, which is downstream of a 3′ splice site, is introduced into an intron by genetic engineering. In another embodiment, an artificial gene construct comprises an RNA sequence comprising exons, one, two or more introns, a 5′ splice site(s), a 3′ splice site(s) and a branch point(s), wherein an intronic REMS, which is downstream of a 3′ splice site, is introduced into an intron by genetic engineering. In some embodiments, an artificial gene construct comprises a DNA sequence that is genetically engineered to comprise one, two, or all of the following: branch point, 3′ splice site and/or intronic REMS. In some embodiments, an artificial gene construct comprises a DNA sequence that is genetically engineered to comprise a branch point, a 3′ splice site and an intronic REMS, in 5′ to 3′ order. In another embodiment, an artificial gene construct comprises an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises in 5′ to 3′ order: a branch point, a 3′ splice site and an intronic REMS, wherein the intronic REMS is endogenously present in an intron. In another embodiment, an artificial gene construct comprises an RNA sequence comprising exons, endogenously having a 5′ splice site(s), a 3′ splice site(s) and a branch point(s), wherein an intron, which is upstream of a 3′ splice site, is modified to introduce a non-endogenous branch point, a non-endogenous 3′ splice site and a non-endogenous intronic REMS. In specific embodiments, the intronic REMS is non-endogenous, i.e., not naturally found in the RNA sequence of the artificial gene construct. In certain embodiments, the artificial gene construct comprises other elements, such as a promoter (e.g., a tissue-specific promoter or constitutively expressed promoter), 5′ untranslated region, 3′ untranslated region, a binding site(s) for RNA binding proteins, a small molecule RNA sensor(s), e.g., riboswitches, stem-loop structures, and/or internal ribosome entry sites (IRES), etc. In certain embodiments, the artificial gene construct comprises at least the introns of a gene encoding a therapeutic protein. In some embodiments, the artificial gene construct comprises at least the introns of a gene listed in Tables 1-7. In a specific embodiment, the artificial gene construct further comprises exons of a gene listed in Table 1-7. In a specific embodiment, the RNA transcript chosen to be used in the production of an artificial gene construct does not contain an intronic REMS. In certain embodiments, the RNA transcript chosen to use in the production of an artificial gene construct contains an intronic REMS and an additional exonic or intronic REMS is introduced. In certain embodiments, the RNA transcript chosen to use in the production of an artificial gene construct contains an intronic REMS and an additional intronic REMS is introduced. In other embodiments, the artificial gene construct comprises at least one intron and two exons of a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta galactosidase, renilla luciferase, firefly luciferase, etc.

In certain embodiments, an artificial gene construct is produced as follows: an intronic REMS is introduced into an existing 5′ splice site of precursor RNA, wherein the RNA comprises two or more exons and one or more introns, and wherein an intronic REMS is upstream of a branch point sequence and a 3′ splice site sequence. In some embodiments, an artificial gene construct is produced as follows: an intronic REMS is introduced upstream of a 3′ splice site of a precursor RNA, wherein the RNA comprises two or more exons and an intron(s). In a specific embodiment, the intronic REMS is introduced internally within an intron. In certain embodiments, an artificial gene construct is produced as follows: a branch point, a 3′ splice site and an intronic REMS are introduced into a precursor RNA, wherein the REMS may be either downstream or upstream of the branch point and 3′ splice site. In certain embodiments, an artificial gene construct is produced as follows: a branch point, a 3′ splice site and an intronic REMS are introduced into an mRNA, wherein the REMS may be either downstream or upstream of the branch point and 3′ splice site. The intronic REMS functions as a 5′ splice site. In some embodiments, in introducing an intronic REMS into an RNA sequence, care should be taken so as not to disrupt an open reading frame or introduce a stop codon. The introduction of an intronic REMS into an RNA transcript may or may not result in an amino acid change at the protein level. In certain embodiments, the introduction of an intronic REMS into an RNA transcript results in an amino acid change at the protein level. In some embodiments, this amino acid change is a conservative amino acid substitution. In other embodiments, the introduction of an intronic REMS into an RNA transcript does not result in an amino acid change at the protein level. Techniques known to one of skill in the art may be used to introduce an intronic REMS and other elements, such as a branch point or 3′ splice site into an RNA transcript.

In some embodiments, an artificial gene construct is present in a viral vector (e.g., an adeno-associated virus (AAV), self-complimentary adeno-associated virus, adenovirus, retrovirus, lentivirus (e.g., Simian immunodeficiency virus, human immunodeficiency virus, or modified human immunodeficiency virus), Newcastle disease virus (NDV), herpes virus (e.g., herpes simplex virus), alphavirus, vaccina virus, etc.), a plasmid, or other vector (e.g., non-viral vectors, such as lipoplexes, liposomes, polymerosomes, or nanoparticles).

In some embodiments, the artificial gene construct is an RNA molecule modified to enable cellular uptake. In certain embodiments, the artificial gene construct is an RNA molecule containing pseudouridine or other modified/artificial nucleotides for enhanced cellular uptake and gene expression.

The use of an artificial gene construct described herein in gene therapy allows one to regulate the amount and type of a protein produced from the construct depending on whether or not a compound described herein is present. The compound is essentially a tunable switch that, depending on the amount and duration of the dose of the compound, regulates the amount and type of protein produced.

In certain embodiments, an RNA transcript transcribed from an artificial gene construct that is DNA would not produce or produce substantially less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein. For example, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, which is downstream of an intronic nucleotide sequence encoding a branch point and a 3′ splice site, then the creation of an intronic exon would ultimately result in less amount of the original protein (i.e., without amino acid sequence derived from the intronic exon) being produced in the presence of a compound described herein. Alternatively, in certain embodiments, an RNA transcript transcribed from an artificial gene construct that is DNA would produce or would produce substantially less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein.

In certain embodiments, an artificial gene construct or vector comprising an artificial gene construct is used in cell culture. For example, in a cell(s) transfected with an artificial gene construct or transduced with a vector comprising an artificial gene construct, the amount and type of a protein produced from the artificial gene construct can be altered depending upon whether or not a compound described herein is contacted with the transfected cell(s). For example, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, which is downstream of a nucleotide sequence encoding a branch point and a 3′ splice site, then the likelihood of producing an intronic exon would be less in the absence of the compound. Thus, the use of an artificial gene construct described herein allows one to regulate the amount and type of a protein produced from the construct depending on whether or not a compound described herein is present. In other words, a compound described herein is essentially a switch that regulates the amount and type of protein produced. This regulation of the production of protein could be useful, e.g., when trying to assess the role of certain genes or the effects of certain agents on pathways. The amount of the protein produced can be modified based on the amount of a compound described herein that is contacted with the transfected cell and/or how long the compound is contacted with the transfected cell.

In certain embodiments, an animal (e.g., a non-human animal, such as a mouse, rat, fly, etc.) is engineered to contain an artificial gene construct or a vector comprising an artificial gene construct. Techniques known to one of skill in the art may be used to engineer such animals. The amount of protein produced by this engineered animal can be regulated by whether or not a compound described herein is administered to the animal. The amount of the protein produced can be titrated based on the dose and/or the duration of administration of a compound described herein to the engineered animal. In certain embodiments, the artificial gene construct encodes a detectable reporter gene, such as green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein, beta galactosidase, renilla luciferase, firefly luciferase, etc. In accordance with this embodiment, the engineered animal may be used to monitor development at different stages, visualize tissue function, etc. In other embodiments, the artificial gene construct encodes a therapeutic gene product, such as described the gene product of a gene in Tables 2-7 and 1. In accordance with this embodiment, the engineered animal may be used to monitor development at different stages or in functional biological studies where a certain protein or protein isoform needs to be expressed only for a period of time and not constitutively, etc.

In certain embodiments, an artificial gene construct or a vector comprising an artificial gene construct are used in gene therapy. Non-limiting examples of vectors include, but are not limited to, plasmids and viral vectors, such as vectors derived from replication defective retroviruses, adenoviruses, adeno-associated viruses and baculoviruses. The vector can be an RNA vector or preferably a DNA vector.

Gene Therapy

In another aspect, provided herein are artificial gene constructs or vectors comprising an artificial gene construct for use in gene therapy. The use of an artificial gene construct described herein in gene therapy allows one to regulate the amount and type of a protein produced from the construct depending on whether or not a compound described herein is present. The compound is essentially a switch that regulates the amount and type of protein produced.

In certain embodiments, an RNA transcript transcribed from an artificial gene construct that is DNA would not produce or would produce substantially more protein in the absence of a compound described herein than the amount of protein produced in the presence of a compound described herein. In certain embodiments, an RNA transcript transcribed from an artificial gene construct would not produce or would produce substantially more protein in the absence of a compound described herein than the amount of protein produced in the presence of a compound described herein. For example, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, which is downstream of a nucleotide sequence encoding a branch point and a 3′ splice site, then the likelihood of producing an intronic exon would be less in the absence of a compound described herein, which would ultimately result in more amount of the original protein (i.e., without amino acid sequence derived from the intronic exon) being produced. Thus, the use of an artificial gene construct or a vector comprising an artificial gene construct may be useful in treating and/or preventing certain conditions or diseases associated with genes. The conditions or diseases may include those described herein. Alternatively, in certain embodiments, an RNA transcript transcribed from an artificial gene construct that is DNA would produce substantially less functional protein in the presence of a compound described herein than the amount of functional protein produced in the absence of a compound described herein. For example, in certain embodiments, if the artificial gene construct comprises a nucleotide sequence encoding an intronic REMS, the production of the original protein (i.e., without amino acid sequence derived from the intronic exon), which is a functional protein, would be reduced in the presence of a compound described herein. However, in the absence of a compound described herein, normal splicing would occur, and the production of the functional protein will not be reduced. The amount and type of the protein produced can be titrated based on dose and duration of dosing of the compound.

In a specific embodiment, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide.

In another specific embodiment, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a first branch point and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), and wherein r is adenine or guanine and n is any nucleotide.

In another specific embodiment, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1A.

In another specific embodiment, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1B.

In another specific embodiment, the artificial gene construct used in gene therapy comprises an RNA sequence comprising two exons and an intron, wherein the RNA sequence comprises exonic and intronic elements illustrated in FIG. 1C.

In another specific embodiment, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: a nucleotide sequence encoding a first 5′ splice site, a nucleotide sequence encoding a first branch point, a nucleotide sequence encoding a first 3′ splice site, an iREMS, a nucleotide sequence encoding a second branch point and a nucleotide sequence encoding a second 3′ splice site, wherein the iREMS comprises a DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In another specific embodiment, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the nucleotide sequence encoding one exon is upstream of the nucleotide sequence encoding the intron and the nucleotide sequence encoding the other exon is downstream of the nucleotide sequence encoding the intron, wherein the nucleotide sequence encoding the intron comprises in 5′ to 3′ order: an iREMS, a nucleotide sequence encoding a first branch point and a nucleotide sequence encoding a first 3′ splice site, wherein the iREMS comprises an DNA sequence GAgtrngn (SEQ ID NO: 4), wherein r is adenine or guanine and n is any nucleotide.

In another specific embodiment, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1A.

In another specific embodiment, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1B.

In another specific embodiment, the artificial gene construct used in gene therapy comprises a DNA sequence encoding two exons and an intron, wherein the DNA sequence comprises exonic and intronic elements illustrated in FIG. 1C.

An artificial gene construct, a vector comprising the artificial gene construct, or an RNA molecule comprising an artificial gene construct modified to enable cellular uptake may be introduced into cells or administered directly to patients. In one embodiment, an artificial gene construct or a vector comprising the artificial gene construct is introduced into cells ex vivo or in vivo. In a specific embodiment, an artificial gene construct or vector is introduced into a cell(s) ex vivo and the cell(s) may be administered to a subject. Various techniques known to one of skill in the art may be used to introduce an artificial gene construct or vector comprising the artificial gene construct into a cell(s), such as electroporation, transfection, transformation, etc. In another embodiment, an artificial gene construct or vector comprising the artificial gene construct is administered to a subject. The artificial gene construct or vector comprising the artificial gene construct may be administered to a subject by any technique known to one skilled in the art, e.g., intramuscularly, intravenously, subcutaneously, intradermally, topically, intrathecally, intraperitoneally, intratumorally, etc. In some embodiments, the artificial gene construct or vector comprising the artificial gene construct is administered to a subject systemically. In other embodiments, the artificial gene construct or vector comprising the artificial gene construct is administered to a subject locally.

Altering Endogenous Genes

In another aspect, provided herein are method for altering an endogenous gene such that it contains a nucleotide sequence encoding an intronic REMS, or contains an additional nucleotide sequence encoding an intronic REMS (in other words, an intronic REMS not naturally found in the endogenous gene, i.e., a non-endogenous intronic REMS). In a specific embodiment, provided herein are method for altering an endogenous gene such that it contains a nucleotide sequence encoding an intronic REMS and contains a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site upstream of the nucleotide sequence encoding the intronic REMS. As used herein, the term “endogenous gene” refers to a gene naturally found in a cell or living subject. Techniques known to one of skill in the art can be used to introduce any one, two, or all of the following: a branch point, a 3′ splice site, and an intronic REMS into an endogenous gene, e.g., the CRISPR-Cas approach, TALEN, or ZFN may be used. In certain embodiments, a nucleotide sequence encoding an existing 5′ splice site can be replaced with an intronic REMS or an intronic REMS may be inserted internally within an intron. In certain embodiments, in introducing a nucleotide sequence encoding an intronic REMS into an endogenous gene, care should be taken so as not to disrupt an open reading frame or introduce a stop codon. The introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene may or may not result in an amino acid change at the protein level. In certain embodiments, the introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene results in an amino acid change at the protein level. In some embodiments, this amino acid change is a conservative amino acid substitution. In other embodiments, the introduction of a nucleotide sequence encoding an intronic REMS into an endogenous gene does not result in an amino acid change at the protein level.

In one aspect, provided herein are kits comprising, in a container, an artificial gene construct or a vector comprising an artificial construct. In certain embodiments, the kits further comprise a compound described herein, in a separate container, and/or a negative control, such as phosphate buffered saline or a compound that does not recognize an intronic REMS, in a separate container. In a specific embodiment, the kits further comprise a positive control, such as a compound described herein as a positive control. In some embodiments, the kits further comprise primers and/or antibodies, in one or more separate containers, for assessing the production of an mRNA transcript from an artificial gene construct and/or protein production therefrom.

In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessary to produce an artificial gene construct and/or a vector comprising an artificial gene construct. In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessary to alter an endogenous gene so that it contains a nucleotide sequence encoding an intronic REMS or an additional nucleotide sequence encoding an intronic REMS (in other words, a REMS not naturally found in the endogenous gene, i.e., a non-endogenous REMS). In another aspect, provided herein are kits comprising, in one or more containers, the components and/or reagents necessary to alter an endogenous gene so that it contains a nucleotide sequence encoding an intronic REMS and contains a nucleotide sequence encoding a branch point and a nucleotide sequence encoding a 3′ splice site upstream of the nucleotide sequence encoding the intronic REMS. In some embodiments, the kits further comprise primers and/or antibodies, in one or more separate containers, for assessing the production of an mRNA transcript from altered endogenous gene and/or protein production therefrom.

In another aspect, provided herein are kits comprising, in a container, a compound described herein, and instructions for use. In some embodiments, the kits further comprise a negative control, such as phosphate buffered saline or a compound that does not recognize an intronic REMS, in a separate container.

Examples

To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed. The example below illustrates the existence of an intronic recognition element for splicing modifier (REMS) that is important for the recognition of a compound described herein, and the binding of such a compound to the intronic REMS on a precursor RNA permits or enhances the splicing of the precursor RNA, and suggests the usefulness of the intronic REMS in combination with a compound described herein for modulating RNA splicing, and for modulating the amount of a gene product.

Materials and Methods

Cell treatment: GM04856 lymphocyte cells were diluted in a medium composed of DMEM, 10% FBS and 1x Pen/Strep to a concentration of 2.5e5 cells/mL. 2 mL (500K cells) were seeded in 6-well plates and recovered for 4 h at 37° C., 5% CO₂. Compound dilutions were prepared as 2× compound stock in medium (e.g. for final 100 nM, make a 200 nM stock). After 4 h recovery, 2 mL of the 2× compound stock were added to each well, resulting in 4 mL/well with 1× final compound concentration. The cells were incubated for ˜20 h at 37° C., 5% CO₂. After incubation, the cells were pelleted for 5 min at 1000 rpm. The supernatant was vacuum-removed and the cells were resuspended in 350 μl of RLT buffer (w/10 μl/mL beta-mercapto-ethanol, RNeasy kit). Total RNA was isolated using the RNeasy Mini Kit from Qiagen according to the manufacturer's instructions. The concentration of the resulting total RNA was determined using Nanodrop and diluted with water to a final concentration of 25 ng/μL.

Endpoint PCR: 20 μL endpoint RT-PCRs were set up in 96-well plates using the AgPath-ID One-Step RT-PCR Reagents (Applied Biosystems) according to the manufacturer. Each reaction contained 200 nM forward primer, 200 nM reverse primer, and 50 ng total RNA. The following RT-PCR protocol was used: reverse transcription at 48° C. for 15 min, denaturation at 95° C. for 10 min, 35 PCR cycles with denaturation at 95° C. for 30 sec, annealing at 58° C. for 30 sec, and elongation at 68° C. for 1 min, final hold at 4° C. 10 μL of each RT-PCR reactions were analyzed on 2% 48-well E-Gels (Invitrogen) (pre-run 1 min, run 14 min) and imaged using an BioRad Gel Doc EZ Imager. The following size markers were used: TrackIt 1 Kb Plus DNA ladder and TrackIt 100 bp DNA ladder (10 μL/well, both Invitrogen).

Results: Oligonucleotides corresponding to exons that flank the intron where an iExon is located were used to amplify total RNA purified from untreated (DMSO) or cells treated with Compound 774 (at dose levels 10 nM, 1 μM or 10 μM). The resulting products were run on an agarose gel and the resulting bands of interest are demarcated by arrowheads, as shown in FIGS. 2A-D and 3-6A. In all cases, the increase of compound concentration results in appearance of a slower migrating PCR product containing the intronic-derived exon. In all cases, additional bands seen are intermediate spliced products.

Endpoint RT-PCR: Analysis of alternatively spliced mRNAs in cultured cells

GM03813 cells (Coriell Institute) derived from a patient with SMA type I (Coriell Institute) were plated at 5,000 cells/well in 200 μL DMEM with 10% FBS in 96-well plates, and incubated for 6 hours in a cell culture incubator (37° C., 5% CO₂, 100% relative humidity). Cells were then treated with certain representative compounds (e.g., Compound 774, Compound 702 and Compound 170) at different concentrations (in 0.5% DMSO) in duplicate for 24 hours. After removal of the supernatant, cells were lysed in Cells-To-Ct lysis buffer (Life Technologies, Inc.). Reverse transcription was performed using 5 μL of cell lysate and the iScript RT enzyme kit (Bio-Rad Laboratories, Inc). PCR was performed using 5 &L of cDNA and Platinum Taq HMFi DNA Polymerase (Life Technologies, Inc.) under the following PCR conditions: Step1: 94° C. (2 min), Step 2: 94° C. (30 sec), Step 3: 55° C. (30 sec), Step 4: 68° C. (1 min), then repeat Steps 2 to 4 for 33 cycles, then hold at 4° C. Alternatively spliced mRNAs were identified using primers listed in Tables 8 and 9. PCR products were separated on 2% agarose E-gels, stained with ethidium bromide and visualized using a gel imager (UVP). Results for genes affected by intronic exons generated by treatment with Compound 774 are shown in Table 10.

TABLE 8 SEQ ID Gene Forward Primer Sequence 5′-3′ NO. ABCB8 ABCB_54-73 GCCGGCGGCTCCTGTTTTAC 3629 ANXA11 ANXA_101-120 AGTCGCTGTACCACGACATC 3630 ARL15 ARL1_87-106-1a-KE GCTGCCGGATGTCTGATCTC 3631 DCAF17 DECA_23-43-KE TGCTGTACCTTGCAGTGTTCC 3632 DHFR DHFR_5-24 CCATGAATCACCCAGGCCAT 3633 FAIM FAIM_197-217-KE GTGAAACCTACCCCAGAGCCT 3634 GXYLT1 GXYL_57-77 GGAAGCAATTGCCAAGAAGCA 3635 HTT HTT_E49_For TGCCCAGTCATTTGCACCTT 3636 MADD MADD_137-156-KE TGCCACAGGAAAGGGTCCTA 3637 MEMO1 MEMO_37-56 TGGAGCTCTGAGTGAGTCAA 3638 OXCT1 OXCT_55-75-KE GGCCTGACAGTGGATGACGTA 3639 PAPD4 PAPD_46-65-KE CCCGGAGCAGTGATGGTGAT 3640 PDXDC1 *PDXD_23-42 TGTGCCGTGTACCCTGTAAC 3641 PMS1 PMS1_104-127-KE TCTCCTCATGAGCTTTGGTATCCT 3642 PPIP5K2 PPIP_34-57-KE TCAGTTGACCTATCTCCCTCATGG 3643 PPP1R26 PPP1R26e3F1 CGTGTGGGAACACTGGCTG 3644 PRPF31 RPRF_50-69-KE GCCAACCGTATGAGCTTCGG 3645 RARS2 RARS_30-53-KE TTGGACATTTGCGTTCTACCATCA 3646 TNS3 TNS3_6-29-KE CCAGGTGATAAACTTGTGATCGTG 3647 WNK1 Wnk1_45-67 GCTGGTGTTTTTAAGATGGGACG 3648 SF3B SF3B_107-127-2a GGCATCAGCTTTGCCATTCAT 3649 SF3B SF3B_134-153-9a TTGGACAGCCTCTCTCCCAT 3650 MEMO1 MEMO_37-56 TGGAGCTCTGAGTGAGTCAA 3651 DHFR DHFR_5-24 CCATGAATCACCCAGGCCAT 3652 GCFC2 GCFC2e2F1 GGAGAAAAAGAACTTTCATCAACAG 3653 FAM174A FAM174Ae2F1 CAGGATGATGAGGATGATGACAAc 3654 SOS2 SOS2e19F1 CTGAAAAAGAGTTTACAGATTATTTGTTC 3655 COPS7B COPS7Be2F1 CGGAGTGTATGTCTTTGGAGAACTT 3656 LMBRD2 LMBRD2e16R1 GGAATCTTCTCTATTGTGTCCATAACG 3657 ASAP1 ASAP1e11F1 TACCCCTTCTTTTCACTGCCAT 3658 PPP1R26 PPP1R26e3F1 CGTGTGGGAACACTGGCTG 3659 NT5C2 NT5C2e12F1 AAACCACTCTTTTTTGGAGAAGGC 3660 ELMO2 ELMO2e2F1 AGGTGTAGAAAGAGGTACATGGAGAA 3661

TABLE 9 SEQ ID Gene Reverse Primer Sequence 5'-3' NO. ABCB8 ABCB_235-254 AGGAGCTGCGGTAGCCATCA 3662 ANXA11 ANXA_302-321 GAGCCACCAGTCACTGTTCA 3663 ARL15 ARL1_392-411-1a-KE TGAGGCCTATGCAAACCAGG 3664 DCAF17 DECA_168-190-KE CCATGAGACAAGGTAGCATCTGT 3665 DHFR DHFR_209-228 TGCCTTTCTCCTCCTGGACA 3666 FAIM FAIM_367-388-KE AGCAACATCCCAAACAGCTACG 3667 GXYLT1 GXYL_246-268 AGGAACGGATGTTGTCATCTTCA 3668 HTT HTT_E51_Rev GGGTATTTGTCCTTCTTTCT 3669 MADD MADD_288-309-KE TCTCCTCTGTCTCACCAAGGTC 3670 MEMO1 MEMO_218-239 TCCCCCTGGGATTCATCATAGT 3671 OXCT1 OXCT_236-256-KE AATGAAAAACACGCAGCCTGG 3672 PAPD4 PAPD_183-205-KE AAGGTGAGTATATGCCGTGCTTC 3673 PDXDC1 *PDXD_179-199 CAAGCAACAGGGGCAGTCTTC 3674 PMS1 PMS1_285-308-KE ACATGAGAGCCATCTTGTGATCTG 3675 PPIP5K2 PPIP_149-172-KE TTCACCTCCCCATTTTAGAACCAA 3676 PPP1R26 PPP1R26e4R1 GCGATGCTTTATTTCTCTACCG 3677 PRPF31 RPRF_218-237-KE TCGTTTACCTGTGTCTGCCG 3678 RARS2 RARS_251-270-KE ATGCCCCAATCGCCAAGGTA 3679 TNS3 TNS3_96-116-KE CGGCTCCTTGTCCTTCAACAT 3680 WNK1 Wnk1_187-207 CTGAGGACTCTGAGGTGCTGG 3681 SF3B SF3B_256-275-2a GTACTTTGCCAGTGTTGGGG 3682 SF3B SF3B_304-324-9a ACTCTCAGAGATGATCGGGGT 3683 MEMO1 MEMO_218-239 TCCCCCTGGGATTCATCATAGT 3684 DHFR DHFR_209-228 TGCCTTTCTCCTCCTGGACA 3685 GCFC2 GCFC2e3R1 GAATAAAAGCTGCATCTGGGATC 3686 FAM174A FAM174Ae3R1 CAACATTGATATAGTGGCTTCTTATTC 3687 SOS2 SOS2e20R1 CTGAAGAAGCAGATACTGGTGGAG 3688 COPS7B COPS7Be3R1 GTATGTCCCATAGGCAAACAGGTT 3689 LMBRD2 LMBRD2e15F1 AAAGGCAAGAAGAAGGTGAAAATC 3690 ASAP1 ASAP1e12R1 GCTAACTGCACTCCGAGACTTAAT 3691 PPP1R26 PPP1R26e4R1 GCGATGCTTTATTTCTCTACCG 3692 NT5C2 NT5C2e13R1 TAGACGATACCATGCTGTAGGGG 3693 ELMO2 ELMO 232-252 TTGATAATGGATGCCAGGGGC 3694

Results: The statistically significant value for the likelihood of iExon production (APSI) according to the Fisher's Exact Test (FET) for PNN and HDF cell lines treated with Compound 774 at 3 μM and Fold Decrease (FD) for certain genes tested, where NR represents “Not Reported,” is shown in Table 10.

The APSI for inclusion of an iExon and resulting modulated expression of RNA transcripts identified is represented by stars, where one star (*) represents ≤25% change in expression, where two stars (**) represent change in expression in a range from <26% to HD 50 change, where three stars (***) represent change in expression in a range from <51% to ≤75% change, and, where four stars (****) represent change in expression in a range from <75% to ≤100% change.

TABLE 10 FET FET Inclusion ΔPSI ΔPSI FD ΔPSI ΔPSI FD Gene Symbol Position (PNN) (PNN) PNN (HDF) (HDF) HDF ABCB8 i1 ** 9.42E−16 NR ** 3.66E−09 NR ABCC3 i30 ** 6.00E−07 −0.25 * 1   −1.03 ADAM17 i1 ** 7.83E−11 VR * 4.87E−08 NR ADCY3 i6 *  0.003 NR *   0.656286 NR AGPAT4 i1 * 1.13E−05 NR ** 1.21E−06 NR ANKRA2 i5 * 0.28 −1.05 *  0.001  0.73 ANXA11 i16 * 9.07E−56 NR * 2.24E−20 NR APIP i1 * 2.52E−11 NR * 1.42E−19 NR APPL2 i1 * 4.28E−06 NR * 0.47 NR ARHGAP1 i1 * 0.34 −0.11 * 0.01 −1.02 ARL15 i4 ** 1.77E−08 NR * 1.94E−05 NR ARL15 i1 **** 1.20E−17 NR *** 2.25E−18 NR ASAP1 i12 * 0   −0.79 * 0   −1.40 ASAP1 i19 * 0   −0.79 * 0   −1.40 ASAP1 i19 *  0.0003 −0.79 * 0.22 −1.40 ASAP1 i12 *  0.004 −0.79 * 1   −1.40 ASPH i24 * 1   NR * 0.19 NR ATAD2B i27 * 0.51 NR * 0.47 NR ATXN1 i7 * 0.08 NR * 1   NR BECN1 i11 * 3.01E−18 NR * 5.27E−06 NR BHMT2 i2 * 0.05 NR * 1   NR BICD1 i5 * 2.64E−05 NR * 0.06 NR BTN3A1 i1 * 0.02 NR *  0.0001 NR C11orf30 i20 *** 3.45E−12 −0.82 *** 3.57E−10 −1.06 C11orf73 i2 ** 1.10E−47 −1.44 * 2.53E−40  0.52 C12orf4 i1 **** 2.07E−43 NR **** 1.91E−66 NR C14orf132 i1 * 0.16 NR * 0.04 NR C8orf44 i1 ***  0.004 NR * 1   NR C8orf44-SGK3 i1 *** 1.17E−08 NR ** 0.06 NR C8orf88 i3 * 0.13 NR * 4.31E−05 NR CASC3 i3 * 0.04 −0.48 * 0.08 −1.14 CASP7 i2 *  0.001 NR * 1.99E−06 NR CCDC122 i6 * 0.29 −1.07 * 1    0.41 CDH13 i7 *  0.0003 −2.06 * 1.32E−05 −0.76 CECR7 i3 **** 3.06E−07 NR **** 0.14 NR CENPI i19 **** 1.62E−50 NR *** 1.78E−58 NR CEP112 i24 * 0.11 −0.96 * 0.02 −0.62 CEP192 i13 * 0.03 NR * 0.34 NR CHEK1 i13 ** 3.38E−05 NR *  0.0002 NR CMAHP i6 * 1   −1.59 ***  0.002 −0.47 CNRIP1 i2 * 3.10E−22 NR * 1.70E−42 NR CNRIP1 i15 * 1.62E−17 NR * 2.06E−34 NR COPS7B i2 * 1.45E−22 NR * 4.58E−14 NR CPSF4 i2 *  0.009 NR * 0.40 NR CRISPLD2 i1 ***  0.009 −0.25 ***  0.001 −1.29 CRYBG3 i17 * 1   −0.33 * 1   −1.08 CSNK1E i3 **** 1.50E−07 NR ***  0.004 NR CSNK1G1 i2 *  0.004 NR * 1   NR DCAF17 i2 * 0.06 NR * 1   NR DCAF17 i6 **** 1.01E−17 NR ** 9.85E−15 NR DCUN1D4 i8 * 0.05 −1.16 * 3.90E−17 −0.01 DDX42 i8 * 9.24E−17 −1.26 *  0.0002 −1.62 DENND1A i10 **  0.0005 −2.20 *** 8.97E−07 −2.09 DENND5A i3 * 0   −2.48 * 0   −2.09 DENND5A i8 * 0   −2.48 * 0   −2.09 DGKA i10 * 0.02 NR * 0.22 NR DHFR i5 **** 2.99E−06 NR ***  0.0006 NR DHFR i5 **** 5.92E−08 NR ***  0.0004 NR DIAPH3 i27 * 8.17E−12 −2.51 * 4.97E−12 −2.14 DIAPH3 i15 ** 8.33E−15 −2.51 * 1.10E−08 −2.14 DNAJC13 i43 * 0.05 −0.23 * 0.33 −1.05 DNMBP i1 * 0.66 −0.32 * 0.62 −0.99 DNMBP i11 *  0.001 −0.32 * 0.11 −0.99 DOCK1 i23 * 2.18E−13 −1.29 *  0.0006 −1.28 DYRK1A i3 * 0.01 NR * 0.33 NR EIF2B3 i6 *  0.0005 −1.86 * 1.49E−06 −0.82 ENAH i1 ** 9.79E−34 NR ** 7.69E−23 NR ENOX1 i5 * 0   −1.28 * 0   −0.68 EP300 i1 *  0.0006  0.13 * 1   −1.19 ERC1 i18 ** 4.96E−20 −0.53 *  0.0002 −1.49 ERLIN2 i1 * 4.62E−06 NR * 0.12 NR ERRFI1 i1 ****  0.004 NR * 1   NR EVC i5 * 1.62E−12 −0.53 * 0.23 −0.96 FAF1 i14 * 0.21 −1.32 *  0.009 −0.83 FAIM i2 * 0.08 NR * 0.30 NR FAM126A i7 * 5.38E−10 NR * 1.31E−05 NR FAM13A i4 * 0.49 NR * 0.04 NR FAM162A i1 **** 2.03E−84 NR *** 6.15E−83 NR FAM174A i2 *  0.001 NR *  0.0006 NR FBN2 i5 ** 5.89E−26 −0.69 ** 9.15E−22 −1.75 FER i13 ** 0.02 −1.81 *  0.001 −1.26 FHOD3 i21 * 2.20E−06 −0.60 * 2.48E−05 −1.23 FOCAD i6 * 0.01 NR * 1   NR GALC i6 *** 2.48E−07 −2.21 *** 2.31E−06 −2.14 GCFC2 i11 * 1   −1.34 * 0.18 −0.27 GGACT i2 * 0.24 NR * 0.49 NR GLCE i2 * 0.01 NR * 0.01 NR GOLGA4 i1 * 1   −0.24 * 0.31 −0.98 GOLGB1 i14 * 1   −1.32 * 1.24E−05 −1.24 GPSM2 i1 **  0.0004 NR * 0.14 NR GULP1 i1 ***  0.001 NR **  0.0006 NR GXYLT1 i7 * 4.54E−05 NR * 0.02 NR HDX i1 **** 1.66E−05 NR *** 1.11E−05 NR HLTF i14 * 1   −1.76 * 0.19 −1.75 HMGA2 i3 * 2.99E−06 NR *  0.003 NR HNMT i1 * 0.03 NR * 0.89 NR HSD17B12 i6 *** 3.41E−16 −2.92 ** 1.16E−39 −2.39 HSD17B4 i2 * 5.71E−06 NR *  0.002 NR HTT i49 ** 6.23E−08 −1.21 *** 2.98E−05 −1.86 IFT57 i5 * 2.26E−15 NR * 1.31E−18 NR IVD i7 * 6.58E−13 NR * 4.50E−12 NR KDM6A i26 ** 4.61E−14 NR ** 1.87E−11 NR KIAA1524 i11 * 0   −1.43 * 0   −0.62 KIAA1715 i6 * 0   −1.41 * 0    0.05 LETM2 i8 ** 5.73E−05 NR * 1   NR LOC400927 i3 **** 1.50E−07 NR *  0.004 NR LRRC42 i2 ** 8.25E−09 NR * 0.01 NR LUC7L3 i1 * 4.59E−06 NR *  0.003 NR LYRM1 i2 * 3.63E−06 NR * 4.98E−14 NR MB21D2 i *  0.007 NR *  0.002 NR MCM10 i15 *  0.0009 NR * 1   NR MED13L i3 * 1   −0.17 * 1   −1.11 MED13L i22 * 0.07 −0.17 * 1   −1.11 MEDAG i2 **  0.0004 −2.40 * 0.01 −1.60 MEMO1 i6 ** 2.42E−35 −1.30 * 5.11E−40 −0.56 MFN2 i1 **** 1.08E−90 NR *** 8.82E−42 NR MMS19 i2 * 0   −1.36 * 0   −1.75 MRPL45 i4 * 4.39E−11 NR * 1.75E−10 NR MRPS28 i2 * 1.43E−09 NR *  0.003 NR MTERF3 i3 * 1.38E−07 −1.63 * 1.74E−18 −0.19 MYCBP2 i80 * 2.71E−06 −0.36 * 0.04 −1.12 MYCBP2 i55 *** 1.44E−05 −0.36 ** 0.03 −1.12 MYLK i5 * 5.54E−09  0.23 * 3.75E−06 −1.10 MYOF i29 * 0.01 −0.82 *  0.003 −1.75 NGF i1 **** 1.75E−69 NR *** 2.47E−53 NR NREP i3 *  0.0002 −1.31 * 0.46 −0.10 NSUN4 i5 ** 1.90E−09 −1.48 * 1.80E−08 −0.67 NT5C2 i11 * 2.32E−11 −1.26 * 4.54E−07 −0.05 OSMR i3 *  0.004 −0.14 * 0.03 −0.97 OXCT1 i16 *  0.0005 NR * 0.46 NR PAPD4 i7 **** 2.37E−32 −2.33 **** 3.72E−52 −1.40 PCM1 i15 * 0.06 −1.30 * 0.10 −0.86 PDE7A i2 *** 1.46E−10 NR *** 3.25E−09 NR PDS5B i13 * 0.03 −0.42 * 0.03 −1.02 PDXDC1 i7 *** 1.09E−13 NR *** 4.13E−18 NR PIGN i22 ** 1.35E−20 NR * 1.27E−26 NR PIK3CD i3 ** 3.02E−06 NR * 0.32 NR PIK3R1 i2 * 0.02 −0.83 ** 6.81E−10 −1.06 PIKFYVE i12 * 0.02 NR *  0.002 NR PITPNB i7 * 1   −1.45 * 0.03 −1.17 PITPNB i7 * 4.52E−05 −1.45 * 2.70E−07 −1.17 PLEKHA1 i1 **  0.006 NR **  0.002 NR PLSCR1 i1 *  0.0008 NR * 1   NR PMS1 i5 **** 1.49E−07 −2.57 *** 3.56E−24 −1.02 POMT2 i13 **** 2.02E−40 NR **** 5.83E−53 NR PPARG i4 * 0.04 NR * 1   NR PPIP5K2 i13 * 4.52E−11 NR * 1.70E−05 NR PPP1R26 i3 ** 3.54E−09 NR *  0.0007 NR PRPF31 i11 ** 2.66E−39 NR * 8.15E−18 NR PRSS23 i3 * 9.82E−07 NR * 0.10 NR PSMA4 i4 * 1.45E−09 NR * 1.80E−20 NR PXK i1 * 8.38E−05 NR * 2.07E−06 NR RAF1 i7 * 4.10E−37 NR * 3.85E−24 NR RAPGEF1 i11 *** 1.30E−07 NR **** 5.56E−05 NR RARS2 i6 * 2.50E−20 NR * 5.90E−08 NR RBKS i1 **  0.0004 NR **  0.002 NR RERE i13 ** 3.04E−07  0.02 ** 3.70E−05 −1.06 RFWD2 i11 * 1.50E−13 −2.40 * 3.95E−16 −0.90 RPA1 i1 * 3.28E−12 NR *  0.006 NR RPS10 i5 * 9.72E−28 NR * 3.15E−20 NR SAMD4A i1 *  0.003 NR *  0.001 NR SAR1A i1 * 1.85E−48 NR * 8.33E−65 NR SCO1 i4 * 5.88E−07 NR * 6.67E−08 NR SEC24A i7 *  0.003 NR *  0.008 NR SENP6 i2 **** 5.51E−84 NR **** 3.10E−77 NR SERGEF i1 **** 0.14 −1.02 * 1   −0.81 SGK3 i1 *** 1.17E−08 NR ** 0.06 NR SLC12A2 i10 *** 7.56E−18 NR *  0.0008 NR SLC25A17 i2 *** 7.32E−38 NR *** 3.49E−74 NR SLC44A2 i21 * 1.56E−06  0.06 *  0.002 −0.99 SMYD3 i5 *  0.0001 −1.40 * 9.36E−06  0.33 SNAP23 i3 ****  6.29E−112 −2.82 ***  1.22E−150 −0.89 SNHG16 i1 * 1.92E−18 −1.68 * 5.75E−14 −0.99 SNX7 i7 * 3.44E−26 NR * 8.14E−24 NR SOS2 i19 ** 1.39E−10 NR * 2.76E−05 NR SPATA5 i10 * 1   NR * 0.27 NR SPIDR i1 * 3.23E−08 NR *  0.007 NR SPRYD7 i4 * 2.80E−05 NR * 7.62E−07 NR SRGAP1 i1 *  0.001 −0.16 *  0.0002 −0.99 SRRM1 i3 * 1    0.14 * 1   −1.05 STAT1 i21 * 7.01E−09 −3.06 * 7.52E−31 −1.86 STXBP6 i2 * 9.26E−08 NR * 1   NR STXBP6 i1 **** 6.15E−14 NR *** 2.75E−05 NR SUPT20H i24 * 5.05E−07 NR * 0.22 NR TAF2 i20 * 0   −1.03 * 0   −0.57 TAF2 i23 *** 6.92E−18   −1.02754 ** 3.95E−12 −0.57 TASP1 i13 *** 7.02E−08 NR ** 6.32E−05 NR TBC1D15 i5 * 0.12 NR * 1   NR TCF12 i3 * 1.21E−22 NR * 3.63E−15 NR TCF4 i4 * 3.51E−22 NR * 7.89E−07 NR TIAM1 i4 *** 0.05 NR * 1   NR TJP2 i1 * 0.02 NR * 0.25 NR TMC3 i2 ** 0.18 NR * 0.45 NR TMEM214 i8 * 1.97E−56 NR * 4.75E−07 NR TNRC6A i4 *** 1.38E−21 NR * 1.08E−10 NR TNS3 i23 **  0.0007 −2.76 *  0.007 −2.74 TOE1 i4 * 3.34E−05 NR *  0.002 NR TRAF3 i8 *  0.0004 −0.54 * 0.14 −0.97 TSPAN2 i4 *** 1.12E−18 −1.06 ** 1.81E−08 −0.58 TTC7B i5 * 3.09E−06 NR * 8.95E−05 NR TYW5 i1 *  0.0009 NR * 0.10 NR UBAP2L i24 ** 5.24E−52 NR * 1.43E−35 NR URGCP i1 * 0.15 NR * 0.32 NR VAV2 i4 ** 2.55E−08 NR ** 1.65E−07 NR WDR27 i2 **  0.003 NR * 1   NR WDR27 i9 **  0.008 NR ** 0.09 NR WDR37 i9 **  0.0009 NR ** 0.03 NR WDR91 i5 *** 7.69E−06 NR **  0.0006 NR WNK1 i23 * 0.01     0.071985 * 1   −1.26 XRN2 i3 * 1     −1.29088 * 1   −0.55 XRN2 i16 * 3.25E−07   −1.29088 * 1.05E−08 −0.55 ZCCHC8 i11 * 5.24E−10 NR * 4.65E−08 NR ZFP82 i4 ** 9.95E−06 NR ** 1.56E−08 NR ZNF138 i3 ***  0.025 NR * 0.07 NR ZNF232 i4 * 0.23 NR * 0.02 NR ZNF37BP i4 ****  0.003 NR *** 0.03 NR

Results: The statistically significant value for the likelihood of exon inclusion (APSI) according to the Fisher's Exact Test (FET) for PNN and HDF cell lines treated with Compound 774 at 3 μM and Fold Decrease (FD) for certain genes tested, where NR represents “Not Reported,” is shown in Table 10a.

The APSI for inclusion of an exon and resulting modulated expression of RNA transcripts identified is represented by stars, where one star (*) represents ≤25% change in expression, where two stars (**) represent change in expression in a range from <26% to ≤50% change, where three stars (***) represent change in expression in a range from <51% to ≤75% change, and, where four stars (****) represent change in expression in a range from <75% to ≤100% change.

TABLE 10a FET FET Inclusion ΔPSI ΔPSI FD ΔPSI ΔPSI FD Gene Symbol Position (PNN) (PNN) PNN (HDF) (HDF) HDF APLP2 e7 ** 0   NR **  2.69E−271 NR AXIN1 e9 **  0.004 NR * 1   NR CECR7 e5 * 0.02 NR * 1   NR DAGLB c4 * 0.74 NR * 0.43 NR DLGAP4 e8 * 1.12E−13 NR * 1.12E−07 NR ERCC1 e8 *  0.0009 NR * 0.20 NR ERGIC3 e8 *  1.44E−220 NR *  2.39E−209 NR FAM198B e3 *  0.003 −1.81 * 0.20 −0.35 GGCT e2 ** 1.36E−30 NR ** 5.86E−45 NR HAT1 e3 * 6.50E−11 NR * 1.34E−10 NR HPS1 e5 * 0.01 NR * 0.34 NR INPP5K e2 * 0.53 NR * 0.14 NR MADD e21 * 2.28E−08 NR * 7.00E−07 NR PPHLN1 e3 *** 8.22E−83 NR ** 8.90E−66 NR PRUNE2 e18 * 0.52 −0.52 ** 0.05 −1.74 RAP1A e2 * 3.80E−15 NR * 4.27E−07 NR RNFT1 e3 * 0.02 NR * 6.02E−07 NR RPS6KB2 e2 * 0.14 NR * 1   NR SH3YL1 e9 *  0.009 NR * 0.08 NR SKA2 e3 *  0.0001 NR * 0.05 NR SPATA18 e4 ** 1.50E−05 NR * 0.29 NR STRN3 e8 **** 4.13E−54 NR *** 4.39E−44 NR TMEM189- e6 * 2.19E−30 NR * 4.66E−20 NR UBE2V1 TRIM65 e5 *** 2.49E−11 NR **  0.0002 NR TUBE1 e4 * 7.36E−05 NR * 2.05E−10 NR UBE2V1 e3 * 2.19E−30 NR * 4.66E−20 NR VPS29 e2 ** 3.05E−17 NR ** 2.61E−38 NR ZNF680 e3 * 0.13 NR * 0.32 NR

Details on the location of the iExon produced in affected genes from Table 10 are shown in Table 11.

TABLE 11 Gene Symbol Ref SeqID Coordinates Description ABCB8 NM_007188 chr7: 150728328- ATP-binding cassette, sub-family B 150728378 (MDR/TAP), member 8 ABCC3 NM_003786 chr17: 48767318- ATP-binding cassette, sub-family C 48767437 (CFTR/MRP), member 3 ADAM17 NM_003183 chr2: 9683889- ADAM metallopeptidase domain 17 9683825 ADCY3 NM_004036 chr2: 25061781- adenylate cyclase 3 25061716 AGPAT4 NM_020133 chr6: 161687802- 1-acylglycerol-3-phosphate O-acyltransferase 4 161687740 ANKRA2 NM_023039 chr5: 72851082- ankyrin repeat, family A (RFXANK-like), 2 72850950 ANXA11 NM_001278407 chr10: 81916254- annexin A11 81916134 APIP NM_015957 chr11: 34933660- APAF1 interacting protein 34933520 APLP2 NM_001642 chr11: 129993507- amyloid beta (A4) precursor-like protein 2 129993674 APPL2 NM_018171 chr12: 105625422- adaptor protein, phosphotyrosine interaction, PH 105625147 domain and leucine zipper containing 2 ARHGAP1 NM_004308 chr11: 46718619- Rho GTPasc activating protein 1 46718571 ARL15 NM_019087 chr5: 53212951- ADP-ribosylation factor-like 15 53212826 ASAP1 NM_001247996 chr8: 131173039- ArfGAP with SH3 domain, ankyrin repeat and 131173031 PH domain 1 ASAP1 NM_001247996 chr8: 131135828- ArfGAP with SH3 domain, ankyrin repeat and 131135650 PH domain 1 ASAP1 NM_001247996 chr8: 131135731- ArfGAP with SH3 domain, ankyrin repeat and 131135650 PH domain 1 ASAP1 NM_001247996 chr8: 131173046- ArfGAP with SH3 domain, ankyrin repeat and 131173031 PH domain 1 ASPH NM_004318 chr8: 62,421,470- aspartate beta-hydroxylase 62,421,527 ATAD2B NM_001242338 chr2: 23976387- ATPase family, AAA domain containing 2B 23976214 ATXN1 NM_000332 chr6: 16409524- ataxin 1 16409426 AXIN1 NM_003502 chr16: 341297- axin 1 341190 BECN1 NM_003766 chr17: 40963348- beclin 1, autophagy related 40963310 BHMT2 NM_017614 chr5: 78374568- betaine--homocysteine S-methyltransferase 2 78374655 BICD1 NM_001714 chr12: 32486172- bicaudal D homolog 1 (Drosophila) 32486263 BTN3A1 NM_001145008 chr6: 26404363- butyrophilin, subfamily 3, member Al 26404455 C11orf30 NM_020193 chr11: 76259972- chromosome 11 open reading frame 30 76260061 C11orf73 NR 024596 chr11: 86037555- chromosome 11 open reading frame 73 86037718 C12orf4 NM_020374 chr12: 4646680- chromosome 12 open reading framc 4 4646546 C14orf132 NM_001252507 chr14: 96506612- chromosome 14 open reading frame 132 96506704 C8orf44 NM_019607 chr8: 67588980- chromosome 8 open reading frame 44 67589137 C8orf44-SGK3 NM_001204173 chr8: 67697924- C8orf44-SGK3 readthrough 67698031 C8orf88 NM_001190972 chr8: 91990874- chromosome 8 open reading frame 88 91990807 CASC3 NM_007359 chr17: 38298307- cancer susceptibility candidate 3 38298353 CASP7 NM_033340 chr10: 115477382- caspase 7, apoptosis-related cysteine peptidase 115477512 CCDC122 NM_144974 chr13: 44431087- coiled-coil domain containing 122 44431054 CDH13 NM_001220488 chr16: 83402146- cadherin 13 83402179 CECR7 NM_014339 chr22: 17,535,915- cat eye syndrome chromosome region, candidate 17,535,996 7 (non-protein coding) CECR7 NR 015352 chr22: 17535855- cat eye syndrome chromosome region, candidate 17535996 7 (non-protein coding) CENPI NM_006733 chrX: 100411511- centromere protein I 100411544 CEP112 NM_001199165 chr17: 63684725- centrosomal protein 112kDa 63684629 CEP192 NM_032142 chr18: 13038514- centrosomal protein 192kDa 13038578 CHEK1 NM_001114121 chr11: 125526101- checkpoint kinase 1 125526230 CMAHP NR 002174 chr6: 25107418- cytidine monophospho-N-acetylneuraminic acid 25107336 hydroxylase, pseudogene CNRIP1 NM_001111101 chr2: 68542975- cannabinoid receptor interacting protein 1 68542840 CNRIP1 NM_000945 chr2: 68,542,833- cannabinoid receptor interacting protein 1 68,542,986 COPS7B NM_001282950 chr2: 232655806- COP9 signalosome subunit 7B 232655883 CPSF4 NM_006693 chr7: 99045396- cleavage and polyadenylation specific factor 4, 99045536 30kDa CRISPLD2 NM_031476 chr16: 84869783- cysteine-rich secretory protein LCCL domain 84870041 containing 2 CRYBG3 NM_153605 chr3: 97635177- beta-gamma crystallin domain containing 3 97635237 CSNK1E NM_001289912 chr22: 38766050- casein kinase 1, epsilon 38765991 CSNK1G1 NM_022048 chr15: 64575350- casein kinase 1, gamma 1 64575317 DAGLB NM_139179 chr7: 6474651- diacylglycerol lipasc, beta 6474425 DCAF17 NM_025000 chr2: 172298369- DDB1 and CUL4 associated factor 17 172298546 DCAF17 NM_025000 chr2: 172309926- DDB1 and CUL4 associated factor 17 172309987 DCUN1D4 NM_001040402 chr4: 52775086- DCN1, defective in cullin neddylation 1, 52775141 domain containing 4 DDX42 NM_007372 chr17: 61883354- DEAD (Asp-Glu-Ala-Asp) box helicase 42 61883511 DENND1A NM_020946 chr9: 126385380- DENN/MADD domain containing 1A 126385322 DENND5A NM_015213 chr11: 9227781- DENN/MADD domain containing 5A 9227736 DENND5A NM_015213 chr11: 9198449- DENN/MADD domain containing 5A 9198319 DGKA NM_201445 chr12: 56333603- diacylglycerol kinasc, alpha 80kDa 56333699 DHFR NM_000791 chr5: 79929807- dihydrofolate reductase 79929696 DHFR NM_000791 chr5: 79928121- dihydrofolate reductase 79928051 DIAPH3 NM_001042517 chr13: 60266972- diaphanous-related formin 3 60266851 DIAPH3 NM_001042517 chr13: 60548266- diaphanous-related formin 3 60548219 DLGAP4 NM_014902 chr20: 35127645- discs, large (Drosophila) homolog-associated 35127724 protein 4 DNAJC13 NM_015268 chr3: 132227720- DnaJ (Hsp40) homolog, subfamily C, member 132227883 13 DNM_BP NM_015221 chr10: 101762780- dynamin binding protein 101762699 DNM_BP NM_015221 chr10: 101654399- dynamin binding protein 101654318 DOCK1 NM_001380 chr10: 128901890- dedicator of cytokinesis 1 128901944 DYRK1A NM_101395 chr21: 38794884- dual-specificity tyrosine-(Y)-phosphorylation 38794954 regulated kinase 1A EIF2B3 NM_020365 chr1: 45350395- eukaryotic translation initiation factor 2B, 45350311 subunit 3 gamma, 58kDa ENAH NM_001008493 chr1: 225788060- enabled homolog (Drosophila) 225787910 ENOX1 NM_017993 chr13: 43,984,307- ecto-NOX disulfide-thiol exchanger 1 43,984,398 EP300 NM_001429 chr22: 41496302- E1A binding protein p300 41496407 ERC1 NR 027948 chr12: 1536281- ELKS/RAB6-interacting/CAST family member 1536343 1 ERCC1 NM_001983 chr19: 45917292- excision repair cross-complementation group 1 45917221 ERGIC3 NM_198398 chr20: 34142143- ERGIC and golgi 3 34142157 ERLIN2 NM_007175 chr8: 37594849- ER lipid raft associated 2 37594946 ERRFI1 NM_018948 chr1: 8,080,640- ERBB receptor feedback inhibitor 1 8,080,926 EVC NM_153717 chr4: 5743061- Ellis van Creveld protein 5743168 FAF1 NM_007051 chr1: 51003153- Fas (TNFRSF6) associated factor 1 51003085 FAIM NM_001033030 chr3: 138335412- Fas apoptotic inhibitory molecule 138335506 FAM126A NM_032581 chr7: 23011932- family with sequence similarity 126, member A 23011871 FAM13A NM_014883 chr4: 89890343- family with scquence similarity 13, member A 89890310 FAM162A NM_014367 chr3: 122120223- family with sequence similarity 162, member A 122120382 FAM174A NM_198507 chr5: 99917051- family with sequence similarity 174, member A 99917108 FAM198B NM_001031700 chr4: 159091499- family with sequence similarity 198, member B 159091399 FBN2 NM_001999 chr5: 127850450- fibrillin 2 127850370 FER NM_005246 chr5: 108321155- fer (fps/fes related) tyrosine kinase 108321188 FHOD3 NM_001281740 chr18: 34322340- formin homology 2 domain containing 3 34322431 FOCAD NM_017794 chr9: 20737106- focadhesin 20737152 GALC NM_001201402 chr14: 88447791- galactosylceramidase 88447758 GCFC2 NM_003203 chr2: 75913102- GC-rich sequence DNA-binding factor 2 75913000 GGACT NM_001195087 chr13: 101194723- gamma-glutamylamine cyclotransferase 101194628 GGCT NM_001199815 chr7: 30540297- gamma-glutamylcyclotransferase 30540152 GLCE NM_015554 chr15: 69517534- glucuronic acid epimerase 69517591 GOLGA4 NM_002078 chr3: 37285619- golgin A4 37285734 GOLGB1 NM_001256486 chr3: 121401810- golgin B1 121401764 GPSM2 NM_013296 chr1: 109420153- G-protein signaling modulator 2 109420396 GULP1 NM_001252668 chr2: 189164835- GULP, engulfment adaptor PTB domain 189164866 containing 1 GXYLT1 NM_173601 chr12: 42489016- glucoside xylosyltransferase 1 42488953 HAT1 NM_003642 chr2: 172803228- histone acetyltransferase 1 172803303 HDX NM_001177479 chrX: 83756519- highly divergent homeobox 83756437 HLTF NM_139048 chr3: 148769931- helicase-like transcription factor 148769832 HMGA2 NM_003483 chr12: 66267911- high mobility group AT-hook 2 66267926 HNM_T NM_006895 chr2: 138724667- histamine N-methyltransferase 138724956 HPS1 NM_000195 chr10: 100195171- Hermansky-Pudlak syndrome 1 100195029 HSD17B12 NM_016142 chr11: 43838189- hydroxystcroid (17-bcta) dchydrogenasc 12 43838222 HSD 17B4 NM_001199291 chr5: 118792986- hydroxysteroid (17-beta) dehydrogenase 4 118793063 HTT NM_002111 chr4: 3215349- huntingtin 3215463 IFT57 NM_018010 chr3: 107911373- intraflagellar transport 57 107911323 INPP5K NM_001135642 chr17: 1419412- inositol polyphosphate-5-phosphatase K 1419182 IVD NM_002225 chr15: 40706629- isovaleryl-CoA dehydrogenase 40706723 KDM6A NM_021140 chrX: 44965787- lysine (K)-specific demethylase 6A 44965894 KIAA1524 NM_020890 chr3: 108284925- KIAA1524 108284745 KIAA1715 NM_030650 chr2: 176835145- KIAA1715 176834927 LETM2 NM_001286787 chr8: 38262801- leucine zipper-EF-hand containing 38262912 transmembrane protein 2 LOC400927 NR 002821 chr22: 38766050- TPTE and PTEN homologous inositol lipid 38765991 phosphatase pseudogene LRRC42 NM_001256409 chr1: 54413535- leucine rich repeat containing 42 54413654 LUC7L3 NM_006107 chr17: 48798190- LUC7-like 3 pre-mRNA splicing factor 48798241 LYRM1 NM_001128301 chr16: 20922505- LYR motif containing 1 20922586 MADD NM_003682 chr11: 47314094- MAP-kinase activating death domain 47314147 MB21D2 NM_178496 chr3: 192555098- Mab-21 domain containing 2 192555020 MCM10 NM_182751 chr10: 13239941- minichromosome maintenance complex 13240039 component 10 MED13L NM_015335 chr12: 116547674- mediator complex subunit 13-like 116547579 MED13L NM_015335 chr12: 116419435- mediator complex subunit 13-like 116419344 MEDAG NM_032849 chr13: 31492953- mesenteric estrogen-dependent adipogenesis 31493127 MEMO1 NM_015955 chr2: 32112156- Methylation modifier for class I HLA 32112104 MFN2 NM_014874 chr1: 12041867- mitofusin 2 12041910 MMS19 NM_022362 chr10: 99241240- MMS19 homolog, cytosolic iron-sulfur 99241106 assembly component MRPL45 NM_032351 chr17: 36468550- mitochondrial ribosomal protein L45 36468624 MRPS28 NM_014018 chr8: 80915355- mitochondrial ribosomal protein S28 80915234 MTERF3 NM_001286643 chr8: 97263851- mitochondrial transcription termination factor 3 97263810 MYCBP2 NM_015057 chr13: 77628142- MYC binding protein 2, E3 ubiquitin protein 77628054 ligase MYCBP2 NM_015057 chr13: 77692630- MYC binding protein 2, E3 ubiquitin protein 77692475 ligase MYLK NM_053025 chr3: 123459382- myosin light chain kinase 123459323 MYOF NM_013451 chr10: 95117679- myoferlin 95117562 NGF NM_002506 chr1: 115843104- nerve growth factor (beta polypeptide) 115843018 NREP NM_001142476 chr5: 111086122- neuronal regeneration related protein 111086049 NSUN4 NR 045789 chr1: 46823248- NOP2/Sun domain family, member 4 46823331 NT5C2 NM_012229 chr10: 104853974- 5′-nucleotidase, cytosolic II 104853926 OSMR NM_003999 chr5: 38876877- oncostatin M receptor 38876923 OXCT1 NM_000436 chr5: 41734751- 3-oxoacid CoA transferase 1 41734677 PAPD4 NM_173797 chr5: 78937278- PAP associated domain containing 4 78937340 PCM1 NM_006197 chr8: 17818551- pericentriolar material 1 17818653 PDE7A NM_001242318 chr8: 66693182- phosphodiesterase 7A 66693079 PDS5B NM_015032 chr13: 33263018- PDS5 cohesin associated factor B 33263158 PDXDC1 NM_001285447 chr16: 15103356- pyridoxal-dependent decarboxylase domain 15103418 containing 1 PIGN NM_176787 chr18: 59764997- phosphatidylinositol glycan anchor biosynthesis, 59764914 class N PIK3CD NM_005026 chr1: 9774095- phosphatidylinositol-4,5-bisphosphate 3-kinase, 9774189 catalytic subunit delta PIK3R1 NM_181523 chr5: 67538784- phosphoinositide-3-kinase, regulatory subunit 1 67538973 (alpha) PIKFYVE NM_015040 chr2: 209176229- phosphoinositide kinase, FYVE finger 209176294 containing PITPNB NM_012399 chr22: 28288318- phosphatidylinositol transfer protein, beta 28288117 PITPNB NM_012399 chr22: 28290410- phosphatidylinositol transfer protein, beta 28290364 PLEKHA1 NM_001195608 chr10: 124148798- pleckstrin homology domain containing, family 124148900 A (phosphoinositide binding specific) member 1 PLSCR1 NM_021105 chr3: 146255831- phospholipid scramblasc 1 146255783 PMS1 NM_000534 chr2: 190683464- PMS1 homolog 1, mismatch repair system 190683555 component POMT2 NM_013382 chr14: 77753614- protein-O-mannosyltransferase 2 77753576 PPARG NM_138712 chr3: 12427535- peroxisome proliferator-activated receptor 12427591 gamma PPHLN1 NM_016488 chr12: 42745687- periphilin 1 42745851 PPIP5K2 NM_015216 chr5: 102492916- diphosphoinositol pentakisphosphate kinase 2 102492948 PPP1R26 NM_014811 chr9: 138376071- protein phosphatase 1, regulatory subunit 26 138376135 PRPF31 NM_015629 chr19: 54632112- pre-mRNA processing factor 31 54632180 PRSS23 NR 120591 chr11: 86651889- protease, serine, 23 86652069 PRUNE2 NM_015225 chr9: 79234303- prune homolog 2 (Drosophila) 79234256 PSMA4 NM_001102667 chr15: 78834921- proteasome subunit alpha 4 78834987 PXK NM_017771 chr3: 58321084- PX domain containing serine/threonine kinase 58321179 RAF1 NM_002880 chr3: 12645036- Raf-1 proto-oncogene, serine/threonine kinase 12644977 RAP1A NM_001010935 chr1: 112170092- RAP1A, member of RAS oncogene family 112170148 RAPGEF1 NM_005312 chr9: 134479440- Rap guanine nucleotide exchange factor 134479348 (GEF) 1 RARS2 NM_020320 chr6: 88257102- arginyl-tRNA synthetase 2, mitochondrial 88256965 RBKS NM_001287580 chr2: 28111807- ribokinasc 28111741 RERE NM_012102 chr1: 8456591- arginine-glutamic acid dipeptide (RE) repeats 8456504 RFWD2 NM_022457 chr1: 176044514- ring finger and WD repeat domain 2, E3 176044399 ubiquitin protein ligase RNFT1 NM_016125 chr17: 58039977- ring finger protein, transmembrane 1 58039901 RPA1 NM_002945 chr17: 1745069- replication protein A1, 70kDa 1745127 RPS10 NM_001204091 chr6: 34385627- ribosomal protein S10 34385575 RPS6KB2 NM_003952 chr11: 67196453- ribosomal protein S6 kinase, 70kDa, polypeptide 67196493 2 SAMD4A NM_015589 chr14: 55115465- sterile alpha motif domain containing 4A 55115566 SAR1A NM_001142648 chr10: 71926149- secretion associated, Ras related GTPasc 1A 71926032 SCO1 NM_004589 chr17: 10594966- SCO1 cytochrome c oxidase assembly protein 10594907 SEC24A NM_021982 chr5: 134013731- SEC24 homolog A, COPII coat complex 134013842 component SENP6 NM_015571 chr6: 76331643- SUMO1/sentrin specific peptidase 6 76331687 SERGEF NR 104040 chr11: 18031686- secretion regulating guanine nucleotide 18031622 exchange factor SGK3 NM_001033578 chr8: 67697924- serum/glucocorticoid regulated kinase family, 67698031 member 3 SH3YL1 NM_015677 chr2: 224920- SH3 and SYLF domain containing 1 224868 SKA2 NM_182620 chr17: 57196856- spindle and kinetochore associated complex 57196757 subunit 2 SLC12A2 NM_001046 chr5: 127478818- solute carrier family 12 127478874 (sodium/potassium/chloride transporter), member 2 SLC25A17 NM_006358 chr22: 41193340- solute carrier family 25 (mitochondrial carrier; 41193288 peroxisomal membrane protein, 34kDa), member 17 SLC44A2 NM_001145056 chr19: 10753573- solute carrier family 44 (choline transporter), 10753697 member 2 SMYD3 NM_001167740 chr1: 246394576- SET and MYND domain containing 3 246394501 SNAP23 NM_003825 chr15: 42805372- synaptosomal-associated protein, 23kDa 42805407 SNHG16 NR 038109 chr17: 74554456- small nucleolar RNA host gene 16 74554545 SNX7 NR 033716 chr1: 99204216- sorting nexin 7 99204359 SOS2 NM_006939 chr14: 50600608- son of sevenless homolog 2 (Drosophila) 50600526 SPATA18 NM_145263 chr4: 52928386- spermatogenesis associated 18 52928498 SPATA5 NM_145207 chr4: 123901321- spermatogenesis associated 5 123901384 SPIDR NM_001080394 chr8: 48185929- scaffolding protein involved in DNA repair 48186042 SPRYD7 NM_020456 chr13: 50492357- SPRY domain containing 7 50492229 SRGAP1 NM_020762 chr12: 64319388- SLIT-ROBO Rho GTPasc activating protein 1 64319457 SRRM1 NM_005839 chr1: 24973570- serine/arginine repetitive matrix 1 24973640 STAT1 NM_007315 chr2: 191843332- signal transducer and activator of 191843254 transcription 1, 91kDa STRN3 NM_001083893 chr14: 31398517- striatin, calmodulin binding protein 3 31398407 STXBP6 NM_014178 chr14: 25411028- syntaxin binding protein 6 (amisyn) 25410930 STXBP6 NM_014178 chr14: 25457178- syntaxin binding protein 6 (amisyn) 25457092 SUPT20H NM_001014286 chr13: 37585794- suppressor of Ty 20 homolog (S. cerevisiae) 37585696 TAF2 NM_003184 chr8: 120771346- TAF2 RNA polymerase II, TATA box binding 120771264 protein (TBP)-associated factor, 150kDa TAF2 NM_003184 chr8: 120757276- TAF2 RNA polymerase II, TATA box binding 120757121 protein (TBP)-associated factor, 150kDa TASP1 NM_017714 chr20: 13395909- taspase, threonine aspartase, 1 13395770 TBC1D15 NM_022771 chr12: 72278640- TBC1 domain family, member 15 72278801 TCF12 NM_207037 chr15: 57227695- transcription factor 12 57227728 TCF4 NM_001243226 chr18: 53202868- transcription factor 4 53202790 TIAM1 NM_003253 chr21: 32641011- T-cell lymphoma invasion and metastasis 1 32640727 TJP2 NM_004817 chr9: 71792959- tight junction protein 2 71793045 TMEM189- NM_199203 chr20: 48713357- TMEM189-UBE2V1 readthrough UBE2V1 48713209 TMEM214 NM_017727 chr2: 27260130- transmembrane protein 214 27260168 TNRC6A NM_014494 chr16: 24769760- trinucleotide repeat containing 6A 24769920 TMC3 NR 120365 chr15: 81633491- transmembrane channel like 3 81633560 TNS3 NM_022748 chr7: 47337036- tensin 3 47336903 TOE1 NM_025077 chr1: 45807382- target of EGR1, member 1 (nuclear) 45807415 TRAF3 NM_145725 chr14: 103356688- TNF receptor-associated factor 3 103356763 TRIM65 NM_173547 chr17: 73887959- tripartite motif containing 65 73887894 TSPAN2 NM_005725 chr1: 115601892- tetraspanin 2 115601858 TTC7B NM_001010854 chr14: 91171677- tetratricopeptide repcat domain 7B 91171544 TUBE1 NM_016262 chr6: 112405449- tubulin, epsilon 1 112405392 TYW5 NR 004862 chr2: 200813345- tRNA-yW synthesizing protein 5 200813295 UBAP2L NM_001287816 chr1: 154234649- ubiquitin associated protein 2-like 154234678 UBE2V1 NM_199144 chr20: 48713357- ubiquitin-conjugating enzyme E2 variant 1 48713209 URGCP NM_001077664 chr7: 43945050- upregulator of cell proliferation 43944971 VAV2 NM_001134398 chr9: 136698500- vav 2 guanine nucleotide exchange factor 136698469 VPS29 NM_057180 chr12: 110937351- VPS29 retromer complex component 110937340 WDR27 NM_182552 chr6: 170087077- WD repeat domain 27 170087013 WDR27 NM_182552 chr6: 170061846- WD repeat domain 27 170061799 WDR37 NM_014023 chr10: 1148398- WD repeat domain 37 1148517 WDR91 NM_014149 chr7: 134890341- WD repeat domain 91 134890209 WNK1 NM_018979 chr12: 1004327- WNK lysine deficient protein kinase 1 1004362 XRN2 NM_012255 chr20: 21307793- 5′-3′ exoribonuclease 2 21307903 XRN2 NM_012255 chr20: 21326472- 5′-3′ exoribonuclease 2 21326525 ZCCHC8 NM_017612 chr12: 122963343- zinc finger, CCHC domain containing 8 122963211 ZFP82 NM_133466 chr19: 36891305- ZFP82 zinc finger protein 36891187 ZNF138 NM_001160183 chr7: 64277652- zinc finger protein 138 64277713 ZNF232 NM_014519 chr17: 5012080- zinc finger protein 232 5012041 ZNF37BP NR 026777 chr10: 43046910- zinc finger protein 37B, pscudogene 43046848 ZNF680 NM_178558 chr7: 64002295- zinc finger protein 680 64002108

The sequences for iExons produced in certain affected genes at the indicated coordinates from Table 11 are shown in Table 12. In certain instances, detection and analysis of the amount and type of iExon sequences are useful biomarkers produced as a result of contacting a cell with a compound as described herein or administering to a subject in need thereof a compound as described herein.

TABLE 12 Gene Symbol Coordinates Sequence ABCC3 chr17:48767318- GGCCCATAGGAAGGACGCAAAGGCCTGTGTGTGCAGGCC 48767437 AGAAAAAGGCTATCCACACAGGGTGGCCAGGACACTTTCT CCTGTAAGGAAGGGATGCACCAGCCAGGCCTGAAAGAAT GA (SEQ ID NO: 3695) ADCY3 chr2:25061781- CGGATCAAAGATTGAAGAAAGATTGTACTCCTGTGTCGTG 25061716 GCTCCAACACTGAGGCTGAGATGGGA (SEQ ID NO: 3696) AGPAT4 chr6:161687802- GATACTGCAGCCATCAGCAGACAATCAATGCAATCATCTC 161687740 AGACTGTGTCCTGCGTCCCAGGA (SEQ ID NO: 3697) ANKRA2 chr5:72851082- AAGTACTGTCAGCTTTGAAGGAGAAGGCTTCATGGAGGAG 72850950 CTGTGACTTGACTCCAGAGTGAAAGGATAATTAGGATTGA TACAGGACGGAGGAAGGAAGGCATCCAGGCAATCTCAAT AAAAGCATCCATGA (SEQ ID NO: 3698) ANXA11 chr10:81916254- AGTATCTCCTGCATGCCAGCAAGCTATGGACATCTGGAAG 81916134 AAGCCACATGCCTTGCCCTCAAGTTGCTTAGGGTGGAAGG AAATGATTAGAAATGAGCCAAGCCGAGCCTGCACTCTTAG A (SEQ ID NO: 3699) APIP chr11:34933660- CTCTGAAATTAAATCCCTACTGACTGGCCCTTGAACTGATT 34933520 TTTTCTAACATCAGCAAAAGTCAAGGAGTGTTTCCCTAAA AAAGAAAGCATTTACTCAGAAACCGTATATTGAAGTCCAG GCTGAAAAATGCAAACATGA (SEQ ID NO: 3700) APPL2 chr12:105625422- TCAGGGCTGTACGCTGTGGACCAAAGATCATGCTCGCTGA 105625147 TGAGAGCCACCCTGCTGGTGACCTCAGTGCTGCCGACCCA TTTACATCCCAGCCCTGCCACATTCCTACAGTGGGAGGTT GAACACATTTCTTAACCTTGATGAGCCTCAGTTTCATCATC AGTAAAATGAAGTTAATGGAACCATGGAATCTACCTTGGA GAGTTGCTAGAAGAATTAAATGAAGTCACATATGTTTAGT GCCCAGCACAGCGTCCAGCACATAGGTGGTACAGA (SEQ ID NO: 3701) ARHGAP1 chr11:46718619- GGCCGTCAACCTTTCCACCTTGAAACTGGTGTCAGGAGCA 46718571 CCCTGCAGA (SEQ ID NO: 3702) ASAP1 chr8:131173039- GTTGTTGCAGCTGCGCACCTGCTCTGTGAAGCACAGATTG 131173031 TCATGGGGGCAGTTCTCTCAAAAACATGGCATATTGTGAT GA (SEQ ID NO: 3703) ASAP1 chr8:131135828- AGCAAACCCCATTGTCAGGGGAAAGCAGAACAAAGAAAA 131135650 GTATTTAGAAATGTATTTCCGGGATGCACAGATTCTTTTCA CCCTCACCTTCCCCTAGGTTGTTGCAGCTGCGCACCTGCTC TGTGAAGCACAGATTGTCATGGGGGCAGTTCTCTCAAAAA CATGGCATATTGTGATGA (SEQ ID NO: 3704) ASAP1 chr8:131135731- TCTAGGAGA (SEQ ID NO: 3705) 131135650 ASAP1 chr8:131173046- ATCGAAGTCTAGGAGA (SEQ ID NO: 3706) 131173031 ASPH chr8:62,421,470- TCATTCTGATCTACTGAAATTCCCCAGTTCAGACTCCATTG 62,421,527 AAAGCCCTGGGATGGCA (SEQ ID NO: 3707) ATAD2B chr2:23976387- GTCATCTGAGCAAATGTAATCACTCATCTACCCACAAAAT 23976214 GGCTAAATGACTTAATTCAACTCCCTTTGTTGATTTGCCTG TTAGTTTGTTTATCTGGTGGTCTATCTATTAAATGTTTATTG AGTACCTGCAGTGCCAGATGCTGTGCTGGGTGTTTGGAAT GCAAAAAATGA (SEQ ID NO: 3708) ATXN1 chr6:16409524- TTTCATAAAGAGGACAGACGCTAAGGCAATTGTGTGGAAC 16409426 AGAGCAGCTTCTCGGGGTAACCATCTCCTGCTGATGTATA AATATCGGGGCAAAACTGA (SEQ ID NO: 3709) BECN1 chr17:40963348- GATCCCATTGATGGATGGAAACTCTAGTTTTTACTTAGA 40963310 (SEQ ID NO: 3710) BHMT2 chr5:78374568- GATGTTTTCATCTGGCCCAAGAAGAACTTGTTCTTAATGTT 78374655 AAAAGACCTTTTTGCTAAACTGGGAAGAAAGTGCTGGAAT AACAAGA (SEQ ID NO: 3711) BICD1 chr12:32486172- GTCAATTTCTGCCTTGTGGATAATTTTCTGAATCTGTAATA 32486263 TTTCTGAAGATTCCTCCAAGTATTTACAGAACATACAGAA GTATTTTATGA (SEQ ID NO: 3712) BTN3A1 chr6:26404363- ATCTTGTTCTCAGAGGCCATTCCCAGACCCACAGCAAGAG 26404455 GGATTATGGCTGCAGGCCTCATGCTCCTTTGTTTTGGAAGA AACTGTTGAGGA (SEQ ID NO: 3713) C11orf30 chr11:76259972- GCCTTGTTCAAAGCTCTGGGCATCTAGCAATGAGTAAGAT 76260061 AGTCAAGATCTGTGCTCTGTCCACGTTCTCTTGGAGCTTAC ATTTTAAGA (SEQ ID NO: 3714) C11orf73 chr11:86037555- GTAATTATTGAACATCTACTTGCTGCCTACTTTCAACATCT 86037718 GCATGTGTGTGTGAATATTAAATATCACACCAAGACATTG TTCAGAGGAGACAGAATAGTGAGCTGAGATAAATGAGAA TCTCTCTATGGAAGATTAGACTGGAGCATGAACTTGAAAT ATGA (SEQ ID NO: 3715) C14orf132 chr14:96506612- AACAAAGACAAATCCCGGATTTCTCCATCAGTCTGTGACC 96506704 CTAGAGAAGACCCAGAGCTGGCTCCAGGGAAGGGCTGCG TTTGGCCTGGGAGA (SEQ ID NO: 3716) C8orf88 chr8:91990874- TGTTCCCTTTCAACTTTCAAAACGAATATCCATGCAACACT 91990807 CAGTGCATACAAAGTGGAGTTAGCAGA (SEQ ID NO: 3717) CASC3 chr17:38298307- GAGAAAGTTTCCTGTCTTTTGGATAAACTACTAGAGATGC 38298353 CATCAGA (SEQ ID NO: 3718) CASP7 chr10:115477382- GGTTGCAGAGAGCACTGGTTGAAGCCTATCCTGAAGCTAC 115477512 CTTGGTAGAGGAGTTAATTGCACCAGGAGACCTAATTTCA GAAAGGTCACAGATTATATTCCACCCTCCACAAAAGTAAC CTGGAAGATGA (SEQ ID NO: 3719) CCDC122 chr13:44431087- TAACATATTTTATTGAGGTATAATTGTCATAAGA (SEQ ID 44431054 NO: 3720) CDH13 chr16:83402146- GTTTTTTGGGAACAGGTGGTGTTTGGTTACATGA (SEQ ID 83402179 NO: 3721) CECR7 chr22:17,535,915- CGAGAGGAAGAGGAGAAGCATGCAGGAGTGTACATGAAA 17,535,996 CAAGATTGGCCACGAGATGACAAATATCTGAATCCGCTGA TGA (SEQ ID NO: 3722) CEP112 chr17:63684725- AACCAACTTCAAGATGGCTGCAGCAGTGCCAGGCATTCTG 63684629 CCCAGATCTGCACTATTCGGAGGCAGAAAAGGGCTGCCAG TTTCTAGGGCCTAATGA (SEQ ID NO: 3723) CMAHP chr6:25107418- AATGAACACTCCATGAGAGCAGGGACCTGCTTTGCCTTGT 25107336 TCACCACTTTATTCCCAGTGGCTAGAACCACGTCTGACAC AGA (SEQ ID NO: 3724) CNRIP1 chr2:68,542,833- GTCTTACTCTTGTCACCGAGGCTGGAGTGCAGTGGTGTGA 68,542,986 TCATAGCTCACTGCAGCCTCAACCTCCTGGATCCAAGTGA TCCTCCTGCCTCAGCCTCCCAAGTTGCTGGCACTACAGGTG TGGTATCACCACACCCGGTTAACTAAAAAAAAT (SEQ ID NO: 3725) CNRIP1 chr2:68542975- TTAACCGGGTGTGGTGATACCACACCTGTAGTGCCAGCAA 68542840 CTTGGGAGGCTGAGGCAGGAGGATCACTTGGATCCAGGA GGTTGAGGCTGCAGTGAGCTATGATCACACCACTGCACTC CAGCCTCGGTGACAAGA (SEQ ID NO: 3726) CPSF4 chr7:99045396- AAGAGACAGGATTTCACCGTGACAGCCAGGATGGTCTCCG 99045536 TGCCAGCCAGGATGGTCTCGATCTCCTGACCTTGTGATCC GCCCACCTCGGCCTTCCAAAGTGCTGGGATTACCAGCGTG ATCCACTGCGCCCGGCCATGA (SEQ ID NO: 3727) CRISPLD2 chr16:84869783- ATTGGGTCTTATCCCCAAGATATCTCATTATGTACATGCAA 84870041 ATCAGCGGAGCATCGTCATGACACCAGGAGGACACCCCGT GACGCCGATTACCGCACTCTCAACCTCAACCCAGCGTCAG AGTTTTCTGGCATCTCTTCTTTGAGCCTGGCCGCCTGCAGC TGGAAATGCTCATATATGGTGGTGTGACTAACCTGAGAGA GAGAGATCAGGGATCCTGAGAAGTTCTGCATTCTTGGTCT GCTTCCCAGTGGGACGA (SEQ ID NO: 3728) CRYBG3 chr3:97635177- GGCCTTTCTGTCTGGTGTGTGCAGAATGATCTGGGTCACCT 97635237 CTGAGGCCCATATTTATAGA (SEQ ID NO: 3729) CSNK1G1 chr15:64575350- GTTATTGGGGTACAGATGGTGTTTGGTTACATGA (SEQ ID 64575317 NO: 3730) DAGLB chr7:6474651- TTGGATCATCATCGCTGCCACAGTGGTTTCCATTATCATTG 6474425 TCTTTGACCCTCTTGGGGGGAAAATGGCTCCATATTCCTCT GCCGGCCCCAGCCACCTGGATAGTCATGATTCAAGCCAGT TACTTAATGGCCTCAAGACAGCAGCTACAAGCGTGTGGGA AACCAGAATCAAGCTCTTGTGCTGTTGCATTGGGAAAGAC GACCATACTCGGGTTGCTTTTTCGA (SEQ ID NO: 3731) DCAF17 chr2: 172298369- TTTTGCCAAGGAGTTTGTCCACAGAGCTCTTCATGCCCTCA 172298546 TGCTGGAAGTGGAAATCTGGACATGTTATCTTATCATGTC ATTATCACACCTAGGAAAATGAGCAACAATTCTTCAGGAT CATTTAATGTCAAGTTTATAACTTCCTGCTTTAACTTAAAA AAAAAATTAAATTAGA (SEQ ID NO: 3732) DCUNID4 chr4:52775086- GCCGAAGATGGTGTTAGTGATTGCGAGCTGCTGGCTGGCA 52775141 CCCTTGCAGAGCAGGA (SEQ ID NO: 3733) DDX42 chr17:61883354- GTGCAGTTTGAACAGGGCTTGACAGTGGCTGGACCATCAC 61883511 TAAGTGAGACTTTAATTCATCAAGCATAACTGAAAATGGA GGCAGTAGATTATATCTTGGTAGCCAGCATGTGTAGACTT GTCTTATTTGGAGCCCACTTGGAATTTTCATTTCAAGA (SEQ ID NO: 3734) DENND1A chr9:126385380- CTGTGGCATAAGAATGAAAAGAAAAGAAACAAAAGCAGA 126385322 TGGCAGAGAAAACGAAAGGA (SEQ ID NO: 3735) DENND5A chr11:9227781- GCCAAAATCATATTATATGATCAACCTCAAGTGCATGGGA 9227736 AGCTGTGAAAGTGAACATTGAACTGGGTATAATGTTACCC TGAACAGTATGAAGGTCTATGAGCAAGAAAGAAGGGGTG AATGAATTATGA (SEQ ID NO: 3736) DENND5A chr11:9198449- ATAGGACAGCATTTAAAAATCTCATGTGGAAGAATATACC 9198319 ACTAGA (SEQ ID NO: 3737) DGKA chr12:56333603- ACCTGGGCCTCCCAAGCATTATCCAGCTCAGTTCCTGCCTG 56333699 GCACATGGATGGTGTGGGGCAGGCATGCAGTAGCAGCTG ATCTTTTAGGAGGAAGA (SEQ ID NO: 3738) DIAPH3 chr13:60266972- GTAAATTAGACCCAAAATAACTCCCAGGGAGCAATACAC 60266851 AGCCTGGAAAACATGAAACAAGGAGCGGCTGTTTGGTGT AATAAAGGAGGAGCACCAGGCTGAATTTTCAGAGGCCTA ATAGA (SEQ ID NO: 3739) DIAPH3 chr13:60548266- GGTTTTGTTCCTAATGTCACATGTTTCCTAAGTAATTCAGC 60548219 ATAAAGA (SEQ ID NO: 3740) DLGAP4 chr20:35127645- GAGAGGACTAGAAGGAACGGTTCCCACCTCTCGGAGGAC 35127724 AACGGACCCAAAGCGATCGATGTGATGGCACCCTCCTCAG A (SEQ ID NO: 3741) DNAJC13 chr3:132227720- CCCACTGTGGAGACCTACTGCTCAGGAAAAAAAGAGCTTT 132227883 CAAAATACTACTGCTCGTTGGCAATGCACCTGGTCACCCA AGAGCTCCGATGGAGATGTACAAGGAGATTAATGTTTTCA TGCCTGCTAATACAGCATCCATTTTGCAGCCCATGGATCA AGGA (SEQ ID NO: 3742) DNMBP chr10:101762780- TTTGAAAATCAAATATTGAATGCAAAAGCTAGGAAGCTGT 101762699 AAACAGGAAACGTAAACGAGAAAGAACAAGCAGTGAATA CGA (SEQ ID NO: 3743) DNMBP chr10:101654399- CATTGGCCAGGACTACTAGAACTGTGTCAAAACAGCTGCT 101654318 ACACTAACGGGCATCTTTGTCTTGTTCTCAGTCTTAAAAAG A (SEQ ID NO: 3744) DOCK1 chr10:128901890- GAACGTTGGGGATGCAGATGACCAGTATCTAGTGCTGCGT 128901944 GACTTTGGATTACGA (SEQ ID NO: 3745) DYRK1A chr21:38794884- GTTCAGGGATGCTGGAAAGGACACTGAAGTAGGCCTTGGC 38794954 TGATGGGCCTTTCAGAAGTGAACACTTAAGA (SEQ ID NO: 3746) EIF2B3 chr1:45350395- GGAACTGACTTGTTTTCCAATGGAGGAGGAACATTTGCTG 45350311 CCTACACTGGTTTGAAGCATTAAAAGGGGAGAAAAAGAG CTAAGA (SEQ ID NO: 3747) ENOX1 chr13:43,984,307- TTACTCTAGAAGTCGTACTACATTTTCTGAGAGAAGTAGG 43,984,398 AGGTGAGACGAGAGTAAGTAACTTCTGCTCTCTGAATATT TCAATTAGGCAG (SEQ ID NO: 3748) ERC1 chr12:1536281- ACAGACCCTTCCAGAACCAGATGACCATCAAGACAAAAG 1536343 CATACTCAAGCAGACAAGAAAGGA (SEQ ID NO: 3749) ERCC1 chr19:45917292- GTGACTGAATGTCTGACCACCGTGAAGTCAGTCAACAAAA 45917221 CGGACAGTCAGACCCTCCTGACCACATTTGGA (SEQ ID NO: 3750) ERGIC3 chr20:34142143- TACATGCTGTGGAGA (SEQ ID NO: 3751) 34142157 ERLIN2 chr8:37594849- GGCCAAAGGAATAACTGGGAAGGTGGATGCGAGGCCAAC 37594946 GAATCCTACCTTGAAACTCTGCTCGCCTGCTGGCTCTGCCA CTCCAGCATCTGAAAGGA (SEQ ID NO: 3752) EVC chr4:5743061- TTCCATACAACTATCCCGCTGATTCTTTCTTCAAAGAAGCA 5743168 AACCCTCCTTTGCTTTTTATATTTTCTTCACACATGGAAAT GGGGGATGTGGAGGGCCTTGCACAGA (SEQ ID NO: 3753) FAF1 chr1:51003153- TAATTTTTAACAGTGTAAAGGGGTCCTGAGACCAAAAAGT 51003085 TTGAGAACTGCTGCAATCAACTATAAAGA (SEQ ID NO: 3754) FAIM chr3:138335412- GCTGGTCTCGAGTTCCTGGCTTCAAATGATTCTCCTGTCTC 138335506 AGCCTCTCAAAGTGCGGGGATTACAGGGATGAGCCACCAT GCACACTCCAAGGA (SEQ ID NO: 3755) FAM126A chr7:23011932- GTCAATTTTTCTGACCACCTGAACAGATTGTTTTCTGTCAA 23011871 TTAAGGGCAGCTTTGTTACGA (SEQ ID NO: 3756) FAM13A chr4:89890343- GTTTTGGGGAAACAGATGGTGTTTGCTTACATGA (SEQ ID 89890310 NO: 3757) FAM174A chr5:99917051- ACTGCTGTGGAATTCCTGAGAAAGAGCAACTGAGGGATA 99917108 GCAACATGGATTTCACTGA (SEQ ID NO: 3758) FAM198B chr4:159091499- CAGCAGCAGCAGCGTGTCTTTCCATGCGCTTGGCATTCTTT 159091399 ATTTTCCCAGCCTGGGAGGATATGAGAGTTCCAGGGAAAT GCTGTATTGGACATGCAAGA (SEQ ID NO: 3759) FBN2 chr5:127850450- GATTAATTACCGTTAATGTCTTGGAGACTATAACGTACAC 127850370 TGCACGTTGTAATAACACAAAAGGACAAGCAAGATGTAA GA (SEQ ID NO: 3760) FER chr5:108321155- GTTTCTGGGGAGCAGGTGGTGTTTGCTTACATGA (SEQ ID 108321188 NO: 3761) FHOD3 chr18:34322340- GACAAAAAGCAAAGAAGAAGACTGTGGTCTAGAAGCCGA 34322431 AGGAAGATGAGAAGGAAGAGTGTCCGAGGAGTCAGCCAC AGCCAGAAAGGAGA (SEQ ID NO: 3762) FOCAD chr9:20737106- CATTGACTCCGTTATCTACACAATAAAATCTGGATCCACA 20737152 GATAAGA (SEQ ID NO: 3763) GALC chr14:88447791- GTTTTTGGAGAATAGGTGGTATTTGGTTACATGA (SEQ ID 88447758 NO: 3764) GCFC2 chr2:75913102- CAAGAGAGAAAGAGAGGAATCAAGAATGGGTCCATTGAG 75913000 GAATTGGCCTGAGCAACTGGAAGGACAGAGGTGCCATTTC CTGAAATGAAAAAGTCTGACAGGA (SEQ ID NO: 3765) GGACT chr13:101194723- TAAGATGCTATGAGGAAATCCGTGCACGAGGGATGACAG 101194628 CGTGGCAGGCTGGAACACGCTTTTTAGATTTACTTTCGTGG ACTGGATCTGTTAAGA (SEQ ID NO: 3766) GLCE chr15:69517534- GGCAGAGGTGGAGAGGGGTTAGATTATTTCATCTGCCCTA 69517591 CAGTTGGCATAATAAAGA (SEQ ID NO: 3767) GOLGA4 chr3:37285619- GTCCAGGGATTGAAGGCTGGGGAGTAGAGCCATCCTGGGT 37285734 CAGGCTGCTGGTAGGAGCGGTGGGACCTGAAAGACGTGG CGGCGTGGCCGGCGTCCAGCGCCCGAGGCTGTCACGA (SEQ ID NO: 3768) GOLGB1 chr3:121401810- AGGTGCCTGATGCTGTTAATTCCTGAGCCTTTTGAAGATTC 121401764 TGCAGA (SEQ ID NO: 3769) GXYLT1 chr12:42489016- GGATTGTTTGTATTCCTGCCAATGATTTGTGAGACAGTCTG 42488953 TTCCCCACATCCTCGTCAACAGA (SEQ ID NO: 3770) HAT1 chr2:172803228- TTCGTTTTCCTGAAGATCTTGAAAATGACATTAGAACTTTC 172803303 TTTCCTGAGTATACCCATCAACTCTTTGGGGATGA (SEQ ID NO: 3771) HLTF chr3:148769931- TCTTGCTCTGTCGCCCAGGCTGGAGTGCAATGGCGCGATC 148769832 TCAGCTCACTGCAACCTCCACCTCCCAGGTTCAAGTGATC CTGCTGCCTCAGCCTCTTGA (SEQ ID NO: 3772) HMGA2 chr12:66267911- CTTGTTGGGAATAAGA (SEQ ID NO: 3773) 66267926 HNMT chr2:138724667- ATACCAGAATTGCTGTTAACAAATAAAATACTGGCCAGAT 138724956 GTGTTGGTTCACGCCTGTAATCCTAGCACTTCGGGAGGCT GAGGCGGGAGGATTACTTGAGCCTAGGAGTTTGAGACCA GCCTGGGCAACATAGCAAGATCCCATCTCTACAAAAAAGT GAAAAAGTTAGCTGAACAAGGCGGCATGCACATGCTACTC CAGACGCTGAAGTGGGAAGATCACTTAAGTCCGAGAGAT CGAGGCTTCAGTGAGATATGGCTGAGACACTGCTCTCAGC CTGGATGACAGA (SEQ ID NO: 3774) HPS1 chr10:100195171- TTTGGAGAATGCCTGTTCATTGCCATCAATGGTGACCACA 100195029 CCGAGAGCGAGGGGGACCTGCGGCGGAAGCTGTATGTGC TCAAGTACCTGTTTGAAGTGCACTTTGGGCTGGTGACTGT GGACGGTCATCTTATCCGAAAGGA (SEQ ID NO: 3775) HSD17B12 chr11:43838189- GTTATTGGGGAACAGGTGGTGTTTGGTTACATGA (SEQ ID 43838222 NO: 3776) HSD17B4 chr5:118792986- CTTTCTGACATCTTAACGAGGCAATACAGAGAGACGAATT 118793063 TTCATCAGTTTGTTCAGGGAGACACATATAACAAAAGA (SEQ ID NO: 3777) HTT chr4:3215349- AGGCAAGCCCTGGTGCTGTGGGAGCCCCAAGGAAGAGCC 3215463 TCTGGCCTGGTGGCCACGTAGCCCAGGAGAGATTTCTACA GGAGCCCACAGCGCTGAAGGAGAGAGAGGCAGCAGA (SEQ ID NO: 3778) IFT57 chr3:107911373- ATCCATACATACTTAATGCTGAAATGTGAAGGGCTGAGAA 107911323 AAAAGAAAAGA (SEQ ID NO: 3779) INPP5K chr17:1419412- CACATACATCAGGAGGTCTGCCTGATCCCATGGTGAACCC 1419182 CGGGAATCCGAAATCAGATTGAGATAAGATCCTTTAGGGA AGTGACTTAGCCTGGTCTCTTGCCTGCTCTTTCACGGGGAA CAACGCTAATCGCCCACTTAGTCTAAGTCACGATGCTTGG ATTTGCTGCTAATCGTCGGATTTGAGAGTGGGAACAAGAA ATCCGGACTTTTGCTCTCCATCCTCTTAGA (SEQ ID NO: 3780) IVD chr15:40706629- CTCTGAATGGCCTGTCTCCTGGACAAAGAAGCTTTCACGG 40706723 ACTACTCTGCAGGGAGGTGACATTGGACCAGAGCTGACTC CACCTGGGGGAAAGA (SEQ ID NO: 3781) KIAA1524 chr3:108284925- GTCAGGAATTATGGTTAAAGGTGGATTTTCACTGATGGTA 108284745 ATAAGATATTACTTTATACCCCTTCCCTCCTCATGAATTAA GTCCATCTAATCTTTACTGAGGACCTGCTGAGTGGTAGAC ACTATGATTTGTTTCTGTTTCCACAGATGTCACAATTGTCA GTAATTGTGGACCTTTAGA (SEQ ID NO: 3782) KIAA1715 chr2:176835145- TTCTCAGGTTTTCTTGACACCAAGAAAGAGAGGGAATCAA 176834927 GAAGATCGGTTGTAAGAGAGCAATTCAACATGAAAATACT GAAGAAGAGATGGGAGAGAGAGAGAGATAATTGTTTTCT TCAGAGTTTTCCACTTTCTATCAGTAACTCTGATCACATGG ATATCTATTGTGGGGCTAGTTGATGCATCCCTTCAGATGTG TTGGAAAGAGGACCAAGA (SEQ ID NO: 3783) LUC7L3 chr17:48798190- TGTAGGAAAGCAAGTTGGTGCTAGATGACTCCTTTTAGGA 48798241 CTTTAAGAAAGA (SEQ ID NO: 3784) LYRM1 chr16:20922505- GTGAAGTAGTATTTGAAGCTTTTCATCAGTTGGCTCATTCT 20922586 TTACTCAAGAATAAACCTCAAGAAACGTCATCAGGGTCAG A (SEQ ID NO: 3785) MADD chr11:47314094- AATTGTGGAACAAGCACCAGGAAGTGAAAAAGCAAAAAG 47314147 CTTTGGAAAAACAGA (SEQ ID NO: 3786) MB21D2 chr3:192555098- GCATGTTTATGTGGGAATGTCTCTCCATGTTTACAAACTTC 192555020 AGAAGGCCCCTTTGGGAAAGAAAACCTCTCAGAGAAGA (SEQ ID NO: 3787) MCM10 chr10:13239941- TCTTGCTCTGTTGCCAGGCTAGAGTGCAGTGGCGCAGTCTT 13240039 GGCTCGCTACAGCCTCTGCCTCCTGGGTTCAAGCGATCCTC CTGCCTCAGCCTCACGA (SEQ ID NO: 3788) MED13L chr12:116547674- GTCATTTTTAACATGGATTCTTAGATGCTGACAAATATTGC 116547579 CAAATTCCATTCCAAAAGAGGTTACACTTATTTCCTTTCAT CAGTGAATGA (SEQ ID NO: 3789) MED13L chr12:116419435- CTCCTCTGAGTGTTCCTCCAAATCTGTCTTTTGGAGTAGAC 116419344 CTAGAAATCATCTGTTACTAAGGTGTACTATGCATGTGGA ACCATTGATTTAAGA (SEQ ID NO: 3790) MEDAG chr13:31492953- GAGAGGCCAGGAACAGAATGCCCAGTAACAAGAAGTGCT 31493127 CATTAGAACATCTGAAGCCCACGTGTTCTTTGGCTTGATTA TAACCAGAAAGCCAGATAGTTCTTTAGGAATGTAATTCAC AGCTGTATCAAGTACACCTCCTGCACCGATCACTCAGGAG GAATCTAAAAAAAGA (SEQ ID NO: 3791) MEMO1 chr2:32112156- AAAGCGTGCTCTGGAATGGATTCACAAATGAGCTACCCTC 32112104 CTTCCCTCAAAGA (SEQ ID NO: 3792) MMS19 chr10:99241240- CATTAATTTACAGAAATACACGTATTCTCCTTGTTTTGGTG 99241106 GAAGCTGCAGCTGCCAATCATCTCTCAAACCCTGTGGGTA GCTGCTAAGCTGTATTTCAGAGGAATGTCACAATCATACC ACTGGGGAGAAAGA (SEQ ID NO: 3793) MRPL45 chr17:36468550- GTCTGGGTGGTGGCTCATACCCGTAATCCAGCACTTTTGG 36468624 AGGCCGAAGTGGGAGGATTGTTTCTGGGCAGCAGA (SEQ ID NO: 3794) MRPS28 chr8:80915355- ATGGGACCTGCAAAGGATAAACTGGTCATTGGACGGATCT 80915234 TTCATATTGTGGAGAATGATCTGTACATAGATTTTGGTGG AAAGTTTCATTGTGTATGTAGAAGACCAGAAGTGGATGGA GA (SEQ ID NO: 3795) MTERF3 chr8:97263851- GGACGTGTCTCCGTGCTAAAGACCTAGAGATTACAACGAT 97263810 GA (SEQ ID NO: 3796) MYCBP2 chr13:77628142- GCATCTAGCATAGAACTCCCTATTCTGCATTATGACTACTG 77628054 GACCACTTATCTCTCTGCCCTACTTGATAAGTTCCATGAGG ACAAAGA (SEQ ID NO: 3797) MYCBP2 chr13:77692630- GTGACCAACTGAGTGCCATATTGAATTCCATTCAGTCACG 77692475 ACCCAATCTCCCAGCTCCTTCCATCTTTGATCAAGCTGCAA AACCTCCCTCTTCCCTAGTACACAGCCCATTTGTGTTCGGA CAGCCCCTTTCCTTCCAGCAGCCTCAGCTTCAGA (SEQ ID NO: 3798) MYOF chr10:95117679- GGTGAGAAGTTTCTGAAGGTGCTTGAACGCTCTTCTTCCA 95117562 CACGAGGGCACCAAGTTGAAGCGGGAAGAACACTGAGCC ATCAGTTAGAAGGCTCAGGATATGGTCCAGTTCTAACGA (SEQ ID NO: 3799) NREP chr5:111086122- TGTTCCAGGGCGCCATTAACGATTGGAGTTGGCACAAAAT 111086049 TTGAAACTAGAAGTGGACTATTTGCTCCTTGAGA (SEQ ID NO: 3800) NSUN4 chr1:46823248- GGGCTCAGGAGTCCAGCGGTCCTAAGTATACCTTGCAGCC 46823331 ATCTTCCTAAAAGTTCTGACCATGACTGAGGACACTGAGA AGGA (SEQ ID NO: 3801) NT5C2 chr10:104853974- AGTTTTGGTCTTAACTGAAACAGTCAAACAAACCCACTAA 104853926 TTGAAAAGA (SEQ ID NO: 3802) OSMR chr5:38876877- CTTCCTGAGAGTTTCTTGGCCTATACCCAGCTGAAGTGCA 38876923 GGGAAGA (SEQ ID NO: 3803) OXCT1 chr5:41734751- ATTTTGAAAGAAGTCTGTCTCTCAAATATTTAAAGAATCA 41734677 AAATGATGTCGTATTAAAGCTTGACAAGCTAATGA (SEQ ID NO: 3804) PAPD4 chr5:78937278- AGCTCTACCTCTGTTTTGAAATGTCATTAGTTTGGATATGT 78937340 TACCAGGATGCAGCAAAGAAGA (SEQ ID NO: 3805) PCM1 chr8:17818551- TTATGGACCAGCATTTCCATCTTTTACTGGCCTGAAATAAT 17818653 ATAATAAAATCTTTAAGCCACCATAAGATATCTAAGGAAA ATAACTGTATGTGGTTTAAAGA (SEQ ID NO: 3806) PDS5B chr13:33263018- GCATTAGAAACATTCATATTATGAAAATACTACCTTTTTAT 33263158 TCTCACTTGGTGTACTGATGTGCATTACGGTGGAGAGCAG TAGGCTGCAGATTTTGTGCTGCATAGCCTGAGCAGCACCG TGTTATAGTTTGACATAAGA (SEQ ID NO: 3807) PIK3R1 chr5:67538784- TGCTCTACAAGTATAGAAAGAAGCCTTCCTCTTCCCACCG 67538973 TCCCCAGACACCACATAATGGAAAAAGCAAGAATTTTCTG CATAAGCAAGGCCTTAAAAAAAAAAAAGCCAGCCTCTGA TGGGACTTCTTTCCTGCCAGAAATCCCACTGGTCCACTGTC GCAATTTTTACAAAAGGCCACGATGAAAGA (SEQ ID NO: 3808) PIKFYVE chr2:209176229- TGGAAAGAACCTCATTTGAGCTATGCTTGGTCACAGACCT 209176294 AGAGAAAGTTCACGGGGAAGTAAAGA (SEQ ID NO: 3809) PITPNB chr22:28288318- GCGAAAATGGGCAGTGTTTACAGGCATGAATGCTGGTGGA 28288117 AAGAGCAGAGTAAGGGCAGATTGCACAAGAACCGTGGAG GCCCTGGTTCCCATCACCTCCACCTCAGCACAGACTTCAG AGAGGAGAGGAGGCACTGGATGCATGACAGCAGCACTTG AGATAGGTGCTCCAGGTGGAAGGCACTGCACATGCAAAG GCTGA (SEQ ID NO: 3810) PITPNB chr22:28290410- TGAGCTTGGAGTGAAGTCTAGTACGTCTGTGCAGCAAAGA 28290364 GACCAGA (SEQ ID NO: 3811) PLSCR1 chr3:146255831- GACCACATAAACCCATTTTGAATTATTCAACCATTGCTGA 146255783 ACTTCTTGA (SEQ ID NO: 3812) PMS1 chr2:190683464- GGATTCCCCCAGCAGACGTTTTTCATCTAAGAAATGGCTT 190683555 GAGTGCTTCCTTTTATCGGGTGCTGTGATAGATTCTCAAAA TATGAAAATGA (SEQ ID NO: 3813) PPIP5K2 chr5:102492916- AACCCAACACAGATCTTAATACCATGAAAAGGA (SEQ ID 102492948 NO: 3814) PRSS23 chr11:86651889- AGCAATCTCTTTGTATTTATACAATTATGACAACAGTAGTA 86652069 AGAGAAGAAGGTTCAGAGGATACAAGGTAACACACCTAC ATAAACGACCTACTGGGTACAAATATTGTAAATCAACATA GGCCTAGAAAAGGTGGTCAGATGCTGAATTTTGACTAAAT ACCTCCGATGGCACATAATGA (SEQ ID NO: 3815) PRUNE2 chr9:79234303- AACTAGCTGCCTTTACAATGATCCAGAAATGTCTTCTATG 79234256 GAGAAGGA (SEQ ID NO: 3816) PSMA4 chr15:78834921- AGAGACGCAACATCCACAAGCTTCTTGATGAAGTCTTTTT 78834987 TTCTGAAAAAATTTATAAACTCAATGA (SEQ ID NO: 3817) PXK chr3:58321084- CTGTAAAGTTTGACTGAGAAATGTTGCATCAGCCCTGAAG 58321179 TTTATTGAGAAAATCTTACGCTGATGCAAACTTTTTGGACT GTTAGTGTCTTATGA (SEQ ID NO: 3818) RAF1 chr3:12645036- AATAACAACCTGAGTGCTTCTCCCAGGGCGTGGTCCAGAC 12644977 GATTTTGTTTGAGGGGAAGA (SEQ ID NO: 3819) RARS2 chr6:88257102- AATTGGAGAAATTAGTACTTGTGGCATAGATTGTTGTGCG 88256965 GTCAGCTCTTACTGTTCTTGAGCAGCATTTTAAGAGAAGA AATGACAGGACTTGATGAAAAAGTATAAGAAATATACAG TATAAAAAAAGCTATATGA (SEQ ID NO: 3820) RFWD2 chr1:176044514- GACTAAGATTTGAATTTATTATGTATATGAAGATCTTAAA 176044399 ATTTAAGCCATTAGCTAAAGAAACTATTGGAGGAGATCTT TTATTGTATTCTGTCAGCTGTTTAACTCAGTAATGA (SEQ ID NO: 3821) RNFT1 chr17:58039977- GAATTTCTCTTGGAATTGGGCTGCTAACAACTTTTATGTAT 58039901 GCAAACAAAAGCATTGTAAATCAGGTTTTTCTAAGA (SEQ ID NO: 3822) RPA1 chr17:1745069- ACGTCAGCTATCAGTTTAAGCATTACTTCTATGCCTAGTTT 1745127 GCTGAGACTTTATAATGA (SEQ ID NO: 3823) RPS6KB2 chr11:67196453- GACGCATGTCCCCTTGCCGAGTTGAGGGCAGCTGGCCTAG 67196493 A (SEQ ID NO: 3824) SAMD4A chr14:55115465- ATGTGATGGGAAGTCTCTGGAAGAGTTGAGAAGGAGAAT 55115566 GAAGGCGCTTCATTGACCCTTGAAAATGACCACTCTGAAT GCGGCACAGAGAGTAATGAAAGA (SEQ ID NO: 3825) SAR1A chr10:71926149- TGCATCTAAGTGGCATTCTGATTCACATTATTGATAAGACT 71926032 GATTTCCTAGAGTIGTTCTTCACTGGATGACAGCAGTCGTA TGTCTAGGGAATGTGAATGAACCGCTGCCTGGAGGA (SEQ ID NO: 3826) SCO1 chr17:10594966- AGAAAGGATTTGAACTTGGCCTTCATGTATCAACTAAGTT 10594907 AATCGAGCCTTGAATTGAGA (SEQ ID NO: 3827) SEC24A chr5:134013731- AGACCGGGTCTCTCGTTGTCACCCAGGTTAGAGTGCAGTT 134013842 CCATGATCATAGCTCACTGCAGCCTTGAACTCTTGGGCTC AAGCAGTCCTCCTGCCTCAGCCTCCAGACAGA (SEQ ID NO: 3828) SERGEF chr11:18031686- GTGTCTTCAAAAACAAACATATTTAAAAGATTTTACTTCTC 18031622 ATCTCCAGGAAGAACCAGCTAGGA (SEQ ID NO: 3829) SH3YL1 chr2:224920-224868 GTAACAGAAATGAATATAAGCTCTATCCTGGACTTTCCAG CTATCATGAGAGA (SEQ ID NO: 3830) SKA2 chr17:57196856- AAAAATCCAGTTACACTCTTAAAGGAATTGTCAGTGATAA 57196757 AGTCTCGATATCAAACTTTGTATGCCCGCTTTAAACCAGTT GCTGTTGAGCAGAAAGAGA (SEQ ID NO: 3831) SMYD3 chr1:246394576- CTATATCAGAAAAGCAGGAAACCAGAGAAAATATACCTA 246394501 TTTGAAAGTGGCATGTCAGCTGGGATGAGAGAGAAGA (SEQ ID NO: 3832) SNAP23 chr15:42805372- TATTGGAATATGACAGGGAAGATGAATTCACTATGA (SEQ 42805407 ID NO: 3833) SNHG16 chr17:74554456- AGGCCTTTCTTTGTTTGGCATCTGCAGAGACGGTGAAAAG 74554545 CAGAGCTCCAGGTTGAAGGATCAGAGTAATAGATGGAGC CCTTAACATGA (SEQ ID NO: 3834) SNX7 chr1:99204216- AGTTTGCAAAGGAAGGAAAGGAGCAGAGACTTGAATGAG 99204359 CAGAAAATCATTTCAGGGCCTGTTCTCTATGTCCTTGCTAT CCCTGTCTTCTGTAGCTATTCTGAAACCATCAACAAAGGA GCACACCATTCCATCAGCAAAAGA (SEQ ID NO: 3835) SPATA5 chr4:123901321- AACCTTTATATAAATGGAATCATACTGTATACAACCTTTTG 123901384 GAATTAGCTTTTTTCACATATGA (SEQ ID NO: 3836) SPIDR chr8:48185929- GTATTCAGTAGAAGCAGATGAACAGCCAGATGAAGAGAT 48186042 GGATAGAGCAAGACATGGACATTATAAAGGAATTCAATA GAAGCACATGAACGGCCAGATGAAGAGATGGATAGA (SEQ ID NO: 3837) SPRYD7 chr13:50492357- GTGTGGTTGTACGTGCCTGTAGTCCCAGCTACTTGAGAGG 50492229 CTGAGCTGAGAGGATCTCTTGAGCCGGGGAGGTCAAGTCT CCTGTGAGCAGTGATCATCGTGCCGCTGCACTCCAGCCTT GGCACCAGA (SEQ ID NO: 3838) SRGAP1 chr12:64319388- TCACAGATACCACGTGTTAATATCTAAAGTAGAAAAAGGA 64319457 ATAAAGCAAAGGAGGACAAAAAGAAAAGGA (SEQ ID NO: 3839) STAT1 chr2:191843332- GTTTGTTATCTGCAGATCAAGGATGTGAGTCAATGTAATC 191843254 TGCAACCCGTTCTTGGAAGGAATCACATTTCCCACAGGA (SEQ ID NO: 3840) STXBP6 chr14:25411028- GTGGTCCCTGAGTTAAGAACATGCAATGGCACTCTCTCAA 25410930 GGAGAGGAAGGAGCCAAAGAAGAAAGAGGTCCAAAGCA GAAAAGAGCAGACAGCTAAGA (SEQ ID NO: 3841) SUPT20H chr13:37585794- TTGAAGACGATAATTCTAACTTCCTGTCAGTTGAAGACGA 37585696 TAATTCTAACTTCCTGTCAGTTGAAGACGATAATTCTAACT TCACACTTAATTAAAAGA (SEQ ID NO: 3842) TAF2 chr8: 120771346- GAAGATGATCACCTTGCCAAGGAAGCATCATGTAATATAT 120771264 CAGCTCATCAGCAGGGAGTGAAGAGGAAGTCTGATACAC CACTGGGGTCCCCACTAGAACCTGGTCAAATACTGGAGAA GAATGAGGATAGCAGTAAAGTCAAACTCAAAATCAGA (SEQ ID NO: 3843) TAF2 chr8:120757276- TTTTGAGATCCACCAAATATGTCATTGTTGCCAGTCTTCTT 120757121 TCCCAAGATGTATGGATAGTTTTTAATGTCTCATAAATATG A (SEQ ID NO: 3844) TBCID15 chr12:72278640- TTTGACAGACCTGAAATCAATCAAGCAAAACAAAGAGGG 72278801 TATGGGCTGGTCCTATTTGGTATTCTGTCTAAAGGATGACG TCGTTCTCCCTGCTCTACACTTTCATCAAGGAGATAGCAAA CTACTGATTGAATCTCTTGAAAAATATGTGGTATTGTGTGA (SEQ ID NO: 3845) TCF12 chr15:57227695- GTTTTTGGGGAACAGGTGGTATTTGGTGACATGA (SEQ ID 57227728 NO: 3846) TJP2 chr9:71792959- GGATTGGTGTCTCTATCATCCAGCTGGCCATTAAACAACC 71793045 AAAGCTTCATCATCCTAGATAACCTGTGAGCTCTCAGAGG AGACAGA (SEQ ID NO: 3847) TMEM189- chr20:48713357- GAGTAAAAGTCCCTCGCAATTTCCGACTGTTGGAAGAACT UBE2V1 48713209 CGAAGAAGGCCAGAAAGGAGTAGGAGATGGCACAGTTAG CTGGGGTCTAGAAGATGACGAAGACATGACACTTACAAG ATGGACAGGGATGATAATTGGGCCTCCAAGA (SEQ ID NO: 3848) TMEM214 chr2:27260130- CCATCCTAGATCTGAGATTTGCAACCTGGAAGTTCAAGA 27260168 (SEQ ID NO: 3849) TNS3 chr7:47337036- GCAGGCCCACCCATGAAACATACACGACACCACAGAGAC 47336903 CTCCCTGAAGGTCCCTCAACTGCATGGACATGTAGTTCTTC CAGCCAAGCAGAGGGATCCCGGCCAGGTCCCCACTGATCC AGTTTGCAAAAAGA (SEQ ID NO: 3850) TOE1 chr1:45807382- GTTTATGGGGAACAGGTGGTGTTTGGTTAAATGA (SEQ ID 45807415 NO: 3851) TRAF3 chr14:103356688- CACCAATACATTATTATGAAGTCAGTACAGAGAGATTGGC 103356763 ATCTTAGTATTTTCTGAGGAAGAGAACAGCCAAAGA (SEQ ID NO: 3852) TSPAN2 chr1:115601892- GTTTTGTGGGGAACAGGTGGTGTTTGGTTACATGA (SEQ ID 115601858 NO: 3853) TUBE1 chr6:112405449- AGTGGTTGGTGATGGTGGAAGTATTTCCAAGGGAAAAATA 112405392 TGTTCTTTAAAAGCACGA (SEQ ID NO: 3854) TYW5 chr2:200813345- TGACAGCATGAACTGTCAGAAGCTTTGAGTTCAAGCATCT 200813295 TGGGAGCAAGA (SEQ ID NO: 3855) UBE2V1 chr20:48713357- GAGTAAAAGTCCCTCGCAATTTCCGACTGTTGGAAGAACT 48713209 CGAAGAAGGCCAGAAAGGAGTAGGAGATGGCACAGTTAG CTGGGGTCTAGAAGATGACGAAGACATGACACTTACAAG ATGGACAGGGATGATAATTGGGCCTCCAAGA (SEQ ID NO: 3856) URGCP chr7:43945050- GCTTTGGGGCAGTGGTCATTTCCGGGACCAGGCCTTTTCAT 43944971 TGCCAGCTGACTACCCAGCACTTTGAGCTCATGAATAGA (SEQ ID NO: 3857) XRN2 chr20:21307793- GTGGTTTGAATTGAGAAGGGAAGTATAGCAAAAGCTTGA 21307903 GAAAGCCTTACCGTCTGGAGTTTGGACTGTATCCTATAGG CAATGAGTAGTCATGAAAATGATTTGAGAGGA (SEQ ID NO: 3858) XRN2 chr20:21326472- CCATCAACAACTCTTAGCTGAAAGAGGGATAAGGCCCAA 21326525 GCAAGGATAGAGAGA (SEQ ID NO: 3859) ZNF232 chr17:5012080- GTGAGAGACTTTGCCTGTTTCATCACTCATAAAATTAGGA 5012041 (SEQ ID NO: 3860) ZNF680 chr7:64002295- GCAGAACTGGCCGTGAACTGTGGCTCAGGGAGCTGGAACT 64002108 GAGTCATCGAACTGCTTCAGAAACCACAGTAAAGGACAA GGTCTGCAGGCCTGCCTGCGTGGCTATAAATGGCTGTCTT CCTCCAGGCCTCTGGAAGGGCACGGTCTCTCCCAGACTGT GGCTGGGAGGAGTTTGGGATGATTAGAGA (SEQ ID NO: 3861)

Diseases or disorders associated with expression of an aberrant gene product for certain genes described herein are listed in Table 15, wherein contacting a patient cell with a compound described herein or administering to a subject in need thereof a compound described herein has been demonstrated to modulate the expression of associated RNA transcripts and are thus expected to be useful in preventing or ameliorating a disease or disorder caused by expression of an aberrant gene product.

TABLE 15 Diseases or disorders associated with expression of an aberrant gene product for certain genes. Gene GeneID Example(s) of Associated Disease or Disorder ABCC3 8714 Cholestasis, Colorectal Neoplasms, Peripheral Nervous System Diseases ADAM17 6868 Blister, Inflammatory Skin and Bowel Disease, Neonatal ANXA11 311 Sarcoidosis APLP2 334 Nerve Degeneration, Myocardial Ischemia ASPH 444 Ectopia Lentis, Spontaneous Filtering Blebs, and Craniofacial Dysmorphism ATXN1 6310 Spinocerebellar Ataxia 1, Spinocerebellar Ataxias AXIN1 8312 Carcinoma, Hepatocellular, Caudal Duplication Anomaly BECN1 8678 Status Epilepticus, Colonic Neoplasms, Lewy Body Disease, Myocardial Infarction, Lung Neoplasms BHMT2 23743 Cleft Lip, Cleft Palate C11orf30 56946 Dermatitis, Atopic, Breast Neoplasms, Polycystic Ovary Syndrome C11orf73 51501 Stomach Neoplasms, Melanoma, Disease Progression CASP7 840 Myocardial Reperfusion Injury, Vitiligo, Breast Neoplasms, Leukemia, Myeloid, Acute CDH13 1012 Lung Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Amphetamine-Related Disorders, Substance-Related Disorders, Barrett Esophagus CHEK1 1111 Glomerulonephritis, IGA, Peripheral Nervous System Diseases CRISPLD2 83716 Neurotoxicity Syndromes, Lung Diseases, Liver Diseases DCAF17 80067 Woodhouse Sakati syndrome DHFR 1719 Megaloblastic Anemia due to Dihydrofolate Reductase Deficiency, Osteosarcoma, Autistic Disorder, Folic Acid Deficiency, Neoplasm Metastasis, Colorectal Neoplasms, Nervous System Diseases, Anemia, Megaloblastic, Drug-Related Side Effects and Adverse Reactions, Metabolism, Inborn Errors, Infertility, Female, Abortion, Spontaneous, Pancytopenia DIAPH3 81624 Neuropathy, auditory neuropathy, benign epilepsy with centrotemporal spikes, prostate cancer, pancreatitis, prostatitis, sensorineural hearing loss DENND5A 23258 Stomatitis DNAJC13 23317 Parkinson Disease DOCK1 1793 Substance-Related Disorders DYRK1A 1859 Mental Retardation, Autosomal Dominant 7 EIF2B3 8891 Leukoencephalopathy with Vanishing White Matter, Vanishing White Matter Leukodystrophy with Ovarian Failure ENAH 55740 Glomerulonephritis, IGA EP300 2033 Rubinstein-Taybi Syndrome, Endometrial Neoplasms, Carcinoma, Transitional Cell, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Colorectal Neoplasms, Carcinoma, Adenoid Cystic, Small Cell Lung Carcinoma, Colon Carcinoma, Rubinstein-Taybi Syndrome 2 ERCC1 2067 Cerebrooculofacioskeletal Syndrome 4, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Neoplasms, Neoplasm Metastasis, Melanoma, Testicular Neoplasms, Peripheral Nervous System Diseases, Adenocarcinoma of lung. Nasopharyngeal carcinoma, Uterine Cervical Ncoplasms, Arsenic Poisoning, Neoplasms, Germ Cell and Embryonal ERLIN2 11160 Intellectual Disability, Spastic Paraplegia 18, Autosomal Recessive ERRFI1 54206 Endometriosis, Polycystic Ovary Syndrome EVC 2121 Ellis-Van Creveld Syndrome, Weyers acrofacial dysostosis FAM126A 84668 Leukodystrophy, Hypomyelinating, 5, Substance-Related Disorders, Intellectual Disability, Peripheral Nervous System Discases FAM13A 10144 Pulmonary Disease, Chronic Obstructive, Idiopathic Pulmonary Fibrosis FAM198B 51313 Glomerulonephritis, IGA FBN2 2201 Congenital contractural arachnodactyly, Colorectal Neoplasms FHOD3 80206 Substance-Related Disorders GALC 2581 Krabbe discasc, leukodystrophy, metachromatic leukodystrophy, lipid storage disease, infantile krabbe disease, chron's disease, neuropathy, neuronitis, motor neuron disease, hereditary spastic paraplegia, cerebritis, peripheral neuropathy, paraplegia, spasticity, Gaucher's disease, blindness, lysosomal storage disease, gangliosidosis, farber lipogranulomatosis, lipogranulomatosis, open-angle glaucoma, primary open angle glaucoma, glaucoma, multiple sclerosis, hepatitis, squamous cell carcinoma, hematopoietic stem cell transplantation, late-infantile or juvenile krabbe disease, adult krabbe disease GGCT 79017 Meningioma, osteosarcoma, tuberculosis, gestational diabetes, leukemia, eczema, eczema herpeticum, myoblastoma GOLGA4 2803 Arsenic Poisoning, Prostatic Neoplasms, Skin Diseases GPSM2 29899 Chudley-Mccullough syndrome GULP1 51454 Thyroid Diseases HLTF 6596 Colon cancer, adenocarcinoma, colorectal cancer, adenoma, gastric cancer, squamous cell carcinoma, cervical squamous cell carcinoma, cervical adenocarcinoma, endometrial adenocarcinoma, cervicitis, gastric cardia adenocarcinoma, cervical cancer, esophagitis, laryngeal squamous cell carcinoma, laryngitis, esophageal squamous cell carcinoma HMGA2 8091 Neoplasms, Lipomatosis, Multiple, Birth Weight HNMT 3176 Asthma, Urticaria, Rhinitis, Drug Hypersensitivity, Susceptibility to Asthma HPS1 3257 Albinism with hemorrhagic diathesis and pigmented reticuloendothelial cells HSD17B4 3295 Bifunctional peroxisomal enzyme deficiency, Gonadal dysgenesis XX type deafness, Zellweger Syndrome, Peroxisomal Disorders, Spasms, Infantile HTT 3064 Huntington Disease, Movement Disorders, Manganese Poisoning, Cadmium Poisoning IVD 3712 Acidemia, isovaleric KDM6A 7403 Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Neoplasms, Carcinoma, Adenoid Cystic, Carcinoma, Transitional Cell, KABUKI SYNDROME 2 MED13L 23389 Transposition of the Great Arteries, Dextro-Looped 1, Intellectual Disability MFN2 9927 Charcot-Marie-Tooth Disease, Axonal, Type 2A2, Hereditary Motor And Sensory Neuropathy VI, Charcot-Marie-Tooth Disease, Cardiomegaly MRPS28 28957 Breast Neoplasms MYLK 4638 Aortic Aneurysm, Familial Thoracic 7, Acute Lung Injury, Pneumonia, Neoplasm Metastasis, Glaucoma, Gastrointestinal Diseases, Vascular Diseases, Hypersensitivity, Brain Edema, Neoplasm Invasiveness, Glioma, Hypercholesterolemia NGF 4803 Neuropathy, Hereditary Sensory And Autonomic, Type V, Inflammation, Cystitis, Hyperalgesia, Urinary Bladder, Overactive, Hereditary Sensory and Autonomic Neuropathies, Glomerulonephritis, Heroin Dependence, Peripheral Nervous System Diseases, Epilepsy, Tonic-Clonic, Hyperkinesis, Neurogenic Inflammation, Lewy Body Discasc, Kidney Failure, Chronic, Nerve Degeneration, Lung Injury, Seizures, Bronchial Hyperreactivity, Nervous System Diseases, Renal Insufficiency, Chronic, Skin Ulcer, Corneal Ulcer, Parkinsonian Disorders, Neurodegenerative Diseases, Amnesia, Status Epilepticus, Parkinson Disease, Cocaine-Related Disorders, Neurobehavioral Manifestations, Nephritis, Interstitial NT5C2 22978 Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Spastic Paraplegia 45, Autosomal Recessive OSMR 9180 Amyloidosis IX, Glomerulonephritis, IGA, Carcinoma, Non-Small-Cell Lung, Amyloidosis, Primary Cutaneous OXCT1 5019 Succinyl-CoA: 3-oxoacid CoA transferase deficiency, Osteoporosis PAPD4 167153 Sleeping sickness PCM1 5108 Schizophrenia, Thyroid cancer, papillary PDXDC1 23042 Carcinoma, Renal Cell, Glomerulonephritis, IGA, Carboxy-lyase activity, pyridoxal phosphate binding PIGN 23556 Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome 1 PIK3CD 5293 Activated PI3K-delta Syndrome, Lymphoma, Large B-Cell, Diffuse, Prostatic Neoplasms PIK3R1 5295 Short Syndrome, Insulin Resistance, Carcinoma, Mammary Neoplasms, Experimental, Burkitt Lymphoma, Mammary Neoplasms, Animal, Autosomal Recessive Agammaglobulinemia 7 PIKFYVE 200576 Corneal Dystrophy, Fleck PITPNB 23760 Obesity PLEKHA1 59338 Macular Degeneration, Age-Related, 1 PLSCR1 5359 Influenza, Human POMT2 29954 Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C, 2, Muscular Dystrophy-Dystroglycanopathy (Congenital with Mental Retardation), Type B, 2, Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies), Type A, 2, Walker-Warburg Syndrome, Congenital muscular dystrophy PPARG 5468 Obesity, Familial Partial Lipodystrophy Type 3, Hypertension, Diabetes Mellitus, Type 2, Inflammation, Acute Lung Injury, Acute Kidney Injury, Diabetes Mellitus, Experimental, Insulin Resistance, Diabetes Mellitus, Atherosclerosis, Colonic Neoplasms, Colorectal Neoplasms, Thyroid Neoplasms, Alzheimer Disease, Adenocarcinoma, Stomach Neoplasms, Dyslipidemias, Pancreatic Neoplasms, Melanoma, Lipodystrophy, Familial Partial, Crohn Disease, Metabolic Diseases, Carcinoma, Hepatocellular, Colon Carcinoma, Psoriasis, Ischemia, Reperfusion Injury, Ostcoarthritis, Glioma, Liver Neoplasms, Polycystic Kidney, Autosomal Dominant, Leukostasis, Thyroid cancer, follicular, Lipidoses, Glomerulonephritis, Nerve Degeneration, Pituitary ACTH Hypersecretion, Carotid Intimal Medial Thickness 1, Barrett Esophagus, Lymphoma, T-Cell, Chronobiology Disorders, Obesity, Morbid PPHLN1 51535 Nervous system disorders, for example, interacts with synphilin-1, mutations of which are implicated in Parkinson's disease, gastric cancer, ichthyosis PRPF31 26121 Retinitis Pigmentosa 11, Retinitis Pigmentosa PRSS23 11098 Melanoma PSMA4 5685 Carcinoma, Mammary Neoplasms, Experimental, HIV Infections, Mammary Neoplasms, Animal, Liver Neoplasms PXK 54899 Lupus Erythematosus, Systemic, Arthritis, Rheumatoid RAF1 5894 Noonan Syndrome 5, Noonan Syndrome, Leopard syndrome, 2, Leopard Syndrome, Glioma, Cardiomyopathy, Hypertrophic, Carcinoma, Non-Small- Cell Lung, Lung Neoplasms, Breast Neoplasms, Liver Neoplasms, Kidney Neoplasms, Cardiomyopathy, Dilated, Hyperalgesia RARS2 57038 Pontocerebellar Hypoplasia Type 6 RFWD2 64326 Autistic Disorder RPA1 6117 Chloracne RPS10 6204 Diamond-Blackfan Anemia 9 RPS6KB2 6199 Breast Neoplasms SAMD4A 23034 Substance-Related Disorders SCO1 6341 Cytochrome-c Oxidase Deficiency, Mitochondrial Discascs SLC12A2 6558 Hypertension, Epilepsy, Epilepsy, Temporal Lobe, Carcinoma, Mammary Neoplasms, Experimental, Glucose Intolerance, Prostatic Neoplasms, Movement Disorders, Cardiovascular Diseases, Mammary Neoplasms, Animal SMYD3 64754 Amphetamine-Related Disorders SNAP23 8773 Myocardial Ischemia SPATA5 166378 Schizophrenia STAT1 6772 Susceptibility ToMycobacterial and Viral Infections, Autosomal Recessive, Candidiasis, Familial, 7, Arthritis, Experimental, Carcinoma, Hepatocellular, Mycobacterium Infections, Candidiasis, Chronic Mucocutaneous, Liver Cirrhosis, Arthritis, Rheumatoid, Cytomegalovirus Infections, Hearing Loss, Disease Progression, Mycobacterium Infections, Nontuberculous, Influenza, Human STRN3 29966 Cerebritis, cerebral cavernous malformation, cavernous malformation, cerebral cavernous malformations 3, neuronitis STXBP6 29091 Autistic Disorder TAF2 6873 Mental Retardation, Autosomal Recessive 40, Intellectual Disability TCF12 6938 Craniosynostosis 3, Craniosynostoses TCF4 6925 Pitt-Hopkins syndrome, Seizures, Peripheral Nervous System Diseases, Craniofacial Abnormalities, Heart Diseases, Microcephaly, Liver Neoplasms TIAM1 7074 Amyotrophic lateral sclerosis 1 TJP2 9414 Hypercholanemia, Familial, Hearing Loss, Cholestasis, Intrahepatic TRAF3 7187 Susceptibility to Herpes Simplex Encephalitis, 3 VPS29 51699 Down syndrome, paraplegia WNK1 65125 Neuropathy, Hereditary Sensory and Autonomic, Type IIA, Pseudohypoaldosteronism, Type IIc, Hypertension, Kidney Diseases, Pseudohypoaldosteronism, Peripheral Nervous System Diseases ZCCHC8 55596 Intellectual Disability

It will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, the invention described herein is not to be limited in scope by the specific embodiments herein disclosed. These embodiments are intended as illustrations of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description, which modification also intended to be within the scope of this invention.

All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. 

What is claimed is:
 1. A method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCB8, ABCC3, ADAM17, ADCY3, AGPAT4, ANKRA2, ANXA11, APIP, APPL2, ARHGAP1, ARL15, ASAP1, ASPH, ATAD2B, ATXN1, BECN1, BHMT2, BICD1, BTN3A1, C11orf30, C11orf73, C12orf4, C14orf132, C8orf44, C8orf44-SGK3, C8orf88, CASC3, CASP7, CCDC122, CDH13, CECR7, CENPI, CEP112, CEP192, CHEK1, CMAHP, CNRIP1, COPS7B, CPSF4, CRISPLD2, CRYBG3, CSNK1E, CSNK1G1, DCAF17, DCUN1D4, DDX42, DENND1A, DENND5A, DGKA, DHFR, DIAPH3, DNAJC13, DNMBP, DOCK1, DYRK1A, EIF2B3, ENAH, ENOX1, EP300, ERC1, ERLIN2, ERRFI1, EVC, FAF1, FAIM, FAM126A, FAM13A, FAM162A, FAM174A, FBN2, FER, FHOD3, FOCAD, GALC, GCFC2, GGACT, GLCE, GOLGA4, GOLGB1, GPSM2, GULP1, GXYLT1, HDX, HLTF, HMGA2, HNMT, HSD17B12, HSD17B4, HTT, IFT57, IVD, KDM6A, KIAA1524, KIAA1715, LETM2, LOC400927, LRRC42, LUC7L3, LYRM1, MB21D2, MCM10, MED13L, MEDAG, MEMO1, MFN2, MMS19, MRPL45, MRPS28, MTERF3, MYCBP2, MYLK, MYOF, NGF, NREP, NSUN4, NT5C2, OSMR, OXCT1, PAPD4, PCM1, PDE7A, PDS5B, PDXDC1, PIGN, PIK3CD, PIK3R1, PIKFYVE, PITPNB, PLEKHA1, PLSCR1, PMS1, POMT2, PPARG, PPIP5K2, PPP1R26, PRPF31, PRSS23, PSMA4, PXK, RAF1, RAPGEF1, RARS2, RBKS, RERE, RFWD2, RPA1, RPS10, SAMD4A, SAR1A, SCO1, SEC24A, SENP6, SERGEF, SGK3, SLC12A2, SLC25A17, SLC44A2, SMYD3, SNAP23, SNHG16, SNX7, SOS2, SPATA5, SPIDR, SPRYD7, SRGAP1, SRRM1, STAT1, STXBP6, SUPT20H, TAF2, TASP1, TBC1D15, TCF12, TCF4, TIAM1, TJP2, TMC3, TMEM214, TNRC6A, TNS3, TOE1, TRAF3, TSPAN2, TTC7B, TYW5, UBAP2L, URGCP, VAV2, WDR27, WDR37, WDR91, WNK1, XRN2, ZCCHC8, ZFP82, ZNF138, ZNF232 or ZNF37BP, and wherein Formula (I) is:

wherein: w₁ and w₅ are independently C—R_(a) or N; w₂ is C—R_(b) or N; w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N; w₆ is C—R₁, C—R₂, C—R_(c) or N; wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or, when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently C—R_(a) or N; or, when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or, when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; and, wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇ may optionally be N; R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈-alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R₃ substituents and optionally, with one additional R₄ substituent; or, wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R₃ substituents; R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino; wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent; R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl or deuterium; R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium; R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium; R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₄alkyl)₂-amino-C₁₋₄alkyl](C₁₋₄alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino; R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or heterocyclyl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R₅ substituents; R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; and, R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl.
 2. A method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: an endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein the pre-mRNA transcript is a pre-mRNA transcript of a gene that is selected from ABCA10, ABCB8, ABCC3, ACTA2, ADAL, ADAMTS1, ADCY3, ADD1, ADGRG6, ADH6, ADHFE1, AFF3, AGPAT4, AKAP3, ANK1, ANK3, ANKRA2, ANKRD33B, ANKRD36, AP4B1-AS1, APIP, ARHGAP1, ARHGAP12, ARHGEF16, ARID5B, ARL15, ARL9, ARMCX6, ASIC1, ATG5, ATP2A3, ATXN1, B3GALT2, B3GNT6, BCL2L15, BCYRN1, BECN1, BHMT2, BIN3-IT1, BIRC3, BIRC6, BTG2, BTN3A1, C10orf54, C11orf70, C11orf94, C12orf4, C12orf56, C14orf132, C19orf47, C1orf86, C3, C7orf31, C8orf34, C8orf44, C8orf44-SGK3, C8orf88, CA13, CA3, CACNA2D2, CACNB1, CADM1, CAND2, CASP7, CCDC122, CCDC79, CCER2, CCNF, CECR7, CELSR1, CEMIP, CENPI, CEP112, CEP170, CEP192, CFH, CHEK1, CIITA, CLDN23, CLTA, CMAHP, CNGA4, CNRIP1, CNTD1, COL11A1, COL14A1, COL15A1, COL5A1, COL5A3, COL6A6, COL8A1, COLEC12, COMP, CPA4, CPQ, CPSF4, CRISPLD2, CRLF1, CRYBG3, CRYL1, CSNK1E, CSNK1G1, CYB5R2, CYGB, CYP1B1, DAGLB, DCAF17, DCLK1, DCN, DDIT4L, DDX50, DEGS1, DEPTOR, DFNB59, DIRAS3, DLG5, DLGAP4, DNAH8, DNAJC13, DNAJC27, DNMBP, DOCK11, DYNC1I1, DYRK1A, DZIP1L, EFEMP1, EGR3, ELN, ELP4, EMX2OS, ENAH, ENPP1, EP300, ERCC1, ERCC8, ERGIC3, ERLIN2, ERRFI1, ESM1, EVC, EVC2, F2R, FAIM, FAM126A, FAM13A, FAM160A1, FAM162A, FAM174A, FAM20A, FAM46B, FAM65B, FAP, FARP1, FBLN2, FBN2, FBXL6, FCHO1, FGFR2, FGL2, FLT1, FRAS1, FSCN2, GAL3ST4, GALNT15, GATA6, GBGT1, GCNT1, GDF6, GGACT, GLCE, GNAQ, GPR183, GPR50, GPRC5A, GPRC5B, GRTP1, GUCA1B, GULP1, GXYLT1, HAPLN1, HAPLN2, HAS3, HAVCR2, HDAC5, HDX, HECTD2-AS1, HEPH, HEY1, HMGA2, HMGN3-AS1, HNMT, HOOK3, HPS1, HSPA1L, HTATIP2, IFT57, IGDCC4, IGF2R, TGFBP3, TL16, INA, TNPP5K, INTU, TQCG, ITGA11, ITGA8, ITGB8, ITIH1, TTPKA, TVD, KAT6B, KCNS1, KCNS2, KDM6A, KDSR, KIAA1456, KIAA1462, KIAA1755, KIT, KLF17, KLRG1, KMT2D, KRT7, KRTAP1-1, KRTAP1-5, L3MBTL2, LAMB2P1, LETM2, LGI2, LGR4, LHX9, LINC00472, LINC00570, LINC00578, LINC00607, LINC00678, LINC00702, LINC00886, LINC00961, LINC01011, LINC01118, LINC01204, LMOD1, LOC400927, LRBA, LRP4, LRRC32, LRRC39, LRRC42, LSAMP, LUM, LYPD1, LYRM1, MAFB, MAMDC2, MAN2A1, MAN2C1, MAPK13, MASP1, MB, MB21D2, MC4R, MCM10, MED13L, MEGF6, MFN2, MIAT, MIR612, MLLT10, MMP10, MMP24, MN1, MOXD1, MRPL45, MRPL55, MRPS28, MRVI1, MSH4, MTERF3, MXRA5, MYCBP2, NA, NAALADL2, NAE1, NAGS, NDNF, NGF, NGFR, NHLH1, NLN, NOTCH3, NOTUM, NOVA2, NOX4, NRROS, OCLN, OLR1, OSBPL10, OXCT1, OXCT2, PAIP2B, PBLD, PDE1C, PDE5A, PDGFD, PDGFRB, PDS5B, PEAR1, PHACTR3, PIGN, PIK3CD, PIK3R1, PIKFYVE, PIM2, PITPNM3, PLEK2, PLEKHA1, PLEKHA6, PLEKHH2, PLSCR1, PNISR, PODN, POLN, POLR1A, POMT2, PPARG, PPIP5K2, PPM1E, PPP1R26, PPP3CA, PRKCA, PRKG1, PRPF31, PRPH2, PRRG4, PRUNE2, PSMD6-AS2, PTGIS, PTX3, PXK, RAB30, RAB38, RAB44, RAD9B, RAF1, RAPGEF1, RARS, RARS2, RBBP8, RBKS, RDX, RERE, RFX3-AS1, RGCC, ROR1, ROR2, RPA1, RPS10, RPS6KB2, SAMD4A, SCARNA9, SEC24A, SENP6, SERGEF, SGK3, SH3YL1, SHROOM3, SIGLEC10, SKA2, SLC12A2, SLC24A3, SLC35F3, SLC39A10, SLC44A2, SLC46A2, SLC4A11, SLC6A15, SLC7A11, SLC9A3, SLIT3, SMG1P3, SMTN, SNED1, SNX7, SORBS2, SORCS2, SOX7, SPATA18, SPATA5, SPDYA, SPEF2, SPIDR, SPRYD7, SRGAP1, SRRM1, STAC2, STAT4, STK32B, STRN4, STS, STXBP6, SULF1, SVEP1, SYNGR2, SYNPO, SYNPO2, SYNPO2L, TAGLN3, TANGO6, TASP1, TCF12, TCF4, TGFA, TGFB2, TGFB3, TGM2, THBS2, TIAM1, TMC3, TMEM102, TMEM119, TMEM134, TMEM189-UBE2V1, TMEM214, TMEM256-PLSCR3, TMEM50B, TNFAIP8L3, TNFRSF14, TNRC18P1, TNRC6A, TNXB, TP53AIP1, TPRG1, TRIM66, TRPC4, TSHZ2, TSPAN11, TSPAN18, TSPAN7, TSSK3, TTC7B, TUBE1, TXNIP, TYW5, URGCP, USP27X, UVRAG, VAV2, VIM-AS1, VPS41, VSTM2L, VWF, WDR27, WDR91, WISP1, WNK1, WNT10B, YDJC, ZBTB26, ZCCHC5, ZCCHC8, ZFP82, ZMIZ1-AS1, ZNF138, ZNF212, ZNF232, ZNF350, ZNF431, ZNF660, ZNF680, ZNF79, or ZNF837, and, wherein Formula (I) is:

wherein: w₁ and w₅ are independently C—R_(a) or N; w₂ is C—R_(b) or N; w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N; w₆ is C—R₁, C—R₂, C—R_(c) or N; wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or, when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently C—R_(a) or N; or, when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or, when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; and, wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇ may optionally be N; R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R₃ substituents and optionally, with one additional R₄ substituent; or, wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R₃ substituents; R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino; wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent; R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl or deuterium; R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium; R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium; R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino; R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or heterocyclyl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R₅ substituents; R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; and, R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl.
 3. The method of claim 2, wherein the intron further comprises a first 5′ splice site, a second branch point, and a second 3′ splice site upstream of the iREMS.
 4. A method for producing a mature mRNA transcript comprising an iExon, the method comprising contacting a pre-mRNA transcript with a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, a non-endogenous intronic recognition element for splicing modifier (iREMS), a second branch point, and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein wherein Formula (I) is:

wherein: w₁ and w₅ are independently C—R_(a) or N; w₂ is C—R_(b) or N; w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N; w₆ is C—R₁, C—R₂, C—R_(c) or N; wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or, when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently C—R_(a) or N; or, when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or, when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; and, wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇ may optionally be N; R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R₃ substituents and optionally, with one additional R₄ substituent; or, wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R₃ substituents; R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino; wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent; R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl or deuterium; R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium; R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium; R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino; R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or heterocyclyl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R₅ substituents; R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; and, R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl.
 5. A method for modulating the amount of a mature mRNA transcript produced by a pre-mRNA transcript, the method comprising contacting the pre-mRNA transcript with the a compound of Formula (I) or a form thereof, wherein the pre-mRNA transcript comprises two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the intron comprises a RNA nucleotide sequence comprising in 5′ to 3′ order: a non-endogenous intronic recognition element for splicing modifier (iREMS), a first branch point, and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide, and wherein wherein Formula (I) is:

wherein: w₁ and w₅ are independently C—R_(a) or N; w₂ is C—R_(b) or N; w₃, w₄ and w₇ are independently C—R₁, C—R₂, C—R_(a) or N; w₆ is C—R₁, C—R₂, C—R_(c) or N; wherein one of w₃, w₄, w₆ and w₇ is C—R₁ and one other of w₃, w₄, w₆ and w₇ is C—R₂, provided that, when w₃ is C—R₁, then w₆ is C—R₂ and w₄ and w₇ are independently C—R_(a) or N; or, when w₃ is C—R₂, then w₆ is C—R₁ and w₄ and w₇ are independently C—R_(a) or N; or, when w₄ is C—R₁, then w₇ is C—R₂ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; or, when w₄ is C—R₂, then w₇ is C—R₁ and w₃ is C—R_(a) or N and w₆ is C—R_(c) or N; and, wherein any one, two or three of w₁, w₂, w₃, w₄, w₅, w₆ and w₇ may optionally be N; R₁ is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, (amino-C₁₋₈alkyl)₂-amino, (amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, amino-C₁₋₈alkoxy, C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, amino-C₂₋₈alkenyl, C₁₋₈alkyl-amino-C₂₋₈alkenyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl, amino-C₂₋₈alkynyl, C₁₋₈alkyl-amino-C₂₋₈alkynyl, (C₁₋₈alkyl)₂-amino-C₂₋₈alkynyl, halo-C₁₋₈alkyl-amino, (halo-C₁₋₈alkyl)₂-amino, (halo-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl-amino, [(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, [(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, heterocyclyl, heterocyclyl-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkoxy, heterocyclyl-amino, (heterocyclyl)(C₁₋₈alkyl)amino, heterocyclyl-amino-C₁₋₈alkyl, heterocyclyl-C₁₋₈alkyl-amino, (heterocyclyl-C₁₋₈alkyl)₂-amino, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heterocyclyl-oxy, heterocyclyl-carbonyl, heterocyclyl-carbonyl-oxy, C₃₋₁₄cycloalkyl, aryl-C₁₋₈alkyl-amino, (aryl-C₁₋₈alkyl)₂-amino, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, (aryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl, heteroaryl, heteroaryl-C₁₋₈alkyl, heteroaryl-C₁₋₈alkoxy, heteroaryl-amino, heteroaryl-C₁₋₈alkyl-amino, (heteroaryl-C₁₋₈alkyl)₂-amino, (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino, heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl, (heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl or (heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl; wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two or three R₃ substituents and optionally, with one additional R₄ substituent; or, wherein, each instance of heterocyclyl, C₃₋₁₄cycloalkyl, aryl and heteroaryl is optionally substituted with one, two, three or four R₃ substituents; R₂ is aryl, aryl-amino, aryl-amino-carbonyl, heterocyclyl, heteroaryl or heteroaryl-amino; wherein, each instance of aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent; R_(a) is, in each instance, independently selected from hydrogen, halogen, C₁₋₈alkyl or deuterium; R_(b) is hydrogen, halogen, C₁₋₈alkyl, C₁₋₈alkoxy or deuterium; R_(c) is hydrogen, halogen, C₁₋₈alkyl or deuterium; R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino; R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl or heterocyclyl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl and heterocyclyl is optionally substituted with one, two or three R₅ substituents; R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio; and, R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocyclyl or heteroaryl.
 6. The method of any one of claims 1-5, wherein the iREMS comprises an RNA sequence GAguragu, and wherein r is adenine or guanine.
 7. The method of any one of claims 1-5, wherein the iREMS comprises an RNA sequence NNGAgurngn (SEQ ID NO: 1), and wherein r is adenine or guanine and n or N is any nucleotide.
 8. The method of claim 7, wherein the RNA sequence NNGAgurngn (SEQ ID NO: 1) is selected from the group consisting of ANGAgurngn (SEQ ID NO: 29), CNGAgurngn (SEQ ID NO: 35), GNGAgurngn (SEQ ID NO: 41), UNGAgurngn (SEQ ID NO: 47), NAGAgurngn (SEQ ID NO: 30), NCGAgurngn (SEQ ID NO: 36), NGGAgurngn (SEQ ID NO: 42), NUGAgumgn (SEQ ID NO: 48), AAGAgurngn (SEQ ID NO: 31), ACGAgurngn (SEQ ID NO: 37), AGGAgurngn (SEQ ID NO: 43), AUGAgumgn (SEQ ID NO: 49), CAGAgurngn (SEQ ID NO: 32), CCGAgurngn (SEQ ID NO: 38), CGGAgurngn (SEQ ID NO: 44), CUGAgurngn (SEQ ID NO: 50), GAGAgurngn (SEQ ID NO: 33), GCGAgumgn (SEQ ID NO: 39), GGGAgurngn (SEQ ID NO: 45), GUGAgumgn (SEQ ID NO: 51), UAGAgurngn (SEQ ID NO: 34), UCGAgumgn (SEQ ID NO: 40), UGGAgurngn (SEQ ID NO: 46) and UUGAgumgn (SEQ ID NO: 52), wherein r is adenine or guanine and n or N is any nucleotide.
 9. The method of any one of claims 1-5, wherein the iREMS comprises an RNA sequence NNGAguragu (SEQ ID NO: 3862), wherein r is adenine or guanine and N is any nucleotide.
 10. The method of claim 9, wherein the RNA sequence NNGAguragu (SEQ ID NO: 3862) is selected from the group consisting of ANGAguragu (SEQ ID NO: 437), CNGAguragu (SEQ ID NO: 443), GNGAguragu (SEQ ID NO: 449), UNGAguragu (SEQ ID NO: 455), NAGAguragu (SEQ ID NO: 438), NCGAguragu (SEQ ID NO: 444), NGGAguragu (SEQ ID NO: 450), NUGAguragu (SEQ ID NO: 456), AAGAguragu (SEQ ID NO: 439), ACGAguragu (SEQ ID NO: 445), AGGAguragu (SEQ ID NO: 451), AUGAguragu (SEQ ID NO: 457), CAGAguragu (SEQ ID NO: 440), CCGAguragu (SEQ ID NO: 446), CGGAguragu (SEQ ID NO: 452), CUGAguragu (SEQ ID NO: 458), GAGAguragu (SEQ ID NO: 441), GCGAguragu (SEQ ID NO: 447), GGGAguragu (SEQ ID NO: 453), GUGAguragu (SEQ ID NO: 459), UAGAguragu (SEQ ID NO: 442), UCGAguragu (SEQ ID NO: 448), UGGAguragu (SEQ ID NO: 454) and UUGAguragu (SEQ ID NO: 460), wherein r is adenine or guanine, and N is any nucleotide.
 11. An artificial gene construct comprising an RNA sequence comprising exons and one or more introns, wherein at least one intron comprises an iREMS that is downstream of a branch point and a 3′ splice site, and wherein the iREMS comprises the sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.
 12. An artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: a first 5′ splice site, a first branch point, a first 3′ splice site, an iREMS, a second branch point and a second 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.
 13. An artificial gene construct comprising an RNA sequence comprising two exons and an intron, wherein one exon is upstream of the intron and the other exon is downstream of the intron, wherein the RNA nucleotide sequence of the intron comprises in 5′ to 3′ order: an iREMS, a first branch point and a first 3′ splice site, wherein the iREMS comprises an RNA sequence GAgurngn (SEQ ID NO: 2), wherein r is adenine or guanine and n is any nucleotide.
 14. The method of any one of claims 1-10, wherein the pre-mRNA transcript is in a cell or a lysate of the cell and the method comprises contacting the cell or cell lysate with the compound.
 15. The method of claim 14, wherein the modulation of the production of the mature mRNA transcript modulates the amount and/or type of a protein translated from the mature mRNA transcript and produced in the cell or lysate of the cell.
 16. The method of any one of claims 1-10, 14 and 15, wherein the pre-mRNA transcript encodes a detectable reporter protein. 